CN101365802A

CN101365802A - Method for detecting cancer

Info

Publication number: CN101365802A
Application number: CNA2006800464334A
Authority: CN
Inventors: 亚历山大·克劳泽; 菲利普·莱斯纳; 马利克·帕耶; 布鲁诺·穆然; 法比安·施魏格霍费尔; 劳伦特·布拉科
Original assignee: Biomerieux SA; ExonHit Therapeutics SA
Current assignee: Biomerieux SA; ExonHit Therapeutics SA
Priority date: 2005-10-28
Filing date: 2006-10-26
Publication date: 2009-02-11
Also published as: FR2892730A1

Abstract

The invention concerns methods and compositions that can be used for detecting cancer in mammals, particularly humans. The invention particularly concerns serum markers of cancers and their use in diagnostic procedures. The invention also concerns tools and/or kits that can be used for carrying out these methods (reagents, probes, primers, antibodies, chips, cells, etc., the preparation thereof and their use. The invention can be used for detecting the presence or the progression of a cancer in mammals, particularly breast cancer including during early stages.

Description

Method for detecting cancer

Technical field

The application relates to can detect Mammals, especially method for cancer among the mankind and composition.It has described serum markers and their application in diagnostic method of cancer significantly.It also relates to instrument and/or test kit (reagent, probe, primer, antibody, chip, cell etc.), their preparation and their application that can be used to implement these methods.The present invention can be used for detecting the cancer of Mammals, especially the existence or the progress of mammary cancer (comprising that it is early stage).

Background technology

In the women, mammary cancer is the first cause of cancer mortality in the industrialized country.Age is most important Hazard Factor.In western countries, every increase by a year, risk improves 0.5%.Other risk factors are known, as the beginning in the quantity of pregnancy and conceived first age, breast-feeding, pubescence and climacteric, postmenopausal estrogen treatment suddenly, stress and nutrition.

The diagnosis of mammary cancer is undertaken by the mammary gland maskaperture mask usually.Yet the tumour size of the minimum that can detect by the mammary gland maskaperture mask is 1cm according to estimates, and it on average has the progress in the past in 8 years when being illustrated in diagnosis.Little tumour is pernicious more much smaller than the tumour that can infer from their size: the aggressiveness of big tumour is not only because their size, also because their " intrinsic aggressivenesies ", it improves (Bucchi etal. along with the growth at tumour age, Br J Cancer 2005, p.156-161; Norden T, Eur J Cancer 1997, p.624-628).

The advantage of mammary gland maskaperture mask is showed in the countless patients that continue 30 years.Yet these tests have bias, as with relevant (referring to Fletcher andElmore to age, hormonotherapy, quantity that the mammary gland maskaperture mask carries out, doctor's experience and other susceptibility, NEJM 2003, p.1672f or Baines CJ, Breast J 2005, S7-10).

The expression analysis of the group of target gene (panel) also is correlated with in to anti-breast cancer, and mention the analysis of the group of 176 genes especially, it is the patient who expresses the ER acceptor and do not express between the patient of ER acceptor and express different (Bertucci et al, HumanMolecular Genetics, 2000; 9:2981-2991).Can also enumerate analysis to the group of 37 genes, its can be used for mammary cancer early diagnosis (Sharma et al, Breastcancer Research 2005,7:R634-R644).Yet, be included in patient in this research and all suspect and suffer from galactophore disease (" suspicious initial mammogram "), and the group of this gene may be not suitable for the routine test of diagnosing mammary cancer before any mammary gland maskaperture mask.

Therefore, being starved of can be reliably, simply and the diagnostic tool of early detection cancer and test.

Summary of the invention

The application provides one group of biological marker, and it can be used alone or in combination, and preferably combination is used, so that detect, characterize or follow the tracks of cancer in the Mammals, the existence or the progress of preferred mammary cancer in reliable mode.Particularly advantageous part of the present invention is that it can utilize whole blood to implement, and does not need to organize biopsy or separating step.

More specifically, the application results from the evaluation of serum genetic marker feature of the human patients of suffering from mammary cancer.These markers are for example corresponding to the variation of montage or gene expression dose, and they separately or advantageously combination can detect the existence or the progress stage of cancer among the patient.They can be advantageously in reliable and simple mode, utilize whole blood sample, detect the existence of mammary cancer from the commitment of mammary cancer (that is, Phase I and II, that is, invalid stage of mammary gland maskaperture mask particularly).They can also be used to detect breast carcinoma of early stage, and this breast carcinoma of early stage can not detect by the mammary gland maskaperture mask, because they are lower than the detection threshold of mammary gland maskaperture mask.

A theme of the present invention relates to and is used for detecting the existence of Mammals cancer or the method for developing risk (stripped or external), comprises determining a kind of or preferred multiple exist (or lacking or (relatively) amount) that is selected from following target molecule in the mammiferous biological sample:

A) comprise the sequence that is selected from SEQ ID NOs:1-437 or have at least 15, the nucleic acid of its specific fragments (fragment distinctif) of preferred at least 16,17,18,19,20,25 or 30 continuous bases,

B) have and nucleic acid according to a) sequence complementary sequence,

C) according to a) or b) the functional analogue of nucleic acid, perhaps

D) by according to a) to c) the polypeptide of nucleic acid encoding,

The existing of such target molecule (or lacking or (relatively) amount) is the indication of cancer existence or developing risk in the described Mammals in the sample.

In a concrete modified example of embodiment, this method comprises at least 5,10,15,20,30,40,50,60,70 or the combine measured of the existence of the target molecules that are defined as above or shortage or (relatively) amount more." combination " measured and indicated such fact, promptly determines to relate to the hybridization collection of illustrative plates (or signature) of a plurality of markers.Combine measured is carried out usually simultaneously, is promptly undertaken by total mensuration of expression map.Yet combine measured can also be undertaken by the parallel or proceeding measurement of a plurality of markers, causes the evaluation of collection of illustrative plates (profil).By the present invention, can set up and determine the hybridization collection of illustrative plates (or signature) of a group echo thing effectively, so that the risk that cancer exists or develops in the assessment Mammals.The hybridization collection of illustrative plates utilizes the combination (for example comprising all these targets) of a plurality of markers that are selected from the target of pointing out above usually, carries out.

In a kind of embodiment, method of the present invention comprises measures the existing of at least 5 of being selected from those target molecules of limiting above in the mammiferous biological sample, preferred at least 10 different target molecules (or lack or (relatively) measures).

In preferred embodiment, method of the present invention comprises and is selected from those the existing of special subgroup (or lack or (relatively) measures) of target molecule of pointing out above in the mammiferous biological sample of combine measured.Describe described subgroup in an embodiment, be particularly suitable for detecting the existence of (especially early stage) mammary cancer among the patient based on whole blood sample.

Therefore, in an embodiment, method of the present invention comprises in the mammiferous biological sample of combine measured, comprises as top a) to d) the existing of the nucleic acid of whole molecules of one of the group 1-11 that limits in whole group the nucleic acid of the target (or mark) of a marker that limits, preferred the application (or lack or (relatively) measures).

Therefore, in an embodiment, method of the present invention comprises whole nucleic acid of the group 1 that comprises the sequence shown in table 4 the 1st row in the combine measured mammalian biological sample, or comprise having at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, or have with the nucleic acid of they complementary sequences and/or be derived from the functional analogue of these nucleic acid of other species, and/or by the existing of the polypeptide of these nucleic acid encodings (or lack or (relatively) measures).The embodiment that the application provides shows effectively: the group of this marker can be used for detecting the existing of cancer, developing risk or progress stage in the mode of prediction.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises and comprises SEQ ID NOs:18 in the combine measured mammalian biological sample, 19,23,26,51,52,53,54,55,69,80,125,145,148,225,228, sequence shown in 240 and 312 (groups 2) or have at least 15, preferably at least 16,17,18,19,20, the nucleic acid of its specific fragment of 25 or 30 continuous bases, perhaps have with the nucleic acid of they complementary sequences and/or be derived from the functional analogue of these nucleic acid of other species, and/or by the existing of the polypeptide of these nucleic acid encodings (or lack or (relatively) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises and comprises SEQ ID NOs:18 in the combine measured mammalian biological sample, 19,23,26,27,51,52,53,54,55,69,80,125,145,148,161,188,225,228,240, sequence shown in 280 and 312 (groups 3) or have at least 15, preferably at least 16,17,18,19,20, the nucleic acid of its specific fragment of 25 or 30 continuous bases, perhaps has nucleic acid with aforementioned sequence complementary sequence, and/or be derived from the functional analogue of these nucleic acid of other species, and/or by the existing of the polypeptide of described nucleic acid encoding (or lack or (relatively) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises one or more other target molecules as previously defined of detection.

In another embodiment, method of the present invention comprises and comprises SEQ ID NOs:13 in the combine measured mammalian biological sample, 16-19,23,26-28,47,51-55,58,69,80,81,89,116,121,125,145,148,158,160,161,164,189,190,225,229,240,248,280,281,284,299,300, sequence shown in 310 and 312 (groups 4) or have at least 15, preferably at least 16,17,18,19,20, the nucleic acid of its specific fragment of 25 or 30 continuous bases, perhaps have with the nucleic acid of these sequence complementary sequences and/or be derived from the functional analogue of these nucleic acid of other species, and/or by the existing of the polypeptide of these nucleic acid encodings (or lack or (relatively) measures).The embodiment that provides among the application shows effectively: existence, developing risk or progress stage that the group of this marker can the property foretold detection cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises and comprises SEQ ID NOs:7 in the combine measured mammalian biological sample, 13,14,16-19,23-28,47,51-55,58,69,80,81,89,116,121,125,137,139,145,148,158,160,161,164,189,190,225,228,229,240,245,248,252,280,281,284,290,298-300, sequence shown in 310 and 312 (groups 5) or have at least 15, preferably at least 16,17,18,19,20, the nucleic acid of its specific fragment of 25 or 30 continuous bases, perhaps have with the nucleic acid of aforementioned sequence complementary sequence and/or be derived from the functional analogue of these nucleic acid of other species, and/or by the existing of aforementioned nucleic acid encoded polypeptides (or lack or (relatively) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises and comprises SEQ ID NOs:5 in the combine measured mammalian biological sample, 7,13,14,16-20,23-28,47,51-55,58,64,69,80,81,88-90,116,121,125,137,139,145,148,158,160,161,164,188-191,208,222,225,228,229,236,240,242,245,248,252,280,281,284,290, sequence shown in 298-300 and the 309-312 (group 6) or these sequences have at least 15, preferably at least 16,17,18,19,20, the nucleic acid of the specific fragment of 25 or 30 continuous bases, perhaps have with the nucleic acid of they complementary sequences and/or be derived from the functional analogue of these nucleic acid of other species, and/or by the existing of aforementioned nucleic acid encoded polypeptides (or lack or (relatively) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises whole nucleic acid of the group 7 that comprises the sequence shown in the table 4 in the combine measured mammalian biological sample or comprises having at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases or have with the nucleic acid of they complementary sequences and/or be derived from the functional analogue of these nucleic acid of other species, and/or by the existing of aforementioned nucleic acid encoded polypeptides (or lack or (relatively) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises whole nucleic acid of the group 8 that comprises the sequence shown in the table 4 in the combine measured mammalian biological sample or comprises having at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases or have with the nucleic acid of they complementary sequences and/or be derived from other species these nucleic acid functional analogue and/or by the existing of aforementioned nucleic acid encoded polypeptides (or lack or (relative) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises whole nucleic acid of the group 9 that comprises sequence shown in the table 4 in the combine measured mammalian biological sample or comprises having at least 15, the nucleic acid of the specific fragment of these sequences of preferred at least 16,17,18,19,20,25 or 30 continuous bases or have with aforementioned sequence complementary sequence and/or be derived from other species these nucleic acid functional analogue and/or by the existing of aforementioned nucleic acid encoded polypeptides (or lack or (relative) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises the whole nucleic acid that comprise the group 10 of sequence shown in the table 4 in the combine measured mammalian biological sample, perhaps comprise having at least 15, the nucleic acid of the specific fragment of these sequences of preferred at least 16,17,18,19,20,25 or 30 continuous bases or have with the nucleic acid of aforementioned sequence complementary sequence and/or be derived from other species these nucleic acid functional analogue and/or by the existing of aforementioned nucleic acid encoded polypeptides (or lack or (relative) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability (or prophesy property) detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In another embodiment, method of the present invention comprises and comprises the sequence shown in the SEQ ID NOs:23,52,53,148 and 225 (group 11) in the combine measured mammalian biological sample, perhaps have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases or have with the nucleic acid of these sequence complementary sequences and/or be derived from the functional analogue of these nucleic acid of other species, and/or by the existing of aforementioned nucleic acid encoded polypeptides (or lack or (relatively) measures).The embodiment that provides among the application shows effectively: the group of this marker can predictability detects existence, developing risk or the progress stage of cancer.In an embodiment, this method also comprises detection one or more other target molecules, target molecule as previously defined.

In an embodiment, method of the present invention comprises exist (or lacking or (relatively) amount) of measuring mammalian biological sample amplifying nucleic acid, described nucleic acid comprises the sequence shown in the SEQID NOs:1-437 respectively or theirs have at least 15, the specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, or have the nucleic acid of their complementary sequence.

Another special theme of the present invention is to detect the existence of cancer in the Mammals or the method for developing risk, be included under the condition that allows to hybridize between the complementary sequence, the nucleic acid that is derived from the mammalian sample contacted for the special probe of following target molecule with one group:

A) comprise the nucleic acid of the sequence as shown in one of group 1-11 of limiting as the front, or have at least 15, its specific fragments of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

B) have and nucleic acid according to a) sequence complementary sequence, and/or

C) be derived from other species according to a) or b) the functional analogue of nucleic acid,

So that obtain the hybridization collection of illustrative plates, described hybridization collection of illustrative plates is the existence of mammary cancer in this Mammals or the feature of developing risk.

And the analysis of the different genes of identifying among the present invention (it is expressed among the patient and changes) shows that they belong to the gene family that relates in cell signal path or the common regulation mechanism.Therefore, especially, the many genes of this analytical proof, described gene relate to being used to transduce stimulates the signal cascade of the information that causes, the secretion or the lymphocytic activation of T of cytokine by TLR.Therefore the present invention proves this fact, be that change in these signal cascades is present among the patient who suffers cancer, and any abnormality that participates in any gene of these cascades or RNA or these genes or RNA can form the marker that cancer exists or the inducement of cancer.Described change can take place during the oxidative stress that is imposed on monocyte, scavenger cell and dendritic cell by tumour cell.These stress be the result's of the different cell interactions that take place between the cancer cells in immunity system and the tumour parts.The proof so the representative that show the molecular events of the change in the signal cascade that relates in the immunne response in the blood circulation can be based on the new tool and the novel methods of the existence of the tumour in the whole blood sample proof body.

Therefore, a special theme of the present invention relates to and being used for (exsomatize or external) and detects the existence of Mammals cancer or the method for developing risk, comprise exist (or shortage) of measuring the gene that participates in the signal path that relates in immunne response (congenital or obtain) in the mammiferous biological sample in (preferred blood (source) sample) or the change among the RNA, the existence of described change is the indication of cancer existence or developing risk in this Mammals.The signal path that relates in the immunne response advantageously is selected from TLR stimulation, cytokine secretion or T-lymphocyte activation.

The representative of the initial impulse of dendritic cell is congenital replys and carries out via to1l sample acceptor (TLR).A plurality of TLR and the different ligands reaction that can carry by pathogenic agent or tumour cell, and cause producing different pro-inflammatory cytokines by dendritic cell.This phenomenon is attended by antigen to ortho states (na

Ve) presenting of T cell caused specificity, acquired immunity is replied thus.In the molecule participant of these signal cascades, those molecules participant that can preferably quote is the factor, chemokine, cytokine and the interleukin that relates in the adjusting of acceptor, aptamers, enzyme, genetic expression.

A special theme of the present invention is to be used for exsomatizing or vitro detection Mammals cancer exists or the method for developing risk, comprises measuring the existing of change (or shortage) that (in preferred blood (source) sample) in the mammiferous biological sample relates to the gene of regulating the signal path that is used for controlling the congenital immunity phenomenon or RNA.More particularly, this phenomenon is mobilized cascade that is caused by TLR and the activity of regulating scavenger cell and dendritic cell.

Another special theme of the present invention is to be used for exsomatizing or vitro detection Mammals cancer exists or the method for developing risk, comprises measuring the existing of change (or shortage) that (in preferred blood (source) sample) in the mammalian biological sample relates to the gene of regulating the signal path that is used for controlling acquired or adaptive immunity phenomenon or RNA.More particularly, this phenomenon relates to T-lymphocyte receptor (TCR).

Another special theme of the present invention is to be used for exsomatizing or vitro detection Mammals cancer exists or the method for developing risk, comprises measuring exist (or shortage) that (in preferred blood (source) sample) in the mammalian biological sample relates to the gene of conversion between congenital and the acquired immunity, coordination or the change among the RNA.More particularly, these genes relate to the biosynthesizing from the lipid molecule of precursor (as arachidonic acid).

Therefore, a special theme of the present invention is that (exsomatize or external) detect that cancer in the Mammals exists or the method for developing risk, comprise and measure the stimulation that relates to TLR in the mammiferous biological sample in (preferred blood (source) sample), the secretion of cytokine, or the existing of the change among lymphocytic activatory gene of T-or the RNA (or shortage), described gene or RNA advantageously are selected from acceptor, aptamers, enzyme, the factor that genetic expression relates in regulating, chemokine, cytokine and interleukin, the existence of described change are that cancer exists or the indication of developing risk in this Mammals.

The change of gene or RNA refers to any change of expression among the present invention, that is, and and the montage abnormality that particularly causes special splicing form to occur, or the change of (relatively) between different splicing form amount or ratio.

Describe as rest part in the text, the application has described in the blood that is present in the cancer patients, relates to the evaluation (table 5) of montage abnormality among the participant of signal cascade of congenital and acquired immunity.Oligonucleotide (is derived from the RNA sequence, the influence that its expression is changed by montage) can deposit or synthesize on any solid-state carrier, and be derived from the contrast blood sample and from the nucleic acid probe hybridization of cancer patients's blood sample, thereby allow to select the distinctive oligonucleotide of tool.Widely, can select described oligonucleotide to represent any proteic any mRNA that relates in encode congenital and the acquired immunity.More specifically, these oligonucleotide can be derived from the gene shown in the table 6.Can also detect change at structure or expression level, for example utilize hereinafter with the specific antibody of describing in detail by these genes or RNA encoded polypeptides.

Therefore a special theme of the present invention is that (exsomatize or external) detect that cancer in the Mammals exists or the method for developing risk, comprise and measuring in the mammalian biological sample, shown in the table 5 at least one in preferred blood (source) sample, change among preferred at least 2,3,4,5,6,7,8,9 or 10 genes or the corresponding RNA, the existing of the change of the montage of particularly described gene or RNA (or shortage), the existence of described change is that cancer exists or the indication of developing risk in this Mammals.

Therefore another special theme of the present invention is to be used for the method that (stripped or external) detects existence of Mammals cancer or developing risk, comprise and measuring in the mammiferous biological sample, shown in the table 6 in preferred blood (source) sample at least one, preferably at least 2,3,4,5,6,7,8,9 or 10 genes or corresponding RNA, the existing of the change of the montage of such gene or RNA (or shortage) particularly, the existence of described change is that cancer exists or the indication of developing risk in this Mammals.

Target molecule

The present invention is based on the proof and the characterization of the peculiar serum biological event that mammary cancer exists in the human patients.These incidents constitute (biology) marker, its detection in the patient, and preferably combination detects, and allows even measure in early days the risk of the described cancer of development or the existence of described cancer.In implication of the present invention, terms tag thing and transcript use convertibly, give their specific implications unless work as context.

The change that the biological event of identifying is regulated corresponding to genetic expression usually.This can relate to the part or all of inhibition of expression of some form of gene or RNA or gene or RNA, the beginning of the raising of the expression of some form of gene or gene or RNA, gene splicing form or disappearance etc.

The present invention is therefore based on one or more representatives detection of the target molecule of the biological event of evaluation thus in the sample.As noted above, these target molecules can be selected from:

A) comprise the sequence that is selected from SEQ ID NOs:1-437 or have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases,

B) have and nucleic acid according to a) sequence complementary sequence,

C) according to a) or b) the functional analogue of nucleic acid, or

D) by according to a) to c) the polypeptide of nucleic acid encoding.

Target molecule can be corresponding to the gene of sequence SEQ ID NOs:1-437 or RNA or proteic sufficient sequence or its specific fragment, promptly, such fragment, its sequence is specific for described gene or RNA or for described albumen, and/or comprises the variable domains (montage, detection, polymorphism etc.) of the biological event that representative will detect.The tabulation fully of marker and corresponding gene is shown in Table 1.

Term " functional analogue " refers to the analogue that is derived from other mammalian species.Sequence SEQ ID NOs:1-437 identifies from the mankind, and these sequences form the significant notation thing that is suitable for detecting the cancer in the human patients.Yet, for method of the present invention being used for mammiferous other species, its common advantageous applications under consideration in described species functional analogue characterization, these sequences.These analogues can utilize any technical evaluation well known by persons skilled in the art, and the sequence that provides among the application and the title of corresponding gene especially will be provided.

In a kind of special embodiment, this method comprises that mensuration is according to a) to c) the existence of at least a nucleic acid.

In a kind of very special embodiment, this method be used for detecting human individual's cancer and comprise mensuration according to a) or b) the existence of at least a nucleic acid.In addition preferably, this method comprises that the group of (group 1 to 11 or table 5 and 6) the target indicia thing that limits among combine measured such as the application exist (or shortage) or (relative or absolute) measure.

A specific embodiment of the present invention is to detect the existence of mammary cancer in the Mammals or the method for developing risk, existence or (relative or absolute) amount of comprising component in the combine measured mammalian sample, the target molecule below described component comprises at least:

A) comprise the group 1 that provides in the table 4 or 11 sequence, perhaps have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

B) have the nucleic acid that is complementary to according to the sequence of a) sequence, and/or

C) be derived from other species according to a) or b) the functional analogue of nucleic acid, and/or

D) by according to a) to c) the polypeptide of nucleic acid encoding,

The existence of target molecule described in the sample is that mammary cancer exists or the indication of developing risk in this Mammals.

A specific embodiment of the present invention is to detect the existence of mammary cancer in the Mammals or the method for developing risk, comprises the existence or the amount of following target molecule in the mammiferous blood sample of combine measured:

A) comprise the sequence of SEQ ID NOs:18,19,23,26,51,52,53,54,55,69,80,125,145,148,225,228,240 and 312 (group 2) or have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

D) by according to a) to c) the polypeptide of nucleic acid encoding,

A specific embodiment of the present invention is to detect the existence of mammary cancer in the Mammals or the method for developing risk, comprises the existence or the amount of following target molecule in the combine measured mammalian sample:

A) comprise the sequence of the group 10 that provides in the table 4, perhaps have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

D) by according to a) to c) the polypeptide of nucleic acid encoding,

Another particular topic of the present invention is to detect the existence of mammary cancer in the Mammals or the method for developing risk, comprises the target molecule below detecting in the mammalian sample:

A) comprise the sequence shown in the SEQ ID NOs:18,19,23,26,51,52,53,54,55,69,80,125,145,148,225,228,240 and 312 (group 2), perhaps have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

D) by according to a) to c) the polypeptide of nucleic acid encoding,

The existence of these target molecules in the sample, shortage or (relatively) amount are that mammary cancer exists or the indication of developing risk in this Mammals.

The present invention can also limit other groups, comprises at least some markers as preceding qualification, and it can make up with other marker alternatively.Described group can obtain by the existence or the shortage of these markers in the test patient sample, is specific other predictability combination to limit if desired for specific pathology.

The detection of nucleic acid

Allow the different technology of test sample amplifying nucleic acid classification to use in the present invention, as the RNA marking, selective cross, utilization are coated with carrier, nucleic acid amplification such as RT-PCR, quantitative PCR or the connection-PCR etc. of probe oligonucleotides.These methods can comprise utilization can selectivity or the specific detection sample in the nucleic acid probe (as oligonucleotide) of target nucleic acid.Can increase according to the known different methods of those skilled in the art itself, as amplification (TMA), strand displacement amplification (SDA), the NASBA of PCR, LCR, transcriptive intermediate, utilize allelotrope-specific oligonucleotide (ASO), allele specific amplification, the DNA marking, single stranded conformational to analyze the analysis etc. of SSCA, in situ hybridization (as FISH), gel shift, heteroduplex.

According to one preferred embodiment, this method comprise by selective cross or selective amplification detect according to a) to c) the existence of nucleic acid or shortage or (relatively) measure.

Selective cross utilizes nucleic acid probe to carry out usually, and this probe preferably is fixed on the carrier, and this carrier for example is solid or the semi-solid support with at least one flat or uneven surface, allows the fixing of nucleic acid probe.Described support is for example slide plate (slide glass), pearl, film, filter, post, plate etc.They can be made by any compatible material, especially glass, silica, plastics, fiber, metal, polymkeric substance etc.Described nucleic acid probe can be any nucleic acid (DNA, RNA, PNA etc.), and preferred strand comprises the target molecule that target molecule (as top a) to c) is limited) specific sequence.Described probe generally includes 5 to 400 bases, preferred 8 to 200 bases, more preferably less than 100 bases, further preferably be less than 75,60,50,40 or even 30 bases.Described probe can be the synthetic oligonucleotide that utilizes conventional synthetic technology to produce based on target molecule sequence base of the present invention.Described oligonucleotide generally includes 10 to 50 bases, preferred 20 to 40 bases, for example about 25 bases.In a particularly advantageous embodiment, a plurality of different oligonucleotide (or probe) are used to detect same target molecule.These can be for to the specific oligonucleotide of the different zones of same target molecule, perhaps aligned (centr é) oligonucleotide differently on an identical zone.Can also use paired probe, one of them member and target molecule mate fully, and another mispairing thus can estimating background noise comprising.In the following embodiments, every pair of 6 to 11 pairs of oligonucleotide with 25 bases are used for each target molecule.

Described probe can utilize the known method of those skilled in the art itself, synthetic in advance being deposited on subsequently on the carrier, and perhaps direct in-situ is synthetic on carrier, and described probe can also utilize gene engineering, as by preparations such as amplification, reorganization, connections.

So the probe that limits constitutes another theme of the application, and they are used for detecting at individuality the application (external basically) of cancer.In particularly preferred mode, the one group of nucleic acid probe that is suitable for comprises each sequence whole of the sequence SEQ ID NO:1-437 that advantageously is fixed on the carrier or has at least 15 continuous bases, preferably fragment or its complementary strand of at least 17,19,20,22 or 25 continuous bases.

Hybridization can be carried out under normal condition, these conditions are known for those skilled in the art and can be by those skilled in the art (Sambrook, Fritsch, Maniatis (1989) Molecular Cloning, Cold Spring Harbor Laboratory Press) adjust.Especially, depend on desirable level of sensitivity, obtainable amount of substance etc., hybridization can be carried out under the condition of strict, medium or low severity.For example, the conditions suitable that is used to hybridize is included in the low density carrier, temperature between 55 and 63 ℃, 2 to 18 hours.Other hybridization conditions can be essential for the high-density carrier, as the hybridization temperature between 45 and 55 ℃.After the hybridization, carry out different flushings removing the molecule of non-hybridization, usually in comprising the SSC damping fluid of SDS, as comprise the damping fluid of 0.1 to 10 X SSC and 0.5-0.01% SDS.Can also use other dcq buffer liquid that comprises SSPE, MES, NaCl or EDTA.

In an exemplary embodiment, nucleic acid (or chip or carrier) the hybridization buffer that comprises 100 μ g/ml salmon sperm dnas usually (Rapid Hybrid Buffer, Amersham) in 65 ℃ of following prehybridizations 30 minutes.Nucleic acid with sample contacts 2 to 18 hours at 65 ℃ with probe (being applied to carrier or chip usually) subsequently.Preferably, utilize any known mark (radioactivity, enzyme, fluorescence, luminous etc.) to come the nucleic acid of mark sample in advance.Subsequently, carrier 65 ℃ of flushings 30 minutes, washes in 0.2X SSC, 0.1% SDS damping fluid in 5X SSC, 0.1% SDS damping fluid subsequently.Utilize routine techniques, for example, (as InstantImager, PackardInstruments) mark on the measurement carrier is analyzed the hybridization collection of illustrative plates by utilizing suitable instrument.Hybridization conditions can be adjusted by those skilled in the art naturally, as salt concn by modification hybridization temperature and/or damping fluid, and by adding complementary material, as methane amide or single stranded DNA.

Other special theme of the present invention is to detect the existence of mammary cancer in the Mammals or the method for developing risk, be included in and can make under the condition of hybridizing between the complementary sequence, the nucleic acid that is derived from described mammiferous blood sample is contacted for the special probe of following at least target molecule with one group:

A) comprise one of previously defined group 1 to 11 sequence, or have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

B) have the described nucleic acid that is complementary to according to the sequence of a) sequence, and/or

To obtain the hybridization collection of illustrative plates, described hybridization collection of illustrative plates is the existence of mammary cancer in this Mammals or the feature of developing risk.

Therefore, a special theme of the present invention is to detect the existence of mammary cancer in the Mammals or the method for developing risk, be included in and can make under the condition of hybridizing between the complementary sequence, the nucleic acid that is derived from described mammiferous blood sample is contacted for the special probe of following target molecule with one group:

A) comprise the sequence shown in one of the

group

1,2,10 that is defined as above or 11, or have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

In special embodiment, method of the present invention is also used the subgroup of the target molecule of mentioning among other target molecule and/or other probe, especially the application.

Therefore, the special theme of another of the application is to detect the existence of cancer in the Mammals or the method for developing risk, be included in and can make under the condition of hybridizing between the complementary sequence, will be derived from nucleic acid and one group of probe contact of described mammiferous blood sample at least two that are selected from following target different molecular specifics:

A) comprise the sequence shown in the SEQ ID NOs:1-437, or have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

To obtain the hybridization collection of illustrative plates, described hybridization collection of illustrative plates is the existence of cancer in this Mammals or the feature of developing risk.

The hybridization collection of illustrative plates can with one or more with reference to collection of illustrative plates relatively, especially with healthy individual and/or suffer from cancer individuality the reference drawing spectrum signature relatively, this patient who relatively allows to measure tested person suffers from the probability or the risk of cancer.Usually, this relatively utilizes the known computer program of those skilled in the art itself to carry out.

The primer of all or part of amplification of one of target nucleic acid or primer are to carrying out selective amplification (if having target nucleic acid in the sample) in the preferred utilization permission sample.This primer can be specific for the target sequence according to SEQ ID NO:1-437, and perhaps the zone for the target sequence flank in the nucleic acid of sample is specific.This primer generally includes single-chain nucleic acid, and its length is advantageously between 5 to 50 bases, preferably between 5 to 30 bases.Such primer with and be used for another theme that purposes that (external basically) detect the cancer of individuality forms the application.

In this respect, another theme of the present invention is the application of nucleotide primer or one group of nucleotide primer, described primer allows to comprise or all or part of amplification of preferably a plurality of gene or RNA according to the target sequence of SEQ ID NO:1-437, be used for detecting the particularly cancer in the mankind of Mammals, preferred mammary cancer.

Another special theme of the present invention is to detect the existence of cancer in the Mammals or the method for developing risk, be included under the condition that can increase, will be derived from the nucleic acid and one group of primer contact of described mammiferous blood sample for the molecular specific of at least two that are selected from following target different (distinct):

C) be derived from other species according to a) or b) the functional analogue of described nucleic acid,

To obtain amplification collection of illustrative plates (profil), described amplification collection of illustrative plates is the existence of cancer in this Mammals or the feature of developing risk.

The detection of polypeptide

Under another embodiment, this method comprises that mensuration is according to d) the existence of polypeptide.Can the known any technology of utilization itself, especially utilize ligands specific, as the derivative or the fragment of antibody or antibody, carry out the proof of polypeptide in the sample.Preferably, this part be to the fragment (as Fab, Fab ', CDR etc.) of special antibody of polypeptide or described antibody or as described in the derivative of antibody (as single-chain antibody, ScFv).This part is fixed on the carrier usually, carrier such as slide plate, pearl, post, plate etc.The hit existence of polypeptide of sample can detect by for example utilizing tagged ligand, utilize the second mark development part complex body between proof targets such as (ligand de r é v é lation) and the part.Operable and immunological technique that know is ELISA, RIA technology etc.

Can utilize routine techniques, especially produce antibody for the target polypeptid specificity by also collecting (polyclone) antibody with the immunogen immune non-human animal who comprises polypeptide (or its immunogen fragment) or producing cell (to produce mono-clonal).The technical description that is used to produce polyclone or monoclonal antibody, ScFV fragment, the mankind or humanized antibodies is at for example Harlow etal., Antibodies:A Laboratory Manual, CSH Press, 1988; Ward et al., Nature 341 (1989) 544; Bird et al., Science 242 (1988) 423; WO94/02602; US5,223,409; US5,877,293; Among the WO93/01288.This immunogen can be by synthesizing or pass through the expression generation of aforesaid target nucleic acid in appropriate host.Described mono-clonal or polyclonal antibody and derivative thereof have same antigen-specific, and they are used for the application of cancer detection, also form theme of the present invention.

The enforcement of method

Mammiferous any biological sample that method of the present invention can be used to detect especially comprises any sample of nucleic acid or polypeptide.Can advantageously list the sample of blood, blood plasma, thrombocyte, saliva, urine, excrement etc., perhaps comprise any tissue, organ or advantageously any biofluid of nucleic acid or polypeptide widely.

In a preferred particularly advantageous embodiment, this sample is blood or plasma sample.The present invention is that the evaluation according to the blood marker of cancer draws, and therefore allows to detect these pathology, need not any examination of living tissue, only utilize blood sample.

The known any technology of utilization itself for example utilizes the Noninvasive technology by obtaining this sample from samplings such as collection or sample libraries.This sample can also be anticipated to promote the accessibility of target molecule, for example by cracking (machinery, chemistry, enzyme etc.), purifying, centrifugal, separation etc.Advantageously use the PaxGene system (Feezor et al., Physiol Genomics2004: pp.247-254).This sample can also be labeled to promote the mensuration to the existence of target molecule (fluorescence, radioactivity, luminous, chemical, enzyme labelling etc.).

One preferred embodiment in, this biological sample is a whole blood sample, that is, it is without any separating step, it can be diluted alternatively.

The present invention can be used for any Mammals, and is preferred human.Method of the present invention is used in particular for the detection of mammary cancer, the especially existence of mammary cancer among the mankind, developing risk or the detection in progress stage.Therefore, the data that provide among the embodiment show that the present invention can detect the existence of mammary cancer, and susceptibility surpasses 92%, and specificity surpasses 86%.It is early stage that it is specially adapted to examination, be Phase I or the II mammary cancer of (as in the malignant tumour classification (TNM, Classification ofMalignant Tumors) of developing and keeping by UICC (＂ International Union AgainstCancer ＂), limiting).The TNM classification is also by AJCC (american cancer joint committee, ＂ American Joint Committee on Cancer ＂) and by IFGO (International Federation of Gynecology and Obstetrics, ＂ International Federation of Gynecologyand Obstetrics ＂) use.

The application's a special theme relates to the method that detects existence, progress or the developing risk of mammary cancer among the human individual, comprises exist (or the lacking or (relatively) amount) that is selected from following target molecule in the biological sample of combine measured from the human individual:

A) comprise the sequence that is selected from SEQ ID NO:1-437 or have at least 15, its segmental nucleic acid of preferred at least 16,17,18,19,20,25 or 30 continuous bases,

B) have the nucleic acid that is complementary to according to the sequence of a) sequence, and

C) by according to a) or b) the polypeptide of nucleic acid encoding.

Preferably, this method comprises existence, shortage or the quantity of 5,10,20,30,40,50 or 60 target molecules that combine measured is defined as above.

The special theme of another of the application relates to the existence that detects mammary cancer among the human individual, progress, or the method for developing risk, comprise that the biological sample that comprises nucleic acid with individuality contacts with the product that comprises carrier, be fixed with nucleic acid on the carrier, this nucleic acid comprises and is complementary to a kind of or preferred multiple target molecule and/or for the specific sequence of a kind of or preferred multiple target molecule, described target molecule is selected from: i) comprise the nucleic acid of the sequence that is selected from SEQ ID NO:1-437 or have at least 15, preferably at least 16,17,18,19,20, its fragment of 25 or 30 continuous bases and the nucleic acid that ii) has the sequence of the sequence that is complementary to basis (i), and measure the hybridization collection of illustrative plates, this collection of illustrative plates shows the existence of mammary cancer among the described human individual, stage, or developing risk.Preferably, this product comprises different nucleic acid, described nucleic acid comprise be complementary to as mentioned above at least 5,10,20,30,40,50,60 or more a plurality of different target molecules and/or for as mentioned above at least 5,10,20,30,40,50,60 or more a plurality of different target molecules show specific sequence.

Another theme of the application relates to the product that comprises the carrier that is fixed with nucleic acid on it, described nucleic acid comprises and is complementary to a kind of or preferred multiple target molecule and/or for the specific sequence of a kind of or preferred multiple target molecule, described target molecule is selected from: (i) comprise the sequence that is selected from SEQ ID NO:1-437 or have at least 15, its segmental nucleic acid of preferred at least 16,17,18,19,20,25 or 30 continuous bases and the nucleic acid that (ii) has the sequence of the sequence that is complementary to basis (i).Preferably, this product comprises different nucleic acid, and described nucleic acid comprises and is complementary to as mentioned above at least 5,10,20,30,40,50,60 or more a plurality of different target molecules and/or for as mentioned above at least 5,10,20,30,40,50,60 or the specific sequence of more a plurality of different target molecules.Preferably, it comprises different nucleic acid, and described nucleic acid comprises one of group of being complementary to as the marker that limits among the application and/or to as one of the group of the marker that limits among the application specific sequence.

Another theme of the application relate to comprise be fixed with on it at least a, the product of the carrier of the preferred multiple nucleic acid that comprises the sequence that is selected from SEQ ID NO:1-437 or its functional analogue.Preferably, this product comprises at least 5,10,20,30,40,50,60 or the how different nucleic acid that is selected from above mentioned nucleic acid.In a special embodiment, this product comprises each of nucleic acid of the sequence of SEQ ID NO:1-376.

Another theme of the application relates to the carrier that comprises at least one part that is fixed with polypeptide on it, polypeptide is by the target nucleic acid coding that is defined as above, target nucleic acid promptly, comprise the sequence that is selected from SEQID NO:1-437, these sequences have at least 15, the nucleic acid of the specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, have nucleic acid or its functional analogue with aforementioned sequence complementary sequence.Preferably, this product comprises at least 5,10,20,30,40,50,60 or more a plurality of part of the not homopolypeptide that is selected from above mentioned polypeptide.

This carrier can be any solid or semi-solid carrier with one (flat or uneven) surface, allows the fixing of nucleic acid or polypeptide.Described carrier is for example slide, pearl, film, filter, post, plate etc.They can be made material such as glass, silica, plastics, fiber, metal, polymkeric substance, polystyrene, teflon etc. by any suitable material.Can utilize known technology or for nucleic acid, directly original position on the carrier synthetic with the surface of described immobilization of reagents at carrier on.Technique for fixing comprises passive absorption (Inouye et al., J.Clin.Microbiol.28 (1990) 1469), covalent attachment.Some technical descriptions are in for example WO90/03382, WO99/46403.Fixed reagent is placed with predetermined order on the carrier, with the detection and the evaluation of the complex body that promote to form, and places according to variable, adaptable density.

In one embodiment, product of the present invention comprise length between 5 to 100 bases, to one or more a) to c) in the specific synthetic oligonucleotide of target nucleic acid of qualification.

Product of the present invention generally includes the contrast molecule, is used for stdn and/or normalized result.

Another theme of the application relates to the test kit that comprises compartment or container, this compartment or container comprise at least one, preferred a plurality of comprise be complementary to and/or specificity in the nucleic acid of the sequence of the target nucleic acid that is defined as above, and/or as a kind of, the preferred multiple part of the target polypeptide of preceding qualification.Preferably, this product comprises at least 5,10,20,30,40,50,60 or a plurality of different nucleic acid and/or part that is selected from above mentioned nucleic acid and part.In a special embodiment, this product comprise SEQ ID NO:1-437 sequence nucleic acid each or for the part of each the target polypeptide in the target polypeptide that is defined as above.This test kit can also comprise and be used for hybridization or immunoreactive reagent and alternatively, contrast and/or directions for use.

Another theme of the present invention relates to the product that is defined as above or the application of test kit, is used to detect mammalian subject, cancer, especially mammary cancer among the preferred human individual.

Another theme of the present invention relates to the nucleic acid with the sequence that is selected from SEQ ID NO:1-437, perhaps comprise at least 15, its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases perhaps has the functional analogue with nucleic acid or these nucleic acid of its complementary sequence.The invention still further relates to the clone or the expression vector that comprise these nucleic acid, and any reconstitution cell that comprises described carrier or nucleic acid.

Another theme of the present invention relates to and comprises the sequence that is selected from SEQ ID NO:1-437 or comprise at least 15, the nucleic acid of the specific fragment of these sequences of preferred at least 16,17,18,19,20,25 or 30 continuous bases, perhaps has nucleic acid with its complementary sequence, or the application of the functional analogue of these nucleic acid, be used for detecting the cancer of (vitro detection basically) mammalian subject.

In a special embodiment of embodiments of the present invention, blood sample picks up from the Mammals that will detect.This blood sample can be processed alternatively, so that nucleic acid more can be approaching, and they is labeled.Whether product that described nucleic acid is applied to be defined as above and mensuration hybridization collection of illustrative plates exist cancer in the Mammals of permission diagnostic detection subsequently.Method of the present invention is simple, can externally carry out and allow early detection cancer from blood sample.

Obviously, any technology that is equal to can be used within the scope of the invention to measure existing of target molecule.

Other aspects and advantages of the present invention can become apparent after reading the following examples, and described embodiment is considered to schematically and is nonrestrictive.

Description of drawings

Fig. 1: utilize 10 pairs half sex change (semi-degenerative) primer to being derived from the pcr amplification of n ° of 1 atlas analysis (profilage) cDNAs DATAS (PBMN).The DATAS atlas analysis carries out (cancer of Phase I and II and contrast, and the cancer of contrast and Phase I and II) on both direction.Comprise the positive control that utilizes the cDNA that is derived from the HepG2 cell.

Fig. 2: utilize the pcr amplification of 10 pairs half sex change primers to the cDNAs DATAS that is derived from n ° of 2 atlas analysis (PBMO).The DATAS atlas analysis carries out (Phase I on both direction; The cancer of IV and contrast, and contrast and Phase I﹠amp; The cancer of IV).Comprise the positive control that utilizes the cDNA that is derived from the HepG2 cell.

Fig. 3: utilize the pcr amplification of 10 pairs half sex change primers to the cDNAs DATAS that is derived from n ° of 3 atlas analysis (PBMP).The DATAS atlas analysis carries out (cancer and the contrast in stage 1 to IV, and contrast and Phase I are to the cancer of IV) on both direction.Comprise the positive control that utilizes the cDNA that is derived from the HepG2 cell.

Fig. 4: the specificity configuration of probe, the expression that is used to measure the variant (variant, spliceosome) that produces by alternative splicing.Probe A is common (shared) for two kinds of hypotypes (isoforme), measures the expression of two kinds of variants.Probe B, for additional (additionelle) sequence specific of elongated (isoforme longue), probe C and D, connection (jonction) sequence specific around the appended sequence hereto, the expression of measuring elongated.Probe E is for connection (point) the performance specificity of the shortage that is derived from appended sequence, the expression of measuring short type.

Fig. 5:The definition of " target " sequence.Each 15 Nucleotide and Nucleotide up to 500 that is connected any side of (jonction) is hunted down for common (commune) sequence of appended sequence and upstream.

Fig. 6:" target " sequence and related data.The description of post: identify number: the evaluation of montage incident number; Describe: the type of montage incident; Elongated: the accession number of elongated; Short type: the accession number of short type; Target A is to E: target A is to the sequence of E; Long: the size of sequence in the post of front.

Fig. 7: utilize 100 oligonucleotide that (clustering hi é rarchique) assembled in 37 contrasts and 55 patients' layering.

Embodiment

1. the feature of biological sample

Embodiment given below is from 92 blood samples (the 5ml whole blood is gathered in two PaxGene pipes) initial preparation.These sample set 37 blood sample and 55 samples from the patient who suffers from Phase I/II mammary cancer (CI/II) from normal healthy controls patient (H obtains from Etablissement Francais du Sang).

2. extract total RNA from blood sample

Blood sample directly is collected in PAXGene ^TMIn the Blood RNA pipe (PreAnalytix, Hombrechtikon, CH).After stage,, described pipe was placed room temperature following 4 hours at blood sampling, be stored in-20 ℃ of extractions subsequently up to biomaterial for obtaining total lysis.More accurately, in this scheme, utilize PAXGene Blood RNA

Test kit (PreAnalytix) is followed manufacturer's explanation, extracts total RNA.In brief, with those test tubes centrifugal (15 minutes, 3000g) to obtain the residue (culot, throw out) of nucleic acid.Wash this residue and it is dissolved in and comprise the damping fluid (10 minutes, 55 ℃) that is used for the required Proteinase K of digestible protein.Carry out further centrifugal (5 minutes, 19 000g) to remove cell debris and to add ethanol to optimize the rigid condition of nucleic acid.Total RNA is fixed on the PAXgene RNA column spinner by specificity, and before its wash-out, and (Qiagen, Hilden Germany) carry out the digestion of contaminating dna to utilize the DNA enzyme group that do not contain the RNA enzyme.In AGILENT 2100 biological analysers (Agilent Technologies, Waldbronn, Germany) quality of last analyzing total RNA.

3.DATAS atlas analysis experiment

Carry out between " DATAS " atlas analysis group below of three series:

DATAS n ° 1: breast carcinoma of early stage (Phase I and II) and control group (PBMN research)

DATAS n ° 2: advanced breast cancer (Phase I and IV) and control group (PBMO research)

DATAS n ° 3: mammary cancer (Phase I, II, III and IV) and control group (PMNP research)

DATAS is a gene expression atlas analytical technology between two samples, and it can be characterized in the qualitative difference alternative splicing of messenger RNA(mRNA) (as those messenger RNA(mRNA)s that produce by alternative splicing) level.This patented technology is described in patent US6, in 251,590.

Utilize above-mentioned PAXgene system (PreAnalytix) from blood sample, to isolate total RNA corresponding to two kinds of situations (a kind of normal (mN), (mP) of another kind of morbid state).Utilize reversed transcriptive enzyme (RT) (Invitrogen) and biotinylated oligonucleotide oligodT25 (Invitrogen) these RNA (every group 50 μ g) are converted into complementary DNA (cN) and (cP).The sample of contributing 50 μ g/ group is shown in Table A in F.

In liquid phase, produce hybrid mN/cP and cN/mP subsequently.Behind the ethanol sedimentation of mN and cP and cN and mP, throw out is dissolved in the hybridization solution that comprises 80% methane amide and 0.1% SDS of 30 μ l, 40 ℃ of night incubation.Utilize streptavidin magnetic bead (Dynal) to catch heteroduplex subsequently.The pearl that magnet is used for holding tube during flushing operation.Pearl/heteroduplex is dissolved in subsequently in the RNA enzyme H damping fluid of 50 μ l and with RNA enzyme H (Invitrogen) and hatched 30 minutes at 37 ℃.Use the back at other magnet and collect supernatant liquor.Residual DNA is removed in effect by DNA enzyme I (Ambion).Behind enzyme deactivation, the RNA fragment is by ethanol sedimentation and be dissolved in being supplemented with in the DPEC treated water of RNAseout (Ambion).Utilize random hexamer oligonucleotide reverse transcription (reverse transcription TaqMan test kit, Applied Biosystem) RNA fragment subsequently.Utilize the complementary DNA of half-(semi-degenerative) primer PCR amplification acquisition of degenerating subsequently.Usually use 10 pairs of primers.The amplicon that obtains can be by electrophoresis on sepharose visual (Fig. 1,2 and 3).Heterogeneous amplification colony can be observed its type and intensity changes according to primer and specimen in use.

These amplifications group is cloned into TOPO TA (Invitrogen) cloning vector and is used for transforming at the bacterial strain of competitive E.Coli bacterium (Invitrogen).Bacterium colony is transferred to 96 orifice plates and incubated overnight in adding the 2XTY substratum of Ampicillin Trihydrate.Use glycerin preparation (50%) to store subsequently.Common 96 orifice plates are handled by every pair of primer in one of both direction.This has provided the bacterium colony by the 96x10x2=1920 of characterization.

1728 clones are used for DATAS n ° of 1 atlas analysis by order-checking, and 1920 quilts are cloned and checked order and are used for DATAS n ° of 2 atlas analysis, and 1920 quilts are cloned and checked order and are used for DATAS n ° of 3 atlas analysis.

4. biology-computerize analysis

Table G has summed up the quantity of the clone of characterization in three atlas analysis storehouses.Qualitative clone for " separately thing " means that this clone's sequence is only identified once and do not have other clone to comprise this sequence in the storehouse." bunch " refer to clone's group that its sequence overlaps.

Therefore described three DATAS atlas analysis produce 1741 nonredundancy clones.

Table G: the clone's who in three DATAS storehouses, obtains feature

The DATAS storehouse

The cancer vs. contrast of Phase I ﹠ II

The cancer vs. contrast of Phase I ﹠IV

The cancer vs. contrast in all stages

Gathering on three storehouses

Clone's quantity of order-checking	1728	1920	1920	5568
Clone's quantity of order-checking	1728	1920	1920	5568	" bunch " quantity	267	347	303	886
The quantity of " thing separately "	239	362	440	855	" bunch " quantity	267	347	303	886
The quantity of " thing separately "	239	362	440	855	Nonredundancy clone's quantity in the storehouse	506	709	743	1741 ^(*)

1741 clones are carried out biology-computerize analysis, to identify gene that they are relevant and known montage incident in the public library of corresponding nucleic.

Therefore, 1741 DATAS clones can interrelate with 1170 different genes, and some non-overlapping DATAS fragments are relevant with the different zones of same gene.

5. be used for the selection and the design of the target incident of microarray configuration

The detection of the expression of the splice variant of each microarray and quantification need be used specific probe configurations.Any contrast messenger RNA(mRNA)/splice variant is to being modeled as elongated/weak point type (Fig. 4).Therefore, relevant with exon skipping splice variant (or splicing variants) will be with respect to the short type that contrasts variant (variant).The splice variant that comprises the reservation of novel exon or intron will be the elongated with respect to the contrast variant.Other alternative splicing incident (use of 5 ' or 3 ' cryptic splice site) can also be in a similar fashion by modeling.

Need the group of the probe of measurement splice variant expression also to be shown in Table 4.This group comprises two routines " exon " probe A and B and three exon-exon types or exon-include linking probe C, D and the E of subtype.Probe A measures the expression of two hypotypes, and probe B, C and D measure the expression of elongated, and probe E measures the expression of short type.

For the design of all these probes, corresponding to must being identified of the segmental montage incident of DATAS, identify " target " zone subsequently, be designed from this zone probe.Target sequence corresponding to linking probe C, D and E is limited by 30 Nucleotide by length, 15 Nucleotide of every side of connection.Therefore can be by 10/15,11/14,12/13,13/12, any connection of probe " covering " of 25 Nucleotide of 14/11et 15/10 (mark/represent connecting zone) type.

To the constraint of " exon " probe A and B too hardly not.For elongated (sequence 2 among Fig. 4) the special appended sequence and the common sequences of splice site upstream, be defined for these and have the target sequence that top limit is the probe of 500 Nucleotide, so that sequence can surpass this size.The definition of target sequence is summarized among Fig. 5.

Therefore, be used for identifying corresponding to 1170 genes of 1741 DATAS clone, for wherein each, the cDNAs et ESTs that keeps in the public database of sequence has in the sequence difference (source of montage incident) qualitatively potentially.Selected incident is positioned at from DATAS segmental 5 ' or 3 ' holds less than 100 Nucleotide.

2180 incidents therefore can be selected and be listed in the Excel file, and a part of wherein describing extraction data provides in Fig. 6.The data of the incident that these are used to provide comprise: the accession number of the evaluation of incident number, event type, length and short type, target sequence A are to the size of E and these target sequences.

Strict quality is used to limit these sequences.Contrasted RNA RefSeq or proofreaied and correct by them about the fuzzy of some Nucleotide from the replacement of the corresponding nucleotide of genomic dna.All target sequences are rearranged to determine that they belong to suitable short type or elongated.

6. the design of probe and chip

In order to measure the expression of previously described 2108 incidents, designed the DNA chip of customization.On this chip, each incident is by its 5 target sequence A-E characterization.For each sequence A and B, designed the probe of 11 pairs of 25 Nucleotide, and the target sequence of Type C, D or E is with 6 pairs of probe in detecting with 25 Nucleotide.

The right implication of probe is: first probe, and itself and one of cDNA that is derived from target transcript hybridization (being called the PM probe that is used for mating fully) fully, and second probe, except mispairing in probe core, identical with first probe (that is the MM probe that, is used for mispairing).Each MM probe is used to estimate background noise (the Affymetrix technical note " Statistical AlgorithmsReference Guide " corresponding to the hybridization between two nucleotide fragments of incomplementarity sequence; Lipshutz, et al (1999) Nat.Genet.1Suppl., 20-24).If it is impossible being used for the design of at least 6 probes of sequence A and B or the design that is used at least 4 probes of C, D and E, these sequences do not appear on the chip of customization.Described position can be obtained by the sequence of the low-complexity that comprises repeating structure or " hair fastener " structure (continuous or discrete).Also cause the eliminating of these probes for the sequence size that is less than 30 Nucleotide of A-E.Only high quality, be oriented in sequence on 5 '-3 ' direction and be used for the probe design of carrying out according to the Affymetrix rules.

7.cRNA synthetic, obtain and mark cDNA and fracture

In order to analyze expression according to target transcript of the present invention, be included in complementary DNA (cDNA) as the mRNA among total RNA of top purifying, by using Klenow 3 '-5 '-exonuclease, the SuperScript II ThermoScript II (Invitrogen) of 100 units, the RNA enzyme inhibitors H Superase-IN (Ambion of 10 units, Huntigdon, UK) and " at random " primer (the RP-T7-primer that comprises the T7 promotor of 200pmol, Eurogenetec, Seraing, Belgium) the total RNA from 400ng obtains.

Thus obtained all cDNA experience in-vitro transcription subsequently, utilize MEGAscriptT7 test kit (Ambion) to carry out 16 hours at 37 ℃.Thus obtained cRNA uses RNeasy Mini test kit (Invitrogen) purifying on post subsequently, utilizes the quality of the cRNA of AGILENT2100 biological analyser analysis acquisition.Quantize the cRNA of purifying subsequently by spectrophotometry, the solution of cRNA is adjusted to the concentration of 1.24 μ g/ μ l cRNA.The cRNA of 26 micrograms is assigned to go into two Eppendorf pipes subsequently, and 3 μ g " at random " primers are added in each pipe.With the inhibitor of the RNA enzyme H of the SuperScriptII (Invitrogen) of 800 units and 10 units, in the presence of the Klenow enzyme, carried out reverse transcription 1 hour at 37 ℃.The double-stranded cDNA that obtains from this method utilizes QIAquickPCR purification kit (Qiagen) to be purified and to be quantized by spectrophotometry subsequently.Be distributed in 3 Eppendorf pipes 16 microgram cRNA subsequently with the DNA enzyme I of every pipe 0.6 unit 37 ℃ of fractures 10 minutes.Utilize the effect of 2100 biological analysers (Agilent) check fracture.Every subsequently microgram cDNA utilizes terminal enzyme (DNA) (the RocheMolecular Biochemicals of 330 units, Meylan, France) and 1 μ l dna marker reagent (DLR-1a, 5mM) [Affymetrix] uses vitamin H to reach 60 minutes at the cDNA of 37 ℃ of marks fractures.

Whole standard crossing schemes that are suitable for 11 μ m chips of finally following of the cDNA of fracture and mark are upward hybridized at customization (à facon) DNA chip (being called " A520138F ", referring to embodiment 6).

8. be used for from the proof of the expression map of blood sample diagnosing mammary cancer

8.1. can distinguish control patients (S) and suffer from the transcribing of patient of Phase I/II cancer The proof of the expression map of body

The expression of the variant of about 2000 RNA (representing about 800 genes) is analyzed and be compared between S patient and Phase I/II cancer patients.For this purpose, cDNA that the 16 μ g that are derived from each sample are cracked add hybridization buffer (Affymetrix) and with this solution of 200 μ l on expression chip 50 ℃ of contacts 16 hours.In order to write down best hybridization and flushing performance level, the RNA and the oligonucleotide (oligo B2) of serving as the biotinylation (bioB, bioC, bioD and cre) of " contrast " are also included within the hybridization buffer.Behind hybridization step, the biotinylated cDNA of hybridizing on chip is developed and utilizes anti--streptavidin antibody this signal that increases by utilizing streptavidin-phycoerythrin solution.Hybridize in (Affymetrix) at " gene chip hybridization stove (GeneChip Hybridisation oven) ", and what be right after is the EukGE-WS2 scheme of Affymetric scheme.Wash and development step on (Affymetrix) at " Fluidics Station 450 ".Under Affymetrix G3000 GeneArray scanner, when being 1.5 microns, resolving power analyzes each chip subsequently, to determine the position in the hybridization zone on the chip.This scanner can utilize the epifluorescence microscope technology for detection to be excited the signal of back by the fluorescence molecule emission by argon laser.Therefore, for each position, the amount of the signal of acquisition and fixed cDNA is proportional.(GCOS 1.2, Affymetrix) analytical signal to utilize gene chip function software (GeneChipOperating Software) subsequently.

Owing to use the variation that different chips obtains, utilize " Bioconductor " execution of instrument standardized method in order to prevent, this instrument can be coordinated being evenly distributed for the raw data of each chip acquisition.The result who obtains on a chip can compare with the result who obtains on another chip subsequently.GCOS 1.2 softwares can comprise that also statistic algorithm is to determine still expression of transcription expression.

From 6242 probe groups of chip, represent about 2000 transcripts, the contriver has selected the associated retroviral thing, and its development with mammary cancer is relevant.Got rid of those expression level is too low on most of chips transcript and those between different chips, do not show any big variation transcript (Li et al, 2001, Bioinformatics, 17:1131-1142).Utilization be called " random forest algorithm " ( Http:// ligarto.org/rdiaz/Papers/jornadas.bioinfo.randomForest.p df) data mining technology distinguish the research of the group of the transcript between EFS and C I/II (being Phase I/II cancer) patient's the group.Except the data analysis (it is the analysis of multivariate type) that utilizes the random forest algorithm, so-called " single argument " analyzes those transcripts that are used to also identify that difference is expressed between EFS and CI/II patient.This analysis that is called SAM (significance analysis of microarray, Significance Analysis of Microarrays) prevents the bias of being introduced by the gene with low variability mainly based on the improvement version of Student ' s t check.Adopt this method, can control the per-cent of false positive gene in the univariate analysis.

Adopt all above-mentioned analyses, can prove first group (referring to table 1, SEQ ID Nos:1-318) comprising according to the transcript of 318 associated retroviral things of the present invention.Raising or reduction in the expression of observed each transcript in the healthy patients of comparing with C I/II patient (S) in table 1, have been provided.

The contriver after deliberation express 318 transcripts the time to obtain expression map.Utilize the random forest method, 90% patient is correctly classified.More accurately, 51 quilts among in 37 contrasts 32 and 55 patients are correctly classified, and it is corresponding to 92.7% sensitivity and 86.4% specificity.

Except the analysis to 92 initial sample, carry out other analysis to verify the dependency of the signal of identifying above: 5 normal healthy controls and 16 Phase I/II patient with breast cancers' independently group experiences blind method research.Independently Zu analysis is one of best approach (referring to The SMRS working group, NatBiotech 2005,7:p.833-838) with the predictor of the signal that detects gene or transcript.Based on sequence SEQ ID Nos:1-318, the random forest algorithm correctly sorts out 13 patients (86% classification) among 5 contrasts in 5 and 16.

By other hybridization and analysis experiment, in 188 patients, 119 other targets are identified, corresponding to sequence SEQ ID NO:319-437 (referring to table 1).

8.2.100 the evaluation of the predictability group of individual marker(group 7)

The contriver expresses when also having studied 100 transcripts of the nucleotide sequence that is selected from the sequence that table 2 provides, to obtain expression map.Utilize the random forest method, 89% patient is by correct classification.More accurately, in 37 contrasts among 31 and 55 patients 51 quilts correctly classify, it is corresponding to 92.7% sensitivity and 83.7% specificity.

These results are by other analytical technology, and hierarchical cluster analysis obtains confirming.In the analysis of this non-supervision, a contrast itself is arranged in patient (in the left side of red dotted line, referring to Fig. 7), and 10 patients appear at (on the right side of red dotted line) in the normal healthy controls.Fig. 7 shows utilization and suffers from the patient of breast carcinoma of early stage (C I/II is also referred to as D) and the hierarchical cluster analysis of the blood sample that 37 contrasts (healthy donors) obtain by 100 expression of gene of Algorithm Analysis evaluation from 55.The hierarchical cluster functional organization of Spotfire software the gene of (en lignes) among the C I/II patient and contrast and line in the hurdle so that be illustrated in patient or the gene that the consecutive position has comparable expression map.Pearson ' the s relation conefficient index similarity that acts on gene and patient.Described result is corresponding to the normalized Affymetrix fluorescence level of " bioconductor " instrument of using.In order to consider the formation differential expression between the gene, make each expression of gene level normalization by the alignment variable (variablecentre r é duite) of calculating yojan.Low expression level illustrates with white, and medium level illustrates with grey, and the strongest level illustrates with black.Dendrogram ramose height has been pointed out the index similarity between the expression map.

Except analysis, also carry out the cognation of other analysis: in 5 contrasts (healthy person) and 16 Phase I/II patient with breast cancers' independently group, carry out blind method research with the signal that confirms to identify above to 92 initial sample.Based on the highest by 100, random forest algorithm 14 patients (90% classification) among 5 contrasts in 5 and 16 that correctly classified.

Have in the combination of 100 marker gene at this, the littler group of contriver's proof also can be carried out the differentiation between control patients and the patient with breast cancer, as describing in the following embodiments.

8.3.66 the evaluation of the predictability group of individual marker(group 6)

The contriver has proved the combination of 66 markers, based on sequence SEQ ID Nos:5,7,13,14,16-20,23-28,47,51-55,58,64,69,80,81,88-90,116,121,125,137,139,145,148,158,160,161,164,188-191,208,222,225,228,229,236,240,242,245,248,252,280,281,284,290,298-300 and 309-312 (referring to table 3).Adopt this combination, classification that can be correct surpasses 80% sample.

8.4.53 the evaluation of the predictability group of individual marker(group 5)

The contriver has also proved the combination of 53 markers, based on sequence SEQ ID Nos:7,13,14,16-19,23-28,47,51-55,58,69,80,81,89,116,121,125,137,139,145,148,158,160,161,164,189,190,225,228,229,240,245,248,252,280,281,284,290,298-300,310 and 312.Adopt this combination, classification that can be correct surpasses 80% sample.

8.5.42 the evaluation of the predictability group of individual marker(group 4)

The contriver has also proved the combination of 42 markers, based on sequence SEQ ID Nos:13,16-19,23,26-28,47,51-55,58,69,80,81,89,116,121,125,145,148,158,160,161,164,189,190,225,229,240,248,280,281,284,299,300,310 and 312.Adopt this combination, also classification that can be correct surpasses 80% sample.

8.6.22 the evaluation of the predictability group of individual marker(group 3)

The contriver has proved the combination of 22 markers, based on sequence SEQ ID Nos:18,19,23,26,27,51,52,53,54,55,69,80,125,145,148,161,188,225,228,240,280 and 312.Adopt this combination, also classification that can be correct surpasses 76% sample.

8.7.18 the evaluation of the predictability group of individual marker(group 2)

The contriver has also proved the combination of 18 markers, based on the target sequence SEQ ID Nos:18,19,23,26,51,52,53,54,55,69,80,125,145,148,225,228,240 and 312 that provides in the table 3.Adopt this combination, classification that can be correct surpasses 76% sample.

This confirms that the expression analysis of these 18 markers is that difference is carried the patient of high risk recurrence and had the patient's of low-risk recurrence good tool.The use of the group of the gene that reduces is particularly suitable for obtaining to detect and forecasting tool.The expression analysis of ten markers does not need the customization manufacturing of DNA chip, and can utilize PCR or NASBA technology or low density chip directly to implement, and it has to simplify implements and quite economic advantage.

8.8. the evaluation of the predictability group of marker(group 1 and 7-9)

The contriver has proved that the combination based on 100,104 and 110 markers of target sequence SEQ ID Nos:1-437 can detect the existence of mammary cancer in the individuality.These groups are described in the table 4.Group 1 comprises and group 7-9 common full sequence.

8.9. The evaluation of the predictability group of 90 markers(group 10 and 11)

By other hybridization and the analysis experiment carried out in 188 patients, the contriver has proved the combination of 90 markers, based on sequence SEQ ID Nos:11; 12; 18; 23; 51-53; 59; 60; 105; 148; 150; 191; 195; 206; 225-227; 229; 280; 281; 308-310; 312; 327; 343; 360; 367; 377-437 (referring to table 4).

Utilize this combination, the sample of 86.1% the breast carcinoma of early stage of can correctly classifying.Gene in this group is special for breast carcinoma of early stage.In other test, on custom chip, analyze 19 blood samples picking up from the women that suffers from colorectal carcinoma as mentioned above and from 20 blood samples of the women who suffers from metastatic breast cancer.For each of this two diseases, only 3 patients have showed the similar expression that is included in 90 markers in the group 10.84.2% therefore, (in 19 16) colorectal carcinoma and 85% (in 20 17) metastatic breast cancer is obscured with breast carcinoma of early stage.

Group 11 comprises and all group 1-10 common all sequences, that is, is included in the nucleic acid (referring to table 4) of the sequence of SEQ ID No:23,52,53,148 and 225 expressions.

8.10. the evaluation of immunoreactive signal cascade

The analysis of the different genes of identifying among the present invention (it is expressed among the patient and changes) shows that they belong to the gene family that relates in cell signal path or the common regulation mechanism.Especially, numerous genes of in immunne response (congenital or obtain), in the used signal cascade and especially in the information transduction that the stimulation by TLR causes, in the secretion of cytokine or lymphocyte-T activation, relating to of this analysis revealed.

Therefore the applicant defines the group that relates to or participate in the gene of immunoreactive signal path, and it is formed for the target of being paid close attention to of cancer detection.These groups provide in table 5 and 6.

Table A: the selection that is used for DATAS n ° 1 (PBMN) is used for the sample of breast carcinoma of early stage group

Sample	Clinical stage	Used amount (ug)
Sample	Clinical stage	Used amount (ug)	D104	I	10.0
D105	I	5.0	D104	I	10.0
D105	I	5.0	D106	I	2.0
D111	I	2.0	D106	I	2.0
D111	I	2.0	D114	I	3.0
D118	I	5.0	D114	I	3.0
D118	I	5.0	D123	I	6.0
D117	II	2.0	D123	I	6.0
D117	II	2.0	D121	II	5.0
D130	II	10.0	D121	II	5.0

Table B: the selection that is used for DATAS n ° 1 (PBMN) is used for the sample of control group

Sample	Clinical stage	Used amount (ug)
Sample	Clinical stage	Used amount (ug)	D1	DFS>5	1.66
D3	DFS>5	1.66	D1	DFS>5	1.66
D3	DFS>5	1.66	D9	DFS>5	1.66
D10	DFS>5	1.66	D9	DFS>5	1.66
D10	DFS>5	1.66	D17	DFS>5	1.66
D28	DFS>5	1.66	D17	DFS>5	1.66
D28	DFS>5	1.66	D36	DFS>5	1.66
D63	DFS>5	1.66	D36	DFS>5	1.66
D63	DFS>5	1.66	D75	DFS>5	1.66
D76	DFS>5	1.66	D75	DFS>5	1.66
D76	DFS>5	1.66	D11	DFS<5	1.66
D14	DFS<5	1.66	D11	DFS<5	1.66
D14	DFS<5	1.66	D15	DFS<5	1.66
D16	DFS<5	1.66	D15	DFS<5	1.66
D16	DFS<5	1.66	D27	DFS<5	1.66
D31	DFS<5	1.66	D27	DFS<5	1.66
D31	DFS<5	1.66	D41	DFS<5	1.66
D66	DFS<5	1.66	D41	DFS<5	1.66
D66	DFS<5	1.66	D102	DFS<5	1.66

D103	DFS<5	1.66
D103	DFS<5	1.66	D67	Optimum	1.66
D69	Optimum	1.66	D67	Optimum	1.66
D69	Optimum	1.66	D70	Optimum	1.66
D71	Optimum	1.66	D70	Optimum	1.66
D71	Optimum	1.66	D72	Optimum	1.66
D73	Optimum	1.66	D72	Optimum	1.66
D73	Optimum	1.66	D74	Optimum	1.66
D79	Optimum	1.66	D74	Optimum	1.66
D79	Optimum	1.66	D115	Optimum	1.66
D125	Optimum	1.66	D115	Optimum	1.66

Table C: the selection that is used for DATAS n ° 2 (PBMO) is used for the sample of advanced breast cancer group

Sample	Clinical stage	Used amount (ug)
Sample	Clinical stage	Used amount (ug)	D55	S III	3.33
D59	S III	3.33	D55	S III	3.33
D59	S III	3.33	D90	S III	3.33
D134	S III	3.33	D90	S III	3.33
D134	S III	3.33	D168	S III	3.33
D178	S III	3.33	D168	S III	3.33
D178	S III	3.33	D126	S III	3.33
D132	S III	3.33	D126	S III	3.33
D132	S III	3.33	D91	S IV	3.33
D92	S IV	3.33	D91	S IV	3.33
D92	S IV	3.33	D101	S IV	3.33
D138	S IV	3.33	D101	S IV	3.33
D138	S IV	3.33	D161	S IV	3.33
D170	S IV	3.33	D161	S IV	3.33
D170	S IV	3.33	D99	S IV	3.33

Table D: the selection that is used for DATAS n ° 2 (PBMO) is used for the sample of control group

Sample	Clinical stage	Used amount (ug)
Sample	Clinical stage	Used amount (ug)	D1	DFS>5	1.66
D3	DFS>5	1.66	D1	DFS>5	1.66
D3	DFS>5	1.66	D9	DFS>5	1.66
D10	DFS>5	1.66	D9	DFS>5	1.66
D10	DFS>5	1.66	D17	DFS>5	1.66
D28	DFS>5	1.66	D17	DFS>5	1.66
D28	DFS>5	1.66	D36	DFS>5	1.66

D63	DFS>5	1.66
D63	DFS>5	1.66	D75	DFS>5	1.66
D76	DFS>5	1.66	D75	DFS>5	1.66
D76	DFS>5	1.66	D11	DFS<5	1.66
D14	DFS<5	1.66	D11	DFS<5	1.66
D14	DFS<5	1.66	D15	DFS<5	1.66
D16	DFS<5	1.66	D15	DFS<5	1.66
D16	DFS<5	1.66	D27	DFS<5	1.66
D31	DFS<5	1.66	D27	DFS<5	1.66
D31	DFS<5	1.66	D41	DFS<5	1.66
D66	DFS<5	1.66	D41	DFS<5	1.66
D66	DFS<5	1.66	D102	DFS<5	1.66
D103	DFS<5	1.66	D102	DFS<5	1.66
D103	DFS<5	1.66	D67	Optimum	1.66
D69	Optimum	1.66	D67	Optimum	1.66
D69	Optimum	1.66	D70	Optimum	1.66
D71	Optimum	1.66	D70	Optimum	1.66
D71	Optimum	1.66	D72	Optimum	1.66
D73	Optimum	1.66	D72	Optimum	1.66
D73	Optimum	1.66	D74	Optimum	1.66
D79	Optimum	1.66	D74	Optimum	1.66
D79	Optimum	1.66	D115	Optimum	1.66
D125	Optimum	1.66	D115	Optimum	1.66

Table E: the selection that is used for DATAS n ° 3 (PBMP) is used for the sample of the mammary cancer group in all stages

Sample	Clinical stage	Used amount (ug)
Sample	Clinical stage	Used amount (ug)	D91	S IV	1.3
D92	S IV	1.3	D91	S IV	1.3
D92	S IV	1.3	D101	S IV	1.3
D138	S IV	1.3	D101	S IV	1.3
D138	S IV	1.3	D161	S IV	1.3
D170	S IV	1.3	D161	S IV	1.3
D170	S IV	1.3	D99	S IV	1.3
D195	S IV	1.3	D99	S IV	1.3
D195	S IV	1.3	D197	S IV	1.3
D205	S IV	1.3	D197	S IV	1.3
D205	S IV	1.3	D55	S III	1.3
D59	S III	1.3	D55	S III	1.3
D59	S III	1.3	D90	S III	1.3
D134	S III	1.3	D90	S III	1.3

D168	S III	1.3
D168	S III	1.3	D178	S III	1.3
D126	S III	1.3	D178	S III	1.3
D126	S III	1.3	D132	S III	1.3
D135	S III	1.3	D132	S III	1.3
D135	S III	1.3	D185	S III	1.3
D108	S II	1.3	D185	S III	1.3
D108	S II	1.3	D109	S II	1.3
D148	S II	1.3	D109	S II	1.3
D148	S II	1.3	D156	S II	1.3
D160	S II	1.3	D156	S II	1.3
D160	S II	1.3	D162	S II	1.3
D163	S II	1.3	D162	S II	1.3
D163	S II	1.3	D166	S II	1.3
D167	S II	1.3	D166	S II	1.3
D167	S II	1.3	D172	S II	1.3
D112	S I	1.3	D172	S II	1.3
D112	S I	1.3	D120	S I	1.3
D122	S I	1.3	D120	S I	1.3
D122	S I	1.3	D127	S I	1.3
D131	S I	1.3	D127	S I	1.3
D131	S I	1.3	D145	S I	1.3
D147	S I	1.3	D145	S I	1.3
D147	S I	1.3	D153	S I	1.3
D173	S I	1.3	D153	S I	1.3
D173	S I	1.3	D176	S I	1.3

Table F: the selection that is used for DATAS n ° 3 (PBMP) is used for the sample of control group

Sample	Clinical stage	Used amount (ug)
Sample	Clinical stage	Used amount (ug)	D1	DFS>5	1.66
D3	DFS>5	1.66	D1	DFS>5	1.66
D3	DFS>5	1.66	D9	DFS>5	1.66
D10	DFS>5	1.66	D9	DFS>5	1.66
D10	DFS>5	1.66	D17	DFS>5	1.66
D28	DFS>5	1.66	D17	DFS>5	1.66
D28	DFS>5	1.66	D36	DFS>5	1.66
D63	DFS>5	1.66	D36	DFS>5	1.66
D63	DFS>5	1.66	D75	DFS>5	1.66
D76	DFS>5	1.66	D75	DFS>5	1.66
D76	DFS>5	1.66	D11	DFS<5	1.66
D14	DFS<5	1.66	D11	DFS<5	1.66
D14	DFS<5	1.66	D15	DFS<5	1.66
D16	DFS<5	1.66	D15	DFS<5	1.66
D16	DFS<5	1.66	D27	DFS<5	1.66

D31	DFS<5	1.66
D31	DFS<5	1.66	D41	DFS<5	1.66
D66	DFS<5	1.66	D41	DFS<5	1.66
D66	DFS<5	1.66	D102	DFS<5	1.66
D103	DFS<5	1.66	D102	DFS<5	1.66
D103	DFS<5	1.66	D67	Optimum	1.66
D69	Optimum	1.66	D67	Optimum	1.66
D69	Optimum	1.66	D70	Optimum	1.66
D71	Optimum	1.66	D70	Optimum	1.66
D71	Optimum	1.66	D72	Optimum	1.66
D73	Optimum	1.66	D72	Optimum	1.66
D73	Optimum	1.66	D74	Optimum	1.66
D79	Optimum	1.66	D74	Optimum	1.66
D79	Optimum	1.66	D115	Optimum	1.66
D125	Optimum	1.66	D115	Optimum	1.66

The tabulation of 437 transcripts that table 1-differently expresses during breast cancer development.

SEQ ID N°	The description of sequence	Gene pool N ° (reference)	Gene pool N ° (variant)	C I/IIvs. health	Target sequence
SEQ ID N°	The description of sequence	Gene pool N ° (reference)	Gene pool N ° (variant)	C I/IIvs. health	Target sequence	1	N,O-Diacetylmuramidase	NM_000239.1	BE720647.1	0.8	ATTTATCCTGCAGTGcttt gctgcaagata
2	CDNA DKFZp451G151 (rich leucine tumor-necrosis factor glycoproteins kinases 2)	AL832453.2	BU634341.1	0.8	AAATAAAATATCAGGGATATGCTCCCCCTTGAGACTGAAGGAACTGAAGA TTTTAAACCTTAGTAAGAACCACATTTCATCCCTATCAGAGAACTTTCTTGAGGCTTGTCCTAAAGT GGAGAGTTTCAGTGCC A	1	N,O-Diacetylmuramidase	NM_000239.1	BE720647.1	0.8	ATTTATCCTGCAGTGcttt gctgcaagata
2		AL832453.2	BU634341.1	0.8		3	CDNA DKFZp451G151 (rich leucine tumor-necrosis factor glycoproteins kinases 2)	AL832453.2	BU634341.1	0.8	GAATGAATTTTCTTGctg ctatgcctttct
4	CDNA DKFZp667I093 (guanine-nucleotide-binding protein, γ 2)	AL832878.1	AI223156.1	0.8	TGCCAAGGAAGACCCC CTCCTGACCCCTGTTCCGGCTTCAGAAAACCCG TTTAGGGAGAAGAAGT TTTTCTGTGCCATCCTTTAA	3		AL832453.2	BU634341.1	0.8	GAATGAATTTTCTTGctg ctatgcctttct
4	CDNA DKFZp667I093 (guanine-nucleotide-binding protein, γ 2)	AL832878.1	AI223156.1	0.8		5	CDNA DKFZp667I093 (guanylic acid	AL832878.1	AI223156.1	0.7	TGCAGATTTGATGGCctactgtgaagcaca

	Conjugated protein, γ 2)
	Conjugated protein, γ 2)					6	Chemokine (C-C motif) acceptor 7	NM_001838.2	BI910219.1	0.8	GATGAGGTCACGGACG ATTACATCGGAGACAA CACCACAGTGGACTAC ACTTTGTTCGAGTCTTT GTGCTCCAAGAAGGAC GTGCGGAACTTTAAAG CCTGGTTCCTCCCTATC ATGTACTCCATCATTTG TTTCGTGGGCCTACTGG GCAATGGGCTGGTCGT GTTGACCTATATCTATTTCAAGAGGCTCAAGACC ATGACCGATACCTACCT GCTCAACCTGGCGGTG GCAGACATCCTCTTCCT CCTGACCCTTCCCTTCT GGGCCTACAGCGCGGC CAAGTCCTGGGTCTTC GGTGTCCACTTTTGCAA GCTCATCTTTGCCATCT ACAAGATGAGCTTCTTC AGTGGCATGCTCCTACT TCTTTGCATCAGCATTG ACCGCTACGTGGCCATC GTCCAGGCTGTCTCAG CTCACCGCCACCGTGC CCGCGTCCTTCTCATCA GCAAGCTGTCCTGTGT GGGCATCTGGATACTAG CCACAGTGCTCTCCATC CC
7	Homo sapiens's imagination protein D KFZp761A052	BC009917.1	BC028225.1	1.4	ATGAAGAAAAACAAAgt gcacagagacccg	6	Chemokine (C-C motif) acceptor 7	NM_001838.2	BI910219.1	0.8
7	Homo sapiens's imagination protein D KFZp761A052	BC009917.1	BC028225.1	1.4	ATGAAGAAAAACAAAgt gcacagagacccg	8	CDNA clones IMAGE:3920936 (high-density lipoprotein (HDL) conjugated protein (vigilin))	BC038965.1	N70893.1	1.2	AGGACAGCCCTGGGCagagatgaggcaggg
9	CDNA clones IMAGE:520760 5 (the constant γ 2 that immunoglobulin (Ig) is heavy (G2m marker))	BC040042.1	BI001496.1	1.3	TAATGCCAAGACAAAgccacgggaggagca	8		BC038965.1	N70893.1	1.2	AGGACAGCCCTGGGCagagatgaggcaggg
9		BC040042.1	BI001496.1	1.3	TAATGCCAAGACAAAgccacgggaggagca	10	CDNA clone IMAGE:520760 5 (the constant γ 2 that immunoglobulin (Ig) is heavy	BC040042.1	BF841656.1	1.3	CACAGGTGTACACCCTGCCCCCATCCCGGGAG GAGATGACCAAGAACCAGGTCAGCCTGACCTG

	(G2m marker))				CCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCCACGGCCGGCAAGCCCCCGCTCCCCAGGCTCTCGGGGTCGCGTGAGGATGCTTGGCACGTACCCCGTGTACATACTTCCCAGGCACCCAGCATGGAAATAAAGCACCCAGCGCT
	(G2m marker))					11	The microtubule monoxygenase of being correlated with transfers peaceful albumen and LIM structural domain to comprise 2	BC048206.1	AW015234.1	1.3	TCTCTCTTTCCAATCTTACGCCATGGCCATCAGTTCATTTCAGCCTTCCAGTGCTACACCCACTTCTTGGCTGACACACTTCTGCTCTAAGGTGACTGGTTTTCTTGCCAATTTTCAAAGAGTGGTACTAACCCCCAACCCGCTTTCCGCACCCCGTCCTCTCCGCCAGCAGTACTGGTTGCACTAACTGTGAGTGTCTTGCATACTGATGGACTCATTTGGTGGCATGGTTGGCTAACAGCATGGCGGGGGGTGTTCAGCTTGAGACCCATGCCTGTGTTCATTTCCCATGGAGCTGGCAGCCTGGTCTACCCCAAGTGCATGCCCCGCCTCTCCTCTCTCCCTTGGGTCTGCCTGCGTGCATGCTTCTCCAGTTGCGTCTGCGAAGCTACCTACTTTCTTGGGAGGGTCGACCTTGATCATGAAACAATACC

					ATGAGGGGGCCTCTGTCACCTTTGAAAAGAACACTTTTTGAGCAGCCTCAAAAAGCTCATACATAC
						12	The microtubule monoxygenase of being correlated with is transferred peaceful albumen and is contained LIM structural domain 2	BC048206.1	AF052170.1	1.4	TGGGAGGGTCGACCTTGATCATGAAACAATACCATGAGGGGGCCTCTGTCACCTTTGAAAAGAACACTTTTTGAGCAGCCTCAAAAAGCTCATACATACCAGCGCCTTCTTAAATTGGCTCTAATGTAAAGATTGTTAATGTCATTTATCAAAACCATAGGTGATTATTTGGAGGGATTTAAAAAACTTAATTACTCTCAGGCCTCATCCCAAGCTTGACACATGCTCTGTAGGTTGAACACATAATCACAAATATTCTAGCAAATGCTGCCTTGGTTGCAGCCTGCACTGTAGACCCAAGGGTTTTGCTGTGGCTCTTCTTATCTCCCTTGGCTCATAAAGCCCCAGATGATGCCAGAGCTTCAATTAGAGCCATCATCATCCCAGGCAGGGATATCTTTGAGAAATGACTCAGTTCAGCCCCAGGCCCCTGTGACTCTGCTTAAAGCACACATTTCTGCTGACTCTTGTACCTGGGGCAGCAGGATAATCACCAACAC
13	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	NM_001997.2	0.5	GTCGCCCAGATCAAGgctcatgtagcctca	12		BC048206.1	AF052170.1	1.4
13		NM_001997.2	NM_001997.2	0.5	GTCGCCCAGATCAAGgctcatgtagcctca	14	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	W17004.1	0.6	GGCCGCATGCTTGGAaggtaaagtccatgg
15	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AU098396.1	0.6	GTCGCCCAGAGCAAGgctcatgtagcctca	14		NM_001997.2	W17004.1	0.6	GGCCGCATGCTTGGAaggtaaagtccatgg
15		NM_001997.2	AU098396.1	0.6	GTCGCCCAGAGCAAGgctcatgtagcctca	16	The Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA063591.1	0.7	TGACCGGCCAGGAAAcggtcgcccagatca

	The cell homologue of middle fox sequence
	The cell homologue of middle fox sequence					17	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA094898.1	0.6	CAGGCCGCATGCTTGag gtaaagtccatgg
18	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA187006.1	0.7	AGGCCGCATGCTTGGag gtaaagtccatgg	17		NM_001997.2	AA094898.1	0.6	CAGGCCGCATGCTTGag gtaaagtccatgg
18		NM_001997.2	AA187006.1	0.7	AGGCCGCATGCTTGGag gtaaagtccatgg	19	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA225636.1	0.6	GGCCAGGAAACGGTCg cccagatcaaggta
20	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	BM820687.1	0.5	GGTCGCCCAGATCAAgc tcatgtagcctca	19		NM_001997.2	AA225636.1	0.6	GGCCAGGAAACGGTCg cccagatcaaggta
20		NM_001997.2	BM820687.1	0.5	GGTCGCCCAGATCAAgc tcatgtagcctca	21	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA491544.1	0.7	GCCGCATGCTTGGAGgta atgtccatggtt
22	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AV743892.1	0.5	GTCGCCCAGATCAAGgc tctgtagcctcac	21		NM_001997.2	AA491544.1	0.7	GCCGCATGCTTGGAGgta atgtccatggtt
22		NM_001997.2	AV743892.1	0.5	GTCGCCCAGATCAAGgc tctgtagcctcac	23	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	BU603086.1	0.6	GAAGTAGCAGGCCGCat gcttggaggtaaa
24	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	BF218408.1	0.6	AGGCCGATGCTTGGAgg taaagtccatggt	23		NM_001997.2	BU603086.1	0.6	GAAGTAGCAGGCCGCat gcttggaggtaaa
24		NM_001997.2	BF218408.1	0.6	AGGCCGATGCTTGGAgg taaagtccatggt	25	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AI499403.1	0.7	CCCGCATGCTTGGAGgta aagtccatggtt
26	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AW795076.1	0.6	CGGTCGCCCAGATCAag gctcatgtagcct	25		NM_001997.2	AI499403.1	0.7	CCCGCATGCTTGGAGgta aagtccatggtt
26		NM_001997.2	AW795076.1	0.6	CGGTCGCCCAGATCAag gctcatgtagcct	27	Finkel-Biskis-R eilly murine sarcoma virus	NM_001997.2	D52122.1	0.6	GGCCGCATGCTTGGggta aagtccatggtt

	The cell homologue of middle fox sequence
	The cell homologue of middle fox sequence					28	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	BE535673.1	0.6	GCCGCATGCTTGGAGgta acagtccatggt
29	Man-6-P acceptor (positively charged ion dependency)	NM_002355.2	CA430891.1	0.8	CGACACACCCTAGCGgacaattttaaccct	28		NM_001997.2	BE535673.1	0.6	GCCGCATGCTTGGAGgta acagtccatggt
29	Man-6-P acceptor (positively charged ion dependency)	NM_002355.2	CA430891.1	0.8	CGACACACCCTAGCGgacaattttaaccct	30	Mitogen-activated protein kinase kinase kinase 11	NM_002419.2	AK090614.1	1.2	TTCCATTCCATGCAGgaaggctggaagcgc
31	Proteoglycan 1, secretory granules	NM_002727.1	BQ051861.1	0.8	AATCCTCAGTTCAAGgtt atcctacgcaga	30	Mitogen-activated protein kinase kinase kinase 11	NM_002419.2	AK090614.1	1.2	TTCCATTCCATGCAGgaaggctggaagcgc
31	Proteoglycan 1, secretory granules	NM_002727.1	BQ051861.1	0.8	AATCCTCAGTTCAAGgtt atcctacgcaga	32	Proteoglycan 1, secretory granules	NM_002727.1	BQ051861.1	0.8	GACTGACCTTTTTCCaaa gacgagaatcca
33	Protein kinase C substrate 80K-H	NM_002743.1	BU631834.1	1.5	CTCGCAGAAACCCAAcc gctccaccaccgt	32	Proteoglycan 1, secretory granules	NM_002727.1	BQ051861.1	0.8	GACTGACCTTTTTCCaaa gacgagaatcca
33	Protein kinase C substrate 80K-H	NM_002743.1	BU631834.1	1.5	CTCGCAGAAACCCAAcc gctccaccaccgt	34	Similar 1 (S.cerevisiae) of SEC14-	NM_003003.1	CD366399.1	1.6	GTAGGTAGGTTCGTAgta gggttcgtaggt
35	SEC14 sample 1 (S. cerevisiae)	NM_003003.1	AK130317.1	1.3	TAGGGCTAGTAGGTAG GGCTAGTAGGTAGGGCTAGTAGGTAGGGCTAGT AGGTAGGGCTAGTAGG TAGGGCTAGTAGGTAG GGCTAGTAGGTAGGGT TCGTAGGTAGGGTTCGTAGGTAGGGTTCGTAGG TAGGGTTAGTAGCGCGTCTGTGCTGCTTCCACCTGGTGCTTCCTGTTCCCAAATCACAAGGGCCTGA AGGTGGTCCCTGCTTTCTCTTTCTCTTTCTCTGT GTCTCAGATGGCGATTTTGCTGACAGCTGCCAA GAAAATGCTTCACTCA ACAGTCCTCATGTGCCCAGAGATGTTTATAGAACTGTTTGAATTGCAGCCATCCCCTGCCCCCTCCCAGGCTGAAGATCTGTTCTTTTTAAGTTGATTCGGGAGTGGCATTCTTTTATACCCAAAGACTGTAGTG CATCTTGAAGAGCTCA AAGCACATGACCGCAC	34	Similar 1 (S.cerevisiae) of SEC14-	NM_003003.1	CD366399.1	1.6	GTAGGTAGGTTCGTAgta gggttcgtaggt

					AAATGCTTACAGGGTTTCCTCCCGAGTAATCCAATCTCACTCCCCTTGTAAGG
					AAATGCTTACAGGGTTTCCTCCCGAGTAATCCAATCTCACTCCCCTTGTAAGG	36	Similar 1 (S.cerevisiae) of SEC14-	NM_003003.1	AK130317.1	1.4	TAGGGTTCGTAGGTAG GGCTAGTAGGTAGGGTTAGTAGGTAGGGCTAGT AGGTAGGGCTAGTAGG TAGGGTTAGTAGGTAGGGTTCGTAGGTAGGGCT GGTAGGTAGGGTTAGTA GGTAGGGCTAGTAGGT AGGGCTAGTAGGTAGG GCTAGTAGGTAGGGTTAGTAGGTAGGGCTAGTA GGTAGGGCTAGTAGGT AGGGTTAGTAGGTAGG GTTCG
37	Similar 1 (S.cerevisiae) of SEC14-	NM_003003.1	AK130317.1	1.5	AGGTAGGGTTCGTAGgta gggctagtaggt	36	Similar 1 (S.cerevisiae) of SEC14-	NM_003003.1	AK130317.1	1.4
37	Similar 1 (S.cerevisiae) of SEC14-	NM_003003.1	AK130317.1	1.5	AGGTAGGGTTCGTAGgta gggctagtaggt	38	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	BG325726.1	1.4	GTGAAGAAGATCCATGAGAATGAGAAGCGCCTGGAG
39	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	BG325726.1	1.3	CTGGACCAGCACCCCatt gacgggtacctc	38	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	BG325726.1	1.4	GTGAAGAAGATCCATGAGAATGAGAAGCGCCTGGAG
39	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	BG325726.1	1.3	CTGGACCAGCACCCCatt gacgggtacctc	40	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	AA325849.1	1.3	CATGGAGCATTGCACC ACCCGCTTTTTCGAGACCTGTGACCTGGACAAT
41	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	AA325849.1	1.3	GAGAATGAGAAGCGCC TGGAGGCAGGAGACCA CCCCGTGGAGCTGCTG GCCCGGGACTTCGAGA AGAACTATAACATGTACATCTTCCCTGTACACTGGCAGTTCGGCCAGCTG GACCA	40	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	AA325849.1	1.3	CATGGAGCATTGCACC ACCCGCTTTTTCGAGACCTGTGACCTGGACAAT
41	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	AA325849.1	1.3		42	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	AA325849.1	1.3	GCACCCCATTGACGGgta cctctcccacac
43	Red corpuscle derives from nf 2 samples 1	NM_003204.1	BM973053.1	1.5	CGGGTCAGTGTACAGga agaggcaggcact	42	Halfcystine-abundant acidic secretion protein (osteonectin)	NM_003118.1	AA325849.1	1.3	GCACCCCATTGACGGgta cctctcccacac

44	Red corpuscle derives from nf 2 samples 1	NM_003204.1	BM973053.1	1.5	TGCTGTGAGGCAGAGga atgatggagaatc
44	Red corpuscle derives from nf 2 samples 1	NM_003204.1	BM973053.1	1.5	TGCTGTGAGGCAGAGga atgatggagaatc	45	Synapse nucleoprotein, α (the non-A4 composition of amyloid protein precursor)	NM_000345.2	NM_007308. 1	1.2	TACGAACCTGAAGCCT AAGAAATATCTTTGCTC CCAGTTTCTTGAGATCT GCTGACAGATGTTCCAT CCTGTACAAGTGCTCA GTTCCAATGTGCCCAGT CATGACATTTCTCAAAG TTTTTACAGTGTATCTC GAAGTCTTCCATCAGC AGTGATTGAAGTATCTG TACCTGCCCCCACTCAG CATTTCGGTGCTTCCCT TTCACTGAAGTGAATAC ATGGTAGCAGGGTCTTT GTGTGCTGTGGATTTTG TGGCTTCAATCTACGAT GTTAAAACAAATTAAA AACACCTAAGTGACTA CCACTTATTTCTAAATC CTCACTATTTTTTTGTT GCTGTTGTTCAGAAGTT GTTAGTGATTTGCTATC ATATATTATAAGATTTTTAGGTGTCTTTTAATGAT ACTGTCTAAGAATAATG ACGTATTGTGAAATTTG TTAATATATATAATACTTAAAAATATGTGAGCATG AAACTATGCACCTATAA ATACTAAATA
46	Synapse nucleoprotein, α (the non-A4 composition of amyloid protein precursor)	NM_000345.2	NM_007308. 1	1.4	CCACAGGAAGGAATTC TGGAAGATATGCCTGTG GATCCTGACAATGAGG CTTAT	45		NM_000345.2	NM_007308. 1	1.2
46		NM_000345.2	NM_007308. 1	1.4	CCACAGGAAGGAATTC TGGAAGATATGCCTGTG GATCCTGACAATGAGG CTTAT	47	Synapse nucleoprotein, α (the non-A4 composition of amyloid protein precursor)	NM_000345.2	NM_007308. 1	1.5	GACCAGTTGGGCAAGaa tgaagaaggagcc
48	Synapse nucleoprotein, α (the non-A4 composition of amyloid protein precursor)	NM_000345.2	L36674.1	1.4	TAAAGGAATTCATTAGCCATGGATGTATTCATGAAAGGACTTTCAAAGGC CAAGGAGGGAGTTGTG GCTGCTGCTGAGAAAA CCAAACAGGGTGTGGC AGAAGCAGCAGGAAA GACAAAAGAGG	47		NM_000345.2	NM_007308. 1	1.5	GACCAGTTGGGCAAGaa tgaagaaggagcc

49	Synapse nucleoprotein, α (the non-A4 composition of amyloid protein precursor)	NM_000345.2	L36674.1	1.3	GTGTTCTCTATGTAGgctc caaaaccaagg
49		NM_000345.2	L36674.1	1.3	GTGTTCTCTATGTAGgctc caaaaccaagg	50	Translation control oncoprotein 1	NM_003295.1	AA223997.1	0.5	AAAACCTTTTATGACAGGGGCTGCAGAACAAAT CAAGCACATCCTTGCTAATTTCAAAAACTACCA G
51	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0.7	AGAtcgcggacgggttgtgcctgg aggTGG	50	Translation control oncoprotein 1	NM_003295.1	AA223997.1	0.5
51	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0.7	AGAtcgcggacgggttgtgcctgg aggTGG	52	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0.5	TCCGACATCTACAAGatc cgggagatcgcg
53	Translation control oncoprotein 1	NM_003295.1	BC022436.1	0.6	CCGACATCTACAAGATCCGGGAGATCGCGGACG GGTTGTGCCTG	52	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0.5	TCCGACATCTACAAGatc cgggagatcgcg
53	Translation control oncoprotein 1	NM_003295.1	BC022436.1	0.6	CCGACATCTACAAGATCCGGGAGATCGCGGACG GGTTGTGCCTG	54	Translation control oncoprotein 1	NM_003295.1	BC040008.1	0.5	GCGCCGCTCCGGCTGC ACCGCGCTCGCTCCGA GTTTCAGGCTCGTGCTA AGCTAGCGCCGTCGTC GTCTCCCTTCAGTCGCCATCATGATTATCTACC
55	The TYRO protein tyrosine kinase is conjugated protein	NM_003332.1	BF092099.1	0.8	GAGGGGCTGCGGAGGc agcgacccggaaac	54	Translation control oncoprotein 1	NM_003295.1	BC040008.1	0.5
55	The TYRO protein tyrosine kinase is conjugated protein	NM_003332.1	BF092099.1	0.8	GAGGGGCTGCGGAGGc agcgacccggaaac	56	Triosephosphate isomerase 1	NM_000365.3	BI226906.1	1.3	CATGCTCTGGCAGAGgat ggctgaagtcca
57	Change glue protein 2	NM_003564.1	AA428309.1	1.3	ATTAACACCACTGACtgt gctcaccacaca	56	Triosephosphate isomerase 1	NM_000365.3	BI226906.1	1.3	CATGCTCTGGCAGAGgat ggctgaagtcca
57	Change glue protein 2	NM_003564.1	AA428309.1	1.3	ATTAACACCACTGACtgt gctcaccacaca	58	Uroporphyrinogen decarboxylase	NM_000374.2	BQ008745.1	1.5	GTGTGCCGCTGATTGtgg accctgatgaca
59	Cold shock territory albumin A	NM_003651.3	BC009744.1	1.3	GAGGAGGAAGGGAGC GGCAGCAGTGAAGGAT TTGACCCCCCTGCCACTGATAGGCAGTTCTCTGGGGCCCGGAATCAGCTG CGCCGCCCCCAGTATCG CCCTCAGTACCGGCAG CGGCGGTTCCCGCCTTACCACGTGGGACAGACC TTTGACCGTCGCTCACGGGTCTTACCCCAT	58	Uroporphyrinogen decarboxylase	NM_000374.2	BQ008745.1	1.5	GTGTGCCGCTGATTGtgg accctgatgaca
59	Cold shock territory albumin A	NM_003651.3	BC009744.1	1.3		60	Cold shock territory albumin A	NM_003651.3	BC009744.1	1.5	CCCAACAGAATACAGgc tggtgagattgga
61	Solute carrier family 7 (cation aminos	NM_003982.2	AW798524.1	0.8	TCTCTGCTCTTCAATggta tcatggcattg	60	Cold shock territory albumin A	NM_003651.3	BC009744.1	1.5	CCCAACAGAATACAGgc tggtgagattgga

	The acid transporter thing, the y+ system), the member 7
	The acid transporter thing, the y+ system), the member 7					62	Annexin A2	NM_004039.1	AV709641.1	0.9	GACGCTTCTGAGCTaaaa gcttccatgaag
63	Annexin A2	NM_004039.1	BF244428.1	1.6	AGCTTGGAGGGTGATgtgtggatgaggtca	62	Annexin A2	NM_004039.1	AV709641.1	0.9	GACGCTTCTGAGCTaaaa gcttccatgaag
63	Annexin A2	NM_004039.1	BF244428.1	1.6	AGCTTGGAGGGTGATgtgtggatgaggtca	64	Beta-2-microglobulin	NM_004048.2	AV734235.1	0.7	ATTTGGATTGGATGAAT TCCAAATTCTGCTTGCT TGCTTTTTAATATTGATATGCTTATACACTTACAC TTTATGCACAAAATGTA GGGTTATAATAATGTTA ACATGGACATGATCTTC TTTATAATTCTACTTTGAGTGCTGTCTCCATGTTT GATGTATCTGAGCAGGT TGCTCCACAGGTAGCT CTAGGAGGGCTGGCAA C
65	Beta-2-microglobulin	NM_004048.2	BF912731.1	0.8	AGATAGTTAAGTGGGatc gagacatgtaag	64	Beta-2-microglobulin	NM_004048.2	AV734235.1	0.7
65	Beta-2-microglobulin	NM_004048.2	BF912731.1	0.8	AGATAGTTAAGTGGGatc gagacatgtaag	66	The calcium reticulin	NM_004343.2	CA306742.1	1.4	GACTCCAAGCCTGAGgc agcagagaaacaa
67	CD74 antigen	NM_004355.1	BQ029721.1	1.5	ACACCCAGACCCCAGga agagccaatgttt	66	The calcium reticulin	NM_004343.2	CA306742.1	1.4	GACTCCAAGCCTGAGgc agcagagaaacaa
67	CD74 antigen	NM_004355.1	BQ029721.1	1.5	ACACCCAGACCCCAGga agagccaatgttt	68	HLA-B associated retroviral thing 1	NM_004640.3	BM980603.1	1.4	GCCCCAGGAGGAGAGc agtttaaagatttt
69	SEC24 genes involved family, member C (S.cerevisiae)	NM_004922.1	AW449995.1	1.8	GCAGCTGTCTGGAATgcagaggcagctgga	68	HLA-B associated retroviral thing 1	NM_004640.3	BM980603.1	1.4	GCCCCAGGAGGAGAGc agtttaaagatttt
69	SEC24 genes involved family, member C (S.cerevisiae)	NM_004922.1	AW449995.1	1.8	GCAGCTGTCTGGAATgcagaggcagctgga	70	Actinine, α 4	NM_004924.3	CB051741.1	0.7	CCATCGGGGCAGAAGaa cttcatcacagct
71	Oxyphorase, α 1/2	NM_000517.3	H78334.1	1.4	CGGTCAACTTTCAAGctc cttaagccactg	70	Actinine, α 4	NM_004924.3	CB051741.1	0.7	CCATCGGGGCAGAAGaa cttcatcacagct
71	Oxyphorase, α 1/2	NM_000517.3	H78334.1	1.4	CGGTCAACTTTCAAGctc cttaagccactg	72	Oxyphorase, α 1/2	NM_000517.3	H55830.1	1.4	TCAAGGCCGCCTGGGga tgttcctgtcctt
73	Cyclin-dependant kinase 5	NM_004935.1	BI669825.1	0.8	GTGGCTCTGAAACGGgg tgtgccgagttcc	72	Oxyphorase, α 1/2	NM_000517.3	H55830.1	1.4	TCAAGGCCGCCTGGGga tgttcctgtcctt
73	Cyclin-dependant kinase 5	NM_004935.1	BI669825.1	0.8	GTGGCTCTGAAACGGgg tgtgccgagttcc	74	Histone deacetylase enzyme 1	NM_004964.2	BF204295.1	1.7	CAGAGGAGAAGAAAGg gtcaaggaggaggt
75	WD duplicate domain 1	NM_005112.3	BC030541.1	1.4	CTAAGGAACATCGACgaccacagccgcttt	74	Histone deacetylase enzyme 1	NM_004964.2	BF204295.1	1.7	CAGAGGAGAAGAAAGg gtcaaggaggaggt
75	WD duplicate domain 1	NM_005112.3	BC030541.1	1.4	CTAAGGAACATCGACgaccacagccgcttt	76	Ubiquitin-specific protease 10	NM_005153.1	W19112.1	0.7	ATCGGCTCTTTGCAGtgg tctaccatcacg
77	V-fos FBJ mouse osteosarcoma virus oncogene homologue	NM_005252.2	BG541010.1	0.8	CCTGTCAACGCGCAGgacttctgcacggac	76	Ubiquitin-specific protease 10	NM_005153.1	W19112.1	0.7	ATCGGCTCTTTGCAGtgg tctaccatcacg

78	V-fos FBJ mouse osteosarcoma virus oncogene homologue	NM_005252.2	BG541010.1	1.5	GGCAAGGTGGAACAGgagacagaccaacta
78	V-fos FBJ mouse osteosarcoma virus oncogene homologue	NM_005252.2	BG541010.1	1.5	GGCAAGGTGGAACAGgagacagaccaacta	79	V-fos FBJ mouse osteosarcoma virus oncogene homologue	NM_005252.2	BI325046.1	1.5	GGCAAGGTGGAACAGgagacaggacaacta
80	Oxyphorase, α 1/2	NM_000558.3	R91899.1	1.7	ACCAAGACCTACTTCcc ggtcaacttcaag	79	V-fos FBJ mouse osteosarcoma virus oncogene homologue	NM_005252.2	BI325046.1	1.5	GGCAAGGTGGAACAGgagacaggacaacta
80	Oxyphorase, α 1/2	NM_000558.3	R91899.1	1.7	ACCAAGACCTACTTCcc ggtcaacttcaag	81	Oxyphorase, α 1/2	NM_000558.3	H58664.1	1.7	GGAGGCCCTGGAGAGct cctaagccactgc
82	Actin associated protein 2/3 complex body, subunit 4,20kDa	NM_005718.2	AI470163.1	0.7	ATTGCTGTGAAACAGgggtatgatatcagc	81	Oxyphorase, α 1/2	NM_000558.3	H58664.1	1.7	GGAGGCCCTGGAGAGct cctaagccactgc
82	Actin associated protein 2/3 complex body, subunit 4,20kDa	NM_005718.2	AI470163.1	0.7	ATTGCTGTGAAACAGgggtatgatatcagc	83	B-cell receptor-associated protein 31	NM_005745.5	AI962313.1	1.3	GCAGTTGCCACCTTCcacgcctgagcgtgg
84	RNA binding motif albumen 5	NM_005778.1	CA488450.1	0.8	GAGCAGACAAGTTTGac tctgaacaggaag	83	B-cell receptor-associated protein 31	NM_005745.5	AI962313.1	1.3	GCAGTTGCCACCTTCcacgcctgagcgtgg
84	RNA binding motif albumen 5	NM_005778.1	CA488450.1	0.8	GAGCAGACAAGTTTGac tctgaacaggaag	85	CD164 antigen, sialomucin	NM_006016.3	AF299342.1	0.8	CTGTGACTCCAACCTC ACAACCTGTGCGAAAG TCTACCTTTGATGCAGC CAGTTTCATTGGAGGAA TTGTCCTGGTCTTGGGT GTGCAGGCTGTAATTTT CTTTCTTTATAAATTCTGCAAATCTAAAGAACGA AATTACCACACTCTGTA AACAGACCCATTGAATT AATAAGGACTGGTGATT CATTTGTGTAACTCACT GAAGCCAAAATACTATC TTTTAAGATGTCCCACA TGGAAGACGCTATTCC AGGATCTTTAAATTTCC ATGGATGCATATAGGAT GTTTGGGAGCATCATCC GTGAAGAAAAAATCAA TTAAATCATTGTGTTCA ACAGGAATATTTAAAAT ATTCTGCATGAATCCTG TGGCTGTCTTATTTTAA ATAGCTGCTGCTGTGGG ATTATATTTTTTTTCCTTAACATGCCAAATATAAC TTTCTGAAAGTGATGG AAAATGTTGTCTTGTGC AGACAACATCATGGCT

					CTTGGCAGTTTA
					CTTGGCAGTTTA	86	CD164 antigen, sialomucin	NM_006016.3	AF299343.1	0.8	CAGCCAATTCTACAGcta aacccacagttc
87	General α tubulin	NM_006082.1	BG981396.1	1.3	CACCCTGAGCAGCTCac cacccacaccacc	86	CD164 antigen, sialomucin	NM_006016.3	AF299343.1	0.8	CAGCCAATTCTACAGcta aacccacagttc
87	General α tubulin	NM_006082.1	BG981396.1	1.3	CACCCTGAGCAGCTCac cacccacaccacc	88	Talin 1	NM_006289.2	AI393487.1	1.4	CCCAGAGTATTAACGCT CCAAGAGTATTATTAAC GCTGCTGTACCTCGATC TGAATCTGCCGGGGCC CCAGCCCACTCCACCC TGCCAGCAGCTTCCAG CCAGTCCCCACAGCCT CATCAGCTCTCTTCACC GTTTTTTGATACTATCTTCCCCCACCCCCAGCTA CCCATAGGGGCTGCAG AGTTATAAGCCCCAAAC AGGTCATGCTCCAATAA AAATGATTCTACCTACA A
89	Talin 1	NM_006289.2	AI393487.1	1.4	TGCTTCGGAAGGAACga gagctggaagagg	88	Talin 1	NM_006289.2	AI393487.1	1.4
89	Talin 1	NM_006289.2	AI393487.1	1.4	TGCTTCGGAAGGAACga gagctggaagagg	90	Talin 1	NM_006289.2	AI417760.1	1.4	AGGAAGAAATGCTTCgg aaggaacgagagc
91	Acidity (rich leucine) phosphocarnic acid protein 32 family, member A	NM_006305.2	AW577170.1	1.4	AGGAGGATGAGGATGga ggatgaagaaggt	90	Talin 1	NM_006289.2	AI417760.1	1.4	AGGAAGAAATGCTTCgg aaggaacgagagc
91		NM_006305.2	AW577170.1	1.4	AGGAGGATGAGGATGga ggatgaagaaggt	92	The translocase (yeast) of inner mitochondria film 23 homologues	NM_006327.1	AU142330.1	0.7	GATGTTGCATGACAGgggcactttgggcta
93	Small sphaeroprotein 1	NM_006337.3	CD369365.1	1.5	AACTCTGTGGTGGAGac aggaagctggggc	92		NM_006327.1	AU142330.1	0.7	GATGTTGCATGACAGgggcactttgggcta
93	Small sphaeroprotein 1	NM_006337.3	CD369365.1	1.5	AACTCTGTGGTGGAGac aggaagctggggc	94	APG7 autophagy 7-sample (S. cerevisiae)	NM_006395.1	BC000091.1	0.7	CTTGTGCCTCACCAGatccggggatttctt
95	Acidity (rich leucine) phosphocarnic acid protein 32 family, member B	NM_006401.1	Y07570.1	1.5	GAAGTCAGTGAGGAGgaagaagaatttgga	94	APG7 autophagy 7-sample (S. cerevisiae)	NM_006395.1	BC000091.1	0.7	CTTGTGCCTCACCAGatccggggatttctt
95		NM_006401.1	Y07570.1	1.5	GAAGTCAGTGAGGAGgaagaagaatttgga	96	Acidity (rich leucine) phosphocarnic acid protein 32 family, member B	NM_006401.1	Y07570.1	1.4	AGGATGAGGATGAAGaggaggaagaaggtg
97	Acidity (rich leucine) phosphocarnic acid protein 32 family, member B	NM_006401.1	BF195216.1	1.6	GAAGTCAGTGAGGAGa ggaggaagaaggtg	96		NM_006401.1	Y07570.1	1.4	AGGATGAGGATGAAGaggaggaagaaggtg

98	Butyrophilin, subfamily 2, member A1	NM_007049.2	BQ929466.1	1.3	CATTCTTACATGCTGaggaccggagaagtg
98	Butyrophilin, subfamily 2, member A1	NM_007049.2	BQ929466.1	1.3	CATTCTTACATGCTGaggaccggagaagtg	99	The EAP30 subunit of ELL complex body	NM_007241.2	BF525899.1	1.2	CTGCAGCTGGCAGAGaa gaatggctacgtg
100	The capside protein complex body, the ε of subunit	NM_007263.2	BM798704.1	1.5	CCACGAGAGTCGGAGg aaggagctgaagag	99	The EAP30 subunit of ELL complex body	NM_007241.2	BF525899.1	1.2	CTGCAGCTGGCAGAGaa gaatggctacgtg
100	The capside protein complex body, the ε of subunit	NM_007263.2	BM798704.1	1.5	CCACGAGAGTCGGAGg aaggagctgaagag	101	Solvable galactoside-binding lectin 9 (galactose agglutinin bindin 9)	NM_009587.1	BG390210.1	1.2	TACATCAGCTTCCAGacc cagacagtcatc
102	Solvable galactoside-binding lectin 9 (galactose agglutinin bindin 9)	NM_009587.1	BG698264.1	0.8	CTCCAGTGGAACCAGgtt tgctgtgaactt	101		NM_009587.1	BG390210.1	1.2	TACATCAGCTTCCAGacc cagacagtcatc
102		NM_009587.1	BG698264.1	0.8	CTCCAGTGGAACCAGgtt tgctgtgaactt	103	CDKN1A interaction zinc finger protein 1	NM_012127.1	AK027287.1	1.3	TAGAAGCTGGTGGAGgt gaggtccagagat
104	CDKN1A interaction zinc finger protein 1	NM_012127.1	AK027287.1	1.2	CAGGCACATTCACAGcc gcatctgccacaa	103	CDKN1A interaction zinc finger protein 1	NM_012127.1	AK027287.1	1.3	TAGAAGCTGGTGGAGgt gaggtccagagat
104	CDKN1A interaction zinc finger protein 1	NM_012127.1	AK027287.1	1.2	CAGGCACATTCACAGcc gcatctgccacaa	105	F frame albumen 7	NM_012179.2	BE905968.1	1.3	AATTTTGAAGCTGAGTCAATTCAAGATAATGCGCATATGGCAGAGGGCAC AGGTTTCTATCCCTCAGAACCCATGCTCTGTAGTGAATCGGTGGAAGGGC AAGTGCCACATTCATTAGAGACCTTGTATCAATCAGCTGACTGTTCTGATGCCAATGATGCCTTGATAGTGTTGATACATCTTCTCATGTTGGAGTCA
106	WW territory conjugated protein 2	NM_012478.2	BG820375.1	1.2	CCACCTCCCTACTACcca ccggaagataag	105	F frame albumen 7	NM_012179.2	BE905968.1	1.3
106	WW territory conjugated protein 2	NM_012478.2	BG820375.1	1.2	CCACCTCCCTACTACcca ccggaagataag	107	Px19 sample albumen	NM_013237.2	BM504662.1	1.3	CACGCCCGGCTGATGgg aatttggtcttgc
108	RhIGF-1 2 acceptors	NM_000876.1	BM787853.1	1.4	GGAAACAGTGATAAGTAAGCTGACCACTTGCT GTAGGAGAAGTTCCAACGTGTCC	107	Px19 sample albumen	NM_013237.2	BM504662.1	1.3	CACGCCCGGCTGATGgg aatttggtcttgc
108	RhIGF-1 2 acceptors	NM_000876.1	BM787853.1	1.4	GGAAACAGTGATAAGTAAGCTGACCACTTGCT GTAGGAGAAGTTCCAACGTGTCC	109	RhIGF-1 2 acceptors	NM_000876.1	BM787853.1	1.3	GACGCATCTCAAAACA GAGGGCTGCATTCGAA GAAACCCTTGCTGCTTT AGTCCCGATAGGGTATT TGACCCCGATATATTTT AGCATTTTAATTCTCTC CCCCTATTTATTGACTTT

					GACAATTACTCAGGTTT GAGAAAAAGGAAAAA AAAACAGCCACCGTTT CTTCCTGCCAGCAGGG GTGTGATGTACCAGTTT GTCCATCTTGAGATGGT GAGGCTGTCAGTGTAT GGGGCAGCTTCCGGCG GGATGTTGAACTGGTCA TTAATGTGTCCCCTGAG TTGGAGCTCATTCTGTC TCTTTTCTCTTTTGCTTTCTGTTTCTTAAGGGCAC ACACACGTGCGTGCGA GCACACACACACATAC GTGCACAGGGTCCCCG AGTGCCTAGGTTTTGG AGAGTTTGCCTGTTCTA TGCCTTTAGTCAGGAAT GGCTGCACCTTTTTGCA TGATATCTTCAAGCCTG GGCGTACAGAGCACAT TTGTCAGTATTTTTGCC G
						110	RhIGF-1 2 acceptors	NM_000876.1	BF222741.1	1.3	AAGGAGGTCAGGCCCC ACTCCTTCCTGATTGTTTACAGTCATTGGAATAAGGCATGGCTCAGATCG GCCACAGGGCGGTACC TTGTGCCCAGGGTTTTGCCCCAAGTCCTCATTTAAAAGCATAAGGCCGGA CGCATCTCAAAACAGA GGGCTGCATTCGAAGA AACCCTTGCTGCTTTAGTCCCGATAGGGTATTTGACCCCGATATATTTTAGCATTTTAATTCTCTCCCCCTATTTATTGACTTTGACAATTACTCAGGTTTGAGAAAAAGGAAAAAA AAACAGCCACCGTTTC TTCCTGCCAGCAGGGG TGTGATGTACCAGTTTGTCCATCTTGAGATGGTGAGGCTGTCAGTGTATG GGGCAGCTTCCGGCGG GATGTTGAACTGGTCATTAATGTGTCCCCTGAGT

					TGGAGCTCATTCTGTCT CTTTTCTCTTTTGCTTTCTGTTTCTTAAGGGCACA CACACGTGCGTGCGAG CACACACACACATACG TGC
						111	RhIGF-1 2 acceptors	NM_000876.1	BF222741.1	1.3	GTGGCTGATGGAAGAga tccagctgcctcc
112	Adducin 1 (α)/adducin 1 (α)	NM_014190.2	CA396829.1	1.3	AGAAGGGCTCTGAAGa gaatctggacgagg	111	RhIGF-1 2 acceptors	NM_000876.1	BF222741.1	1.3	GTGGCTGATGGAAGAga tccagctgcctcc
112	Adducin 1 (α)/adducin 1 (α)	NM_014190.2	CA396829.1	1.3	AGAAGGGCTCTGAAGa gaatctggacgagg	113	Eukaryotic translation initiation factor 2-alpha kinase 1	NM_014413.2	BM142283.1	1.3	GTTAACCTCACCCTACAGATGAAGATAATAGAGCAAGAAAAAGAAATTGC AGAACTAAAGAAGCAG CTAAACCTCCTTTCTCAAGACAAAGGGGTGAGG GATGACGGAAAGGATG GGGGCGTGGGATGAAA GTGGAC
114	KIAA0040	NM_014656.1	CB050264.1	1.7	ATGGTTCCCAAGTGTgtg taagtgtgtgta	113	Eukaryotic translation initiation factor 2-alpha kinase 1	NM_014413.2	BM142283.1	1.3
114	KIAA0040	NM_014656.1	CB050264.1	1.7	ATGGTTCCCAAGTGTgtg taagtgtgtgta	115	Homocysteine-derivable, er stress-derivable, ubiquitin spline structure territory member 1	NM_014685.1	BG828243.1	0.8	TGCATCAGGGGCTTTTGTTCCACCACCAAGTGC ACAAGAGATACCTGTG GTCTCTGCACCTGCTCCAGCCCCTATTCACAACCAGTTTCCAGCTGAAAA CCAGCCTGCCAATCAG AATGCTGCTCCTCAAGTGGTTGTTAATCCTGGAGCCAATCAAAATTTGCGGATGAATGCACAAGGTG GCCCTATTGTGGAAGA AGATGATGAAATAAATCGAGATTGGTTGGATTGGACCTATTCAGCAGCTACATTTTCTGTTTTTCTCAGTATCCTCTACTTCTACTCCTCCCTGAGCAGATTCCTCATGGTCATGGGGGCCACCGTTGTTATGTACCT
116	Homocysteine-derivable, derivable, the ubiquitin spline structure territory member 1 of er stress	NM_014685.1	BG828243.1	0.7	GGAAAACATCTCAAGgcctgaagctgccca	115		NM_014685.1	BG828243.1	0.8
116		NM_014685.1	BG828243.1	0.7	GGAAAACATCTCAAGgcctgaagctgccca	117	Homocysteine-	NM_014685.1	BG828243.1	0.8	GTACTACATGCAATAttta

	Derivable, er stress is derivable, ubiquitin spline structure territory member 1				gcagccactgc
					gcagccactgc	118	Lysosome 4 the transmembrane protein α that are correlated with	NM_014713.2	AL039105.1	0.8	CTGATTCCATTCTTCTGTTACCGACTTTTTGACTTCGTCCTCAGTTGCCTGGTTGCTATTAGTTCTCTCACCTATTTGCCAAGAATCAAAGAATATCTGGATCAACTA
119	DAZ associated protein 2	NM_014764.1	AU118651.1	0.8	AGCAGTACCTCCCTAA AGCATTTTGAGGTAGG GGAGGTATCCATTCATAAAATGAATGTGGG	118		NM_014713.2	AL039105.1	0.8
119	DAZ associated protein 2	NM_014764.1	AU118651.1	0.8		120	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	CGAGAGCGCAGGATTG AGATAGAGGAGAACA
121	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	AGAAACAGGGCAAGTa cccagaagtccaca	120	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	CGAGAGCGCAGGATTG AGATAGAGGAGAACA
121	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	AGAAACAGGGCAAGTa cccagaagtccaca	122	Ring finger protein 10	NM_014868.3	BF815780.1	1.3	CAGAAGTCCACATTCC CCTCGAGAATCTACAG CAGTTTCCTGCCTTCAATTCTTATACCTGCTCCTCTGATTCTGCTTTGGGTCCCACCAGCACCGAGG GCCATGGGGCCCTCTCCATTTCTCCTCTCAGCAGAAGTC
123	Ring finger protein 10	NM_014868.3	BF815780.1	1.4	CAGGTTCCCATGCAGact ttctgctgaccc	122	Ring finger protein 10	NM_014868.3	BF815780.1	1.3
123	Ring finger protein 10	NM_014868.3	BF815780.1	1.4	CAGGTTCCCATGCAGact ttctgctgaccc	124	Ribosomal protein L 4	NM_000968.2	BM846228.1	0.7	TCAGTGAATTAGCAGgtc atcagactagtg
125	Ribosomal protein L 4	NM_000968.2	CB141160.1	0.7	GTCATCAGACTAGTGCT GAGTCTTGGGGTACTG GCAGAGCTGTGGCTCG AATTCCCAGAGTTCGA GGTGGTGGGACTCACC GCTCTGGCCAGGGTGC TTTTGGAAACatgtgtcgtg	124	Ribosomal protein L 4	NM_000968.2	BM846228.1	0.7	TCAGTGAATTAGCAGgtc atcagactagtg
125	Ribosomal protein L 4	NM_000968.2	CB141160.1	0.7		126	Ribosomal protein L 4	NM_000968.2	CD686462.1	0.6	GCGTGTGCTCGCCCAC TGATATCGGTGTACTCCGAAAAGGGGGAGTCAT CTGGCAAAAATGTCAC TTTGCCTGCTGTATTCAAGGCTCCTATTCGACCAGATATTGTGAACTTTGTTCACACCAACTTGCGC AAAAACAACAGACAGC

					CCTATGCTG
					CCTATGCTG	127	Ribosomal protein L 4	NM_000968.2	CD686462.1	0.7	TGGTCATGTCTAAAGgtc atcgtattgagg
128	Ribosomal protein L 5	NM_000969.2	BE879402.1	0.8	GATATCATTTGTCAGattg cttatgcccgt	127	Ribosomal protein L 4	NM_000968.2	CD686462.1	0.7	TGGTCATGTCTAAAGgtc atcgtattgagg
128	Ribosomal protein L 5	NM_000969.2	BE879402.1	0.8	GATATCATTTGTCAGattg cttatgcccgt	129	Comprise BAT2 structural domain 1	NM_015172.1	AB029019.2	1.4	CACTTCCACCTTCAAcct tagctccagttt
130	Adenosine deaminase, RNA is specific	NM_015841.1	AA096321.1	1.3	TCACACAGGACAGAGg aggcagagcttctg	129	Comprise BAT2 structural domain 1	NM_015172.1	AB029019.2	1.4	CACTTCCACCTTCAAcct tagctccagttt
130	Adenosine deaminase, RNA is specific	NM_015841.1	AA096321.1	1.3	TCACACAGGACAGAGg aggcagagcttctg	131	Endoplasmic reticulum Trx superfamily member, 18kDa	NM_015913.2	CA418006.1	0.8	TTCCCAAATTTCTACagcctctttcctctt
132	Imagination albumen MGC8721	NM_016127.3	AA576624.1	0.8	GGAGTCAAACACTGGat gcagaaattttgg	131	Endoplasmic reticulum Trx superfamily member, 18kDa	NM_015913.2	CA418006.1	0.8	TTCCCAAATTTCTACagcctctttcctctt
132	Imagination albumen MGC8721	NM_016127.3	AA576624.1	0.8	GGAGTCAAACACTGGat gcagaaattttgg	133	Triangle tetrapeptide iteron 19	NM_017775.2	BE164618.1	1.5	TTTTGATGCACAGAGcta ccaccacagtgc
134	Imagination albumen FLJ20487	NM_017841.1	BI553945.1	0.8	TCTTTTTGCTAAAGAACATCTGCAGCACATGAC AGAAAAGCAGCTGAAC CTCTATGACCGCCTGATTAACGAGCCTAGTAATGACTGGGATATTT	133	Triangle tetrapeptide iteron 19	NM_017775.2	BE164618.1	1.5	TTTTGATGCACAGAGcta ccaccacagtgc
134	Imagination albumen FLJ20487	NM_017841.1	BI553945.1	0.8		135	Imagination albumen FLJ20531	NM_017865.2	AK001070.1	1.6	ACCAGAGACCTTCCCA CCTCCAGGAGAGGAAG AGGGTGAGGAAGAAG AGGACAATGATGAGGA TGAAGAGGAGATGCTC AGTGATGCCAGCTTATGGACCTACAG
136	Ubiquitin B	NM_018955.2	BE708511.1	1.4	CCCTGACCGGCAAGAca tcactctggaggt	135	Imagination albumen FLJ20531	NM_017865.2	AK001070.1	1.6
136	Ubiquitin B	NM_018955.2	BE708511.1	1.4	CCCTGACCGGCAAGAca tcactctggaggt	137	Ubiquitin B	NM_018955.2	AA206538.1	1.4	CAGGTCAAAATGCAGat cttcgtgaaaacc
138	Ubiquitin B	NM_018955.2	AA206538.1	1.3	CAGGTCAAAATGCAGat cttcgtgaagacc	137	Ubiquitin B	NM_018955.2	AA206538.1	1.4	CAGGTCAAAATGCAGat cttcgtgaaaacc
138	Ubiquitin B	NM_018955.2	AA206538.1	1.3	CAGGTCAAAATGCAGat cttcgtgaagacc	139	Ubiquitin B	NM_018955.2	AA340917.1	1.4	AGATCTTCGTGAAGAC CCTGACCGGCAAGACC ATCACTCTGGAGGTGG AGCCCAGTGACACCAT CGAAAATGTGAAGGCC AAGATCCAAGATAAAG AAGGCATCCCCCCCGA CCAGCAGAGGCTCATC TTTGCAGGCAAGCAGC TGGAAGATGGCCGCAC TCTTTCTGACTACAACATCCAGAAAGAGTCGAC CCTGCACCTGGTCCTGC

					GCCTGAGGGGTGGCTG TTAATTCTTCAGTCATGGCATTCGCAGTGCCCA GTGATGGCATTACTCTGCACTATAGCCATTTGCCCCAACTTAAGTTTAGAAATTACAAGTTTCAGTAATAGCTGAACCTGTTCA AAATGTTAATAAAGG
						140	Ubiquitin B	NM_018955.2	BU661443.1	1.4	TCCCTGTGGGTGGACGTGGTTGGTGATTGGCAGGATCCT
141	Ubiquitin B	NM_018955.2	BU661443.1	1.5	GGTTGGCTTTGTTGGgtg agcttgtttgtg	140	Ubiquitin B	NM_018955.2	BU661443.1	1.4	TCCCTGTGGGTGGACGTGGTTGGTGATTGGCAGGATCCT
141	Ubiquitin B	NM_018955.2	BU661443.1	1.5	GGTTGGCTTTGTTGGgtg agcttgtttgtg	142	DnaJ (Hsp40) homologue, subfamily C, the member 10	NM_018981.1	AF490904.1	1.3	CTTAGTGGCATGTTGgatggtcttgttaat
143	Major histocompatibility complex, class II, DR α	NM_019111.2	AA505585.1	0.8	AGAGAGAAGATCACTG AAGAAACTTCTGCTTTAATGACTTTACAAAGCTGGCAATATTACAATCCTTGACCTCAGTGAAAGCA GTCATCTTCAGCGTTTTCCAGCCCTATAGCCACCCCAAGTGTGGTTATGCCTCCTCGATTGCTCCGTACTCTAAC	142	DnaJ (Hsp40) homologue, subfamily C, the member 10	NM_018981.1	AF490904.1	1.3	CTTAGTGGCATGTTGgatggtcttgttaat
143	Major histocompatibility complex, class II, DR α	NM_019111.2	AA505585.1	0.8		144	Major histocompatibility complex, class II, DR α	NM_019111.2	AA505585.1	0.8	ATCTAGCTGGCTTTCcctgtctattgcctt
145	Major histocompatibility complex, class II, DR α	NM_019111.2	CD686254.1	0.7	TCAGAGACAGTCTTCC TGCCCAGGGAAGACCA CCTTTTCCGCAAGTTCC ACTATCTCCCCTTCCTG CCCTCAACTGAGGACG TTTACGACTGCAGGGT GGAGCACTGGGGCTTG GATGAGCCTCTTCTCAA GCACTGGGagtttgatgctccaagccctctc	144	Major histocompatibility complex, class II, DR α	NM_019111.2	AA505585.1	0.8	ATCTAGCTGGCTTTCcctgtctattgcctt
145	Major histocompatibility complex, class II, DR α	NM_019111.2	CD686254.1	0.7		146	KIAA1191 albumen	NM_020444.2	BE313670.1	1.7	GCAGCAGGATCACAGgt ggaggaaggagag
147	KIAA1191 albumen	NM_020444.2	BI254429.1	1.5	GCAGCAGGATCACAGaa cagacccaggaaa	146	KIAA1191 albumen	NM_020444.2	BE313670.1	1.7	GCAGCAGGATCACAGgt ggaggaaggagag
147	KIAA1191 albumen	NM_020444.2	BI254429.1	1.5	GCAGCAGGATCACAGaa cagacccaggaaa	148	Mesoderm is induced and is replied 1 in early days	NM_020948.1	AY124186.1	0.7	TTTCTCACACAGGCAtac tccaaatgcttc
149	Actinine, α 1	NM_001102.2	BG036045.1	0.7	AACCACTTTGACCGGgg agaagcagaattt	148	Mesoderm is induced and is replied 1 in early days	NM_020948.1	AY124186.1	0.7	TTTCTCACACAGGCAtac tccaaatgcttc

150	Stride film 4-structural domain, subfamily A, member 6A	NM_022349.2	NM_152851.1	0.8	GGAACTCTCTCTCTGATGCTGATTTGCACTCTGCTGGAATTCTGCCTAGCTGTGCTCACTGCTGTGCTGCGGTGGAAACAGGCT TAC
150	Stride film 4-structural domain, subfamily A, member 6A	NM_022349.2	NM_152851.1	0.8		151	Myelin protein zero sample 1	NM_024569.2	AI693779.1	0.9	TGCCCTGGCATTCTGGCAGAGAATCCTCACCAG TTCTCACCAACCTTCCCCCCAGGCAAGGGCAGC TGCCAGCATGGTGCTCTGCCAGGACAGGTTTCC CTGAAGGAAGCTGCTC ACACTGAGATGAGCCT CTCAGGGCAGGACCTC TTCCCAAGCCCTGCAC ACCCACCCCTGCAGCC CTTTTGGCTC
152	The possible lineal homologue of mouse limb-bud and heart gene	NM_030915.1	W45195.1	1.1	GCTTCAGTCCGCCGAgagcagtaccgtgtg	151	Myelin protein zero sample 1	NM_024569.2	AI693779.1	0.9
152		NM_030915.1	W45195.1	1.1	GCTTCAGTCCGCCGAgagcagtaccgtgtg	153	Heterogeneous karyon ribonucleoprotein C (C1/C2)	NM_031314.1	CF128443.1	1.2	CTGACCCAGATAAAACAAAAAGTGGATTCTCTCCTGGAAAACCTGGAAAAAATGGAAAAGGAACAGAGCAAACAAGCAG
154	Polysaccharase (RNA) II (DNA instructs) peptide C, 33kDa	NM_032940.1	NM_002694.2	1.3	GGTGGGGGTGGAAGCa gccgcaggagcaag	153	Heterogeneous karyon ribonucleoprotein C (C1/C2)	NM_031314.1	CF128443.1	1.2
154	Polysaccharase (RNA) II (DNA instructs) peptide C, 33kDa	NM_032940.1	NM_002694.2	1.3	GGTGGGGGTGGAAGCa gccgcaggagcaag	155	Apoptosis enzyme 4, the apoptosis L-Cysteine HCL Anhydrous of being correlated with	NM_033306.1	NM_001225.2	1.2	TGTTCCCTATGGCAGaaggcaaccacagaa
156	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.8	GTCGCTGAGAGCCTCT TCCTGCCCAGAACAGA TTACAGCTTCCACAAGTTCCATTACCTGACCTTTGTGCCCTCAGCAGAGG ACTTCTATGACTGCAGGGTGGAGCACTGGGGCT TGGACCAGCCGCTCCT CAAGCACTGGG	155		NM_033306.1	NM_001225.2	1.2	TGTTCCCTATGGCAGaaggcaaccacagaa
156	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.8		157	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.7	ACCCTCATCTGCCACATTGACAAGTTCTTCCCACCAGTGCTCAACGTCAC GTGG
158	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.7	AAGGAGCCTGTGGAGct gggccagcccaac	157	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.7	ACCCTCATCTGCCACATTGACAAGTTCTTCCCACCAGTGCTCAACGTCAC GTGG

159	The conjugated protein 1A of FK506,12kDa	NM_054014.1	NM_000801. 2	0.8	GCTCCCTGTTCTTGGatct gccatggaggg
159	The conjugated protein 1A of FK506,12kDa	NM_054014.1	NM_000801. 2	0.8	GCTCCCTGTTCTTGGatct gccatggaggg	160	Muriate cell interior passageway 1	NM_001288.3	BG491600.1	0.8	CCAGGGACGGCCACTTCCTGGTCCCCGACGCAACCATGGCTGAAGAACAACCGCAGGTCGAATTGTTCGTGAAG
161	Muriate cell interior passageway 1	NM_001288.3	AV683308.1	0.7	GGGCAGCTCCCATTCctg ctgtatggcact	160	Muriate cell interior passageway 1	NM_001288.3	BG491600.1	0.8
161	Muriate cell interior passageway 1	NM_001288.3	AV683308.1	0.7	GGGCAGCTCCCATTCctg ctgtatggcact	162	Vacuole protein sorting protein 41 (yeast)	NM_080631.1	BX648347.1	1.4	ACCGGAGGGAAGAAGg tgtgctcagtgaag
163	Zinc finger protein 38 4	NM_133476.2	BC053361.1	1.5	TGGAAAGGAGAAGGAATAAGACGGCAGGAGGAAGAGAGAGAGAGG	162	Vacuole protein sorting protein 41 (yeast)	NM_080631.1	BX648347.1	1.4	ACCGGAGGGAAGAAGg tgtgctcagtgaag
163	Zinc finger protein 38 4	NM_133476.2	BC053361.1	1.5	TGGAAAGGAGAAGGAATAAGACGGCAGGAGGAAGAGAGAGAGAGG	164	Karyomit(e) 19 open reading frame 22	NM_138774.2	AI375989.1	1.4	ACCTCATCTCGGCCAgtg ctgacctggagg
165	Nuclear receptor subunit family 3, group C, member 1 (glucocorticoid receptor)	NM_000176.1	X03348.1	0.8	TTCCTAAGGACGGTCT GAAGAGCCAAGAGCTA TTTGATGAAATTAGAATGACCTACATCAAAGAG CTAGGAAAAGCCATTG TCAAGAGGGAAGGAAA CTCCAGCCAGAACTGG CAGCGGTTTTATCAACTGACAAAACTCTTG	164	Karyomit(e) 19 open reading frame 22	NM_138774.2	AI375989.1	1.4	ACCTCATCTCGGCCAgtg ctgacctggagg
165		NM_000176.1	X03348.1	0.8		166	Nucleosome assembly protein 1-sample 1	NM_139207.1	BU620919.1	0.8	AGTGATATGGTTCAGgaa cacgatgaacct
167	Nucleosome assembly protein 1-sample 1	NM_139207.1	AU117948.1	0.8	ATGAATATTTTACAAATGAAGTGCTGACAAAGA CATACAGGATGAGGTC AGAA	166	Nucleosome assembly protein 1-sample 1	NM_139207.1	BU620919.1	0.8	AGTGATATGGTTCAGgaa cacgatgaacct
167	Nucleosome assembly protein 1-sample 1	NM_139207.1	AU117948.1	0.8	ATGAATATTTTACAAATGAAGTGCTGACAAAGA CATACAGGATGAGGTC AGAA	168	Nucleosome assembly protein 1-sample 1	NM_139207.1	AU117948.1	0.8	GCTGGCCAGCCTATGagt tttgtcttagaa
169	Nucleosome assembly protein 1-sample 1	NM_139207.1	AK122670.1	0.8	CCTGCCTAGGGTAGTTAAAAGACGAGTGAATGC TCTCAAAAACCTGCAA GTTAAATGTGCACAGAT AGAAGCCAAATTCTATGAGGAAGTTCACGATCT TGAAAGGAAGTATGCT GTTCTCTATCAG	168	Nucleosome assembly protein 1-sample 1	NM_139207.1	AU117948.1	0.8	GCTGGCCAGCCTATGagt tttgtcttagaa
169	Nucleosome assembly protein 1-sample 1	NM_139207.1	AK122670.1	0.8		170	The TAF15RNA polymerase II, TATA box binding protein (TBP) correlation factor, 68kDa	NM_139215.1	BF812650.1	1.3	GCTATGGTGGGGACAGAGGAGGCGGCTATGGAGGAGACCGAGGAGGTGGCTATGGAGGAGATCGAGGTGGCTATGGAGGAGACCGAGGTGGAGGCT

					ATGGTGGAGACCGAGGAGGCTATGGAGGAGATCGAGGAGGTTACGGAGGAGATCGAGGAGGTTATGGAGGAGATCGAGGAGGCTATGGAGGAGACAGAAGCCGGGGGGGCTATGGAGGAGACCGTGGTGGTGGCAGTGGCTACGGTGGAGACCGAAGTGGAGGCTATGGAGGAGACAGGAGTGGTGGCGGCTATGGAGGAGACCGAGGTGGGGGCTACGGAGGAGACCGAGGTGGCTATGGAGG
						171	The TAF15 rna plymerase ii, TATA box binding protein (TBP) correlation factor, 68kDa	NM_139215.1	BF812650.1	1.3	GGGACAGAGGCGGCGgctatggtggggaca
172	DEAD (Asp-Glu-Ala-A sp) box polypeptide 3, X-connects	NM_001356.2	BE000596.1	0.8	GACCACAGCAATGACC AGCCCTCATTAGGGCCC TGGATGATTTTTGGTCT AATAACGCATGCTAGTG TTGATGTTTTTTGGTCA GAGGGTATGAACAGGA AGAATTAAATGCAGCA GGCTTTATTTTAAATGC CGATTCACATTACTCTG TTCAAGCTGCGTTGAG ATGTTAAACTGGCTTAC TATAGACTTCGTAAAAA TGGCTCCAGAAAAGTA ACAAACTGAAATCTTT GAGATCACACAGGTTG GAAATATGTACATAACT GCACAAGGTGTCAATT CTGCTCTACAGTGCAGT TTTAGTCAGTTTTAGTT GCATAGGTTTCCATTGT ATTTATAGTCTGTTTATGCTAAATCTGGCCAAAG ATGAACATTGTCCACCA CTAAAATGCCTCTGCCA CTTTGAATTCTGTGCTA ATTTTGTGGCCAGAATG CGGTGATCAAAACGCT CCATCTTTTTACAGTGG	171		NM_139215.1	BF812650.1	1.3	GGGACAGAGGCGGCGgctatggtggggaca

					CATAGGAAGACGGCAA AAATTTCCTAAAGTGCA
					CATAGGAAGACGGCAA AAATTTCCTAAAGTGCA	173	copine II	NM_152727.4	AK094867.1	1.4	ACCCCTTCTGCTCAGgtg tggatggtattg
174	Heat-shocked 70kDa albumen 8	NM_153201.1	BU731317.1	0.8	ACTCGTATCCCCAAGatt cagaagcttctc	173	copine II	NM_152727.4	AK094867.1	1.4	ACCCCTTCTGCTCAGgtg tggatggtattg
174	Heat-shocked 70kDa albumen 8	NM_153201.1	BU731317.1	0.8	ACTCGTATCCCCAAGatt cagaagcttctc	175	Imagination albumen FLJ36445	NM_153233.1	BC038360.1	1.4	ACTGGCCAGGACCTGga agcagacacctct
176	Dynein, tenuigenin, middle polypeptide 2/ dynein, tenuigenin, middle polypeptide 2	NM_001378.1	U39575.1	1.4	GGAAGACAAAGAAGGagagattcaagcagg	175	Imagination albumen FLJ36445	NM_153233.1	BC038360.1	1.4	ACTGGCCAGGACCTGga agcagacacctct
176		NM_001378.1	U39575.1	1.4	GGAAGACAAAGAAGGagagattcaagcagg	177	Tropomyosin 3	NM_153649.1	BM006741.1	1.3	TGATGAGAGTGAGAGgc agagacccgtgct
178	Tropomyosin 3	NM_153649.1	BM006741.1	1.3	TGATGAGAGTGAGAGag gatgctggaccag	177	Tropomyosin 3	NM_153649.1	BM006741.1	1.3	TGATGAGAGTGAGAGgc agagacccgtgct
178	Tropomyosin 3	NM_153649.1	BM006741.1	1.3	TGATGAGAGTGAGAGag gatgctggaccag	179	EST BE881352.1		BE881352.1	1.3	TCAATATAAAACCCCcac ctaccacacatt
180	EST AW368637.1	-	AW368637.1	1.4	CTTAAACTCCAGCACcat catagccaccat	179	EST BE881352.1		BE881352.1	1.3	TCAATATAAAACCCCcac ctaccacacatt
180	EST AW368637.1	-	AW368637.1	1.4	CTTAAACTCCAGCACcat catagccaccat	181	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	AU146228.1	1.5	CACCAATGGAAGCAGtg gacaagaaggctg
182	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BU580573.1	0.8	CATCAAAGCAGTGGAC AAGAAGGCTGCTGGAG CTGGCAAGGTCACCAA GTCTGCCCAGAAAGCT CAGAAGGCTAAATGAA TATTATCCCTAATACCTGCCACCCCACTCTTAATC AGTGGTGGAAGAACGG TCTCAGAACTGTTTGTT TCAATTGGCCATTTAAG TTTAGTAGTAAAAGACT GGTTAATGATAACAATG CATCGTAAAACCTTCAG AAGGAAAGGAGAATGT TTTGTGGACCACTTTGG TTTTCTTTTTTGCGTGT GGCAGTTTTAAGTTATT AGTTTTTAAAATCAGTA CTTTTTAATGGAAACAA CTTGACCAAAAATTTGT CACAGAATTTTGAGAC CCATTAAAAAAGTTAAA TGAG	181	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	AU146228.1	1.5	CACCAATGGAAGCAGtg gacaagaaggctg
182	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BU580573.1	0.8		183	Eukaryotic translation prolongs	NM_001402.4	AA595862.1	0.8	TGCGGTGGGTGTCATC AAAGCAGTGGACAAGA

	The factor 1 α 1				AGGCTGCTGGAGCTGGCAAGGTCACCAAGTCTGCCCAGAAAGCTCAGAAGGCTAAATGAATATTATCCCTAATACCTGCCACCCCACTCTTAATCAGTGGTGGAAGAACGGTCTCAGAACTGTTTGTTTCAATTGGCCATTTAAGTTTAGTAGTAAAAGACTGGTTAATGATAACAATGCATCGTAAAACCTTCAGAAGG
	The factor 1 α 1					184	Eukaryotic translation elongation factor 1 γ	NM_001404.3	AA206367.1	0.7	CTGAGTCCAGATTGGCAGGTGGACTACGAGTCATACACATGGCGGAAACTGGATCCTGGCAGCGAGGAGACCCAGACGCTGGTT
185	Eukaryotic translation elongation factor 1 γ	NM_001404.3	AA206367.1	0.6	CAGCATGTGGGCAAAGCCTTCAATCAGGGCAAGATCTTCAAGTGAACATCTCTTGCCATCACCTAG	184	Eukaryotic translation elongation factor 1 γ	NM_001404.3	AA206367.1	0.7
185	Eukaryotic translation elongation factor 1 γ	NM_001404.3	AA206367.1	0.6		186	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BQ375267.1	0.8	GTTCTAGAGCCTTCTTTCCGCCAGGCCTTCCCAATACCAACCGCTGGTTCCTCACCTGCATTAACCAGCCCCAGTTCCGGGCTGTCTTGGGCGAAGTGAAACTGTGTGAGAAGATGGCCCAGTTTGATGctaaaaagtttgcagag
187	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BU783548.1	0.6	ATTTAAGCGCAAGTACTCCAATGAGGACACACTCTCTGTGGCACTGCCATATTTCTGGGAGCACTTTGATAAGGACGGCTGGTCCCTGTGGTACTCAGAGTATCGCTTCCCTGAAGAACTCACTCAGACCTTCATGAGCTGCAATCTCATCACTG	186	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BQ375267.1	0.8
187	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BU783548.1	0.6		188	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	TGGACAAGCTGAGGAAGAATGCCTTCGCCAGTGTCATCCTTTTTGGAACCAACAATAGCAGCTCCATTTCTGGAGTCTGGGTCTTCCGAGGCCAG
189	Eukaryotic translation prolongs	NM_001404.3	BE502067.1	0.6	CAGGTGGACTACGAGT	188	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6

	The factor 1 γ				CATACACATGGCGGAA ACTGGATCCTGGCAGC GAGGAGACCCAGACGC TGGTTCGAGAGTACTTTTCCTGGGAGGGGGCCT TCCAGCATGTGGGCAA AGCCTTCAA
	The factor 1 γ					190	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	GAGCTTGCCTTTCCGctg agtccagattgg
191	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG533219.1	0.8	AAGGAGGAGAAAAAG GCGGCTGCCCCTGCTCCTGAGGAGGAGATGGATGAATGTGAGCAGGCG CTGGCTGCTGAGCCCAAGGCCAAGGACCCCTTCGCTCACCTGCCCAAGAG	190	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	GAGCTTGCCTTTCCGctg agtccagattgg
191	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG533219.1	0.8		192	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG615194.1	0.7	TTCCGCCAGGCCTTTCCCAATACCAACCGCTGG TTCCTCACCTGCATTAACCAGCCCCAGTTCCGG GCTGTCTTGGGCGAAG TGAAACTGTGTGAGAA GA
193	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG702200.1	0.8	GTTCACGGGAAGAGAAGCAGAAGCCCCAGGCTGAGCGGA	192	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG615194.1	0.7
193	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG702200.1	0.8	GTTCACGGGAAGAGAAGCAGAAGCCCCAGGCTGAGCGGA	194	N-acetylglucosamine (GlcNAc) transferring enzyme that O-connects	NM_181673.1	AW002377.1	0.8	AAAGAATATCTAGCCctct gttcaacacca
195	N-acetylglucosamine (GlcNAc) transferring enzyme that O-connects	NM_181673.1	AW002377.1	0.8	CACGAAAAGTAGCCGct ctggttgaagctt	194		NM_181673.1	AW002377.1	0.8	AAAGAATATCTAGCCctct gttcaacacca
195		NM_181673.1	AW002377.1	0.8	CACGAAAAGTAGCCGct ctggttgaagctt	196	WD and triangle tetrapeptide repeat 1	AB028960.1	AK023778.1	1.3	CCAATTTCTTTGGCAgca acgctcagtata
197	Actin muscle, γ 1	NM_001614.2	CD687776.1	1.2	CATGGAGAAGATCTGgg cgcaccactggca	196	WD and triangle tetrapeptide repeat 1	AB028960.1	AK023778.1	1.3	CCAATTTCTTTGGCAgca acgctcagtata
197	Actin muscle, γ 1	NM_001614.2	CD687776.1	1.2	CATGGAGAAGATCTGgg cgcaccactggca	198	Arachidonic acid 5 lipoxygenase activators	NM_001629.2	BX366320.1	1.3	AGAGAGAACGCAGAGgccacggaagccctg
199	Homo sapiens cDNA:FLJ22720 learns the excellent fis that holds concurrently, clone HSI14320	AK026373.1	AV725084.1	1.2	ATTTCAACAGCTGAGgaaggtgtcttgctg	198	Arachidonic acid 5 lipoxygenase activators	NM_001629.2	BX366320.1	1.3	AGAGAGAACGCAGAGgccacggaagccctg
199		AK026373.1	AV725084.1	1.2	ATTTCAACAGCTGAGgaaggtgtcttgctg	200	Homo sapiens cDNA:FLJ22720 fis,	AK026373.1	BQ276346.1	0.8	TTTGGCAGGAAGGTGT CTTGCTGCAGGTAACTA

	Clone HSI14320				ATGAAGAAGTGGTCAA CCACAGAGTCTTCAAG AAATAAGAAATTCTGTACCATCTGAAAGTAGTTCTTGTTGGTGCCTTCATTTAAAAAGCACTCTTTAAAATAAAAGGGAAATGT TTTCTGATAAAA
	Clone HSI14320					201	DKFZp586K2322 (NM_006386 or NM_030881)	AL080113.1	AV751235.1	0.8	TTTATTTTCAAATGCAG TGTAGAGCTAGATTAAA AGCAACTCTTTGCCAC CTACTCTGCCCTTTTGG CAAAGTTACCTTGAAC AAAGAATCTTAAGGGT TTATTAAGAACTCTTTA TTTTCTTCATACCCTGT TCTCTGCAGTGCTTTCT AACAGCTTCTGGGTGC AGATTTTCTTCGGCATC CTTTTGCACTCAGCTTA TTACAGGTAGGTAGTGC TTAAGAAAAGTCATGG AGGACTAAAGCCTAAG TCCTTTTCACTTTTCCT CCATCTGAAGGTAGGT GAGTTCATCCTCTTCAT AGTAATGCTGTTTTACC AAGACTTTATAGCAGAT GGACCCAGAAAGAATT TTCTGCTATTGTGTTCA CTACAACAGGATAGGG ACATCAGACAGCCCCA GAAACCCCTTCCAGAT CTGATATGGGACTATTA ATTTTTATGCTGTTAATTGGTATTCATTCACAATG CAGTTGAAGGGGGAAG GCTCCACTGCATTCTTT G
202	Calmodulin 2 (phosphorylase kinase, δ)	NM_001743.3	BF701704.1	0.8	ATTGCAAAACGGGTGtat tatccaggtact	201	DKFZp586K2322 (NM_006386 or NM_030881)	AL080113.1	AV751235.1	0.8
202	Calmodulin 2 (phosphorylase kinase, δ)	NM_001743.3	BF701704.1	0.8	ATTGCAAAACGGGTGtat tatccaggtact	203	Calpain, small subunit 1/ calpain, small subunit 1	NM_001749.1	BE907701.1	1.4	CCTTTGAGGCAGCAGatgaaagtgggaaca
204	Cysteinyl-tRNA synthetic enzyme	NM_001751.3	AK125503.1	1.5	AAACAGGAACAAGAAg cagcaaagctggcc	203	Calpain, small subunit 1/ calpain, small subunit 1	NM_001749.1	BE907701.1	1.4	CCTTTGAGGCAGCAGatgaaagtgggaaca
204	Cysteinyl-tRNA synthetic enzyme	NM_001751.3	AK125503.1	1.5	AAACAGGAACAAGAAg cagcaaagctggcc	205	CD97 antigen	NM_001784.2	NM_078481. 1	1.3	ATACCGTCTGTGAAGatg tggacgagtgca

206	CD97 antigen	NM_001784.2	BI028545.1	1.2	CAGGCTGGAAGCCCAGACACGGAATCCCGGAT AACCAAAAGGACACTGTCTGTGAAG
206	CD97 antigen	NM_001784.2	BI028545.1	1.2	CAGGCTGGAAGCCCAGACACGGAATCCCGGAT AACCAAAAGGACACTGTCTGTGAAG	207	Homo sapiens's immunoglobulin (Ig) κ constant, mRNA	BC034141.1	AV688287.1	1.4	CAAGGGACCAAGGTGgagcagttgaaatct
208	Ferritin, heavy polypeptide 1	NM_002032.1	BG248923.1	0.6	TGTCTCTGGGGATCCCT AGTATAACACATGCA	207	Homo sapiens's immunoglobulin (Ig) κ constant, mRNA	BC034141.1	AV688287.1	1.4	CAAGGGACCAAGGTGgagcagttgaaatct
208	Ferritin, heavy polypeptide 1	NM_002032.1	BG248923.1	0.6	TGTCTCTGGGGATCCCT AGTATAACACATGCA	209	Homo sapiens chromosome 4 open reading frame 9	BC053635.1	AI806846.1	1.5	CCGGCTGGTCAAAGTgt gggtgctggcagc
210	Homo sapiens T cytoactive acceptor β chain V-D-J-β-1.2-C-β-1 (TCRB) mRNA	K02885.1	U85050.1	0.8	GGTTCGGGGACCAGGtt aaccgttgtagag	209	Homo sapiens chromosome 4 open reading frame 9	BC053635.1	AI806846.1	1.5	CCGGCTGGTCAAAGTgt gggtgctggcagc
210		K02885.1	U85050.1	0.8	GGTTCGGGGACCAGGtt aaccgttgtagag	211	Homo sapiens T cytoactive acceptor β chain V-D-J-β-1.2-C-β-1 (TCRB) mRNA	K02885.1	AF043180.1	0.8	GAGGACCTGAACAAGG TGTTCCCACCCGAGGT CGCTGTGTTTGAGCCATCAGAAGCAGAGATCTC CCACACCCAAAAGGCC ACACTGGTGTGCCTGG CCACAGGTATCTTCCCTGACCACGTGGAGCTGA GCTGGTGGGTGAATGG GAAGGAGGTGCACAGT GGGGTCAGCACGGACC CGCAGCCCCTCAAGGA GCAGCCCGCCCTCAAT GACTCCAGATACTGCCTGAGCAGCCGCCTGAGG GTCTCGGCCACCTTCTGGCAGAACCCCCGCAAC CACTTCCGCTGTCAAGTCCAGTTCTACGGGCTCTCGGAGAATGACGAGTG GACCCAGGATAGGGCC AAACCCGTCACCCAGA TCGTCAGCGCCGAG
212	Homo sapiens T cytoactive acceptor β chain V-D-J-β-1.2-C-β 1 (TCRB) mRNA	K02885.1	AF317590.1	1.2	TCTGTGCCAGCAGCCttggacagatttatg	211		K02885.1	AF043180.1	0.8
212		K02885.1	AF317590.1	1.2	TCTGTGCCAGCAGCCttggacagatttatg	213	Homo sapiens T cytoactive acceptor β chain V-D-J-β-1.2-C-β	K02885.1	AF327908.1	0.7	ATATCTCTGCAGCGTcgggggtcaatctgg

	-1(TCRB)mRNA
	-1(TCRB)mRNA					214	Homo sapiens T cytoactive acceptor β chain V-D-J-β-1.2-C-β-1 (TCRB) mRNA	K02885.1	AF327022.1	0.7	CTGCAGTGCTAGAGAtc cggggtcccatca
215	Human T cytoactive acceptor β chain mRNA	M12886.1	BC036926.1	0.8	CCAGATCGTCAGCGCcgaggcctggggtag	214		K02885.1	AF327022.1	0.7	CTGCAGTGCTAGAGAtc cggggtcccatca
215	Human T cytoactive acceptor β chain mRNA	M12886.1	BC036926.1	0.8	CCAGATCGTCAGCGCcgaggcctggggtag	216	Human myosin-IXb mRNA	U42391.1	BF948234.1	1.3	CCTCTGGCCTCACAGtgt cccaggagcaca
217	Selenoperoxidase 4 (phospholipid hydrogen peroxidas)	NM_002085.1	BI254515.1	0.8	TGGAACTTCACCAAGttcctcatcgacaag	216	Human myosin-IXb mRNA	U42391.1	BF948234.1	1.3	CCTCTGGCCTCACAGtgt cccaggagcaca
217	Selenoperoxidase 4 (phospholipid hydrogen peroxidas)	NM_002085.1	BI254515.1	0.8	TGGAACTTCACCAAGttcctcatcgacaag	218	Poly-(A) is conjugated protein, tenuigenin 1	NM_002568.1	AA033548.1	0.9	TTCCAACTGTTTAAAatt gatcagggacca
219	Statin	NM_002634.2	BI261762.1	1.4	CAGTATGGTGAGGAGgt gtgagagggtcca	218	Poly-(A) is conjugated protein, tenuigenin 1	NM_002568.1	AA033548.1	0.9	TTCCAACTGTTTAAAatt gatcagggacca
219	Statin	NM_002634.2	BI261762.1	1.4	CAGTATGGTGAGGAGgt gtgagagggtcca	220	Statin	NM_002634.2	BM014639.1	1.6	TCAGAGTGGAAGCAGgt gagaatggagggg
221	Statin	NM_002634.2	BM014639.1	1.4	CTTTGGGCGAGGAGAgt gtgagagggtcca	220	Statin	NM_002634.2	BM014639.1	1.6	TCAGAGTGGAAGCAGgt gagaatggagggg
221	Statin	NM_002634.2	BM014639.1	1.4	CTTTGGGCGAGGAGAgt gtgagagggtcca	222	Statin	NM_002634.2	BE536369.1	1.4	GCGAGGAGAGTGCGTgt gtgagagggtcca
223	Spermidine/spermine N1-Transacetylase	NM_002970.1	CD108391.1	0.8	TTCCAGAAGCCAGAGA GACCAAGTGTTATGTAAGAAGTAGTGTCGGCTG TGTAGAACCACTGACT ACACAGGCCGAAGTTA CTGAGAACTTGGACAG AAAAAATAGCCAGCAA GTGTTCAAACTACTGA GGAAAAAAAAAAATTA GATATGCTGCACTTAAGAATACTAGGGCAGGTT	222	Statin	NM_002634.2	BE536369.1	1.4	GCGAGGAGAGTGCGTgt gtgagagggtcca
223	Spermidine/spermine N1-Transacetylase	NM_002970.1	CD108391.1	0.8		224	Halfcystine enriches acidic secretion protein (osteonectin)	NM_003118.1	BG424815.1	1.4	GAGAATGAGAAGCGCTGGAGGCAGGAGACACCCCG
225	Translation control oncoprotein 1	NM_003295.1	BG284235.1	0.6	TTCTTTATTGGTGAAAA CATGAATCCAGATGGCA TGGTTGCTCTATTGGAC TACCGTGAGGATGGTG TGACCCCATATATGATTTTCTTTAAGGATGGTTTA	224	Halfcystine enriches acidic secretion protein (osteonectin)	NM_003118.1	BG424815.1	1.4	GAGAATGAGAAGCGCTGGAGGCAGGAGACACCCCG
225	Translation control oncoprotein 1	NM_003295.1	BG284235.1	0.6		226	Translation control oncoprotein 1	NM_003295.1	BG284235.1	0.7	GAAATGGAAAAATGTta acaaatgtggcaa

227	Translation control oncoprotein 1	NM_003295.1	CD641954.1	0.7	TTATTTTGGATCTATCACCTGTCATCATAACTGGC TTCTGCTTGTCATCCAC ACAACACCAGGACTTA AGACAAATGGGACTGA TGTCATCTTGAGCTCTT CATTTATTTTGACTGTG ATTTATTTGGAGTGGAG GCATTGTTTTTAAGAAA AACATGTCATGTAGGTT GTCTAAAAATAAAATGC ATTTAAAC
227	Translation control oncoprotein 1	NM_003295.1	CD641954.1	0.7		228	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	CGTCGTCTCCCTTCAGTCGCCATCATGATTATCTACC
229	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	GGGACCTCATCAGCCac gatgagatgttct	228	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	CGTCGTCTCCCTTCAGTCGCCATCATGATTATCTACC
229	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	GGGACCTCATCAGCCac gatgagatgttct	230	Vasodilation stimulates phosphorprotein	NM_003370.1	BQ340296.1	1.5	TTTATTTCCTACCAGcag gaggagccagag
231	Cold shock territory albumin A	NM_003651.3	BG739968.1	1.2	CCCAAGGTACCGTAGca ggggacctcctcg	230	Vasodilation stimulates phosphorprotein	NM_003370.1	BQ340296.1	1.5	TTTATTTCCTACCAGcag gaggagccagag
231	Cold shock territory albumin A	NM_003651.3	BG739968.1	1.2	CCCAAGGTACCGTAGca ggggacctcctcg	232	Cold shock territory albumin A	NM_003651.3	BE935120.1	1.5	AATAACCCACGGAAATATCTGCGCAGTGTAGGA GATGGAGAAACTGTAG AGTTTGATGTGGTTGAAGGAGAGAA
233	Cold shock territory albumin A	NM_003651.3	BE935120.1	1.5	GTATTTGTACATCAGactg ccatcaagaag	232	Cold shock territory albumin A	NM_003651.3	BE935120.1	1.5
233	Cold shock territory albumin A	NM_003651.3	BE935120.1	1.5	GTATTTGTACATCAGactg ccatcaagaag	234	Chromosome 22 open reading frame 19	NM_003678.2	AK122673.1	1.5	GAAGCAGAAGAGGTGTGAAAGAAGGTGCTGCT GGGAGGGGAGTCTGACAACCCAGC
235	Homo sapiens's vesicle related membrane protein 8 (endobrevin)	NM_003761.2	BG623073.1	0.8	ACGACATCGCAGAAGG TGGCTCGGAAATTCTG GTGGAAGAACGTGAAG ATGATTGTCCTTATCTG CGTGATTGTTTTTATCATCATCCTCTTCATTGTGC TCTTTGCCACTGGTGCC TTCTCTTAAGTAACAGG GAACCTCTCCCACCTG CCCTTCTTTTCAGGGAC AACCCTCCATAAATGTG TGCCAAGAGGGTCTCC TTTCCTGTCTTCCTCTA CAGAGAATGCTGCTCG GTCCTCCTACCCCTCTT CCCGAGGCCTGCTGCC	234	Chromosome 22 open reading frame 19	NM_003678.2	AK122673.1	1.5	GAAGCAGAAGAGGTGTGAAAGAAGGTGCTGCT GGGAGGGGAGTCTGACAACCCAGC

					ACGTTGTATGCCCCAGAAGGTACCTTGGTCCCCCGGAAGGAGAGAA
					ACGTTGTATGCCCCAGAAGGTACCTTGGTCCCCCGGAAGGAGAGAA	236	Homo sapiens's vesicle related membrane protein 8 (endobrevin)	NM_003761.2	BG623073.1	0.7	GATCTGGAAGCCACAtctgagcacttcaag
237	CASP8 and FADD sample apoptosis regulator	NM_003879.3	BI871546.1	1.3	AGTACAAGCAGTCTGgtggatggaatggaa	236		NM_003761.2	BG623073.1	0.7	GATCTGGAAGCCACAtctgagcacttcaag
237	CASP8 and FADD sample apoptosis regulator	NM_003879.3	BI871546.1	1.3	AGTACAAGCAGTCTGgtggatggaatggaa	238	Beta-2-microglobulin	NM_004048.2	BM831738.1	0.8	AGGTTTACTCACGTCATCCAGCAGAGAATGGAA AGTCAAATTTCCTGAATTGCTATGTGTCTGGGTTTCATCCATCCGACATTGAAGTTGACTTACTGAA GAATGGAGAGAGAATT GAAAAAGTGGAGCATT CAGACTTGTCTTTCAGCAAGGACTGGTCTTTCTATCTCTTGTACTACACTGAATTCACCCCCACTGA AAAAGATGAGTATGCC TGCCGTGTGAACCATGTGACTTTGTCACAGCCC AAGATAGTTAAGTGGG
239	Beta-2-microglobulin	NM_004048.2	BM831738.1	0.7	TGGAGGCTATCCAGCgta ctccaaagattc	238	Beta-2-microglobulin	NM_004048.2	BM831738.1	0.8
239	Beta-2-microglobulin	NM_004048.2	BM831738.1	0.7	TGGAGGCTATCCAGCgta ctccaaagattc	240	Guanine-nucleotide-binding protein, γ 10	NM_004125.2	BC015206.1	0.6	GTGGAGAGGATCAAGgt ctctcaggcagct
241	The BCL2 inhibitor of apoptosis protein of being correlated with	NM_004323.2	BI826041.1	1.2	TGACTGTCACCCACAgc aatgagaagcacg	240	Guanine-nucleotide-binding protein, γ 10	NM_004125.2	BC015206.1	0.6	GTGGAGAGGATCAAGgt ctctcaggcagct
241		NM_004323.2	BI826041.1	1.2	TGACTGTCACCCACAgc aatgagaagcacg	242	The c-src Tyrosylprotein kinase	NM_004383.1	BG953215.1	1.1	CCTCAAGTTCTCGCTaga tgtctgcgaggc
243	HLA-B associated retroviral thing 1	NM_004640.3	CB148695.1	1.4	GCCCCAGGAGGAGAGgt gagctgaagatgg	242	The c-src Tyrosylprotein kinase	NM_004383.1	BG953215.1	1.1	CCTCAAGTTCTCGCTaga tgtctgcgaggc
243	HLA-B associated retroviral thing 1	NM_004640.3	CB148695.1	1.4	GCCCCAGGAGGAGAGgt gagctgaagatgg	244	Family 50 with sequence similarity, member A	NM_004699.1	AA024425.1	0.8	CACGGGGGAAGAGTGgaccactcttcaact
245	Family 50 with sequence similarity, member A	NM_004699.1	AA584911.1	1.6	TCAAGAGTGAGTGTTtgcggagtcagacgc	244	Family 50 with sequence similarity, member A	NM_004699.1	AA024425.1	0.8	CACGGGGGAAGAGTGgaccactcttcaact
245	Family 50 with sequence similarity, member A	NM_004699.1	AA584911.1	1.6	TCAAGAGTGAGTGTTtgcggagtcagacgc	246	The GNAS complex loci	NM_000516.3	BU784018.1	1.5	CTACTCCTGAGGATGgtg tgtatggcttcc
247	The GNAS complex loci	NM_000516.3	BG911454.1	1.4	GACGCCAGGGTTTGGgt gctggagaatctg	246	The GNAS complex loci	NM_000516.3	BU784018.1	1.5	CTACTCCTGAGGATGgtg tgtatggcttcc
247	The GNAS complex loci	NM_000516.3	BG911454.1	1.4	GACGCCAGGGTTTGGgt gctggagaatctg	248	Oxyphorase, α	NM_000517.3	AA343446.1	1.7	TGCTTCTCCCCGCAGgat

	1/2				gttcctgtcctt
	1/2				gttcctgtcctt	249	WD repeating structure territory 1	NM_005112.3	BX648190.1	1.2	AAGTTCACAATTGGCga ccacagccgcttt
250	Retinoblastoma binding protein white 4	NM_005610.1	BF475362.1	0.8	TTTATTCATGGTGGTCATACTGCCAAGATATCTGA TTTCTCCTGGAATCCCA ATGAACCTTGGGTGATT TGTTCTGTATCAGAAGA CAATATCATG	249	WD repeating structure territory 1	NM_005112.3	BX648190.1	1.2	AAGTTCACAATTGGCga ccacagccgcttt
250	Retinoblastoma binding protein white 4	NM_005610.1	BF475362.1	0.8		251	Little EDRK enriches the factor 2	NM_005770.2	BG435668.1	0.9	CCGTCGCCATGACCCgc ggtaaccagcgtg
252	Infer translation initiation factor	NM_005801.2	BG655736.1	0.7	CCTTTGTGCTTGCAGaag tttgcctgcaat	251	Little EDRK enriches the factor 2	NM_005770.2	BG435668.1	0.9	CCGTCGCCATGACCCgc ggtaaccagcgtg
252	Infer translation initiation factor	NM_005801.2	BG655736.1	0.7	CCTTTGTGCTTGCAGaag tttgcctgcaat	253	Film component, karyomit(e) 11, surface marker 1	NM_005898.2	AA437165.1	0.8	AACAGCTTCAAACAGtggttggcacttacc
254	Capping protein (actin filament) flesh Z-line, α 2	NM_006136.1	BG702980.1	0.7	AGCAAAAAATTTTTGgaatggtcgttggag	253	Film component, karyomit(e) 11, surface marker 1	NM_005898.2	AA437165.1	0.8	AACAGCTTCAAACAGtggttggcacttacc
254	Capping protein (actin filament) flesh Z-line, α 2	NM_006136.1	BG702980.1	0.7	AGCAAAAAATTTTTGgaatggtcgttggag	255	Small sphaeroprotein 1	NM_006337.3	CB110581.1	1.4	AACTCTGTGGTGGAGgt gagctggggagga
256	Conversion contains coiled coil acidic repeat protein 3 (TACC3)	NM_006342.1	BM313828.1	1.3	ACAGTGGAGCAGAAGgtgggtgcgggaagc	255	Small sphaeroprotein 1	NM_006337.3	CB110581.1	1.4	AACTCTGTGGTGGAGgt gagctggggagga
256		NM_006342.1	BM313828.1	1.3	ACAGTGGAGCAGAAGgtgggtgcgggaagc	257	Acidity (rich leucine) phosphocarnic acid protein 32 family, member B	NM_006401.1	AI446778.1	1.2	AAGACGAGGACGATGA GGATGGTGAAGAAGAG GAGTTTGATGAAGAAG ATGATGAAGATGAAGATGTAGAAGGGGATGAGG ACGACGATGAAGTCAG TGAGGAG
258	Acidity (rich leucine) phosphocarnic acid protein 32 family, member B	NM_006401.1	AI446778.1	1.3	AGGAGGAGGACGAAGaaggagaagatgagg	257		NM_006401.1	AI446778.1	1.2
258		NM_006401.1	AI446778.1	1.3	AGGAGGAGGACGAAGaaggagaagatgagg	259	Particle cytolysin/particle cytolysin	NM_006433.2	BI838502.1	0.8	GATAAGCCCACCCAGag aagtgtttccaat
260	The lysosome membrane-spanning proteins 5 of being correlated with	NM_006762.1	BQ006415.1	1.4	agatgctccagaaggtgagtgtggct gcag	259	Particle cytolysin/particle cytolysin	NM_006433.2	BI838502.1	0.8	GATAAGCCCACCCAGag aagtgtttccaat
260		NM_006762.1	BQ006415.1	1.4	agatgctccagaaggtgagtgtggct gcag	261	The lysosome membrane-spanning proteins 5 of being correlated with	NM_006762.1	BQ006415.1	1.5	AAGATGCTCCAGAAGgt gagtgtggctgca
262	Transforming growth factor, β 1 (Camurati-Engelmann disease)	NM_000660.1	AI610679.1	1.4	CGGGCTACNANATGCGCTTGGGGGGAGCCAGGACGGAGGAAGAGGAG AGAGAAAGAGA	261		NM_006762.1	BQ006415.1	1.5	AAGATGCTCCAGAAGgt gagtgtggctgca
262		NM_000660.1	AI610679.1	1.4	CGGGCTACNANATGCGCTTGGGGGGAGCCAGGACGGAGGAAGAGGAG AGAGAAAGAGA	263	Myoglobulin I F	NM_012335.2	BF823263.1	1.3	GTGGACAATGGGAAGct gctggaagggcct

264	Ribosomal protein L 13a	NM_012423.2	BM826692.1	0.8	AAGCCTACAAGAAAGttt gcctatctgggg
264	Ribosomal protein L 13a	NM_012423.2	BM826692.1	0.8	AAGCCTACAAGAAAGttt gcctatctgggg	265	Glutathione S-transferase π hypotype	NM_000852.2	N59567.1	1.4	CATGCTGTTCCTTCCTC GCCACCCTCTGCTTC
266	Karyomit(e) 11 open reading frame 10	NM_014206.1	BE041814.1	0.8	TCGCGGGGCAAAATGga gctcgaggccatg	265	Glutathione S-transferase π hypotype	NM_000852.2	N59567.1	1.4	CATGCTGTTCCTTCCTC GCCACCCTCTGCTTC
266	Karyomit(e) 11 open reading frame 10	NM_014206.1	BE041814.1	0.8	TCGCGGGGCAAAATGga gctcgaggccatg	267	Integrin, α X (antigens c D11C (p150), α polypeptide)	NM_000887.3	AA251543.1	1.4	TGCGACCGCCTACAGgtgacctccaaagct
268	Ring finger protein 10	NM_014868.3	BM471027.1	1.3	ACTTTCTGCTGACCCCTCTGTCACCCACTGCCA GTCAGGGCAGTCCCTC ATTCTGCGTTGGGAGTCTGGAAGAAGACTCTCC CTTC	267	Integrin, α X (antigens c D11C (p150), α polypeptide)	NM_000887.3	AA251543.1	1.4	TGCGACCGCCTACAGgtgacctccaaagct
268	Ring finger protein 10	NM_014868.3	BM471027.1	1.3		269	Ribosomal protein L 4	NM_000968.2	CB164625.1	0.7	GGTGCTTTTGGAAACatg tgtcgtggaggc
270	KIAA0690	NM_015179.2	BG506709.1	1.6	TCTCTGGGCAAGCAGaa agcaaaaggtgat	269	Ribosomal protein L 4	NM_000968.2	CB164625.1	0.7	GGTGCTTTTGGAAACatg tgtcgtggaggc
270	KIAA0690	NM_015179.2	BG506709.1	1.6	TCTCTGGGCAAGCAGaa agcaaaaggtgat	271	KIAA0690	NM_015179.2	BG506709.1	1.6	GAATACAAGGCCAAGaa agcaaaaggtgat
272	Bridging conformity gene 2	NM_016187.1	AK093638.1	0.9	AAGGCCATCGTATGGaat aatgatctcctt	271	KIAA0690	NM_015179.2	BG506709.1	1.6	GAATACAAGGCCAAGaa agcaaaaggtgat
272	Bridging conformity gene 2	NM_016187.1	AK093638.1	0.9	AAGGCCATCGTATGGaat aatgatctcctt	273	Ribosomal protein L 2 7a	NM_000990.2	BG824148.1	0.8	CAACTTCGACAAATAcc acccaggctactt
274	Ribosomal protein L 2 7a	NM_000990.2	BI906450.1	0.8	gccacccaggctactttgggaaagt	273	Ribosomal protein L 2 7a	NM_000990.2	BG824148.1	0.8	CAACTTCGACAAATAcc acccaggctactt
274	Ribosomal protein L 2 7a	NM_000990.2	BI906450.1	0.8	gccacccaggctactttgggaaagt	275	Ribosomal protein L 2 7a	NM_000990.2	CB119057.1	0.7	GCCACGGCCGCATAGgc aagcaccggaagc
276	Ankyrin repeating structure territory 10	NM_017664.1	BC039715.1	0.7	GGAGCATTCCATATAGAAACTGCTGAAACTGCC ACAGGTGCTTCTCCGA AAACCTTACAGTTGTG GCATTGAATGTTCAGTATCGCTTCCTTTCTGCACACG	275	Ribosomal protein L 2 7a	NM_000990.2	CB119057.1	0.7	GCCACGGCCGCATAGgc aagcaccggaagc
276	Ankyrin repeating structure territory 10	NM_017664.1	BC039715.1	0.7		277	Ribosomal protein L 29	NM_000992.2	BQ335217.1	0.7	CCAAGTTCCTGAGGAac atgcgctttgcca
278	Ribosomal protein S13	NM_001017.2	CA843486.1	0.8	TTCCGTCTGATTCTAAT AGAGAGCCGGATTCAC CGTTTGGCTCGATATTAT AAGACCAAGCGAGTCC TCCCTCCCAATTGGAAA TA	277	Ribosomal protein L 29	NM_000992.2	BQ335217.1	0.7	CCAAGTTCCTGAGGAac atgcgctttgcca
278	Ribosomal protein S13	NM_001017.2	CA843486.1	0.8		279	CNDP pepx 2 (metallopeptidase M20 family)	NM_018235.1	AW502844.1	1.5	CACAGCAGCATCAAGgtggagtgcagcaac

280	Ribosomal protein S17	NM_001021.2	BE731466.1	0.5	AATTATGTTCCTGAGgtct cagccttggat
280	Ribosomal protein S17	NM_001021.2	BE731466.1	0.5	AATTATGTTCCTGAGgtct cagccttggat	281	Ribosomal protein S17	NM_001021.2	AV752729.1	0.6	GCCGCGTTCCACCAAA ACCGTGAAGAAAGCGG CCCGGGTCATCATAGAAAAGTACTACACGCGCC TGGGCAACGACTTCCA CACGAACAAGCGCGTG TGCGAGGAGATCGCCA TTATCCCCAGCAAAAA GCTCCG
282	Sulfatase 2	NM_018837.1	AB033073.2	1.5	GCGAGAGTGTGTCGAgt gagtgtgcgtctg	281	Ribosomal protein S17	NM_001021.2	AV752729.1	0.6
282	Sulfatase 2	NM_018837.1	AB033073.2	1.5	GCGAGAGTGTGTCGAgt gagtgtgcgtctg	283	Ubiquitin B	NM_018955.2	BG286180.1	1.6	GAAGGCGGAAAAGAGg tcaaaatgcagatc
284	Ubiquitin B	NM_018955.2	BG286180.1	1.4	GGTATCCGCTAACAGgtc aaaatgcagatc	283	Ubiquitin B	NM_018955.2	BG286180.1	1.6	GAAGGCGGAAAAGAGg tcaaaatgcagatc
284	Ubiquitin B	NM_018955.2	BG286180.1	1.4	GGTATCCGCTAACAGgtc aaaatgcagatc	285	Glycogen Synthase kinase 3 α	NM_019884.1	BQ927367.1	1.3	ACTTCAGTGCTGGTGgtg agggcatagcct
286	KIAA1185 albumen	NM_020710.1	BQ352354.1	1.1	GTGTTAGGAGCGGAGat accttcacttgct	285	Glycogen Synthase kinase 3 α	NM_019884.1	BQ927367.1	1.3	ACTTCAGTGCTGGTGgtg agggcatagcct
286	KIAA1185 albumen	NM_020710.1	BQ352354.1	1.1	GTGTTAGGAGCGGAGat accttcacttgct	287	Peptidyl prolyl isomerase A (cyclophilin A)	NM_021130.1	AA340318.1	0.8	CGCGTCTCCTTTGAGctgtttgcagacaag
288	Peptidyl prolyl isomerase A (cyclophilin A)	NM_021130.1	AA357116.1	0.8	TCCCAAAGACAGCAGaaaattttcgtgctc	287	Peptidyl prolyl isomerase A (cyclophilin A)	NM_021130.1	AA340318.1	0.8	CGCGTCTCCTTTGAGctgtttgcagacaag
288	Peptidyl prolyl isomerase A (cyclophilin A)	NM_021130.1	AA357116.1	0.8	TCCCAAAGACAGCAGaaaattttcgtgctc	289	Peptidyl prolyl isomerase A (cyclophilin A)	NM_021130.1	BE293161.1	0.7	CGCGTCTCCTTTGAGgtacggggcctggat
290	Imagination albumen FLJ14213	NM_024841.1	BQ919225.1	1.4	ATTGTTGAACTGGATgcg gctgttgaagag	289	Peptidyl prolyl isomerase A (cyclophilin A)	NM_021130.1	BE293161.1	0.7	CGCGTCTCCTTTGAGgtacggggcctggat
290	Imagination albumen FLJ14213	NM_024841.1	BQ919225.1	1.4	ATTGTTGAACTGGATgcg gctgttgaagag	291	Imagination albumen FLJ14213	NM_024841.1	AK055042.1	0.8	GATCAACGTTTTCAAAGGGGGTGGCTTGCAAA GCAACGAGCTCTATGCCCT
292	Ring finger protein 34	NM_025126.2	NM_194271. 1	0.9	GTCGCGGCCATGAAGgt gggggagtggtac	291	Imagination albumen FLJ14213	NM_024841.1	AK055042.1	0.8	GATCAACGTTTTCAAAGGGGGTGGCTTGCAAA GCAACGAGCTCTATGCCCT
292	Ring finger protein 34	NM_025126.2	NM_194271. 1	0.9	GTCGCGGCCATGAAGgt gggggagtggtac	293	T-complex body 1	NM_030752.1	AA160249.1	0.7	TTCTTCTTTTCCTAGgggt ctcgggaacag
294	RAB34, member RAS oncogene family	NM_031934.3	W32152.1	1.6	AAGAAGGATCTGAGTgtgagtgtgccagtg	293	T-complex body 1	NM_030752.1	AA160249.1	0.7	TTCTTCTTTTCCTAGgggt ctcgggaacag
294	RAB34, member RAS oncogene family	NM_031934.3	W32152.1	1.6	AAGAAGGATCTGAGTgtgagtgtgccagtg	295	Zinc refers to that the CCHC structural domain comprises 7	NM_032226.1	BG530408.1	0.8	ACTGGTCCATCAGTGA CAAAGACATTGAG
296	Guanine nucleotide binding protein 5	NM_052942.2	AA164465.1	1.5	AAAAAAAGAAGAAAGa ggcacaagtgaaag	295	Zinc refers to that the CCHC structural domain comprises 7	NM_032226.1	BG530408.1	0.8	ACTGGTCCATCAGTGA CAAAGACATTGAG

297	Ubiquitin-conjugate enzyme E2, J2	NM_058167.2	BG766070.1	1.4	TGCGCGGAACCCGAGat gagcagcaccagc
297	Ubiquitin-conjugate enzyme E2, J2	NM_058167.2	BG766070.1	1.4	TGCGCGGAACCCGAGat gagcagcaccagc	298	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	CCTGAGTCCAACACAG CTGGGCTGGACATATTTGCCAAATTTTCTGCCTACATCAAGAATTCAAAC CCAGCACTCAATGACA
299	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.7	CCCAGGTACCCCAAGct ggcagctctgaac	298	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8
299	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.7	CCCAGGTACCCCAAGct ggcagctctgaac	300	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	GCTGTGCCCTCCCAGgta ccccaagctggc
301	Peptidyl prolyl isomerase (cyclophilin) sample 3	NM_130906.1	BU195819.1	1.4	CCCAAAACATGTGAGgctggagtacaatgg	300	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	GCTGTGCCCTCCCAGgta ccccaagctggc
301	Peptidyl prolyl isomerase (cyclophilin) sample 3	NM_130906.1	BU195819.1	1.4	CCCAAAACATGTGAGgctggagtacaatgg	302	CAMP reactive element conjugated protein 1	NM_134442.2	BI831922.1	0.8	GCCACATTAGCCCAGgta tctatgccagca
303	Heat-shocked 70kDa albumen 8	NM_153201.1	CD655642.1	0.8	GCCTACCTTGGGAAGact gttaccaatgct	302	CAMP reactive element conjugated protein 1	NM_134442.2	BI831922.1	0.8	GCCACATTAGCCCAGgta tctatgccagca
303	Heat-shocked 70kDa albumen 8	NM_153201.1	CD655642.1	0.8	GCCTACCTTGGGAAGact gttaccaatgct	304	E74-like factor 1 (ets structural domain transcription factor)	NM_172373.2	AA251399.1	0.8	GCCAAGAAGCTTGAGA GAAGAAAAATTTCAGA AAAATTGTCTCAATTTGACTAGAATATCAATGAACCAGGAAAACTGAAGC ACCTTCCCTAAAGAAA ACTTGGGTATACAATTACTCCACAGACAGAGCT GAGGGTTTTTTACCCAAATCAGTCACTGGATTTTGCTGCCTGATACGTGAATCTTCTTGGAATTTTTCTCATGTGGATCTAAGGGGAATGCTTTATTATGGCTGCTGTTGTCCAACAG AACGACCTAGTATTTGAATTTGCTAGTAACGTCATG
305	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BX454657.1	0.8	GGCTTCACTGCTCAGgtg attatcctgaac	304		NM_172373.2	AA251399.1	0.8
305	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BX454657.1	0.8	GGCTTCACTGCTCAGgtg attatcctgaac	306	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BQ365319.1	0.8	AGCTTCTCAGACTATcca cctttgggtaag
307	Arachidonic acid 5-lipoxygenase activator	NM_001629.2	BF892107.1	0.9	AAGTGGAGCACGAAAG CAGGACCCAGAATGGG AGGAGCTTCCAGAGGA CCGGAACACTTGCCTTTGAGCGGGTCTACACTG CCAA	306	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BQ365319.1	0.8	AGCTTCTCAGACTATcca cctttgggtaag
307	Arachidonic acid 5-lipoxygenase activator	NM_001629.2	BF892107.1	0.9		308	Ribosomal protein	NM_021104.1	EXH-001	0.7	AAGAAAGATGAGGCAG

	L41				AGGTCCAAGTAAACCGCTAGCTTGTTG
	L41				AGGTCCAAGTAAACCGCTAGCTTGTTG	309	Ribosomal protein L 41	NM_021104.1	EXH-002	0.6	GAAGCGAATGCGCAGgc tgaagcgcaaaag
310	Translation control oncoprotein 1	NM_003295.1	EXH-003	0.5	AATGCATATTTAAACTAAATTGATCCTGTAGTGTTCCTGGAGAAGCTAGA GCCTGATTGTAGGCTAC TACTCATCAATTAACTTCTACAGTGGAGACTAC TTCTGGGACTGGAATATAAAAA	309	Ribosomal protein L 41	NM_021104.1	EXH-002	0.6	GAAGCGAATGCGCAGgc tgaagcgcaaaag
310	Translation control oncoprotein 1	NM_003295.1	EXH-003	0.5		311	G1 to S phase transition 1/G1 to S phase transition 1	NM_002094.1	EXH-004	1.5	ATTACCGTTTATTCCATATCTGGATAATTTGCCGA ACTTCAATAGATCAGTT GATGGACCAATCAGGC TGCCAATTGTGG
312	Cyclin T2	NM_001241.2	EXH-005	0.5	ttgtgtgagctattcaaactcttcaacc cctga	311	G1 to S phase transition 1/G1 to S phase transition 1	NM_002094.1	EXH-004	1.5
312	Cyclin T2	NM_001241.2	EXH-005	0.5	ttgtgtgagctattcaaactcttcaacc cctga	313	Cyclin T2	NM_001241.2	EXH-006	0.7	AGCCAGTTGTCATTTttac aggattgtgtg
314	Zinc finger protein 38 4	NM_133476.2	EXH-007	1.5	AGTTCAGGAGCCCTGGAAAGGAGAAGGAATAA GACGGCAGGAGGAAG AGA	313	Cyclin T2	NM_001241.2	EXH-006	0.7	AGCCAGTTGTCATTTttac aggattgtgtg
314	Zinc finger protein 38 4	NM_133476.2	EXH-007	1.5	AGTTCAGGAGCCCTGGAAAGGAGAAGGAATAA GACGGCAGGAGGAAG AGA	315	TBC1 structural domain family, the member 14	NM_020773.1	EXH-008	0.7	CTACCTAATTGATTGccc ggggccctgatt
316	F frame albumen 7	NM_012179.2	EXH-009	1.3	GGAAGCGCGGGTGGTCGGCTGGGGTCCGGCTC CTGGAGAACATGGCCCGGCCTCCCGGGGGCT	315	TBC1 structural domain family, the member 14	NM_020773.1	EXH-008	0.7	CTACCTAATTGATTGccc ggggccctgatt
316	F frame albumen 7	NM_012179.2	EXH-009	1.3		317	F frame albumen 7	NM_012179.2	EXH-010	1.4	CTGGTCCCCTCCTCGttct aatacccgatt
318	Maltin-glucoamylase (alpha-glucosidase)	NM_004668.1	EXH-011	1.4	GTAATTCAACTGCCAA GTGGTGGAAGAGGGAA ATAGAAGAACTATACAACAATCCACAGAATCCA GAGAG	317	F frame albumen 7	NM_012179.2	EXH-010	1.4	CTGGTCCCCTCCTCGttct aatacccgatt
318	Maltin-glucoamylase (alpha-glucosidase)	NM_004668.1	EXH-011	1.4		319	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BU783548.1	0.6	TCACCTGCCCAAGAGta cctttgtgttgga
320	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG615194.1	0.8	ACCCTGTACACGTATCCTGAAAACTGGAGGGCC TTCAAGGCTCTCATCGC TGCTCAGTACAGCGGG GCTCAGGTCCGCGTGC ACTCCGCACCAC	319	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BU783548.1	0.6	TCACCTGCCCAAGAGta cctttgtgttgga
320	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG615194.1	0.8		321	KIAA1037	AB028960.1	NM_015023. 2	1.1	TTGCCCCCCCGCCAGca acgctcagtatat

323	Integrin β 2	NM_000211.1	AU185877.1	1.3	GTCGCCGCCTGCCCGagt gtgtggcaggcc
323	Integrin β 2	NM_000211.1	AU185877.1	1.3	GTCGCCGCCTGCCCGagt gtgtggcaggcc	323	DKFZp586K232 2	AL080113.1	AI741782.1	0.7	CCCAGAAAGAATTTTCT GCTATTGTGTTCACTAC AACAGGATAGGGACAT CAGACAGCCCCAGAAA CCCCTTCCAGATCTGAT ATGGGACTATTAATTTTTATGCTGTTAATTGGTAT TCATTCACAATGCAGTT GAAGGGGGAAGGCTCC ACTGCATTCTTTGGCTA AGGCCTGAATGCTTGCT CATCTGTAAGATCTATA CTCGAGGTTTTGTTTTC CTTTTAAAATTCTTTAG GGAGAGAGGGATGGTT TCTGAGGGGTTCTGAA AGTATGATTCAATGTGC AACATACAGGTAGGTCT TCAGCATAAGCTGAAAT ATATGCATGTAAAAACT TTGACATCTTTTTTTTTAATTTTCCACTTTCTTCTTAACTTTACTTCTCTTTT TGTCCCCCCCCCATCTT ACAGAAGTTGAGGCCA AGGGAGAATGGTAGGC ACAGAAGAAACATGGC AAACTGCTCTGTGCTTT CAAACCAAAGTGTTCC CCCCAACCCCAAA
324	Calpain, little subunit 1	NM_001749.1	BF939173.1	1.2	CAACTTCATCAGCTGcca ggcccaggagga	323	DKFZp586K232 2	AL080113.1	AI741782.1	0.7
324	Calpain, little subunit 1	NM_001749.1	BF939173.1	1.2	CAACTTCATCAGCTGcca ggcccaggagga	325	Glyceraldehyde-3-phosphate dehydrogenase	NM_002046.2	BE255095.1	0.8	GCCAAGGTCATCCATG ACAACTTTGGTATCGTGGAAGGACTC
326	Major histocompatibility complex, class II, DP β 1	NM_002121.4	BG759187.1	0.7	GATCTGCATAAACAGggttcctgagctcac	325	Glyceraldehyde-3-phosphate dehydrogenase	NM_002046.2	BE255095.1	0.8	GCCAAGGTCATCCATG ACAACTTTGGTATCGTGGAAGGACTC
326	Major histocompatibility complex, class II, DP β 1	NM_002121.4	BG759187.1	0.7	GATCTGCATAAACAGggttcctgagctcac	327	N,O-Diacetylmuramidase (renal amyloidosis)	NM_000239.1	BE720647.1	0.8	TCGTTGTCAAAACAGA GATGTCCGTCAGTATGTTCAAGGTTGTGGAGTG TAACTCCAGAATTTTCCTTCTTCAGCTCATTTTG TCTCTCTCACATTAAGGGAGTAGGAATTAAGTG AAAGGTCACACTACCA TTATTTCCCCTTCAAAC

					AAATAATATTTTTACAG AAGCAGGAGCAAAATA TGGCCTTTCTTCTAAGA GATATAATGTTCACTAA TGTGGTTATTTTACATTAAGCCT
						328	Translation control oncoprotein 1	NM_003295.1	AA223997.1	0.8	GAAACTTGAAGAACAg agaccagaaagagt
329	Homo sapiens family 101 with sequence similarity, member B	BC014203.1	AK093557.1	0.8	CAAACCTGCTTTGCTgaaagttgcagaaaa	328	Translation control oncoprotein 1	NM_003295.1	AA223997.1	0.8	GAAACTTGAAGAACAg agaccagaaagagt
329	Homo sapiens family 101 with sequence similarity, member B	BC014203.1	AK093557.1	0.8	CAAACCTGCTTTGCTgaaagttgcagaaaa	330	N,O-Diacetylmuramidase (renal amyloidosis)	NM_000239.1	BE549820.1	0.7	AATATGAAATTTTTAAA GGAGTAGAATACCAAA TGATAGAAACAGACTG CCTGAATTGAGAATTTT GATTTCTTAAAGTGTGT TTCTTTCTAAATTGCTG TTCCTTAATTTGATTAAT TTAATTCATGTATTATGATTAAATCTGAGGCAGAT GAGCTTACAAGTATTGA AATAATTACTAATTAATCACAAATGTGAAGTTATG CATGATGTAAAAAATAC AAACATTCTAATTA
331	N,O-Diacetylmuramidase (renal amyloidosis)	NM_000239.1	BE549820.1	0.7	GGAGCAAAATATGGCC TTTCTTCTAAGAGATAT AATGTTCACTAATGTGG TTATTTTACATTAAGCCTACAACATTTTTCAGTTT GCAAATAGAACTAATAC TGGTGAAAATTTACCTA AAACCTTGGTTATCAAA TACATCTCCAGTACATT CCGTTCTTTTTTTTTTTTGAGACAGTCTCGCTCT GTCGCCCAGGCTGGAG TGCAGTGGCGCAATCT CGGCTCACTGCAACCT CCACCTCCCGGGTTCA CGCCATTCTCCTGCCTC AGCCTCCCGAGTAGCT GGGATTACGGGCGCCC GCCACCACGCCCGGCT AATTTTTTGTATTTTTAGTAGAGACAGGGTTTCA CCGTGTTAGCCAGGAT GGTCTCGATCTCCTGAC CTTGTGATCCACCCACC	330	N,O-Diacetylmuramidase (renal amyloidosis)	NM_000239.1	BE549820.1	0.7

					TCGGCCTCCCAAAGTG CTGGGATTACAGGCGT GAGCCACTGCGCCCGG CCACATTCAGTTCTTATCAAAGAAATAACCCAG ACTTAATCTTGAATGATAC
						332	The homo sapiens transfers peaceful albumen 2 (CNN2), transcribes spliceosome (transcript variant, transcriptional variation body) 1	NM_004368.1	BU630244.1	1.4	TTGTGGTTTCTATGCccg cctccgcctccc
333	Ubiquitin-specific peptase 10	NM_005153.1	W19112.1	0.8	GCAACAGTGCGACGGG CGGCCATTACACTACAGACGTCTTCCAGATCGGTCTGAATGGCTGGCTGC G	332		NM_004368.1	BU630244.1	1.4	TTGTGGTTTCTATGCccg cctccgcctccc
333	Ubiquitin-specific peptase 10	NM_005153.1	W19112.1	0.8		334	SUMO-1 activating enzymes subunit 1	NM_005500.1	BI463391.1	1.1	GTGCTGCCGGCGGCGgc tgcgggcctctcg
335	Homo sapiens's lim domain kinase 2 (LIMK2) is transcribed spliceosome 2a	NM_005569.2	BX368816.1	1.2	ATCGCCTCCGGAATGgcc tatttgcactct	334	SUMO-1 activating enzymes subunit 1	NM_005500.1	BI463391.1	1.1	GTGCTGCCGGCGGCGgc tgcgggcctctcg
335		NM_005569.2	BX368816.1	1.2	ATCGCCTCCGGAATGgcc tatttgcactct	336	Actin associated protein 2/3 complex body, the 1B of subunit, 41kDa	NM_005720.2	BI160852.1	0.9	GCGTCTGTTTCTCAGcca gcgggagccgcg
337	Tubulin, α, ubiquitous	NM_006082.1	BE278798.1	0.6	CTGTCAGTTGATTATGGCAAGAAATCCAAGCTG GAGTTCTCCATTTACC	336		NM_005720.2	BI160852.1	0.9	GCGTCTGTTTCTCAGcca gcgggagccgcg
337	Tubulin, α, ubiquitous	NM_006082.1	BE278798.1	0.6	CTGTCAGTTGATTATGGCAAGAAATCCAAGCTG GAGTTCTCCATTTACC	338	Mannosidase, α, the 2A type, the member 2	NM_006122.1	AI480034.1	1.5	GACATCGACAGCCAGgg tgcagccccgacg
339	Golgi apparatus protein 1	NM_012201.1	BC031836.1	1.2	ACATCACTGAGTATCAGTGTCACCAGTACATTACCAAGATGACGGCCATC ATTTTTAGTGATTACCGTTTAATCTGTGGCTTCA TGGATGACTGCAAAAA TGACATCAACATTCTGAAATGTGGCAGTATTCGGCTTGGAGAAAAG	338	Mannosidase, α, the 2A type, the member 2	NM_006122.1	AI480034.1	1.5	GACATCGACAGCCAGgg tgcagccccgacg
339	Golgi apparatus protein 1	NM_012201.1	BC031836.1	1.2		340	C-myc is conjugated protein	NM_012333.2	AI291757.1	1.4	GGCGCCAGCTACGCCG CTGCCGCTGTCACTATG GCCCATTACAAAGCCG CCGACTCGAAGCG
341	Relevant 4 times of lysosome	NM_014713.2	R61059.1	0.7	CTGAGAGAATGGCTGat	340	C-myc is conjugated protein	NM_012333.2	AI291757.1	1.4

	Transmembrane protein α				aatgcctgtgttc
	Transmembrane protein α				aatgcctgtgttc	342	Eukaryotic translation initiation factor 3, subunit's 6 interaction proteins	NM_016091.1	CD389782.1	0.7	CGTTCCAATCCCAAAATCTGGAATGTTCATAGTGTCCTCAATGTCCTTCATTCCCTGGTAGACAAATCCAACATCAACCGACAG TTGGAGGTATACACAA GCGGAG
343	Homo sapiens's flesh is blind-sample (fruit bat) (MBNL1), transcribe spliceosome 1	NM_021038.1	BM083621.1	0.6	TTTGTAATTAGTTATTATAAGAAGATCTAGATCCT AGATATTAGAATAAAAT TTATTTTCTACTGTATCCATTTCAAATGTTAAAAT ATTGTTTAATATTTTTGAAATCCCTGAGTATCAGG CCTTGTTATAAATAAGC TGCATAATCAATAAATA GAACAAGGGACTTTTT GTTGATAATCCAAATAC TCAAAGTTTACGTAATG AAAATTATAGCGTGTGT GCAAACTCTTGAGGGT TGATTATGCTGCAATTT AGCATGTTGGAACGTCT AGGGAGAAGGTTGACT TTTTGCACTTCTGTATATAGTCAAAAGAGAGAAA CCTGTATAATAGTAAGA TCTTATTTTGAATAAAA ACGTCTATAATTACAAG GAGTTTTGTTAAGGCTA ATACAATGACAGACTG AGCAAAATTGCTTGCA AAAGTGGCACAGAGTT AGCACTCCATACCCCTT CAAACATGTTGCTTTGC TTTCTTGTGGACAGCTT GTAGTTTGCC	342		NM_016091.1	CD389782.1	0.7
343		NM_021038.1	BM083621.1	0.6		344	Enzyme is cut amino-terminal enhancement factor (AES), transcribes spliceosome 2	NM_001130.4	BE857026.1	1.3	ATCATCCGACAGCAGctccacgcccacctg
345	Heterogeneous ribosomal protein C (C1/C2) (HNRPC) transcribes spliceosome 1, mRNA	NM_031314.1	BU570812.1	0.8	TTCAGGCCATTAAGAAGGAGCTGACCCAGATAAAACAAAAAGTGGATTCTCTCCTGGAAAACCTGGAAAAAATGGAAAAGGAAC	344		NM_001130.4	BE857026.1	1.3	ATCATCCGACAGCAGctccacgcccacctg
345		NM_031314.1	BU570812.1	0.8		346	Homo sapiens clump shape albumen	NM_032812.6	AK027529.1	0.9	TGTGAGAATACAGAAC CAGTGGAAACTTCTTCT

	Structural domain 2 (PLXDC2)				CGAACCACCACAACCA TAGGAGCGACAACCAC CCAGTTCAGGGTCCTA ACTACCACCAGAAGAG CAGTGACTTCTCAGTTTCCCACCAGCCTCCCTACAGAAG
	Structural domain 2 (PLXDC2)					347	Homo sapiens cDNA clones IMAGE:5212028, part cds	BC051834.1	AA225636.1	0.7	GTAGCCTCACTGGAGG GCATTGCCCCGGAAGA TCAAGTCGTGCTCCTG GCAGGCGCGCCCCTGG AGGATGAGGCCACTCT GGGCCAGTGCGGGGTG GAGGCCCTGACTACCC TGGAAGTAGCAGGCCG CATGCTTGGAGGTGAG TGAGAGAGGAATGTTC TTTGAAGTACCGGTAA GCGTCTAGTGAGTGTG GGGTGCATAGTCCTGA CAGCTGAGTGTCACAC CTATGGTAATAGAGTACTTCTCACTGTCTTCAGTTCAGAGTGATTCTTCCTGTTTACATCCCTCATGTTGAACACAGACGTCCA TGGGAGACTGAGCCAG AGTGTAGTTGTATTTCAGTCACATCACGAGATCCTAGTCTGGTTATCAGCTTCCACACTAAAATTAGGTCAGACCAGGGCCCCC AAAGTGCTCTATAAAATTAGAAGCTGGAAGATC CTGAAATGAAACTTAA GATTTCAAGGTCAAATATCTGCAACTTTGTTCTCATTACCTAT
348	Muriate cell interior passageway 1	NM_001288.3	AI334086.1	0.9	CTGGCTGACTGCAACct gttgccaaagtta	347	Homo sapiens cDNA clones IMAGE:5212028, part cds	BC051834.1	AA225636.1	0.7
348	Muriate cell interior passageway 1	NM_001288.3	AI334086.1	0.9	CTGGCTGACTGCAACct gttgccaaagtta	349	HLA-B associated retroviral thing 3 (BAT3) is transcribed spliceosome 3	NM_080703.1	BF025832.1	1.3	ATTCTGGCACACAGCCTGGTGGTGTTCCGAGTG CTCCCACTGGCCCCC
350	Nucleosome assembly protein 1-sample 1 (NAP1L1) transcribes spliceosome 1	NM_139207.1	BG110891.1	0.8	TTGCCCCTCCTGAAGttc ctgagagtggag	349		NM_080703.1	BF025832.1	1.3	ATTCTGGCACACAGCCTGGTGGTGTTCCGAGTG CTCCCACTGGCCCCC
350		NM_139207.1	BG110891.1	0.8	TTGCCCCTCCTGAAGttc ctgagagtggag	351	The enoyl-coenzyme A	NM_001398.1	BG333307.1	1.4	CGGCCCAACAAGAGGtg

	Hydratase 1, peroxidase				ccccaagcccgtg
	Hydratase 1, peroxidase				ccccaagcccgtg	352	EST clones CB962365.1	NM_173703.1	CB962365.1	1.1	AACACAAACTACCACct actcatgcaccta
353	Dicer1, Dcr-1 homologue (fruit bat)	NM_177438.1	BQ009528.1	0.8	ACTAAAGTCCTCCTGcca ggtagttcccac	352	EST clones CB962365.1	NM_173703.1	CB962365.1	1.1	AACACAAACTACCACct actcatgcaccta
353	Dicer1, Dcr-1 homologue (fruit bat)	NM_177438.1	BQ009528.1	0.8	ACTAAAGTCCTCCTGcca ggtagttcccac	354	Beta tubulin (TUBB)	NM_178014.2	N85882.1	0.7	TCCCATCTCAGCTTCAAGGGAGGTGTCAGCAGT ATTATCTCCACTTTCAATCTCCCTCCAAGCTCTACTCTGGAGGAGTCTGT CCCACTCTGTCAAGTG GAATCCTTCCCTTTCCAACTCTACCTCCCTCACTCAGCTCCTTTCCCCTGATCAGAGAAAGGGATCA AGGGGGTTGGGAGGGG GGAAAGAGACCAGCCT TGGTCCCTAAGCCTCCAGAAACGTCTTCTTAATCCCCACCTTTTCTTACTCCCAAAAAAGAATGAAC ACCCCTGACTCTGGAG TGGTGTATACTGCCACATCAGTGTTTGAGTCAGTCCCCAGAGGAGAGGGG AACCCTCCTCCATCTTTTTTGCAACATCTCATTTCTTCCTTTTGCTGTTGCTTCCCCCCTCACACACTTGGTTTTGTTCTATCCTACATTTGAGATTTCTATTTTATGTTGAACTTGCTGCTTTTTTTCATATTGAAAAGATGACATCGCCC CAAGAGCCAAAAATAA A
355	Immunoglobulin (Ig) κ variable chains 1-5, mRNA	BC034142.1	BC030813.1	1.2	GAGGAACTGCTCAGTT AGGACCCAGACGGAAC CATGGAAGCCCCAGCG CAGCTTCTCTTCCTCCTGC	354	Beta tubulin (TUBB)	NM_178014.2	N85882.1	0.7
355	Immunoglobulin (Ig) κ variable chains 1-5, mRNA	BC034142.1	BC030813.1	1.2		356	Immunoglobulin (Ig) κ variable chains 1-5, mRNA	BC034142.1	AF027158.2	1.2	ATGGAAACCCCAGCGC AGCTTCTCTTCCTCCTGC
357	The active beta chain V-D-J-of homo sapiens's TXi Baoshouti β-1.2-C-β	K02885.1	AF327294.1	0.8	CAAGGCACCAGACTCacagttgtagaggac	356	Immunoglobulin (Ig) κ variable chains 1-5, mRNA	BC034142.1	AF027158.2	1.2	ATGGAAACCCCAGCGC AGCTTCTCTTCCTCCTGC

	-1(TCRB)
	-1(TCRB)					358	Selenoperoxidase 4 (phospholipid hydrogen peroxidas)	NM_002085.1	AI188779.1	0.8	tgccatcaagtggaacttcaccaag
359	Secretory protein, acidity is rich in halfcystine (osteonectin)	NM_003118.1	BG424815.1	1.1	AAGCAGAAGCTGCGGgtgaagaagatccat	358	Selenoperoxidase 4 (phospholipid hydrogen peroxidas)	NM_002085.1	AI188779.1	0.8	tgccatcaagtggaacttcaccaag
359		NM_003118.1	BG424815.1	1.1	AAGCAGAAGCTGCGGgtgaagaagatccat	360	Translation control oncoprotein 1	NM_003295.1	BI909906.1	0.7	ATGGTCAGTAGGACAG AAGGTAACATTGATGA CTCGCTCATTGGTGGAAATGCCTCCGCTGAAGG CCCCGAGGGCGAAGGT ACCGAAAGCACAGTAA TCACTGGTGTCGATATTGTCATGAACCATCACCTGCAGGAAACAAGTTTC ACAAAAGAAGCCTACA AGAAGTACATCAA
361	Imagination albumen LOC552891 (LOC552891)	NM_004125.2	U31383.1	0.8	GCAGAGCTTCAACAGT ACTGTATGCAGAATGCCTGCAAGGATGCCCTGC TGGTGGGTGTTCCAGC TGGAAGTAACCCCTTC CGGGAGCCTAGATCCT GTGCTTTACTCTGAAGACTC	360	Translation control oncoprotein 1	NM_003295.1	BI909906.1	0.7
361	Imagination albumen LOC552891 (LOC552891)	NM_004125.2	U31383.1	0.8		362	The sin3 related polypeptide, 18kDa	NM_005870.3	AA346556.1	0.8	GCAGATCTACACTTGgat ggatgcaacctt
363	Acidity (rich leucine) phosphocarnic acid protein 32 family, member A	NM_006305.2	BF038728.1	1.2	TATAACGATGGAGAGGTAGATGACGAGGAAGAT GAAGAAGAGCTTGGTG	362	The sin3 related polypeptide, 18kDa	NM_005870.3	AA346556.1	0.8	GCAGATCTACACTTGgat ggatgcaacctt
363		NM_006305.2	BF038728.1	1.2	TATAACGATGGAGAGGTAGATGACGAGGAAGAT GAAGAAGAGCTTGGTG	364	Syntaxin conjugated protein 2	NM_006949.1	BQ002314.1	1.3	CGCCCCCGCCCACGCC TGGGTCTGTGTTAGGTGGGCGGCCTGGCGGCGG TGAGGGCCTCCTGCCT GGACTTTCTGC
365	Anaphase-promoting complex subunit 2	NM_013366.2	BQ045327.1	1.4	GAGGAGGAGCTGCTGgt gcgcgtgcaggcc	364	Syntaxin conjugated protein 2	NM_006949.1	BQ002314.1	1.3
365	Anaphase-promoting complex subunit 2	NM_013366.2	BQ045327.1	1.4	GAGGAGGAGCTGCTGgt gcgcgtgcaggcc	366	Integrin, α X (antigens c D11C (p150), α polypeptide)	NM_000887.3	AA251543.1	1.3	CCGACCCAGGACACCC TGACCTCTGGAGTCCC CCATCCCAGGCCCCTGTCTCCCACCCTGCTCATTGTCCACCCAAGGAGTT CCTGTCTCAACGCCGTCCCT
367	Ring finger protein 10	NM_014868.3	BM471027.1	1.4	CCTTCCTTTGCCCAGatg ctgagggttgga	366	Integrin, α X (antigens c D11C (p150), α polypeptide)	NM_000887.3	AA251543.1	1.3

368	Conjugated protein 1 (SERBP1) of SERPINE1 mRNA transcribes spliceosome 4	NM_015640.1	BC003049.1	1.1	TTTTTCACATTACAGtgg cctgaagcacga
368		NM_015640.1	BC003049.1	1.1	TTTTTCACATTACAGtgg cctgaagcacga	369	Ribosomal protein L 2 7a	NM_000990.2	BG824148.1	0.8	TGGGAAAGTTGGTATG AAGCATTACCACTTAAAGAGGAACCAGAGCTTC TGCCCAACTGTCAACC TTGACAAATTGTGGACT TTGGTCAGTGAACAGA CACGGGTGAATGCTGC TAAAAACAAGACTGGG GCTGCTCCCATCATTGATGTGGTGCGATCG
370	Actinine, α 1	NM_001102.2	AK098203.1	1.3	ATGGACACGGATGATTTCCGCGCCTGCCTGATCT CC	369	Ribosomal protein L 2 7a	NM_000990.2	BG824148.1	0.8
370	Actinine, α 1	NM_001102.2	AK098203.1	1.3	ATGGACACGGATGATTTCCGCGCCTGCCTGATCT CC	371	Karyomit(e) 6 open reading frame 62	NM_030939.2	BE813002.1	0.8	GATGTAATTGGCTGTACTCAGGAGATGGATTTCATTCTTTGGCCTCGGAATGATATTGAAAAAATCGTCTGTCTCCTGTTTTCTAGGTGGAAAGAATCTGA TGAGCCT
372	Homo sapiens's immunoglobulin (Ig) κ constant chain (cDNA clones MGC 32713)	BC034141.1	BF870126.1	1.1	AGGTGGAGATCAGACga actgtggctgcac	371	Karyomit(e) 6 open reading frame 62	NM_030939.2	BE813002.1	0.8
372		BC034141.1	BF870126.1	1.1	AGGTGGAGATCAGACga actgtggctgcac	373	The CL/CP transmembrane protein 1 of being correlated with	NM_001294.1	AK027698.1	1.3	GACGGGCCAGCCCGAC CTCACACTGCCT
374	Enoyl-coenzyme A hydratase 1, peroxidase	NM_001398.1	CB268506.1	1.0	GAACGCAGTAGACGAAGGCGGCGGCGTAGGCGGCGGGGATAGTGGCTTCTCGCAGACTCCGCG	373	The CL/CP transmembrane protein 1 of being correlated with	NM_001294.1	AK027698.1	1.3	GACGGGCCAGCCCGAC CTCACACTGCCT
374	Enoyl-coenzyme A hydratase 1, peroxidase	NM_001398.1	CB268506.1	1.0		375	The film fourth finger (C3HC4) of being correlated with	NM_145021	EXH-PBMP 0572-01	1.5	GCCACTGTGAAGGAGA TGATGAGAGCCCCCTG ATCACCCCCTGCCACTGCACAGGAAGCCTCCAC TTCGTGCACCAGGCCT GCCTGCAGCAGTGGAT CAA
376	Maltin-glucoamylase (alpha-glucosidase)	NM_004668	EXH-PBMO1078-01	1.3	GGGAGCAGATATCTGT GGGTTCTTTCAAGATGCTGAATATGAGATGTGTGTTCGCTGGATGCAGCTG GGGGCCTTTTACCCCTTCTCAAGAAACCACAAC ACCATTGGGA	375	The film fourth finger (C3HC4) of being correlated with	NM_145021	EXH-PBMP 0572-01	1.5

377	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.8	TGCCATCACCTAGCTGCCTGCACCTGCCCTTCAGGGAGATGGGGGTCATT AAAGGAAACTGAACAT TGA
377	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.8		378	N-acetylglucosamine (GlcNAc) transferring enzyme that O-connects	NM_181673.1	AW002377.1	0.6	CTCTGGTTGAAGCTTTG CTTATTGTAACAGGCTT TTATTTCCAGGTAATAT GTCTTGGAAGACTTAAT TCTGATTAGAGATATAG ATATTACTGGAAACTAA TTGTTTTTTTTCTATTGTACTCTGCTTTATCAAAG AAGTAAAACATTTAAAT CGTACTACAGAAATTAA GATGTTGTCTTGCGATC CTTAATAAAT
379	Homo sapiens cDNA:FLJ22720fis, clone HSI14320	AK026373.1	BG699574.1	0.7	TTTTCCTTTGGCAGGaaggtgtcttgctgc	378		NM_181673.1	AW002377.1	0.6
379	Homo sapiens cDNA:FLJ22720fis, clone HSI14320	AK026373.1	BG699574.1	0.7	TTTTCCTTTGGCAGGaaggtgtcttgctgc	380	The cell homologue of the fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AW795076.1	0.8	CTGGAGGGCATTGCCC CGGAAGATCAAGTCGT GCTCCTGGCAGGCGCG CCCCTGGAGGATGAGG CCACTCTGGGCCAGTG CGGGGTGGAGGCCCTG ACTACCCTGGAAGTAG CAGGCCGCATGCTTGG AGGTGAGTGAGAGAGG AATGTTCTTTGAAGTACCGGTAAGCGTCTAGTG AGTGTGGGGTGCATAG TCCTGACAGCTGAGTG TCACACCTATGGTAATAGAGTACTTCTCACTGTCTTCAGTTCAGAGTGATTCTTCCTGTTTACATCCCTCATGTTGAACACAGA CGTCCATGGGAGACTG AGCCAGAGTGTAGTTG TATTTCAGTCACATCACGAGATCCTAGTCTGGTTATCAGCTTCCACACTAAAATTAGGTCAGACCAG GGCCCCCAAAGTGCTC TATAAAATTAGAAGCTGGAAGATCCTGAAATGA AACTTAAGATTTCAAG GTCAAATATCTGCAACT

					TTGTTCTCATTACCTATTGGGCGCAG
					TTGTTCTCATTACCTATTGGGCGCAG	381	The cell homologue of the fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	W05251.1	0.7	TTCCCTGGCCCGTGCTGGAAAAGTGAGAGGTCA GACTCCTAAGGTGAGT GAGAGTATTAGTGGTCATGGTGTTAGGACCTTTTTTCCTTTCACAGCTAAACCAAGTCCCTGGGCTC TTACTCGGTTTGCCTTCTCCCTCCCTGGAGATGAGCCTGAGGGAAGGGAT GCTAGGTGTGGAAGAC AGGAACCAGGGCCTGA TTAACCTTCCCTTCTCCAGGTGGCCAAACAGGA GAAGAAGAAGAAGAA GACAGGTCGGGCTAAG CGGCGGATGCAGTACA ACCGGCGCTTTGTCAA CGTTGTGCCCACCTTTGGCAAGAAGAAGGGCCC CAATGCCAACTCTTAAGTCTTTTGTAATTCTGGCTTTCTCTAATAAAAAAGCCACTTAGTTCA
382	Pyruvate kinase, flesh (PKM2) is transcribed spliceosome 1	NM_002654.3	AI186154.1	1.2	TTGCCATGAATGTTGgcaaggcccgaggct	381		NM_001997.2	W05251.1	0.7
382	Pyruvate kinase, flesh (PKM2) is transcribed spliceosome 1	NM_002654.3	AI186154.1	1.2	TTGCCATGAATGTTGgcaaggcccgaggct	383	Translation control oncoprotein 1	NM_003295.1	AA223997.1	0.6	AGATTACATGAAATCaat caaaggggaact
384	Translation control oncoprotein 1	NM_003295.1	BC040008.1	0.6	TGAAGAACAGAGACCAGAAAGAGTAAAACCTTTTATGACAGGGGCTGCAGAACAAATCAAGCACATCCTTGCTAAT	383	Translation control oncoprotein 1	NM_003295.1	AA223997.1	0.6	AGATTACATGAAATCaat caaaggggaact
384	Translation control oncoprotein 1	NM_003295.1	BC040008.1	0.6		385	N,O-Diacetylmuramidase	NM_000239.1	BE720647.1	0.9	AGGCATTAGAGCATGggt ggcatggagaaa
386	Cold shock territory albumin A	NM_003651.3	BC009744.1	1.6	GGCCCTCCCCGGAATgct ggtgagattgga	385	N,O-Diacetylmuramidase	NM_000239.1	BE720647.1	0.9	AGGCATTAGAGCATGggt ggcatggagaaa
386	Cold shock territory albumin A	NM_003651.3	BC009744.1	1.6	GGCCCTCCCCGGAATgct ggtgagattgga	387	Beta-2-microglobulin	NM_004048.2	AV734235.1	0.8	AGCAGCATCATGGAGgtt tgaagatgccgc
388	The homo sapiens transfers peaceful albumen 2 (CNN2), transcribes spliceosome 1	NM_004368.1	BX371275.1	1.1	CCTCCTGAGTAGCTAGGACTGCAGGTGCTCCAC CACGCCCGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCCCCATGTTGGCCAGGCTGGTCTCG	387	Beta-2-microglobulin	NM_004048.2	AV734235.1	0.8	AGCAGCATCATGGAGgtt tgaagatgccgc

					AACTCCTGGCCTCAGG TGTGATCCGCCCGCCTCCGCCTCCCCAAGCGCT GAGATTACAGGTGTGA GCCACCGTGCCCAGGC CCTCAGTAGGTTTT
						389	PBX/ knotting dna homolog frame 1 (PKNOX1) transcribes spliceosome 1	NM_004571.3	NM_197976. 1	1.1	GCTGGGATTACAGGTgtg agccaccgcgcc
390	The VIIa of cytochrome c oxidase subunit polypeptide 2 samples (COX7A2L)	NM_004718.2	BG496431.1	0.7	CCCTTTGAAGTTCCTTT TTCATTGTTAAATTAAA ATTTTTTTTTTTACTTGGATGGCTTAACATTTTTG CAAGAAAAATAGGAAG ATATGAAGATGATGTTT TGGTTTGTTTATGAAAT GCATATGGCTTGTCAGA GCTCATTCGACAGTTAA AGCCATTGTTTAAAGA AATGGTGCTTTGCTCTG TGTTTGTGCTCCTGATT TCCCTGGAGGTTCTGGA TGAAGGCTGAACACAG GCTTGTTAATGTCAGTC TGTGCTGAGGACCTCA GGGACTTGAGGTTGCA TTTTTGAGCATGGGGTG CAGGAGCCTTTCTGGAT TTGGATGTGGCTATGGA AAGAACACAGAAGCCA AGGTCATGTGCATGAAA TGAGGAGTTTGAGTTA GTCACCTCGGGGATTTT TTCCATTTTGCAGTAAA ATGTTAAATTAATGTAG CCTGCCTCTATTTGTTG GGCAGGTAATTTCAAA GGGTTATTTGCCTCATC TCCTATCTTTAGTG	389		NM_004571.3	NM_197976. 1	1.1	GCTGGGATTACAGGTgtg agccaccgcgcc
390		NM_004718.2	BG496431.1	0.7		391	Acceptor accessory protein 5 (REEP5),	NM_005669.3	BF589237.1	0.7	TATATTAAATTCTGAATGCAATTTTTTTTTGTTCC CTTGAGACCAAAATTTA AGTTAACTGTTGCTGGC AGTCTAAGTGTAAATGT TAACAGCAGGAGAAGT TAAGAATTGAGCAGTT CTGTTGCATGATTTCCC AAATGAAATACTGCCTT

					GGCTAGAGTTTGAAAAACTAATTGAGCC
					GGCTAGAGTTTGAAAAACTAATTGAGCC	392	Acceptor accessory protein 5 (REEP5),	NM_005669.3	BF589237.1	0.6	TGTGCCTGGCTAGAAaa caagcgtttattt
393	Nf (red corpuscle source 2), 45kDa (NFE2),	NM_006163.1	BC005044.1	1.5	TGGGCTTTCCGGGAAC CTGGACCAGACTCTGG CCCAGTAGGATGTCCCCGTGTCCTCCCCAGCAG AGCAGGAACAGGGTGA TACAGCTGTCCACTTCAGAGCTAGGAGAGATGG AACTGACTTGGCAGGA GATCATGTCCATCACCGAGCTGCAG	392	Acceptor accessory protein 5 (REEP5),	NM_005669.3	BF589237.1	0.6	TGTGCCTGGCTAGAAaa caagcgtttattt
393	Nf (red corpuscle source 2), 45kDa (NFE2),	NM_006163.1	BC005044.1	1.5		394	Nf (red corpuscle-source 2), 45kDa (NFE2),	NM_006163.1	BC005044.1	1.3	GTGACTCCACCACAGgtttctagagccatc
395	F frame albumen 7	NM_012179.2	BF727126.1	2.1	AATGACGACAGTATGtta gggcctagtcaa	394	Nf (red corpuscle-source 2), 45kDa (NFE2),	NM_006163.1	BC005044.1	1.3	GTGACTCCACCACAGgtttctagagccatc
395	F frame albumen 7	NM_012179.2	BF727126.1	2.1	AATGACGACAGTATGtta gggcctagtcaa	396	Cornichon homologue 4 (fruit bat) (CNIH4)	NM_014184.1	BI196635.1	0.8	ATACATTATGGTGCCGAGTGGTAACATGGGAGT GTTTGATCCAACAGAA ATACACAATCGAGGGC AGCTGAAGTCACACAT GAAAGAAGCCATGATC AAGCTTGGTTTCCACTTGCTCTGCTTCTT
397	Cornichon homologue 4 (fruit bat) (CNIH4)	NM_014184.1	BI752106.1	0.7	GGCAGCTGAAGTCACA CATGAAAGAAGCCATG ATCAAGCTTGGTTTCCACTTGCTCTGCTTCTTCATGTATCTTTATAG	396	Cornichon homologue 4 (fruit bat) (CNIH4)	NM_014184.1	BI196635.1	0.8
397	Cornichon homologue 4 (fruit bat) (CNIH4)	NM_014184.1	BI752106.1	0.7		398	Lysosome 4 the transmembrane protein α that are correlated with	NM_014713.2	BE314894.1	0.8	GTAGTAAACCTATTGATGGCAATTTTGCTGACTGTGGAAGTGACTCATCC AAACTCCATGCCAGCT GTCAACATTC
399	Contain BAT2 territory 1	NM_015172.1	AB029019.2	1.2	CCCAGCTCCAACCCCC ATCCTTGCCTCAGTTTCAACCCCAGCTTCTGTC ACCATTCTTGCCTCAGCCTCAATTCCCATTCTTGCTTCAGCCCTAGCATCA ACTTCAGCTCCAACGC CAGCCCCAGCAGCCTC TTCCCCAGCTGCCCCA GTCATCACAGCACCAA CTATCCCAGCCTCAGCCCCAACTGCCTCAGTCC	398		NM_014713.2	BE314894.1	0.8

					CACTTGCCCCTGCCTCAGCTTCAGCCCCAGCCC CAGCCCCTACCCCAGT CTCAGCCCCAAATCCTGCCCCACCTGCCCCAGC CCAGACTCAGGCACAG ACCCACAAACCAGTCC AGAATCCACTACAGACTACATCTCAGTCTTCAAAACAACCACCACCATCA ATTAGGCTGCCTTCAGCTCAAACACCTAATGGC ACAGATTATGTAGCCTCAGGAAAATCCATCCAG ACCCCACAGTCACATG GCACTCTGACAGCTGA ATTATGGGATAACAAGGTGGCCCCACCAGCTGT GCTGAATG
						400	Adenosine deaminase, RNA is special	NM_015841.1	BQ448703.1	1.7	TTCTGAGATTCTTTCcttg tgatctgaatg
401	The microtubule monoxygenase of being correlated with is transferred peaceful albumen and is contained LIM structural domain 2	BC048206.1	AW015234.1	1.1	GTATTTGTGCAGATCCT GGCCAGTACAAAGTCG TTGCTCTTGTCTTATCTTCTCTTACAGAGTCTCCC TCCCTTTATAGAATGTC AACCAAAGAGTGCCCT CCTCCCCTCTCAGCCTC CTCTTTAGCTAGCCTCC CCATCTCATCACAACGC ATGTCTGTGACCTTTGG TAATCATTTACAGTGCC ACACGGAACCCTGTATT TTGCACACAGCAAAAC AAACAATGTTTAGCTTT ATTTATGGTATTTGATGCTGTAAATGGAAATAAAT	400	Adenosine deaminase, RNA is special	NM_015841.1	BQ448703.1	1.7	TTCTGAGATTCTTTCcttg tgatctgaatg
401		BC048206.1	AW015234.1	1.1		402	The microtubule monoxygenase of being correlated with is transferred peaceful albumen and is contained LIM structural domain 2	BC048206.1	AW015234.1	1.4	TGCTGCACGCTCACTgta tttgtgcagatc
403	Major histocompatibility complex, class II, DR α	NM_019111.2	AV704276.1	0.8	AGTTTGATGCTCCAAGCCCTCTCCCAGAGACTA CAGAGAACGTGGTGTG TGCCCTGGGCCTGACT GTGGGTCTGGTGGGCA TCATTATTGGGACCATCTTCATC	402		BC048206.1	AW015234.1	1.4	TGCTGCACGCTCACTgta tttgtgcagatc

404	The blind sample of homo sapiens's flesh (fruit bat) (MBNL1) is transcribed spliceosome 1	NM_021038.1	BM083621.1	0.6	TCAGTGGTTTATTGTTC ACAAAAAAATCTTCAA AACAAGTATTGACTTTC ACAAAATTTAAATCATA AACAGGCAAACCAAAC AGCACACTGTAGCTATA GTTGTTATGTGATTGTT TTTTAATTGCTGTAGGA TCCTGTTCTTTCAGCAG GTGAAAAATAAAACGC AGTTCAAATTTCATGGT TTTAATTTTCAACTCAG AAGCACTCAAAAATGC AAAATGTGATAATGGGC ACTTGTTTAAAAGAATT AGTGTATCCAGCCTTCA CTCCAGCTGGTTAAAA ATGTTGCACTTATCAGC AACCCTACCACTTTCAT CTGCTGAAAGGACAAA TGTGCTTGGTTTTACTA TTATGTAATCACAACTT ACTTTCTGCTTGTAGTT GCTTAAAATTATGTATTTTGTCTTGGGCTGCAATT TGTTTTATGCTTATTTTATTATTACTGCAGTAGTT GACTTTGCTGTATGGAA AAATAAAGTGAAATTG CCCTAATAAAAC
404		NM_021038.1	BM083621.1	0.6		405	Stride film 4-structural domain, subfamily A, member 6A	NM_022349.2	NM_152851.1	0.5	TCTGACTTCCCTGGGagtgtacttttcctg
406	Contain calm territory and WD duplicate domain 1 (BRWD1), transcribe spliceosome 2	NM_033656.1	NM_018963. 2	0.8	TTGCACTTGCTGGTCTT TGTAGCAGCATTCAGC ACAGGTGCCAAAATAT GCTTCATTTTGGGGGCA GATCTATTTTGACAGTA TTTGACTACATATAGCA AGAGTTTGAAATATGTT AAACACTAGACATCCT GGTTATCAAAACCAATG AGCATTACTTTCATGGC AGCAAGTGTCATGCAG TTATTTTCTGAATTTGTCAAAGAGGCAGTAGTTT CTAACCCCTGTTCTATA GTAGTTACAACAATTTC ACAACCTATGTTTACAG	405	Stride film 4-structural domain, subfamily A, member 6A	NM_022349.2	NM_152851.1	0.5	TCTGACTTCCCTGGGagtgtacttttcctg

					ATTCTTCATAAATACAT GCATACTGACACTATAA TCATGGGAGGTGTAAC CATGATTAGTAGGCGAG GTACCTACCACTTTTTT TTTTTTCTTCCCCTGGC TACTTGAGTAGAATGCA TTATACCAGATCTGGTC ACTTTCATTGAAATGGT TTCTAATTTTCTTCCCA AGTGCTGTTGGGTTTTT TTCTTCTTAAGGAAAAC GTTGTCACTTTTATGTTATAAACTTGAAT
						407	Karyomit(e) 19 open reading frame 22	NM_138774.2	AI375989.1	1.2	GCCTCTGCCCTTGCACTACCTTGTCTGTCACCCCATCCCGTGTCCCCTCGTCCCCCAGCCTGACTCCTGCCTGATAGCTCCTGTGTCCCCATGCTGGTCCTCCTGGCCCAGGCTGCAG GAGCCAGGCTGGGGGG CCTCCGCACCCCCTTGCTGCGTGTGGGTAATTGTGTTTTGGGGGAAAGTG GGGAATTTAATAAATTTCTGGTGCT
408	CD97 antigen	NM_001784.2	BI030515.1	1.3	GGAGTCCACAGCCAGac gctttcccgattc	407	Karyomit(e) 19 open reading frame 22	NM_138774.2	AI375989.1	1.2
408	CD97 antigen	NM_001784.2	BI030515.1	1.3	GGAGTCCACAGCCAGac gctttcccgattc	409	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	BF311566.1	0.4	gtagaagccctcatgctgagCTTTGTGTCC
410	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	BF311566.1	0.7	CGTAGGGAGATTTGGgtagaagccctcatg	409	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	BF311566.1	0.4	gtagaagccctcatgctgagCTTTGTGTCC
410	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	BF311566.1	0.7	CGTAGGGAGATTTGGgtagaagccctcatg	411	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	BF311566.1	0.7	AGCCCTCATGCTGAGctttgtgtccctggt
412	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BM475798.1	0.8	AGCAGCTGGCTTCACtg ctcaggtgattat	411	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	BF311566.1	0.7	AGCCCTCATGCTGAGctttgtgtccctggt
412	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BM475798.1	0.8	AGCAGCTGGCTTCACtg ctcaggtgattat	413	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BM999355.1	0.9	GTGATTATCCTGAACCATCCAGGCCAAATAAGC GCCGGCTATGCCCCTGTATTGGATTGCCACACGG CTCACATTGCATGCAAGTTTGCTGAGCTGAAGG AAAAGATTGATCGCCG TTCTGGTAAAAAGCTG

					GAAGATGGCCCTAAATTCT
					GAAGATGGCCCTAAATTCT	414	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	AU120105.1	0.8	GCTGACTGTGCTGTCCTGATTGTTGCTGCTGGTGTTGGTGAATTTGAAGCTGGTATCTCCAAGAATGGGCAGACCCGAGAGCAT GCCCTTCTGGCTTACAC ACTGGGTGTGAAACAA CTAATTGTCGGTGTTAACAAAATGGATTCCACTGAGCCACCCTACAGCCA GAAGAGATATGAGGAA ATTGTTAAG
415	Adducin 1 (α) (ADD1) is transcribed spliceosome 4	NM_176801.1	AI962551.1	1.1	TCATGTGGCATTCTCTCTGCTCAGTGATCTCACTTAAATCTATATACAAAGCCTTGGTCCCGTGAAA ACACTCGTGTGCCCAC CAGCGGCCTTGAAGAG GCAGGTCTGGGCCAGA TGCTGGGCAGGAAACC CCAGCGGCAGATGGGC CTGTGTGCACCCAACG TGATGCTATGCATGTCTGACCGACGATCCCTCG ACCAGAATCAGATTCA GGAGCTCAGTTTCTTTTTCACTTGGGTCTCTGGATTCCTGTCATAGGGAAGGTATATCAGGAGGGGA AGAGGCCTTTCTAGAATTTTCTTTGAGCAGGTTTACAATTTAGCTTACATTTTTCGACTGTGAACGT GAATAGGCTGCTTTTTGCTTTCTTCTTTCCAGACCCCACAGTAGAGCACT TTTCACTTATTTGGGGGAGGCTTCAGGGGACTG TTCTCACCTTAACTCAGCCAGAAAGATGCCCTA GTTGTGATCAAAGGTA ACTCGAGGTGGAGGGT AGCCCT	414	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	AU120105.1	0.8
415	Adducin 1 (α) (ADD1) is transcribed spliceosome 4	NM_176801.1	AI962551.1	1.1		416	CD97 antigen	NM_001784.2	BF763029.1	1.3	GCTCCGGGCAGCATCA GTGTGACAGCTCCACC GTCTGCTTCAACACCGTGGGTTCATACAGCTGCC

					GCTGCCGCCCAGGCTGGAAGCCCAGACACGGAATCCCGAATAACCAAAAGGACACTGTCTGTGAAG
						417	Homo sapiens's imagination protein D KFZp761A052	BC009917.1	BI914208.1	1.1	CCCCGGAAAGCCAGCG CCACATGCAGTTCGGC CACAGCAGCAGCCTCC AGTGGCCTGGAGGAGT GGACTAGCCGGTCCCC GCGGCAGCGGAGTTCA GCCTCGTCACCTGAGC ACCCTGAGCTGCATGCTGAATTGGGCATGAAGC CCCCTTCCCCAGGCACTGTTTTAGCTCTTGCCAAACCTCCTT
418	Translation control oncoprotein 1	NM_003295.1	BI909906.1	0.6	AGATTACATGAAATCaat caaagggaaact	417	Homo sapiens's imagination protein D KFZp761A052	BC009917.1	BI914208.1	1.1
418	Translation control oncoprotein 1	NM_003295.1	BI909906.1	0.6	AGATTACATGAAATCaat caaagggaaact	419	Cold shock territory albumin A	NM_003651.3	BU665383.1	1.8	CCCACGACCTGCCCCA GCAGTTGGAGAGGCTG AAGATAAAGAAAATCA GCAAGCCACCAGTGGT CCAAACCAGCCGTCTG TTCGCCGTGGATATCGGCGTCCCTACAATTACCGGCGTCGCCCGCGTCCT CCTAACGCTCCTTCACAAGATGGCAAAGAG
420	Cold shock territory albumin A	NM_003651.3	BF740038.1	1.5	GGTGCAGAAGCTGCCA ATGTGACTGGCCCGGATGGAGTTCCTGTGGAAG GGAGTCGTTACGCTGC AGATCGGCGCCGTTAC AGACGTGGCTACTATGGAAGGCGCCGT	419	Cold shock territory albumin A	NM_003651.3	BU665383.1	1.8
420	Cold shock territory albumin A	NM_003651.3	BF740038.1	1.5		421	Kynureninase (L-kynurenine hydrolase) (KYNU) is transcribed spliceosome 1	NM_003937.2	BG220595.1	0.8	TCTGTGAGATGAATTTAAAAGTGCCTCAGAATG CAGTTGCCCTTATTGTG
422	Tubulin, α 1 (TUBA1),	NM_006000.1	AL533321.2	1.2	CGTGAATGCATCTCAGTCCACGTGGGGCAGGCA GGTGTCCAGATGGGCA ATGCCTGCTGGGAGCT CTATTGCTTGGAACATGGGATTCAGCCTGATGG GCAGATGCCCAGTGAC AAGACCATTGGTGGAG	421		NM_003937.2	BG220595.1	0.8	TCTGTGAGATGAATTTAAAAGTGCCTCAGAATG CAGTTGCCCTTATTGTG

					GGGACGACTCCTTCAC CACCTTCTTCTGTGAAACTGGTGCTGGAAAACA CGTACCCCGGGCAGTT TTTGTGGATCTGG
						423	Syntaxin conjugated protein 2	NM_006949.1	CD722977.1	1.2	CCTGCCCCGAGCCCCTGTTCAGTGAGCTAGGCCGCTCTCGTCTGGCAA AGGTGGTGAAGACGTTGAAGGAGATTCACCTTGCCTTCCTC
424	F frame albumen 7	NM_012179.2	BX648151.1	1.3	CTTTTACCCGACAAGcac tgaacctaccag	423	Syntaxin conjugated protein 2	NM_006949.1	CD722977.1	1.2
424	F frame albumen 7	NM_012179.2	BX648151.1	1.3	CTTTTACCCGACAAGcac tgaacctaccag	425	Ribosome protein S 4-9, (RPS4X) that X-connects,	NM_001007.2	CB150953.1	1.1	CCTGAGGAGGCCAAGtacaagttgtgcaaa
426	Ribosomal protein S17	NM_001021.2	AV752729.1	0.5	CAACAAGATAGCAGGtta tgtcacgcatct	425	Ribosome protein S 4-9, (RPS4X) that X-connects,	NM_001007.2	CB150953.1	1.1	CCTGAGGAGGCCAAGtacaagttgtgcaaa
426	Ribosomal protein S17	NM_001021.2	AV752729.1	0.5	CAACAAGATAGCAGGtta tgtcacgcatct	427	Actin muscle, β (ACTB),	NM_001101.2	BE930510.1	1.4	AGCCTTCCTTCCTGGgca tggagtcctgtg
428	Actin muscle, β (ACTB),	NM_001101.2	BM927346.1	1.3	TTCCAGCCTTCCTTCcct gggcatggagtc	427	Actin muscle, β (ACTB),	NM_001101.2	BE930510.1	1.4	AGCCTTCCTTCCTGGgca tggagtcctgtg
428	Actin muscle, β (ACTB),	NM_001101.2	BM927346.1	1.3	TTCCAGCCTTCCTTCcct gggcatggagtc	429	Zinc refers to, contains CCHC structural domain 7	NM_032226.1	BQ422572.1	0.8	CGGGGTCAATGTCAGA TTTAGTCATGCTGTTATT TTAGCCCAGTGGTCCA G
430	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	AW873139.1	0.8	GTGCGGAGCTCTGGAC TGGGATTAAGAAGGGG CCCCCACGCAAACTCA AATTCCCTGAGCCTCAAGAGGTGGTGGAAGAGT TGAAGAAGTACCTGTC GTAGGGAGATTTGGGT AGA	429	Zinc refers to, contains CCHC structural domain 7	NM_032226.1	BQ422572.1	0.8	CGGGGTCAATGTCAGA TTTAGTCATGCTGTTATT TTAGCCCAGTGGTCCA G
430	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	AW873139.1	0.8		431	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	AW873139.1	0.7	GCCCGGACGGCAGCAgtgcggagctctgga
432	Eukaryotic translation elongation factor 1 α 1	NM_001402.4	BX454657.1	0.9	CATCCAGGCCAAATAA GCGCCGGCTATGCCCCTGTATTGGATTGCCACACGGCTCACATTGCATGCAAGTTTGCTGAGCTGAA GGAAAAGATTGATCGC CGTTCTGGTAAAAAGC TGGAAGATGGCCCTAA ATTCTTGAAGTCTGGTGATGCTGCCATTGTTGATATGGTTCCTGGCAAGC	431	Karyomit(e) 11 open reading frame 31 (C11orf31),	NM_170746.1	AW873139.1	0.7	GCCCGGACGGCAGCAgtgcggagctctgga

					CCATGTGTGTTGAGAG CTTCTCAGACTATCCACCTTTGG
					CCATGTGTGTTGAGAG CTTCTCAGACTATCCACCTTTGG	433	CDNA FLJ90737fis, clone PLACE1010827	AK075218.1	AV748031.1	0.8	AAAATTATATAGATATTTGCTTTTCTGCTGGTTTT TTTTTTTTAATTGCAAC TGCTTTTCTGCCGTGCC TCTCTTCCCTACCCGTG ATG
434	The interleukin-22 acceptor, γ (IL2RG)	NM_000206.1	EXH-PBMO 0419-01	1.2	GACGATGCCCCGAATTCCCACCCTGAAGAACCT AGAGGATCTTGTTACTGAATAC	433	CDNA FLJ90737fis, clone PLACE1010827	AK075218.1	AV748031.1	0.8
434	The interleukin-22 acceptor, γ (IL2RG)	NM_000206.1	EXH-PBMO 0419-01	1.2	GACGATGCCCCGAATTCCCACCCTGAAGAACCT AGAGGATCTTGTTACTGAATAC	435	The interleukin-22 acceptor, γ (IL2RG)	NM_000206.1	EXH-PBMO 0419-01	1.3	CACGGGAACTTTTCGgc ctggagtggtgtg
436	Translation control oncoprotein 1	NM_003295.1	PBMNOP_C 1221_1	0.5	AGGCATTGTTTTTAAGAAAAACATGTCATGTAG GTTGTCTAAAAATAAAATGCATTT	435	The interleukin-22 acceptor, γ (IL2RG)	NM_000206.1	EXH-PBMO 0419-01	1.3	CACGGGAACTTTTCGgc ctggagtggtgtg
436	Translation control oncoprotein 1	NM_003295.1	PBMNOP_C 1221_1	0.5	AGGCATTGTTTTTAAGAAAAACATGTCATGTAG GTTGTCTAAAAATAAAATGCATTT	437	Translation control oncoprotein 1	NM_003295.1	PBMNOP_C 1221_1	0.4	AAACTCATTTGAGAGaat gccttttagttt

Variant SEQ ID Nos:308-318 is corresponding to new E STs

Table 2-mammary cancer is heavily distinguished the group (group 7) of 100 markers of expression

SEQID N°	Sequence description	Gene pool N ° (reference)	Gene pool N ° (variant)	C I/IIvs. health	Target sequence
SEQID N°	Sequence description	Gene pool N ° (reference)	Gene pool N ° (variant)	C I/IIvs. health	Target sequence		3	CDNA DKFZp451G151 (rich leucine tumor-necrosis factor glycoproteins kinases 2)	AL832453.2	BU634341.1	0.8	GAATGAATTTTCTTGctgc tatgcctttct
5	CDNA DKFZp667I093 (guanine-nucleotide-binding protein, γ 2)	AL832878.1	AI223156.1	0.7	TGCAGATTTGATGGCctactgtgaagcaca		3		AL832453.2	BU634341.1	0.8	GAATGAATTTTCTTGctgc tatgcctttct
5	CDNA DKFZp667I093 (guanine-nucleotide-binding protein, γ 2)	AL832878.1	AI223156.1	0.7	TGCAGATTTGATGGCctactgtgaagcaca	7	Homo sapiens's imagination protein D KFZp761A052	BC009917.1	BC028225.1	1.4	ATGAAGAAAAACAAAgt gcacagagacccg
12	The microtubule monoxygenase of being correlated with is transferred peaceful albumen and is contained LIM structural domain 2	BC048206.1	AF052170.1	1.4	TGGGAGGGTCGACCTTG ATCATGAAACAATACCA TGAGGGGGCCTCTGTCA CCTTTGAAAAGAACACT TTTTGAGCAGCCTCAAA AAGCTCATACATACCAG CGCCTTCTTAAATTGGC TCTAATGTAAAGATTGTTAATGTCATTTATCAAAA	7	Homo sapiens's imagination protein D KFZp761A052	BC009917.1	BC028225.1	1.4	ATGAAGAAAAACAAAgt gcacagagacccg

					CCATAGGTGATTATTTGGAGGGATTTAAAAAACTT AATTACTCTCAGGCCTC ATCCCAAGCTTGACACA TGCTCTGTAGGTTGAAC ACATAATCACAAATATTCTAGCAAATGCTGCCTTG GTTGCAGCCTGCACTGT AGACCCAAGGGTTTTGC TGTGGCTCTTCTTATCTCCCTTGGCTCATAAAGCC CCAGATGATGCCAGAGC TTCAATTAGAGCCATCA TCATCCCAGGCAGGGAT ATCTTTGAGAAATGACT CAGTTCAGCCCCAGGCC CCTGTGACTCTGCTTAA AGCACACATTTCTGCTG ACTCTTGTACCTGGGGC AGCAGGATAATCACCAA CAC
						14	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	W17004.1	0.6	GGCCGCATGCTTGGAagg taaagtccatgg
16	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA063591.1	0.7	TGACCGGCCAGGAAAcg gtcgcccagatca	14		NM_001997.2	W17004.1	0.6	GGCCGCATGCTTGGAagg taaagtccatgg
16		NM_001997.2	AA063591.1	0.7	TGACCGGCCAGGAAAcg gtcgcccagatca	17	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA094898.1	0.6	CAGGCCGCATGCTTGagg taaagtccatgg
18	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA187006.1	0.7	AGGCCGCATGCTTGGagg taaagtccatgg	17		NM_001997.2	AA094898.1	0.6	CAGGCCGCATGCTTGagg taaagtccatgg
18		NM_001997.2	AA187006.1	0.7	AGGCCGCATGCTTGGagg taaagtccatgg	19	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA225636.1	0.6	GGCCAGGAAACGGTCgc ccagatcaaggta
23	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	BU603086.1	0.6	GAAGTAGCAGGCCGCatg cttggaggtaaa	19		NM_001997.2	AA225636.1	0.6	GGCCAGGAAACGGTCgc ccagatcaaggta
23		NM_001997.2	BU603086.1	0.6	GAAGTAGCAGGCCGCatg cttggaggtaaa	24	Finkel-Biskis-Re illy murine sarcoma virus	NM_001997.2	BF218408.1	0.6	AGGCCGATGCTTGGAggt aaagtccatggt

	The cell homologue of middle fox sequence
	The cell homologue of middle fox sequence					25	The cell homologue of fox sequence in the FinkelBiskis-Reilly murine sarcoma virus	NM_001997.2	AI499403.1	0.7	CCCGCATGCTTGGAGgta aagtccatggtt
26	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AW795076.1	0.6	CGGTCGCCCAGATCAagg ctcatgtagcct	25		NM_001997.2	AI499403.1	0.7	CCCGCATGCTTGGAGgta aagtccatggtt
26		NM_001997.2	AW795076.1	0.6	CGGTCGCCCAGATCAagg ctcatgtagcct	35	SEC14 sample 1 (S. cerevisiae)	NM_003003.1	AK130317.1	1.3	TAGGGCTAGTAGGTAGG GCTAGTAGGTAGGGCTA GTAGGTAGGGCTAGTAG GTAGGGCTAGTAGGTAG GGCTAGTAGGTAGGGCT AGTAGGTAGGGTTCGTA GGTAGGGTTCGTAGGTA GGGTTCGTAGGTAGGGT TAGTAGCGCGTCTGTGC TGCTTCCACCTGGTGCT TCCTGTTCCCAAATCAC AAGGGCCTGAAGGTGG TCCCTGCTTTCTCTTTCTCTTTCTCTGTGTCTCAG ATGGCGATTTTGCTGAC AGCTGCCAAGAAAATG CTTCACTCAACAGTCCT CATGTGCCCAGAGATGT TTATAGAACTGTTTGAA TTGCAGCCATCCCCTGC CCCCTCCCAGGCTGAAG ATCTGTTCTTTTTAAGTTGATTCGGGAGTGGCATT CTTTTATACCCAAAGAC TGTAGTGCATCTTGAAG AGCTCAAAGCACATGAC CGCACAAATGCTTACAG GGTTTCCTCCCGAGTAA TCCAATCTCACTCCCCT TGTAAGG
43	Nf (red corpuscle-source 2)-sample 1	NM_003204.1	BM973053.1	1.5	CGGGTCAGTGTACAGgaagaggcaggcact	35	SEC14 sample 1 (S. cerevisiae)	NM_003003.1	AK130317.1	1.3
43	Nf (red corpuscle-source 2)-sample 1	NM_003204.1	BM973053.1	1.5	CGGGTCAGTGTACAGgaagaggcaggcact	44	Red corpuscle derives from nf 2 samples 1	NM_003204.1	BM973053.1	1.5	TGCTGTGAGGCAGAGga atgatggagaatc
46	Synapse nucleoprotein, α is (before the amyloid	NM_000345.2	NM_007308. 1	1.4	CCACAGGAAGGAATTCTGGAAGATATGCCTGTGG ATCCTGACAATGAGGCT	44	Red corpuscle derives from nf 2 samples 1	NM_003204.1	BM973053.1	1.5	TGCTGTGAGGCAGAGga atgatggagaatc

	The non-A4 composition of body)				TAT
	The non-A4 composition of body)				TAT	47	Synapse nucleoprotein, α (the non-A4 composition of amyloid precursor)	NM_000345.2	NM_007308. 1	1.5	GACCAGTTGGGCAAGaat gaagaaggagcc
51	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0.7	AGAtcgcggacgggttgtgcctgga ggTGG	47		NM_000345.2	NM_007308. 1	1.5	GACCAGTTGGGCAAGaat gaagaaggagcc
51	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0.7	AGAtcgcggacgggttgtgcctgga ggTGG	52	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0.5	TCCGACATCTACAAGatcc gggagatcgcg
53	Translation control oncoprotein 1	NM_003295.1	BC022436.1	0.6	CCGACATCTACAAGATCCGGGAGATCGCGGACG GGTTGTGCCTG	52	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0.5	TCCGACATCTACAAGatcc gggagatcgcg
53	Translation control oncoprotein 1	NM_003295.1	BC022436.1	0.6	CCGACATCTACAAGATCCGGGAGATCGCGGACG GGTTGTGCCTG	54	Translation control oncoprotein 1	NM_003295.1	BC040008.1	0.5	GCGCCGCTCCGGCTGCACCGCGCTCGCTCCGAGTTTCAGGCTCGTGCTAAG CTAGCGCCGTCGTCGTCTCCCTTCAGTCGCCATCATGATTATCTACC
55	The TYRO protein tyrosine kinase is conjugated protein	NM_003332.1	BF092099.1	0.8	GAGGGGCTGCGGAGGcagcgacccggaaac	54	Translation control oncoprotein 1	NM_003295.1	BC040008.1	0.5
55	The TYRO protein tyrosine kinase is conjugated protein	NM_003332.1	BF092099.1	0.8	GAGGGGCTGCGGAGGcagcgacccggaaac	60	Cold shock territory albumin A	NM_003651.3	BC009744.1	1.5	CCCAACAGAATACAGgct ggtgagattgga
64	Beta-2-microglobulin	NM_004048.2	AV734235.1	0.7	ATTTGGATTGGATGAATTCCAAATTCTGCTTGCTT GCTTTTTAATATTGATATGCTTATACACTTACACTTTATGCACAAAATGTAGG GTTATAATAATGTTAACA TGGACATGATCTTCTTTATAATTCTACTTTGAGTG CTGTCTCCATGTTTGATGTATCTGAGCAGGTTGCT CCACAGGTAGCTCTAGG AGGGCTGGCAAC	60	Cold shock territory albumin A	NM_003651.3	BC009744.1	1.5	CCCAACAGAATACAGgct ggtgagattgga
64	Beta-2-microglobulin	NM_004048.2	AV734235.1	0.7		69	SEC24 genes involved family, member C (S.cerevisiae)	NM_004922.1	AW449995.1	1.8	GCAGCTGTCTGGAATgcagaggcagctgga
71	Oxyphorase, α 1/2	NM_000517.3	H78334.1	1.4	CGGTCAACTTTCAAGctc cttaagccactg	69	SEC24 genes involved family, member C (S.cerevisiae)	NM_004922.1	AW449995.1	1.8	GCAGCTGTCTGGAATgcagaggcagctgga
71	Oxyphorase, α 1/2	NM_000517.3	H78334.1	1.4	CGGTCAACTTTCAAGctc cttaagccactg	72	Oxyphorase, α 1/2	NM_000517.3	H55830.1	1.4	TCAAGGCCGCCTGGGgat gttcctgtcctt
80	Oxyphorase, α 1/2	NM_000558.3	R91899.1	1.7	ACCAAGACCTACTTCccg gtcaacttcaag	72	Oxyphorase, α 1/2	NM_000517.3	H55830.1	1.4	TCAAGGCCGCCTGGGgat gttcctgtcctt
80	Oxyphorase, α 1/2	NM_000558.3	R91899.1	1.7	ACCAAGACCTACTTCccg gtcaacttcaag	81	Oxyphorase, α 1/2	NM_000558.3	H58664.1	1.7	GGAGGCCCTGGAGAGct cctaagccactgc
85	CD164 antigen, saliva	NM_006016.3	AF299342.1	0.8	CTGTGACTCCAACCTCA	81	Oxyphorase, α 1/2	NM_000558.3	H58664.1	1.7	GGAGGCCCTGGAGAGct cctaagccactgc

	Liquid acid Saliva Orthana				CAACCTGTGCGAAAGTC TACCTTTGATGCAGCCA GTTTCATTGGAGGAATT GTCCTGGTCTTGGGTGT GCAGGCTGTAATTTTCT TTCTTTATAAATTCTGCAAATCTAAAGAACGAAAT TACCACACTCTGTAAAC AGACCCATTGAATTAAT AAGGACTGGTGATTCAT TTGTGTAACTCACTGAA GCCAAAATACTATCTTTTAAGATGTCCCACATGGA AGACGCTATTCCAGGAT CTTTAAATTTCCATGGATGCATATAGGATGTTTGG GAGCATCATCCGTGAAG AAAAAATCAATTAAATC ATTGTGTTCAACAGGAA TATTTAAAATATTCTGCATGAATCCTGTGGCTGTC TTATTTTAAATAGCTGCTGCTGTGGGATTATATTTTTTTTCCTTAACATGCCA AATATAACTTTCTGAAA GTGATGGAAAATGTTGT CTTGTGCAGACAACATC ATGGCTCTTGGCAGTTT A
	Liquid acid Saliva Orthana					86	CD164 antigen, sialomucin	NM_006016.3	AF299343.1	0.8	CAGCCAATTCTACAGctaa acccacagttc
88	Talin 1	NM_006289.2	AI393487.1	1.4	CCCAGAGTATTAACGCT CCAAGAGTATTATTAAC GCTGCTGTACCTCGATC TGAATCTGCCGGGGCCC CAGCCCACTCCACCCTG CCAGCAGCTTCCAGCCA GTCCCCACAGCCTCATC AGCTCTCTTCACCGTTT TTTGATACTATCTTCCCCCACCCCCAGCTACCCAT AGGGGCTGCAGAGTTAT AAGCCCCAAACAGGTC ATGCTCCAATAAAAATG ATTCTACCTACAA	86	CD164 antigen, sialomucin	NM_006016.3	AF299343.1	0.8	CAGCCAATTCTACAGctaa acccacagttc
88	Talin 1	NM_006289.2	AI393487.1	1.4		89	Talin 1	NM_006289.2	AI393487.1	1.4	TGCTTCGGAAGGAACga gagctggaagagg
90	Talin 1	NM_006289.2	AI417760.1	1.4	AGGAAGAAATGCTTCgg aaggaacgagagc	89	Talin 1	NM_006289.2	AI393487.1	1.4	TGCTTCGGAAGGAACga gagctggaagagg

95	Acidity (rich leucine) phosphocarnic acid protein 32 family, member B	NM_006401.1	Y07570.1	1.5	GAAGTCAGTGAGGAGgaagaagaatttgga
95		NM_006401.1	Y07570.1	1.5	GAAGTCAGTGAGGAGgaagaagaatttgga	102	Solvable galactoside-binding lectin 9 (galactose agglutinin bindin 9)	NM_009587.1	BG698264.1	0.8	CTCCAGTGGAACCAGgtt tgctgtgaactt
116	Homocysteine-derivable, er stress-derivable, ubiquitin spline structure territory member 1	NM_014685.1	BG828243.1	0.7	GGAAAACATCTCAAGgcctgaagctgccca	102		NM_009587.1	BG698264.1	0.8	CTCCAGTGGAACCAGgtt tgctgtgaactt
116		NM_014685.1	BG828243.1	0.7	GGAAAACATCTCAAGgcctgaagctgccca	120	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	CGAGAGCGCAGGATTG AGATAGAGGAGAACA
121	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	AGAAACAGGGCAAGTac ccagaagtccaca	120	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	CGAGAGCGCAGGATTG AGATAGAGGAGAACA
121	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	AGAAACAGGGCAAGTac ccagaagtccaca	125	Ribosomal protein L 4	NM_000968.2	CB141160.1	0.7	GTCATCAGACTAGTGCTGAGTCTTGGGGTACTGGCAGAGCTGTGGCTCGAATTCCCAGAGTTCGAGGTGGTGGGACTCACCGCTCTGGCCAGGGTGCTTTTGGAAACatgtgtcgtg
126	Ribosomal protein L 4	NM_000968.2	CD686462.1	0.6	GCGTGTGCTCGCCCACTGATATCGGTGTACTCCGAAAAGGGGGAGTCATC TGGCAAAAATGTCACTTTGCCTGCTGTATTCAAG GCTCCTATTCGACCAGATATTGTGAACTTTGTTCACACCAACTTGCGCAA AAACAACAGACAGCCC TATGCTG	125	Ribosomal protein L 4	NM_000968.2	CB141160.1	0.7
126	Ribosomal protein L 4	NM_000968.2	CD686462.1	0.6		137	Ubiquitin B	NM_018955.2	AA206538.1	1.4	CAGGTCAAAATGCAGatc ttcgtgaaaacc
138	Ubiquitin B	NM_018955.2	AA206538.1	1.3	CAGGTCAAAATGCAGatc ttcgtgaagacc	137	Ubiquitin B	NM_018955.2	AA206538.1	1.4	CAGGTCAAAATGCAGatc ttcgtgaaaacc
138	Ubiquitin B	NM_018955.2	AA206538.1	1.3	CAGGTCAAAATGCAGatc ttcgtgaagacc	139	Ubiquitin B	NM_018955.2	AA340917.1	1.4	AGATCTTCGTGAAGACCCTGACCGGCAAGACCATCACTCTGGAGGTGGAG CCCAGTGACACCATCGAAAATGTGAAGGCCAAG ATCCAAGATAAAGAAGGCATCCCCCCCGACCAGCAGAGGCTCATCTTTGCAGGCAAGCAGCTGGAAG ATGGCCGCACTCTTTCT

					GACTACAACATCCAGAA AGAGTCGACCCTGCAC CTGGTCCTGCGCCTGAG GGGTGGCTGTTAATTCT TCAGTCATGGCATTCGC AGTGCCCAGTGATGGCA TTACTCTGCACTATAGCCATTTGCCCCAACTTAAG TTTAGAAATTACAAGTT TCAGTAATAGCTGAACC TGTTCAAAATGTTAATA AAGG
						140	Ubiquitin B	NM_018955.2	BU661443.1	1.4	TCCCTGTGGGTGGACGTGGTTGGTGATTGGCAGGATCCT
141	Ubiquitin B	NM_018955.2	BU661443.1	1.5	GGTTGGCTTTGTTGGgtg agcttgtttgtg	140	Ubiquitin B	NM_018955.2	BU661443.1	1.4	TCCCTGTGGGTGGACGTGGTTGGTGATTGGCAGGATCCT
141	Ubiquitin B	NM_018955.2	BU661443.1	1.5	GGTTGGCTTTGTTGGgtg agcttgtttgtg	145	Major histocompatibility complex, class II, DR α	NM_019111.2	CD686254.1	0.7	TCAGAGACAGTCTTCCT GCCCAGGGAAGACCAC CTTTTCCGCAAGTTCCA CTATCTCCCCTTCCTGCC CTCAACTGAGGACGTTT ACGACTGCAGGGTGGA GCACTGGGGCTTGGATG AGCCTCTTCTCAAGCAC TGGGagtttgatgctccaagccctctc
147	KIAA1191 albumen	NM_020444.2	BI254429.1	1.5	GCAGCAGGATCACAGaa cagacccaggaaa	145	Major histocompatibility complex, class II, DR α	NM_019111.2	CD686254.1	0.7
147	KIAA1191 albumen	NM_020444.2	BI254429.1	1.5	GCAGCAGGATCACAGaa cagacccaggaaa	148	Mesoderm is induced and is replied 1 in early days	NM_020948.1	AY124186.1	0.7	TTTCTCACACAGGCAtact ccaaatgcttc
151	Myelin protein zero sample 1	NM_024569.2	AI693779.1	0.9	TGCCCTGGCATTCTGGCAGAGAATCCTCACCAGTTCTCACCAACCTTCCCCCCAGGCAAGGGCAGCT GCCAGCATGGTGCTCTGCCAGGACAGGTTTCCCT GAAGGAAGCTGCTCAC ACTGAGATGAGCCTCTCAGGGCAGGACCTCTTCCCAAGCCCTGCACACCC ACCCCTGCAGCCCTTTTGGCTC	148	Mesoderm is induced and is replied 1 in early days	NM_020948.1	AY124186.1	0.7	TTTCTCACACAGGCAtact ccaaatgcttc
151	Myelin protein zero sample 1	NM_024569.2	AI693779.1	0.9		152	The possible lineal homologue of mouse limb-bud and heart gene	NM_030915.1	W45195.1	1.1	GCTTCAGTCCGCCGAgagcagtaccgtgtg
155	Apoptosis enzyme 4, the apoptosis halfcystine of being correlated with	NM_033306.1	NM_001225. 2	1.2	TGTTCCCTATGGCAGaag gcaaccacagaa	152		NM_030915.1	W45195.1	1.1	GCTTCAGTCCGCCGAgagcagtaccgtgtg

	Proteolytic enzyme
	Proteolytic enzyme					158	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.7	AAGGAGCCTGTGGAGct gggccagcccaac
159	The conjugated protein 1A of FK506,12kDa	NM_054014.1	NM_000801. 2	0.8	GCTCCCTGTTCTTGGatct gccatggaggg	158	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.7	AAGGAGCCTGTGGAGct gggccagcccaac
159	The conjugated protein 1A of FK506,12kDa	NM_054014.1	NM_000801. 2	0.8	GCTCCCTGTTCTTGGatct gccatggaggg	160	Muriate cell interior passageway 1	NM_001288.3	BG491600.1	0.8	CCAGGGACGGCCACTT CCTGGTCCCCGACGCAACCATGGCTGAAGAACA ACCGCAGGTCGAATTGTTCGTGAAG
161	Muriate cell interior passageway 1	NM_001288.3	AV683308.1	0.7	GGGCAGCTCCCATTCctg ctgtatggcact	160	Muriate cell interior passageway 1	NM_001288.3	BG491600.1	0.8
161	Muriate cell interior passageway 1	NM_001288.3	AV683308.1	0.7	GGGCAGCTCCCATTCctg ctgtatggcact	164	Karyomit(e) 19 open reading frame 22	NM_138774.2	AI375989.1	1.4	ACCTCATCTCGGCCAgtg ctgacctggagg
177	Tropomyosin 3	NM_153649.1	BM006741.1	1.3	TGATGAGAGTGAGAGgc agagacccgtgct	164	Karyomit(e) 19 open reading frame 22	NM_138774.2	AI375989.1	1.4	ACCTCATCTCGGCCAgtg ctgacctggagg
177	Tropomyosin 3	NM_153649.1	BM006741.1	1.3	TGATGAGAGTGAGAGgc agagacccgtgct	184	Eukaryotic translation elongation factor 1 γ	NM_001404.3	AA206367.1	0.7	CTGAGTCCAGATTGGCAGGTGGACTACGAGTCATACACATGGCGGAAACT GGATCCTGGCAGCGAG GAGACCCAGACGCTGG TT
185	Eukaryotic translation elongation factor 1 γ	NM_001404.3	AA206367.1	0.6	CAGCATGTGGGCAAAG CCTTCAATCAGGGCAAG ATCTTCAAGTGAACATCTCTTGCCATCACCTAG	184	Eukaryotic translation elongation factor 1 γ	NM_001404.3	AA206367.1	0.7
185	Eukaryotic translation elongation factor 1 γ	NM_001404.3	AA206367.1	0.6		187	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BU783548.1	0.6	ATTTAAGCGCAAGTACTCCAATGAGGACACACTCTCTGTGGCACTGCCATATTTCTGGGAGCACTTTGATAAGGACGGCTGGTCC CTGTGGTACTCAGAGTATCGCTTCCCTGAAGAACTCACTCAGACCTTCATGAGCTGCAATCTCATCACTG
188	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	TGGACAAGCTGAGGAA GAATGCCTTCGCCAGTGTCATCCTTTTTGGAACC AACAATAGCAGCTCCATTTCTGGAGTCTGGGTCTTCCGAGGCCAG	187	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BU783548.1	0.6
188	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6		189	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	CAGGTGGACTACGAGTCATACACATGGCGGAAACTGGATCCTGGCAGCGAGGAGACCCAGACGCTGG TTCGAGAGTACTTTTCC

					TGGGAGGGGGCCTTCCAGCATGTGGGCAAAGCCTTCAA
					TGGGAGGGGGCCTTCCAGCATGTGGGCAAAGCCTTCAA	190	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	GAGCTTGCCTTTCCGctga gtccagattgg
191	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG533219.1	0.8	AAGGAGGAGAAAAAGG CGGCTGCCCCTGCTCCTGAGGAGGAGATGGATG AATGTGAGCAGGCGCTGGCTGCTGAGCCCAAGG CCAAGGACCCCTTCGCTCACCTGCCCAAGAG	190	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	GAGCTTGCCTTTCCGctga gtccagattgg
191	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BG533219.1	0.8		203	Calpain, small subunit 1/ calpain, small subunit 1	NM_001749.1	BE907701.1	1.4	CCTTTGAGGCAGCAGatgaaagtgggaaca
204	Cysteinyl-tRNA synthetic enzyme	NM_001751.3	AK125503.1	1.5	AAACAGGAACAAGAAgc agcaaagctggcc	203	Calpain, small subunit 1/ calpain, small subunit 1	NM_001749.1	BE907701.1	1.4	CCTTTGAGGCAGCAGatgaaagtgggaaca
204	Cysteinyl-tRNA synthetic enzyme	NM_001751.3	AK125503.1	1.5	AAACAGGAACAAGAAgc agcaaagctggcc	222	Statin	NM_002634.2	BE536369.1	1.4	GCGAGGAGAGTGCGTgtgtgagagggtcca
225	Translation control oncoprotein 1	NM_003295.1	BG284235.1	0.6	TTCTTTATTGGTGAAAA CATGAATCCAGATGGCA TGGTTGCTCTATTGGAC TACCGTGAGGATGGTGT GACCCCATATATGATTTTCTTTAAGGATGGTTTA	222	Statin	NM_002634.2	BE536369.1	1.4	GCGAGGAGAGTGCGTgtgtgagagggtcca
225	Translation control oncoprotein 1	NM_003295.1	BG284235.1	0.6		227	Translation control oncoprotein 1	NM_003295.1	CD641954.1	0.7	TTATTTTGGATCTATCACCTGTCATCATAACTGGC TTCTGCTTGTCATCCAC ACAACACCAGGACTTA AGACAAATGGGACTGAT GTCATCTTGAGCTCTTC ATTTATTTTGACTGTGATTTATTTGGAGTGGAGGC ATTGTTTTTAAGAAAAA CATGTCATGTAGGTTGT CTAAAAATAAAATGCAT TTAAAC
228	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	CGTCGTCTCCCTTCAGT CGCCATCATGATTATCTA CC	227	Translation control oncoprotein 1	NM_003295.1	CD641954.1	0.7
228	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	CGTCGTCTCCCTTCAGT CGCCATCATGATTATCTA CC	229	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	GGGACCTCATCAGCCacg atgagatgttct
232	Cold shock territory albumin A	NM_003651.3	BE935120.1	1.5	AATAACCCACGGAAATATCTGCGCAGTGTAGGAGATGGAGAAACTGTAGA GTTTGATGTGGTTGAAGGAGAGAA	229	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	GGGACCTCATCAGCCacg atgagatgttct
232	Cold shock territory albumin A	NM_003651.3	BE935120.1	1.5		236	Homo sapiens's vesicle is relevant	NM_003761.2	BG623073.1	0.7	GATCTGGAAGCCACAtct

	Membranin 8 (endobrevin)				gagcacttcaag
	Membranin 8 (endobrevin)				gagcacttcaag	237	CASP8 and FADD sample apoptosis regulator	NM_003879.3	BI871546.1	1.3	AGTACAAGCAGTCTGgtggatggaatggaa
239	Beta-2-microglobulin	NM_004048.2	BM831738.1	0.7	TGGAGGCTATCCAGCgta ctccaaagattc	237	CASP8 and FADD sample apoptosis regulator	NM_003879.3	BI871546.1	1.3	AGTACAAGCAGTCTGgtggatggaatggaa
239	Beta-2-microglobulin	NM_004048.2	BM831738.1	0.7	TGGAGGCTATCCAGCgta ctccaaagattc	240	Guanine-nucleotide-binding protein, γ 10	NM_004125.2	BC015206.1	0.6	GTGGAGAGGATCAAGgtc tctcaggcagct
242	The c-src Tyrosylprotein kinase	NM_004383.1	BG953215.1	1.1	CCTCAAGTTCTCGCTagat gtctgcgaggc	240	Guanine-nucleotide-binding protein, γ 10	NM_004125.2	BC015206.1	0.6	GTGGAGAGGATCAAGgtc tctcaggcagct
242	The c-src Tyrosylprotein kinase	NM_004383.1	BG953215.1	1.1	CCTCAAGTTCTCGCTagat gtctgcgaggc	248	Oxyphorase, α 1/2	NM_000517.3	AA343446.1	1.7	TGCTTCTCCCCGCAGgat gttcctgtcctt
253	Film component, karyomit(e) 11, surface marker 1	NM_005898.2	AA437165.1	0.8	AACAGCTTCAAACAGtggttggcacttacc	248	Oxyphorase, α 1/2	NM_000517.3	AA343446.1	1.7	TGCTTCTCCCCGCAGgat gttcctgtcctt
253	Film component, karyomit(e) 11, surface marker 1	NM_005898.2	AA437165.1	0.8	AACAGCTTCAAACAGtggttggcacttacc	254	Capping protein (actin filament) flesh Z-line, α 2	NM_006136.1	BG702980.1	0.7	AGCAAAAAATTTTTGgaatggtcgttggag
258	Acidity (rich leucine) phosphocarnic acid protein 32 family, member B	NM_006401.1	AI446778.1	1.3	AGGAGGAGGACGAAGaa ggagaagatgagg	254	Capping protein (actin filament) flesh Z-line, α 2	NM_006136.1	BG702980.1	0.7	AGCAAAAAATTTTTGgaatggtcgttggag
258		NM_006401.1	AI446778.1	1.3	AGGAGGAGGACGAAGaa ggagaagatgagg	261	The lysosome membrane-spanning proteins 5 of being correlated with	NM_006762.1	BQ006415.1	1.5	AAGATGCTCCAGAAGgtg agtgtggctgca
266	Karyomit(e) 11 open reading frame 10	NM_014206.1	BE041814.1	0.8	TCGCGGGGCAAAATGga gctcgaggccatg	261		NM_006762.1	BQ006415.1	1.5	AAGATGCTCCAGAAGgtg agtgtggctgca
266	Karyomit(e) 11 open reading frame 10	NM_014206.1	BE041814.1	0.8	TCGCGGGGCAAAATGga gctcgaggccatg	269	Ribosomal protein L 4	NM_000968.2	CB164625.1	0.7	GGTGCTTTTGGAAACatgt gtcgtggaggc
276	Ankyrin repeating structure territory 10	NM_017664.1	BC039715.1	0.7	GGAGCATTCCATATAGAAACTGCTGAAACTGCCACAGGTGCTTCTCCGAAA ACCTTACAGTTGTGGCATTGAATGTTCAGTATCGCTTCCTTTCTGCACACG	269	Ribosomal protein L 4	NM_000968.2	CB164625.1	0.7	GGTGCTTTTGGAAACatgt gtcgtggaggc
276	Ankyrin repeating structure territory 10	NM_017664.1	BC039715.1	0.7		280	Ribosomal protein S17	NM_001021.2	BE731466.1	0.5	AATTATGTTCCTGAGgtct cagccttggat
281	Ribosomal protein S17	NM_001021.2	AV752729.1	0.6	GCCGCGTTCCACCAAA ACCGTGAAGAAAGCGG CCCGGGTCATCATAGAAAAGTACTACACGCGCCTGGGCAACGACTTCCAC ACGAACAAGCGCGTGT GCGAGGAGATCGCCATTATCCCCAGCAAAAAGCTCCG	280	Ribosomal protein S17	NM_001021.2	BE731466.1	0.5	AATTATGTTCCTGAGgtct cagccttggat

282	Sulfatase 2	NM_018837.1	AB033073.2	1.5	GCGAGAGTGTGTCGAgtg agtgtgcgtctg
282	Sulfatase 2	NM_018837.1	AB033073.2	1.5	GCGAGAGTGTGTCGAgtg agtgtgcgtctg	283	Ubiquitin B	NM_018955.2	BG286180.1	1.6	GAAGGCGGAAAAGAGgt caaaatgcagatc
284	Ubiquitin B	NM_018955.2	BG286180.1	1.4	GGTATCCGCTAACAGgtc aaaatgcagatc	283	Ubiquitin B	NM_018955.2	BG286180.1	1.6	GAAGGCGGAAAAGAGgt caaaatgcagatc
284	Ubiquitin B	NM_018955.2	BG286180.1	1.4	GGTATCCGCTAACAGgtc aaaatgcagatc	290	Imagination albumen FLJ14213	NM_024841.1	BQ919225.1	1.4	ATTGTTGAACTGGATgcg gctgttgaagag
298	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	CCTGAGTCCAACACAG CTGGGCTGGACATATTTGCCAAATTTTCTGCCTACATCAAGAATTCAAACCCAGCACTCAATGACA	290	Imagination albumen FLJ14213	NM_024841.1	BQ919225.1	1.4	ATTGTTGAACTGGATgcg gctgttgaagag
298	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8		299	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.7	CCCAGGTACCCCAAGctg gcagctctgaac
300	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	GCTGTGCCCTCCCAGgta ccccaagctggc	299	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.7	CCCAGGTACCCCAAGctg gcagctctgaac
300	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	GCTGTGCCCTCCCAGgta ccccaagctggc	307	Arachidonic acid 5 lipoxygenase activators	NM_001629.2	BF892107.1	0.9	AAGTGGAGCACGAAAG CAGGACCCAGAATGGG AGGAGCTTCCAGAGGA CCGGAACACTTGCCTTTGAGCGGGTCTACACTGCCAA
309	Ribosomal protein L 41	NM_021104.1	EXH-002	0.6	GAAGCGAATGCGCAGgct gaagcgcaaaag	307	Arachidonic acid 5 lipoxygenase activators	NM_001629.2	BF892107.1	0.9
309	Ribosomal protein L 41	NM_021104.1	EXH-002	0.6	GAAGCGAATGCGCAGgct gaagcgcaaaag	312	Cyclin T2	NM_001241.2	EXH-005	0.5	ttgtgtgagctattcaaactcttcaaccc ctga
314	Zinc finger protein 38 4	NM_133476.2	EXH-007	1.5	AGTTCAGGAGCCCTGGAAAGGAGAAGGAATAA GACGGCAGGAGGAAGAGA	312	Cyclin T2	NM_001241.2	EXH-005	0.5	ttgtgtgagctattcaaactcttcaaccc ctga

The group (group 6) of 66 markers that difference is expressed in the table 3-mammary cancer

SEQID N°	Sequence description	Gene pool N ° (reference)	Gene pool N ° (variant)	C I/IIvs. health	Target sequence
SEQID N°	Sequence description	Gene pool N ° (reference)	Gene pool N ° (variant)	C I/IIvs. health	Target sequence		5	CDNA DKFZp667I093 (guanine-nucleotide-binding protein, γ 2)	AL832878.1	AI223156.1	0.7	TGCAGATTTGATGGCctactgtgaagcaca
7	Homo sapiens's imagination protein D KFZp761A052	BC009917.1	BC028225.1	1.4	ATGAAGAAAAACAAAgt gcacagagacccg		5	CDNA DKFZp667I093 (guanine-nucleotide-binding protein, γ 2)	AL832878.1	AI223156.1	0.7	TGCAGATTTGATGGCctactgtgaagcaca
7	Homo sapiens's imagination protein D KFZp761A052	BC009917.1	BC028225.1	1.4	ATGAAGAAAAACAAAgt gcacagagacccg	13	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	NM_001997. 2	0.5	GTCGCCCAGATCAAGgct catgtagcctca

14	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	W17004.1	0.6	GGCCGCATGCTTGGAag gtaaagtccatgg
14		NM_001997.2	W17004.1	0.6	GGCCGCATGCTTGGAag gtaaagtccatgg	16	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA063591.1	0.7	TGACCGGCCAGGAAAcg gtcgcccagatca
17	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA094898.1	0.6	CAGGCCGCATGCTTGagg taaagtccatgg	16		NM_001997.2	AA063591.1	0.7	TGACCGGCCAGGAAAcg gtcgcccagatca
17		NM_001997.2	AA094898.1	0.6	CAGGCCGCATGCTTGagg taaagtccatgg	18	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA187006.1	0.7	AGGCCGCATGCTTGGag gtaaagtccatgg
19	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AA225636.1	0.6	GGCCAGGAAACGGTCgc ccagatcaaggta	18		NM_001997.2	AA187006.1	0.7	AGGCCGCATGCTTGGag gtaaagtccatgg
19		NM_001997.2	AA225636.1	0.6	GGCCAGGAAACGGTCgc ccagatcaaggta	20	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	BM820687.1	0.5	GGTCGCCCAGATCAAgct catgtagcctca
23	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	BU603086.1	0.6	GAAGTAGCAGGCCGCat gcttggaggtaaa	20		NM_001997.2	BM820687.1	0.5	GGTCGCCCAGATCAAgct catgtagcctca
23		NM_001997.2	BU603086.1	0.6	GAAGTAGCAGGCCGCat gcttggaggtaaa	24	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	BF218408.1	0.6	AGGCCGATGCTTGGAggt aaagtccatggt
25	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AI499403.1	0.7	CCCGCATGCTTGGAGgta aagtccatggtt	24		NM_001997.2	BF218408.1	0.6	AGGCCGATGCTTGGAggt aaagtccatggt
25		NM_001997.2	AI499403.1	0.7	CCCGCATGCTTGGAGgta aagtccatggtt	26	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	AW795076.1	0.6	CGGTCGCCCAGATCAag gctcatgtagcct
27	The cell homologue of fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus	NM_001997.2	D52122.1	0.6	GGCCGCATGCTTGGggta aagtccatggtt	26		NM_001997.2	AW795076.1	0.6	CGGTCGCCCAGATCAag gctcatgtagcct
27		NM_001997.2	D52122.1	0.6	GGCCGCATGCTTGGggta aagtccatggtt	28	Finkel-Biskis-Re	NM_001997.2	BE535673.1	0，6	GCCGCATGCTTGGAGgta

	The cell homologue of fox sequence in the illy murine sarcoma virus				acagtccatggt
					acagtccatggt	47	Synapse nucleoprotein, α (the non-A4 composition of amyloid precursor)	NM_000345.2	NM_007308.1	1，5	GACCAGTTGGGCAAGaat gaagaaggagcc
51	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0，7	AGAtcgcggacgggttgtgcctgga ggTGG	47		NM_000345.2	NM_007308.1	1，5	GACCAGTTGGGCAAGaat gaagaaggagcc
51	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0，7	AGAtcgcggacgggttgtgcctgga ggTGG	52	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0，5	TCCGACATCTACAAGatc cgggagatcgcg
53	Translation control oncoprotein 1	NM_003295.1	BC022436.1	0，6	CCGACATCTACAAGATCCGGGAGATCGCGGACG GGTTGTGCCTG	52	Translation control oncoprotein 1	NM_003295.1	CA848049.1	0，5	TCCGACATCTACAAGatc cgggagatcgcg
53	Translation control oncoprotein 1	NM_003295.1	BC022436.1	0，6	CCGACATCTACAAGATCCGGGAGATCGCGGACG GGTTGTGCCTG	54	Translation control oncoprotein 1	NM_003295.1	BC040008.1	0，5	GCGCCGCTCCGGCTGCACCGCGCTCGCTCCGAGTTTCAGGCTCGTGCTAAG CTAGCGCCGTCGTCGTCTCCCTTCAGTCGCCATCATGATTATCTACC
55	The TYRO protein tyrosine kinase is conjugated protein	NM_003332.1	BF092099.1	0，8	GAGGGGCTGCGGAGGca gcgacccggaaac	54	Translation control oncoprotein 1	NM_003295.1	BC040008.1	0，5
55	The TYRO protein tyrosine kinase is conjugated protein	NM_003332.1	BF092099.1	0，8	GAGGGGCTGCGGAGGca gcgacccggaaac	58	Uroporphyrinogen decarboxylase	NM_000374.2	BQ008745.1	1，5	GTGTGCCGCTGATTGtgg accctgatgaca
64	Beta-2-microglobulin	NM_004048.2	AV734235.1	0，7	ATTTGGATTGGATGAATTCCAAATTCTGCTTGCTTGCTTTTTAATATTGATATGCTTATACACTTACACTTTATGCACAAAATGTAGGGTTATAATAATGTTAACATGGACATGATCTTCTTTATAATTCTACTTTGAGTGCTGTCTCCATGTTTGATGTATCTGAGCAGGTTGCTCCACAGGTAGCTCTAGGAGGGCTGGCA AC	58	Uroporphyrinogen decarboxylase	NM_000374.2	BQ008745.1	1，5	GTGTGCCGCTGATTGtgg accctgatgaca
64	Beta-2-microglobulin	NM_004048.2	AV734235.1	0，7		69	SEC24 genes involved family, member C (S.cerevisiae)	NM_004922.1	AW449995.1	1，8	GCAGCTGTCTGGAATgcagaggcagctgga
80	Oxyphorase, α 1/2	NM_000558.3	R91899.1	1，7	ACCAAGACCTACTTCccg gtcaacttcaag	69	SEC24 genes involved family, member C (S.cerevisiae)	NM_004922.1	AW449995.1	1，8	GCAGCTGTCTGGAATgcagaggcagctgga
80	Oxyphorase, α 1/2	NM_000558.3	R91899.1	1，7	ACCAAGACCTACTTCccg gtcaacttcaag	81	Oxyphorase, α 1/2	NM_000558.3	H58664.1	1，7	GGAGGCCCTGGAGAGct cctaagccactgc
88	Talin 1	NM_006289.2	AI393487.1	1，4	CCCAGAGTATTAACGCT CCAAGAGTATTATTAAC	81	Oxyphorase, α 1/2	NM_000558.3	H58664.1	1，7	GGAGGCCCTGGAGAGct cctaagccactgc

					GCTGCTGTACCTCGATCTGAATCTGCCGGGGCCCCAGCCCACTCCACCCTGCCAGCAGCTTCCAGCCAGTCCCCACAGCCTCATCAGCTCTCTTCACCGTTTTTTGATACTATCTTCCCCCACCCCCAGCTACCCATAGGGGCTGCAGAGTT ATAAGCCCCAAACAGG TCATGCTCCAATAAAAATGATTCTACCTACAA
						89	Talin 1	NM_006289.2	AI393487.1	1，4	TGCTTCGGAAGGAACga gagctggaagagg
90	Talin 1	NM_006289.2	AI417760.1	1.4	AGGAAGAAATGCTTCggaaggaacgagagc	89	Talin 1	NM_006289.2	AI393487.1	1，4	TGCTTCGGAAGGAACga gagctggaagagg
90	Talin 1	NM_006289.2	AI417760.1	1.4	AGGAAGAAATGCTTCggaaggaacgagagc	116	Homocysteine-derivable, er stress is derivable, ubiquitin spline structure territory member 1	NM_014685.1	BG828243.1	0.7	GGAAAACATCTCAAGgcctgaagctgccca
121	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	AGAAACAGGGCAAGTac ccagaagtccaca	116		NM_014685.1	BG828243.1	0.7	GGAAAACATCTCAAGgcctgaagctgccca
121	Ring finger protein 10	NM_014868.3	BU626650.1	1.5	AGAAACAGGGCAAGTac ccagaagtccaca	125	Ribosomal protein L 4	NM_000968.2	CB141160.1	0.7	GTCATCAGACTAGTGCTGAGTCTTGGGGTACTGGCAGAGCTGTGGCTCGA ATTCCCAGAGTTCGAGGTGGTGGGACTCACCGCTCTGGCCAGGGTGCTTTTGGAAACatgtgtcgtg
137	Ubiquitin B	NM_018955.2	AA206538.1	1.4	CAGGTCAAAATGCAGatc ttcgtgaaaacc	125	Ribosomal protein L 4	NM_000968.2	CB141160.1	0.7
137	Ubiquitin B	NM_018955.2	AA206538.1	1.4	CAGGTCAAAATGCAGatc ttcgtgaaaacc	139	Ubiquitin B	NM_018955.2	AA340917.1	1.4	AGATCTTCGTGAAGACCCTGACCGGCAAGACCA TCACTCTGGAGGTGGAGCCCAGTGACACCATCG AAAATGTGAAGGCCAA GATCCAAGATAAAGAA GGCATCCCCCCCGACCAGCAGAGGCTCATCTTTG CAGGCAAGCAGCTGGA AGATGGCCGCACTCTTTCTGACTACAACATCCAGAAAGAGTCGACCCTGC ACCTGGTCCTGCGCCTGAGGGGTGGCTGTTAATTCTTCAGTCATGGCATTCGCAGTGCCCAGTGATG

					GCATTACTCTGCACTATAGCCATTTGCCCCAACTTAAGTTTAGAAATTACAAGTTTCAGTAATAGCTGAACCTGTTCAAAATGTTAATAAAGG
						145	Major histocompatibility complex, class II, DR α	NM_019111.2	CD686254.1	0.7	TCAGAGACAGTCTTCCT GCCCAGGGAAGACCAC CTTTTCCGCAAGTTCCA CTATCTCCCCTTCCTGC CCTCAACTGAGGACGTT TACGACTGCAGGGTGG AGCACTGGGGCTTGGAT GAGCCTCTTCTCAAGCA CTGGGagtttgatgctccaagccctctc
148	Mesoderm is induced and is replied 1 in early days	NM_020948.1	AY124186.1	0.7	TTTCTCACACAGGCAtact ccaaatgcttc	145	Major histocompatibility complex, class II, DR α	NM_019111.2	CD686254.1	0.7
148	Mesoderm is induced and is replied 1 in early days	NM_020948.1	AY124186.1	0.7	TTTCTCACACAGGCAtact ccaaatgcttc	158	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.7	AAGGAGCCTGTGGAGct gggccagcccaac
160	Muriate cell interior passageway	NM_001288.3	BG491600.1	0.8	CCAGGGACGGCCACTT CCTGGTCCCCGACGCAACCATGGCTGAAGAACA ACCGCAGGTCGAATTGTTCGTGAAG	158	Major histocompatibility complex, class II, DP α 1	NM_033554.2	BU621846.1	0.7	AAGGAGCCTGTGGAGct gggccagcccaac
160	Muriate cell interior passageway	NM_001288.3	BG491600.1	0.8		161	Muriate cell interior passageway	NM_001288.3	AV683308.1	0.7	GGGCAGCTCCCATTCctg ctgtatggcact
164	Karyomit(e) 19 open reading frame 22	NM_138774.2	AI375989.1	1.4	ACCTCATCTCGGCCAgtg ctgacctggagg	161	Muriate cell interior passageway	NM_001288.3	AV683308.1	0.7	GGGCAGCTCCCATTCctg ctgtatggcact
164	Karyomit(e) 19 open reading frame 22	NM_138774.2	AI375989.1	1.4	ACCTCATCTCGGCCAgtg ctgacctggagg	188	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	TGGACAAGCTGAGGAA GAATGCCTTCGCCAGTGTCATCCTTTTTGGAACC AACAATAGCAGCTCCATTTCTGGAGTCTGGGTCTTCCGAGGCCAG
189	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	CAGGTGGACTACGAGT CATACACATGGCGGAA ACTGGATCCTGGCAGCGAGGAGACCCAGACGCT GGTTCGAGAGTACTTTTCCTGGGAGGGGGCCTTCCAGCATGTGGGCAAAG CCTTCAA	188	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6
189	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6		190	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	GAGCTTGCCTTTCCGctga gtccagattgg
191	Eukaryotic translation prolongs	NM_001404.3	BG533219.1	0.8	AAGGAGGAGAAAAAGG CGGCTGCCCCTGCTCCT	190	Eukaryotic translation elongation factor 1 γ	NM_001404.3	BE502067.1	0.6	GAGCTTGCCTTTCCGctga gtccagattgg

	The factor 1 γ				GAGGAGGAGATGGATG AATGTGAGCAGGCGCT GGCTGCTGAGCCCAAG GCCAAGGACCCCTTCGCTCACCTGCCCAAGAG
	The factor 1 γ					208	Ferritin, heavy polypeptide 1	NM_002032.1	BG248923.1	0.6	TGTCTCTGGGGATCCCT AGTATAACACATGCA
222	Statin	NM_002634.2	BE536369.1	1.4	GCGAGGAGAGTGCGTgt gtgagagggtcca	208	Ferritin, heavy polypeptide 1	NM_002032.1	BG248923.1	0.6	TGTCTCTGGGGATCCCT AGTATAACACATGCA
222	Statin	NM_002634.2	BE536369.1	1.4	GCGAGGAGAGTGCGTgt gtgagagggtcca	225	Translation control oncoprotein 1	NM_003295.1	BG284235.1	0.6	TTCTTTATTGGTGAAAACATGAATCCAGATGGC ATGGTTGCTCTATTGGACTACCGTGAGGATGGTGTGACCCCATATATGATTTTCTTTAAGGATGGTTTA
228	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	CGTCGTCTCCCTTCAGTCGCCATCATGATTATCTACC	225	Translation control oncoprotein 1	NM_003295.1	BG284235.1	0.6
228	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	CGTCGTCTCCCTTCAGTCGCCATCATGATTATCTACC	229	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	GGGACCTCATCAGCCacg atgagatgttct
236	Homo sapiens's vesicle-related membrane protein 8 (endobrevin)	NM_003761.2	BG623073.1	0.7	GATCTGGAAGCCACAtctgagcacttcaag	229	Translation control oncoprotein 1	NM_003295.1	AV749932.1	0.6	GGGACCTCATCAGCCacg atgagatgttct
236		NM_003761.2	BG623073.1	0.7	GATCTGGAAGCCACAtctgagcacttcaag	240	Guanine-nucleotide-binding protein, γ 10	NM_004125.2	BC015206.1	0.6	GTGGAGAGGATCAAGgt ctctcaggcagct
242	The c-src Tyrosylprotein kinase	NM_004383.1	BG953215.1	1.1	CCTCAAGTTCTCGCTagat gtctgcgaggc	240	Guanine-nucleotide-binding protein, γ 10	NM_004125.2	BC015206.1	0.6	GTGGAGAGGATCAAGgt ctctcaggcagct
242	The c-src Tyrosylprotein kinase	NM_004383.1	BG953215.1	1.1	CCTCAAGTTCTCGCTagat gtctgcgaggc	245	Family 50 with sequence similarity, member A	NM_004699.1	AA584911.1	1.6	TCAAGAGTGAGTGTTtgcggagtcagacgc
248	Oxyphorase, α 1/2	NM_000517.3	AA343446.1	1.7	TGCTTCTCCCCGCAGgat gttcctgtcctt	245	Family 50 with sequence similarity, member A	NM_004699.1	AA584911.1	1.6	TCAAGAGTGAGTGTTtgcggagtcagacgc
248	Oxyphorase, α 1/2	NM_000517.3	AA343446.1	1.7	TGCTTCTCCCCGCAGgat gttcctgtcctt	252	Suppose translation initiation factor	NM_005801.2	BG655736.1	0.7	CCTTTGTGCTTGCAGaagt ttgcctgcaat
280	Ribosomal protein S17	NM_001021.2	BE731466.1	0.5	AATTATGTTCCTGAGgtct cagccttggat	252	Suppose translation initiation factor	NM_005801.2	BG655736.1	0.7	CCTTTGTGCTTGCAGaagt ttgcctgcaat
280	Ribosomal protein S17	NM_001021.2	BE731466.1	0.5	AATTATGTTCCTGAGgtct cagccttggat	281	Ribosomal protein S17	NM_001021.2	AV752729.1	0.6	GCCGCGTTCCACCAAA ACCGTGAAGAAAGCGG CCCGGGTCATCATAGAAAAGTACTACACGCGCCTGGGCAACGACTTCCAC ACGAACAAGCGCGTGT GCGAGGAGATCGCCAT TATCCCCAGCAAAAAG CTCCG
284	Ubiquitin B	NM_018955.2	BG286180.1	1.4	GGTATCCGCTAACAGgtc	281	Ribosomal protein S17	NM_001021.2	AV752729.1	0.6

					aaaatgcagatc
					aaaatgcagatc	290	Imagination albumen FLJ14213	NM_024841.1	BQ919225.1	1.4	ATTGTTGAACTGGATgcg gctgttgaagag
298	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	CCTGAGTCCAACACAG CTGGGCTGGACATATTTGCCAAATTTTCTGCCTACATCAAGAATTCAAACCCAGCACTCAATGACA	290	Imagination albumen FLJ14213	NM_024841.1	BQ919225.1	1.4	ATTGTTGAACTGGATgcg gctgttgaagag
298	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8		299	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.7	CCCAGGTACCCCAAGctg gcagctctgaac
300	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	GCTGTGCCCTCCCAGgta ccccaagctggc	299	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.7	CCCAGGTACCCCAAGctg gcagctctgaac
300	Muriate cell interior passageway 1	NM_001288.3	AA126087.1	0.8	GCTGTGCCCTCCCAGgta ccccaagctggc	309	Ribosomal protein L 41	NM_021104.1	EXH-002	0.6	GAAGCGAATGCGCAGgc tgaagcgcaaaag
310	Translation control oncoprotein 1	NM_003295.1	EXH-003	0.5	AATGCATATTTAAACTAAATTGATCCTGTAGTGTTCCTGGAGAAGCTAGA GCCTGATTGTAGGCTAC TACTCATCAATTAACTTCTACAGTGGAGACTACTTCTGGGACTGGAATATAAAAA	309	Ribosomal protein L 41	NM_021104.1	EXH-002	0.6	GAAGCGAATGCGCAGgc tgaagcgcaaaag
310	Translation control oncoprotein 1	NM_003295.1	EXH-003	0.5		311	G1 to S phase transition 1/G1 to S phase transition 1	NM_002094.1	EXH-004	1.5	ATTACCGTTTATTCCATATCTGGATAATTTGCCGAACTTCAATAGATCAGTTGATGGACCAATCAGG CTGCCAATTGTGG
312	Cyclin T2	NM_001241.2	EXH-005	0.5	ttgtgtgagctattcaaactcttcaaccc ctga	311	G1 to S phase transition 1/G1 to S phase transition 1	NM_002094.1	EXH-004	1.5

Table 4-distinguishes the summary sheet of the group 1-11 of the marker of expressing in mammary cancer

1	2	3	4	5	6	7	8	9	10	11	SEQ ID N°
1	2	3	4	5	6	7	8	9	10	11	SEQ ID N°							＊		1
							＊				2							＊		1
							＊				2					＊	＊			3
					＊	＊	＊				5					＊	＊			3
					＊	＊	＊				5			＊	＊	＊	＊			7
									＊		11			＊	＊	＊	＊			7
									＊		11					＊	＊		＊	12
			＊	＊	＊						13					＊	＊		＊	12
			＊	＊	＊						13			＊	＊	＊	＊			14
＊			＊	＊	＊	＊	＊	＊			16			＊	＊	＊	＊			14
＊			＊	＊	＊	＊	＊	＊			16	＊	＊	＊	＊	＊	＊	＊		17

	＊	＊	＊	＊	＊	＊			＊		18
	＊	＊	＊	＊	＊	＊			＊		18	＊	＊	＊	＊	＊	＊	＊	＊	＊			19
					＊						20	＊	＊	＊	＊	＊	＊	＊	＊	＊			19
					＊						20	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	23
＊				＊	＊	＊	＊	＊			24	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	23
＊				＊	＊	＊	＊	＊			24					＊	＊	＊	＊				25
＊	＊	＊	＊	＊	＊	＊	＊	＊			26					＊	＊	＊	＊				25
＊	＊	＊	＊	＊	＊	＊	＊	＊			26			＊	＊	＊	＊						27
			＊	＊	＊						28			＊	＊	＊	＊						27
			＊	＊	＊						28									＊			33
						＊	＊				35									＊			33
						＊	＊				35								＊				37
								＊			40								＊				37
								＊			40									＊			41
						＊					43									＊			41
						＊					43	＊						＊	＊	＊			44
						＊	＊				46	＊						＊	＊	＊			44
						＊	＊				46				＊	＊	＊	＊	＊				47
								＊			50				＊	＊	＊	＊	＊				47
								＊			50		＊	＊	＊	＊	＊	＊	＊		＊		51
＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	52		＊	＊	＊	＊	＊	＊	＊		＊		51
＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	52	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	53
＊	＊	＊	＊	＊	＊	＊	＊	＊			54	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	53
＊	＊	＊	＊	＊	＊	＊	＊	＊			54		＊	＊	＊	＊	＊	＊					55
			＊	＊	＊						58		＊	＊	＊	＊	＊	＊					55
			＊	＊	＊						58										＊		59
						＊	＊		＊		60										＊		59
						＊	＊		＊		60						＊	＊	＊				64
	＊	＊	＊	＊	＊	＊	＊				69						＊	＊	＊				64
	＊	＊	＊	＊	＊	＊	＊				69							＊					71
						＊	＊				72							＊					71
						＊	＊				72									＊			75
								＊			79									＊			75
								＊			79		＊	＊	＊	＊	＊	＊	＊				80
			＊	＊	＊	＊	＊				81		＊	＊	＊	＊	＊	＊	＊				80
			＊	＊	＊	＊	＊				81							＊	＊				85
						＊	＊				86							＊	＊				85
						＊	＊				86						＊	＊	＊				88

	＊	＊	＊	＊		＊		89
	＊	＊	＊	＊		＊		89						＊	＊	＊				90
				＊	＊			95						＊	＊	＊				90
				＊	＊			95							＊					102
						＊		104							＊					102
						＊		104										＊		105
					＊			107										＊		105
					＊			107				＊	＊	＊	＊	＊				116
					＊	＊		119				＊	＊	＊	＊	＊				116
					＊	＊		119	＊						＊	＊	＊			120
＊	＊	＊	＊	＊	＊	＊		121	＊						＊	＊	＊			120
＊	＊	＊	＊	＊	＊	＊		121		＊	＊	＊	＊	＊	＊	＊				125
＊				＊	＊	＊		126		＊	＊	＊	＊	＊	＊	＊				125
＊				＊	＊	＊		126									＊			135
					＊			136									＊			135
					＊			136	＊				＊	＊	＊	＊	＊			137
				＊	＊			138	＊				＊	＊	＊	＊	＊			137
				＊	＊			138	＊				＊	＊	＊	＊	＊			139
				＊	＊			140	＊				＊	＊	＊	＊	＊			139
				＊	＊			140							＊	＊				141
						＊		144							＊	＊				141
						＊		144	＊	＊	＊	＊	＊	＊	＊	＊	＊			145
				＊	＊			147	＊	＊	＊	＊	＊	＊	＊	＊	＊			145
				＊	＊			147	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	148
							＊	150	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	148
							＊	150							＊	＊				151
				＊	＊			152							＊	＊				151
				＊	＊			152							＊	＊				155
	＊	＊	＊	＊	＊			158							＊	＊				155
	＊	＊	＊	＊	＊			158							＊	＊				159
	＊	＊	＊	＊	＊			160							＊	＊				159
	＊	＊	＊	＊	＊			160			＊	＊	＊	＊	＊	＊				161
					＊			163			＊	＊	＊	＊	＊	＊				161
					＊			163				＊	＊	＊	＊	＊				164

							＊	＊		171
							＊	＊		171									＊			172
						＊	＊			177									＊			172
						＊	＊			177									＊			178
								＊		182									＊			178
								＊		182							＊					184
						＊	＊			185							＊					184
						＊	＊			185	＊						＊	＊	＊			187
		＊			＊	＊	＊			188	＊						＊	＊	＊			187
		＊			＊	＊	＊			188	＊			＊	＊	＊	＊	＊	＊			189
＊			＊	＊	＊	＊	＊	＊		190	＊			＊	＊	＊	＊	＊	＊			189
＊			＊	＊	＊	＊	＊	＊		190						＊	＊	＊		＊		191
								＊		192						＊	＊	＊		＊		191
								＊		192									＊			194
								＊	＊	195									＊			194
								＊	＊	195									＊			201
						＊				203									＊			201
						＊				203							＊					204
							＊		＊	206							＊					204
							＊		＊	206						＊						208
							＊			216						＊						208
							＊			216									＊			217
					＊	＊	＊			222									＊			217
					＊	＊	＊			222	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	225
									＊	226	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	＊	225
									＊	226							＊		＊	＊		227
＊	＊	＊		＊	＊	＊	＊	＊		228							＊		＊	＊		227
＊	＊	＊		＊	＊	＊	＊	＊		228	＊			＊	＊	＊	＊	＊	＊	＊		229
						＊	＊			232	＊			＊	＊	＊	＊	＊	＊	＊		229
						＊	＊			232									＊			235
					＊	＊				236									＊			235
					＊	＊				236							＊	＊				237
						＊	＊			239							＊	＊				237
						＊	＊			239	＊	＊	＊	＊	＊	＊	＊	＊	＊			240
					＊	＊	＊			242	＊	＊	＊	＊	＊	＊	＊	＊	＊			240

			＊	＊					245
			＊	＊					245									＊		246
		＊	＊	＊	＊	＊			248									＊		246
		＊	＊	＊	＊	＊			248									＊		250
			＊	＊					252									＊		250
			＊	＊					252							＊	＊			253
＊					＊	＊	＊		254							＊	＊			253
＊					＊	＊	＊		254							＊	＊			258
					＊				261							＊	＊			258
					＊				261							＊				266
							＊		267							＊				266
							＊		267							＊		＊		269
＊					＊	＊	＊		276							＊		＊		269
＊					＊	＊	＊		276									＊		278
	＊	＊	＊	＊	＊	＊		＊	280									＊		278
	＊	＊	＊	＊	＊	＊		＊	280	＊			＊	＊	＊	＊	＊	＊	＊	281
＊					＊	＊	＊		282	＊			＊	＊	＊	＊	＊	＊	＊	281
＊					＊	＊	＊		282	＊						＊	＊	＊		283
		＊	＊	＊	＊	＊			284	＊						＊	＊	＊		283
		＊	＊	＊	＊	＊			284					＊	＊	＊	＊			290
			＊	＊	＊	＊			298					＊	＊	＊	＊			290
			＊	＊	＊	＊			298				＊	＊	＊	＊	＊			299
		＊	＊	＊	＊	＊			300				＊	＊	＊	＊	＊			299
		＊	＊	＊	＊	＊			300									＊		306
					＊	＊			307									＊		306
					＊	＊			307										＊	308
				＊	＊	＊		＊	309										＊	308
				＊	＊	＊		＊	309				＊	＊	＊				＊	310
				＊		＊			311				＊	＊	＊				＊	310
				＊		＊			311		＊	＊	＊	＊	＊	＊	＊		＊	312
					＊	＊			314		＊	＊	＊	＊	＊	＊	＊		＊	312
					＊	＊			314								＊			315
						＊	＊		319								＊			315
						＊	＊		319									＊		320
							＊		321									＊		320

	＊	322
	＊	322		＊		323
	＊	324		＊		323
	＊	324		＊		325
	＊	326		＊		325
	＊	326	＊		＊	327
	＊	328	＊		＊	327
	＊	328		＊		329
	＊	330		＊		329
	＊	330	＊			331
	＊	332	＊			331
	＊	332		＊		333
	＊	334		＊		333
	＊	334		＊		335
＊		336		＊		335
＊		336		＊		337
	＊	338		＊		337
	＊	338	＊			339
	＊	340	＊			339
	＊	340		＊		341
	＊	342		＊		341
	＊	342		＊	＊	343
	＊	344		＊	＊	343
	＊	344		＊		345
	＊	346		＊		345
	＊	346		＊		347
	＊	348		＊		347
	＊	348		＊		349
	＊	350		＊		349
	＊	350		＊		351
	＊	352		＊		351
	＊	352		＊		353
	＊	354		＊		353
	＊	354		＊		355
	＊	356		＊		355

	＊		357
	＊		357		＊		358
	＊		359		＊		358
	＊		359		＊	＊	360
	＊		361		＊	＊	360
	＊		361		＊		362
＊			363		＊		362
＊			363		＊		364
	＊		365		＊		364
	＊		365		＊		366
	＊	＊	367		＊		366
	＊	＊	367	＊			368
	＊		369	＊			368
	＊		369		＊		370
	＊		371		＊		370
	＊		371		＊		372
	＊		373		＊		372
	＊		373		＊		374
	＊		375		＊		374
	＊		375		＊		376
		＊	377		＊		376
		＊	377			＊	378
		＊	379			＊	378
		＊	379			＊	380
		＊	381			＊	380
		＊	381			＊	382
		＊	383			＊	382
		＊	383			＊	384
		＊	385			＊	384
		＊	385			＊	386
		＊	387			＊	386
		＊	387			＊	388
		＊	389			＊	388
		＊	389			＊	390
		＊	391			＊	390

＊	392
＊	392	＊	393
＊	394	＊	393
＊	394	＊	395
＊	396	＊	395
＊	396	＊	397
＊	398	＊	397
＊	398	＊	399
＊	400	＊	399
＊	400	＊	401
＊	402	＊	401
＊	402	＊	403
＊	404	＊	403
＊	404	＊	405
＊	406	＊	405
＊	406	＊	407
＊	408	＊	407
＊	408	＊	409
＊	410	＊	409
＊	410	＊	411
＊	412	＊	411
＊	412	＊	413
＊	414	＊	413
＊	414	＊	415
＊	416	＊	415
＊	416	＊	417
＊	418	＊	417
＊	418	＊	419
＊	420	＊	419
＊	420	＊	421
＊	422	＊	421
＊	422	＊	423
＊	424	＊	423
＊	424	＊	425

＊	426
＊	426	＊	427
＊	428	＊	427
＊	428	＊	429
＊	430	＊	429
＊	430	＊	431
＊	432	＊	431
＊	432	＊	433
＊	434	＊	433
＊	434	＊	435
＊	436	＊	435
＊	436	＊	437

Table 5. comes from the tabulation of genes identified/transcript in the DATAS storehouse of patient with breast cancer's blood sample atlas analysis, and these gene/transcripts are relevant with immune signal path.

Representative transcript	The title of gene
Representative transcript	The title of gene	NM_000061	Homo sapiens Bruton agammaglobulinemia Tyrosylprotein kinase (BTK), mRNA.11/2005
NM_002661	Homo sapiens's Phospholipase C, γ 2 (phosphatidylinositols-specific) (PLCG2), mRNA.11/2005	NM_000061
NM_002661		NM_003177	Homo sapiens's spleen tyrosine kinase (SYK), mRNA.11/2005
NM_021601	Homo sapiens CD79A antigen (immunoglobulin (Ig)-relevant α) (CD79A), is transcribed spliceosome 2, mRNA.10/2005	NM_003177	Homo sapiens's spleen tyrosine kinase (SYK), mRNA.11/2005
NM_021601		NM_080548	Homo sapiens protein tyrosine phosphatase, non--receptor type 6 (PTPN6), transcribe spliceosome 2, mRNA.11/2005
AB209585	Homo sapiens mRNA is used for the Fc fragment of IgG, and low affinity IIb is for the acceptor of (CD32) hypotype 1 misfolded proteins.3/2005	NM_080548
AB209585		AF025529	Homo sapiens leukocyte immunoglobulin-like receptor-6b (LIR-6) mRNA, cds fully.9/2002
AJ001685	Homo sapiens NKG2E gene.4/2005	AF025529
AJ001685	Homo sapiens NKG2E gene.4/2005	AL353611	From the human DNA sequence of clone RP11-447M12, comprise the FCN1 gene and the novel gene that are used for fiber gelatinized protein (comprising collagen/fibrin prodomain) 1, sufficient sequence on the karyomit(e) 9.5/2005

AL591704	Karyomit(e) 1q21.1-21.3 goes up the 5 ' end that comprises this gene that is used for peptidoglycan recognition protein-I-α (PGLYRPI α) from the human DNA sequence of clone RP1-128L15, is used for the PGLYRP4 gene of peptidoglycan recognition protein 4, S100A9gen...5/2005
AL591704		NM_000239	Homo sapiens's N,O-Diacetylmuramidase (renal amyloidosis) (LYZ), mRNA.11/2005
NM_000442	Homo sapiens's thrombocyte/endothelial cell adhesion molecule (CD31 antigen) (PECAM1), mRNA.11/2005	NM_000239
NM_000442		NM_000566	The Fc fragment of homo sapiens IgG, high-affinity Ia, acceptor (CD64) (FCGR1A), mRNA.10/2005
NM_000570	The Fc fragment of homo sapiens IgG, low affinity IIjIb, acceptor (CD16b) (FCGR3B), mRNA.11/2005	NM_000566
NM_000570		NM_000616	Homo sapiens's T4 antigen (p55) (CD4), mRNA.10/2005
NM_000629	Homo sapiens's Interferon, rabbit (α, β and ω) acceptor 1 (IFNAR1), mRNA.11/2005	NM_000616	Homo sapiens's T4 antigen (p55) (CD4), mRNA.10/2005
NM_000629		NM_001066	The sapiens tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B), mRNA.11/2005
NM_002121	Homo sapiens's major histocompatibility complex, class II, DP β 1 (HLA-DPB1), mRNA.11/2005	NM_001066
NM_002121		NM_002535	Homo sapiens 2 '-5 '-oligoadenylate synthetase 2,69/71kDa (OAS2) transcribes spliceosome 2, mRNA.9/2005
NM_003190	Homo sapiens TAP conjugated protein (first mercapto albumen) (TAPBP), transcribes spliceosome 1, mRNA.10/2005	NM_002535
NM_003190		NM_003332	Homo sapiens TYRO protein tyrosine kinase conjugated protein (TYROBP) is transcribed spliceosome 1, mRNA.10/2005
NM_005514	Homo sapiens's major histocompatibility complex, class I, B (HLA-B), mRNA.11/2005	NM_003332
NM_005514		NM_005810	Homo sapiens killer cell agglutinin receptor subfamily G, member 1 (KLRG1), mRNA.11/2005
NM_005874	The homo sapiens leukocyte immunoglobulin-like receptor, subfamily B (having TM and ITIM structural domain), member 2 (LILRB2), mRNA.10/2005	NM_005810
NM_005874		NM_006433	Homo sapiens's particle cytolysin (GNLY) is transcribed spliceosome NKG5, mRNA.10/2005
NM_021642	The Fc fragment of homo sapiens IgG, low affinity IIa, acceptor (CD32) (FCGR2A), mRNA.10/2005	NM_006433
NM_021642		NM_022555	Homo sapiens's major histocompatibility complex, class II, DR β 3 (HLA-DRB3), mRNA.10/2005
NM_033130	Homo sapiens's sialic acid is in conjunction with Ig-sample lectin 10 (SIGLEC10), mRNA.9/2005	NM_022555
NM_033130		NM_152855	Homo sapiens's immunoglobulin (Ig) λ sample polypeptide 1 (IGLL1) transcribes spliceosome 2, mRNA.9/2005

NM_173065	Homo sapiens's interleukin-22 8 acceptors, α (Interferon, rabbit, λ acceptor) (IL28RA), transcribes spliceosome 3, mRNA.10/2005
NM_173065		NM_174892	Homo sapiens CD300 antigen sample family member B (CD300LB), mRNA.9/2005
NM_181985	The homo sapiens leukocyte immunoglobulin-like receptor, subfamily A (having the TM structural domain), member 5 (LILRA5) transcribes spliceosome 2, mRNA.9/2005	NM_174892
NM_181985		NM_203458	The terminal sample (NOTCH2NL) of homo sapiens Notch homologue 2 (fruit bat) N-, mRNA.9/2005
X96735	H.sapiens FALL-39 gene.9/2004	NM_203458
X96735	H.sapiens FALL-39 gene.9/2004	BC070085	Homo sapiens's G CFS 2 acceptors, β, low affinity (granulocyte-macrophage), mRNA (cDNA clones MGC:87425IMAGE:30344148), cds fully.7/2005
NM_000211	Homo sapiens's integrin, β 2 (antigens c D18 (p95), LFA 1; Scavenger cell antigen 1 (mac-1) β subunit) (ITGB2), mRNA.11/2005	BC070085
NM_000211		NM_000560	Homo sapiens CD53 antigen (CD53), mRNA.10/2005
NM_001838	Homo sapiens's chemokine (C-C motif) acceptor 7 (CCR7), mRNA.11/2005	NM_000560	Homo sapiens CD53 antigen (CD53), mRNA.10/2005
NM_001838		NM_002983	Homo sapiens's chemokine (C-C motif) part 3 (CCL3), mRNA.10/2005
NM_014358	Homo sapiens C-type lectin structural domain family 4, member E (CLEC4E), mRNA.9/2005	NM_002983
NM_014358		NM_173216	Homo sapiens ST6 β-galactosamide α-2,6-sialyltranferase1 (ST6GAL1) transcribes spliceosome 1, mRNA.11/2005
AB209647	The homo sapiens mRNA that is used for the neutrophil leucocyte cytosol factor 2 misfolded proteins.3/2005	NM_173216
AB209647		AB209656	The homo sapiens mRNA that is used for G CFS 3 receptor subtype c precursor misfolded proteins.3/2005
AC079855	Homo sapiens BAC clone RP11-332L16 from 7, sufficient sequence.1/2004	AB209656
AC079855		AK127905	Homo sapiens cDNA FLJ46012fis, clone SPLEN2007689 highly is similar to the neutrophil leucocyte cytosol factor 1.2/2004
AL390725	3 ' the end that comprises the ZNF364 gene that is used for zinc finger protein 36 4 on the karyomit(e) 1 from the human DNA sequence of clone RP11-373C9, be used for the antigenic CD160 gene of CD160, the PDZK1 gene that comprises PDZ structural domain 1 is used for expressing ... 3 ' end of gene.5/2005	AK127905
AL390725		AY131997	The sapiens tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene, encoding sequence (cds.) fully.7/2002
AY692262	Homo sapiens's interleukin-22 acceptor, γ (serious binding immunoassay defective) are (IL2RG) and gene, encoding sequence fully.8/2004	AY131997
AY692262		D14041	The homo sapiens mRNA that is used for H-2K binding factor-2, encoding sequence fully.2/1999

NM_000246	Homo sapiens's class II, major histocompatibility complex, trans-activator (CIITA), mRNA.11/2005
NM_000246		NM_000295	Homo sapiens's Serine peptide enzyme inhibition factor, differentiation branch A (α-1 protease inhibitor, antitrypsin), member 1 (SERPINA1) transcribes spliceosome 1, mRNA.11/2005
NM_000544	The homo sapiens transports thing 2, ATP-binding cassette, and Asia-B of family (MDR/TAP) (TAP2) transcribes spliceosome 1, mRNA.11/2005	NM_000295
NM_000544		NM_000591	Homo sapiens CD14 antigen (CD14), mRNA.11/2005
NM_000593	The homo sapiens transports thing 1, ATP-binding cassette, Asia-B of family (MDR/TAP) (TAP1), mRNA.11/2005	NM_000591	Homo sapiens CD14 antigen (CD14), mRNA.11/2005
NM_000593		NM_000611	Homo sapiens CD59 antigen p18-20 (by monoclonal antibody 16.3A5, EJ16, EJ30, the antigen that EL32 box G344 identifies) (CD59), transcribes spliceosome 2, mRNA.10/2005
NM_000634	Homo sapiens's interleukin 8 acceptor, α (IL8RA), mRNA.11/2005	NM_000611
NM_000634		NM_000660	Homo sapiens's transforming growth factor, β 1 (Camurati-Engelmann disease) (TGFB1), mRNA.11/2005
NM_001001887	Have homo sapiens's Interferon, rabbit-inducible protein of triangle tetrapeptide repetition 1 (IFIT1), transcribe spliceosome 1, mRNA.10/2005	NM_000660
NM_001001887		NM_001008540	Homo sapiens's chemokine (C-X-C motif) acceptor 4 (CXCR4) is transcribed spliceosome 1, mRNA.11/2005
NM_001013255	Homo sapiens's lymphocyte-specific proteins 1 (LSP1) is transcribed spliceosome 4, mRNA.10/2005	NM_001008540
NM_001013255		NM_001018076	Homo sapiens's nuclear receptor subunit family 3, group C, member 1 (glucocorticoid receptor) (NR3C1) transcribes spliceosome 4, mRNA.11/2005
NM_001157	Homo sapiens's annexin A11 (ANXA11) transcribes spliceosome a, mRNA.10/2005	NM_001018076
NM_001157		NM_001175	Homo sapiens Rho GDP inhibitor (GDI) β (ARHGDIB) that dissociates, mRNA.10/2005
NM_001421	Homo sapiens E74-like factor 4 (ets structural domain transcription factor) (ELF4), mRNA.10/2005	NM_001175
NM_001421		NM_001465	Homo sapiens FYN conjugated protein (FYB-120/130) (FYB) transcribes spliceosome 1, mRNA.11/2005
NM_001557	Homo sapiens's interleukin 8 acceptor, β (IL8RB), mRNA.11/2005	NM_001465
NM_001557		NM_001629	Homo sapiens's arachidonic acid 5 lipoxygenase activators (ALOX5AP), mRNA.11/2005
NM_001637	Homo sapiens's carboxylic acyl lytic enzyme (neutrophil leucocyte) (AOAH), mRNA.9/2005	NM_001629
NM_001637		NM_001760	Homo sapiens's cyclin D3 (CCND3), mRNA.10/2005
NM_001784	Homo sapiens CD97 antigen (CD97) is transcribed spliceosome 2, mRNA.10/2005	NM_001760	Homo sapiens's cyclin D3 (CCND3), mRNA.10/2005
NM_001784		NM_002032	Homo sapiens's ferritin, heavy polypeptide 1 (FTH1), mRNA.11/2005

NM_002221	Homo sapiens's inositol 1,4,5-triphosphoric acid 3-kinase b (ITPKB), mRNA.10/2005
NM_002221		NM_002468	Homo sapiens's marrow breaks up main reaction gene (88) (MYD88), mRNA.11/2005
NM_002756	Homo sapiens's mitogen-activated protein kinase kinases 3 (MAP2K3) is transcribed spliceosome A, mRNA.10/2005	NM_002468
NM_002756		NM_002985	Homo sapiens's chemokine (C-C motif) part 5 (CCL5), mRNA.11/2005
NM_003110	Homo sapiens Sp2 transcription factor (SP2), mRNA.10/2005	NM_002985
NM_003110	Homo sapiens Sp2 transcription factor (SP2), mRNA.10/2005	NM_003204	Homo sapiens's nf (red corpuscle-source 2)-sample 1 (NFE2L1), mRNA.10/2005
NM_003407	Homo sapiens's zinc finger protein 36, C3H type, homologue (mouse) (ZFP36), mRNA.11/2005	NM_003204
NM_003407		NM_003820	The sapiens tumor necrosis factor receptor superfamily, member 14 (simplexvirus enters medium) (TNFRSF14), mRNA.11/2005
NM_003853	Homo sapiens's interleukin 18 acceptor accessory protein (IL18RAP), mRNA.10/2005	NM_003820
NM_003853		NM_004120	Homo sapiens's guanosine is conjugated protein 2, Interferon, rabbit-derivable (GBP2), mRNA.9/2005
NM_004356	Homo sapiens CD81 antigen (target of antiproliferation antibodies 1) (CD81), mRNA.10/2005	NM_004120
NM_004356		NM_004688	Homo sapiens N-myc (and STAT) interacts sub (NMI), mRNA.11/2005
NM_005621	Homo sapiens S100 calcium binding protein A12 (calgranulin C) (S100A12), mRNA.10/2005	NM_004688
NM_005621		NM_005745	Homo sapiens B-cell receptor-related protein 31 (BCAP31), mRNA.10/2005
NM_005849	Homo sapiens's immunoglobulin superfamily, member 6 (IGSF6), mRNA.10/2005	NM_005745
NM_005849		NM_005902	Homo sapiens SMAD, at DPP homologue 3 (fruit bat) (SMAD3), the parent of mRNA.11/2005
NM_006263	(precursor, macropain) activator subunit 1 (PA28 α) (PSME1) transcribes spliceosome 1, mRNA to sapiens protein enzyme body.10/2005	NM_005902
NM_006263		NM_006665	Homo sapiens's heparitinase (HPSE), mRNA.11/2005
NM_012072	Homo sapiens's complement component 1, q subcomponent, acceptor 1 (C1QR1), mRNA.10/2005	NM_006665	Homo sapiens's heparitinase (HPSE), mRNA.11/2005
NM_012072		NM_013237	Homo sapiens px19-sample albumen (PX19), mRNA.4/2005
NM_014146	Be used for the activatory homo sapiens of T cell family connexon, member 2 (LAT2) transcribes spliceosome 3, mRNA.10/2005	NM_013237	Homo sapiens px19-sample albumen (PX19), mRNA.4/2005
NM_014146		NM_020980	Homo sapiens's aquaporin 9 (AQP9), mRNA.10/2005
NM_021649	Homo sapiens toll-sample acceptor adaptor molecule 2 (TICAM2), mRNA.10/2005	NM_020980	Homo sapiens's aquaporin 9 (AQP9), mRNA.10/2005
NM_021649		NM_032924	Homo sapiens's zinc finger protein 3 (A8-51) (ZNF3) is transcribed spliceosome 2, mRNA.9/2005
NM_052942	Conjugated protein 5 (GBP5) of homo sapiens's guanosine, mRNA.10/2005	NM_032924

NM_133437	Homo sapiens's connetin (TTN) is transcribed spliceosome novex-2, mRNA.11/2005
NM_133437		NM_145640	Homo sapiens's lipophorin L, 3 (APOL3) transcribe spliceosome α/d, mRNA.10/2005
NM_148919	Sapiens protein enzyme body (precursor, macropain) subunit, the β type, 8 (big multifunctional polypeptide enzymes 7) (PSMB8), are transcribed spliceosome 2, mRNA.10/2005	NM_145640
NM_148919		NM_172373	Homo sapiens E74-like factor 1 (ets structural domain transcription factor) (ELF1), mRNA.10/2005
NM_002463	Homo sapiens myxovirus (influenza virus) is resisted 2 (mouse) (MX2), mRNA.9/2005	NM_172373
NM_002463		NM_003264	Homo sapiens toll-sample acceptor 2 (TLR2), mRNA.11/2005
NM_004946	Homo sapiens's cell fission acting factor 2 (DOCK2), mRNA.10/2005	NM_003264	Homo sapiens toll-sample acceptor 2 (TLR2), mRNA.11/2005
NM_004946		BC013629	Homo sapiens WNK Methionin lacks protein kinase 1, and mRNA (the cDNA clone [MAGE:3445410), the part encoding sequence.1/2005
NM_000733	Homo sapiens CD3E antigen, ε polypeptide (TiT3 complex body) (CD3E), mRNA.10/2005	BC013629
NM_000733		NM_001556	The homo sapiens of kappa light polypeptide genetic enhancer suppresses son, kinase beta (IKBKB), mRNA in the B-cell.11/2005
NM_001743	Homo sapiens's calmodulin 2 (phosphorylase kinase, δ) (CALM2), mRNA.10/2005	NM_001556
NM_001743		NM_002122	Homo sapiens's major histocompatibility complex, class II, DQ α 1 (HLA-DQA1), mRNA.11/2005
NM_002576	Homo sapiens p21/Cdc42/Rac1-activated protein kinase 1 (STE20 homologue, yeast) (PAK1), mRNA.11/2005	NM_002122
NM_002576		NM_002647	Homo sapiens's phosphoinositide-3-kinases, class 3 (PIK3C3), mRNA.10/2005
NM_002745	Homo sapiens's mitogen-activated protein kinase 1 (MAPK1) is transcribed spliceosome 1, mRNA.11/2005	NM_002647
NM_002745		NM_002872	Homo sapiens ras-is correlated with C3 Toxins, botulin matrix 2 (rho family, little gtp binding protein Rac2) (RAC2), mRNA.10/2005
NM_003998	In the B-cell homo sapiens's nf (p105) of kappa light polypeptide genetic enhancer (NFKB1), mRNA.11/2005	NM_002872
NM_003998		NM_004048	Homo sapiens's beta-2-microglobulin (B2M), mRNA.11/2005
NM_004383	Homo sapiens c-src Tyrosylprotein kinase (CSK), mRNA.11/2005	NM_004048	Homo sapiens's beta-2-microglobulin (B2M), mRNA.11/2005
NM_004383		NM_005026	Homo sapiens's phosphoinositide-3-kinases, catalytic, δ polypeptide (PIK3CD), mRNA.11/2005
NM_005252	Homo sapiens v-fos FBJ mouse osteosarcoma virus oncogene homologue (FOS), mRNA.11/2005	NM_005026
NM_005252		NM_005428	Homo sapiens vav 1 oncogene (VAV1), mRNA.11/2005

NM_005565	Homo sapiens's lymphocyte plasmosin 2 (the white corpuscle albumen that comprises the SH2 structural domain, 76kDa) (LCP2), mRNA.10/2005
NM_005565		NM_006139	Homo sapiens CD28 antigen (Tp44) (CD28), mRNA.11/2005
NM_006257	The sapiens protein kinase c, θ (PRKCQ), mRNA.11/2005	NM_006139	Homo sapiens CD28 antigen (Tp44) (CD28), mRNA.11/2005
NM_006257	The sapiens protein kinase c, θ (PRKCQ), mRNA.11/2005	NM_019111	Homo sapiens's major histocompatibility complex, class II, DR α (HLA-DRA), mRNA.10/2005
NM_020529	Homo sapiens's nf of kappa light polypeptide genetic enhancer in the B-cytostatics, α (NFKBIA), mRNA.10/2005	NM_019111
NM_020529		NM_033554	Homo sapiens's major histocompatibility complex, class II, DP α 1 (HLA-DPA1), mRNA. 10/2005
NM_182811	Homo sapiens's Phospholipase C, γ 1 (PLCG1) transcribes spliceosome 2, mRNA.10/2005	NM_033554
NM_182811		AB209870	Homo sapiens mRNA is used for HLA class I histocompatibility antigen, E α chain precursor misfolded proteins.3/2005
AF110908	Homo sapiens TNF-receptor associated factor-3 (TRAF-3) mRNA, part cds; And 3 ' UTR.5/1999	AB209870
AF110908		BC025727	Homo sapiens's TXi Baoshouti α is variable 20, mRNA (cDNA clone MGC:34712 MAGE:5201547), encoding sequence fully.6/2005
BC028068	Homo sapiens Janus kinases 3 (protein tyrosine kinase, white corpuscle), mRNA (cDNA clones MGC:39993IMAGE:5212575), encoding sequence fully.10/2003	BC025727
BC028068		K02885	The active beta chain V-D-J-of homo sapiens's T-cell receptors β-1.2-C-β-1 (TCRB) mRNA, the part encoding sequence.3/1999
L34703	Homo sapiens's T-cell receptors α chain (TCRA) mRNA (HLA-A1,24; B7,8; DR1,3), complete encoding sequence.12/2001	K02885
L34703		M12886	The active beta chain mRNA of human T-cell receptors, encoding sequence fully.1/1995
NM_000416	Homo sapiens's interferon gamma receptor 1 (IFNGR1), mRNA.10/2005	M12886
NM_000416		NM_000433	Homo sapiens's neutrophil leucocyte endochylema factor 2 (65kDa, chronic granulomatous disease, euchromosome 2) (NCF2), mRNA.10/2005
NM_001010972	Homo sapiens's zyxin (ZYX) is transcribed spliceosome 2, mRNA.10/2005	NM_000433
NM_001010972		NM_001012631	Homo sapiens's interleukin-13 2 (IL32) is transcribed spliceosome 1, mRNA.10/2005
NM_001558	Homo sapiens's interleukin-11 0 acceptor, α (IL10RA), mRNA.10/2005	NM_001012631
NM_001558		NM_002227	Homo sapiens Janus kinases 1 (a protein tyrosine kinase) (JAK1), mRNA.11/2005
NM_002298	Homo sapiens's lymphocyte plasmosin 1 (L-plastin) (LCP1), mRNA.10/2005	NM_002227
NM_002298		NM_002923	The regulon of homo sapiens G-protein signal 2,24kDa (RGS2), mRNA.11/2005

NM_003877	Inhibition of homo sapiens's cytokine signaling 2 (SOCS2), mRNA.10/2005
NM_003877		NM_004117	Conjugated protein 5 (FKBP5) of homo sapiens FK506, mRNA.10/2005
NM_004489	Homo sapiens G albumen path suppresses son 2 (GPS2), mRNA.10/2005	NM_004117
NM_004489		NM_006058	Homo sapiens TNFAIP3 interaction protein 1 (TNIP1), mRNA.10/2005
NM_006449	Homo sapiens CDC42 effect protein (combination of Rho GTP enzyme) 3 (CDC42EP3), mRNA.9/2005	NM_006058
NM_006449		NM_006726	Homo sapiens LPS-replys the vesicle transportation, comprises beach strand and grappling (LRBA), mRNA.10/2005
NM_006779	Homo sapiens CDC42 effect protein (combination of Rho GTP enzyme) 2 (CDC42EP2), mRNA.9/2005	NM_006726
NM_006779		NM_014663	Homo sapiens jumonji structural domain 2A (JMJD2A), mRNA.11/2005
NM_015015	Homo sapiens jumonji structural domain 2B (JMJD2B), mRNA.10/2005	NM_014663
NM_015015		NM_054014	The conjugated protein 1A of homo sapiens FK506,12kDa (FKBP1A) transcribes spliceosome 12A, mRNA.11/2005
NM_172313	Homo sapiens's G CFS 3 acceptors (granulocyte) (CSF3R) are transcribed spliceosome 4, mRNA.10/2005	NM_054014
NM_172313		NM203346	Homo sapiens's high-density lipoprotein (HDL) conjugated protein (watchful element) (HDLBP), mRNA.10/2005

The tabulation of gene/transcript that table 6. is relevant with immune signal path

With reference to entering gene	Representative transcript	The gene title
With reference to entering gene	Representative transcript	The gene title	1	NM_130786	α-1-B glycoprotein; A1BG
12	NM_001085	A-1-chymotrypsin inhibitor precursor (ACT) [comprising: A-1-chymotrypsin inhibitor His-Pro-less] .[source: Uniprot/SWISSPROT; Acc:P01011]	1	NM_130786	α-1-B glycoprotein; A1BG
12	NM_001085		23	NM_001025091	ATP-binding cassette Asia-F the member of family 1 (ATP-binding cassette 50) (TNF-α-stimulation ABC albumen) .[source: Uniprot/SWISSPROT; Acc:Q8NE71]
100	NM_000022	Adenosine deaminase (EC3.5.4.4) (adenosine aminohydrolase) .[source: Uniprot/SWISSPROT; Acc:P00813]	23	NM_001025091
100	NM_000022		103	NM_001111	Double-stranded RNA-specificity adenosine deaminase (EC 3.5.4.-) is (136kDa double-strand RNA binding protein) (P136) (K88DSRBP) (Interferon, rabbit-inducible protein 4) (IFI-4 albumen) .[source: Uniprot/SWISSPROT (DRADA); Acc:P55265]
134	NM_000674	Adenosine A	103	NM_001111		1 receptor .[source: Uniprot/SWISSPROT; Acc:P30542]
134	NM_000674	Adenosine A	135	NM_000675	Adenosine A 2a acceptor .[source: Uniprot/SWISSPROT; Acc:P29274]	1 receptor .[source: Uniprot/SWISSPROT; Acc:P30542]
136	NM_000676	Adenosine A 2b acceptor .[source: Uniprot/SWISSPROT; Acc:P29275]	135	NM_000675

140	NM_020683; NM_000677	Adenosine A	3 receptor; ADORA3
140	NM_020683; NM_000677	Adenosine A	3 receptor; ADORA3	143	NM_006437	Poly-[ADP-ribose] polysaccharase 4 (EC2.4.2.30) (PARP-4) (arched roof gather (ADP-ribose) polysaccharase) (VPARP) (193-kDa arched roof albumen) (PARP-is relevant/the relevant H5/ proline(Pro) of I α I--abundant) (PH5P) .[originate: Uniprot/SWISSPROT; Acc:Q9UKK3]
174	NM_001134	α-Jia Taidanbai precursor (α-Jia Taidanbai) (α-1-alpha-fetoprotein) .[source: Uniprot/SWISSPROT; Acc:P02771]		143	NM_006437
174	NM_001134		177	NM_172197; NM_001136	Advanced glycosylation end product-specific receptors; AGER
182	NM_000214	Agged1 (Alagille syndromes); JAG1	177	NM_172197; NM_001136	Advanced glycosylation end product-specific receptors; AGER
182	NM_000214	Agged1 (Alagille syndromes); JAG1	197	NM_001622	(Pp63 glycophosphoproteins-A) (α-2-Z-sphaeroprotein) (Ba-α-2-glycoprotein) [comprises: α-2-HS-glycoprotein chains A α-2-HS-glycoprotein precursor; α-2-HS-glycoprotein chains B] .[source: Uniprot/SWISSPROT; Acc:P02765]
199	NM_001623	Allotransplantation inflammatory factor 1 (AIF-1) (ionised calcium-in conjunction with aptamer molecule 1) (G1 albumen) .[source: Uniprot/SWISSPROT; Acc:P55008]	197	NM_001622
199	NM_001623		207	NM_001014431; NM_001014432; NM_005163	V-akt mouse thymoma viral oncogene homologue 1; AKT1
208	NM_001626	V-akt mouse thymoma viral oncogene homologue 2; AKT2	207	NM_001014431; NM_001014432; NM_005163	V-akt mouse thymoma viral oncogene homologue 1; AKT1
208	NM_001626	V-akt mouse thymoma viral oncogene homologue 2; AKT2	214	NM_001627	CD166 antigen precursor (activated leukocyte cell-cell adhesion molecule) is the .[source (ALCAM): Uniprot/SWISSPROT; Acc:Q13740]
240	NM_000698	Arachidonic acid 5 lipoxygenases (EC1.13.11.34) (5-lipoxygenase) are the .[source (5-LO): Uniprot/SWISSPROT; Acc:P09917]	214	NM_001627
240	NM_000698		241	NM_001629	Arachidonic acid 5 lipoxygenases-activator (FLAP) (MK-886-is conjugated protein).[source: Uniprot/SWISSPROT; Acc:P20292]
246	NM_001140	Arachidonic acid 15-lipoxygenase (EC 1.13.11.33) (arachidonic acid Ω-6 lipoxygenase) is the .[source (15-LOX): Uniprot/SWISSPROT; Acc:P16050]	241	NM_001629
246	NM_001140		259	NM_001633	The AMBP amyloid protein precursor [comprises: α-1-microglobulin (albumen HC) (complex body-formation glycoprotein electric charge is heterogeneous) (the little glycoprotein of α-1); Inter-α-trypsinase suppresses light chain (ITI-LC) (Bikunin) (HI-30)] .[source: Uniprot/SWISSPROT; Acc:P
283	NM_001145	Rnase 4 precursors (EC 3.1.27.-) (RNA enzyme 4) .[source: Uniprot/SWISSPROT; Acc:P34096]	259	NM_001633
283	NM_001145		301	NM_000700	Annexin A1 (annexin I) (lipocortin I) (calcium-dependent protein II) (chromobindin-9) is (macrocortin) .[source (p35): Uniprot/SWISSPROT; Acc:P04083]
311	NM_145869	Annexin A11 (annexin XI) (calcyclin be correlated with annexin 50) is (56kDa self antigen) .[source (CAP-50): Uniprot/SWISSPROT; Acc:P50995]	301	NM_000700

313	NM_001637	Carboxylic acyl lytic enzyme precursor (EC3.1.1.77) [comprises: the little subunit of carboxylic acyl lytic enzyme; Carboxylic acyl lytic enzyme large subunit] .[source: Uniprot/SWISSPROT; Acc:P28039]
313	NM_001637		316	NM_001159	Aldehyde oxidase (EC1.2.3.1) .[source: Uniprot/SWISSPROT; Acc:Q06278]
325	NM_001639	Amyloid P composition, serum; APCS	316	NM_001159
325	NM_001639	Amyloid P composition, serum; APCS	326	NM_000383	Autoimmunization conditioning agent (the multiple incretopathy moniliosis of autoimmunity ectoderm malnutrition albumen) (APECED albumen) .[source: Uniprot/SWISSPROT; Acc:O43918]
336	NM_001643	Apolipoprotein A-1 I precursor (Apo-AII) (ApoA-II) [comprises: apolipoprotein A-1 I (1-76)] .[and originates: Uniprot/SWISSPROT; Acc:P02652]	326	NM_000383
336	NM_001643		355	NM_000043	Tumor necrosis factor receptor super family member 6 precursors (FASL acceptor) (apoptosis mediation surface antigen FAS) (Apo-1 antigen) (CD95 antigen) .[source: Uniprot/SWISSPROT; Acc:P25445]
356	NM_000639	Tumour necrosis factor part superfamily member 6 (FAS antigen part) (apoptotic antigen part) (APTL) (CD178 antigen) [comprises: tumour necrosis factor part superfamily member 6, film form; Tumour necrosis factor part superfamily member 6, soluble	355	NM_000043
356	NM_000639		366	NM_020980	Aquaporin-9 (AQP-9) (little solute passage 1) .[source: Uniprot/SWISSPROT; Acc:O43315]
369	NM_001654	V-raf rat meat knurl 3611 viral oncogene homologues; ARAF	366	NM_020980
369	NM_001654	V-raf rat meat knurl 3611 viral oncogene homologues; ARAF	397	NM_001175	Rho GDP-(Ly-GDI) .[source of inhibitor 2 (Rho GDI2) (Rho-GDI β): the Uniprot/SWISSPROT that dissociates; Acc:P52566]
399	NM_004310	Rho-correlative GTP-conjugated protein RhoH (the conjugated protein TTF of GTP-) .[source: Uniprot/SWISSPROT; Acc:Q15669]	397	NM_001175
399	NM_004310		563	NM_001185	α-2-glycoprotein 1, zinc; AZGP1
566	NM_001700	Reddish black element 1 (the cationic antibacterial agent protein 37) that kill; AZU1	563	NM_001185	α-2-glycoprotein 1, zinc; AZGP1
566	NM_001700		567	NM_004048	Beta-2-microglobulin; B2M
572	NM_032989	Bcl2-antagonist (BAD) (Bcl-2 binding constituents 6) (Bcl-XL/Bcl-2-associated death promotor) (Bcl-2-sample 8 albumen) the .[source of necrocytosis: Uniprot/SWISSPROT; Acc:Q92934]	567	NM_004048	Beta-2-microglobulin; B2M
572	NM_032989		596	NM_000657	Apoptosis regulon Bcl-2.[source: Uniprot/SWISSPROT; Acc:P10415]
604	NM_001706	B-cell lymphoma 6 albumen (BCL-6) (zinc finger protein 51) (LAZ-3 albumen) are (zinc refers to comprise albumen 27 with the BTB structural domain) .[source (BCL-5): Uniprot/SWISSPROT; Acc:P41182]	596	NM_000657
604	NM_001706		608	NM_001192	Tumor necrosis factor receptor super family member 17 (B-cell maturation albumen) (CD269 antigen) .[source: Uniprot/SWISSPROT; Acc:Q02223]
623	NM_000710	B1 bradykinin receptor (BK-1 acceptor) is the .[source (B1R): Uniprot/SWISSPROT; Acc:P46663]	608	NM_001192
623	NM_000710		624	NM_000623	B2 bradykinin receptor (BK-2 acceptor) is the .[source (B2R): Uniprot/SWISSPROT; Acc:P30411]

629	NM_001710	The B-factor, properdin; BF
629	NM_001710	The B-factor, properdin; BF	640	NM_001715	B lymph Tyrosylprotein kinase; BLK
641	NM_000057	Bloom ' s syndromes albumen (EC 3.6.1.-) (RecQ albumen-sample 3) (dna helicase, RecQ-sample type 2) .[source: Uniprot/SWISSPROT; Acc:P54132]	640	NM_001715	B lymph Tyrosylprotein kinase; BLK
641	NM_000057		643	NM_032966	C-X-C Chemokine Receptors type 5 (CXC-R5) is (Burkitt ' S lymphoma acceptor 1) (acceptor 15 in monocyte-source) (MDR15) (CD185 antigen) .[source: Uniprot/SWISSPROT (CXCR-5); Acc:P32302]
648	NM_005180	Many comb basic ring finger protein 4 (combing complex body protein B MI-1) (ring finger protein 51) .[source: Uniprot/SWISSPROT more; Acc:P35226]	643	NM_032966
648	NM_005180		660	NM_203281；NM_001721	BMX is non--receptor tyrosine kinase; BMX
671	NM_001725	Sterilization/permeability-increase albumen; BPI	660	NM_203281；NM_001721	BMX is non--receptor tyrosine kinase; BMX
671	NM_001725	Sterilization/permeability-increase albumen; BPI	673	NM_004333	V-raf murine sarcoma virus oncogene homologue B1; BRAF
683	NM_004334	ADP-ribosyl cyclase 2 precursors (EC3.2.2.5) (ring-type ADP-ribose lytic enzyme 2) (cADPr lytic enzyme 2) (bone marrow interstital antigen 1) (BST-1) (CD157 antigen) .[source: Uniprot/SWISSPROT; Acc:Q10588]	673	NM_004333	V-raf murine sarcoma virus oncogene homologue B1; BRAF
683	NM_004334		684	NM_004335	Bone marrow interstital antigen 2 (BST-2) (CD317 antigen) .[source: Uniprot/SWISSPROT; Acc:Q10589]
695	NM_000061	Bruton agammaglobulinaemia Tyrosylprotein kinase; BTK	684	NM_004335
695	NM_000061	Bruton agammaglobulinaemia Tyrosylprotein kinase; BTK	708	NM_001212	Complement component	1, the q subcomponent is conjugated protein; C1QBP
710	NM_000062	Plasma proteinase C1 suppresses (C1Inh) .[source: Uniprot/SWISSPROT of sub-precursor (C1 Inh); Acc:P05155]	708	NM_001212	Complement component	1, the q subcomponent is conjugated protein; C1QBP
710	NM_000062		712	NM_015991	Complement component	1, q subcomponent, α polypeptide; C1QA
713	NM_000491	Complement component	712	NM_015991	Complement component	1, q subcomponent, α polypeptide; C1QA	1, q subcomponent, beta polypeptides; C1QB
713	NM_000491	Complement component	714	NM_172369	Complement component	1, q subcomponent, γ polypeptide; C1QG	1, q subcomponent, beta polypeptides; C1QB
715	NM_001733	Complement component	714	NM_172369	Complement component	1, q subcomponent, γ polypeptide; C1QG	1, the r subcomponent; C1R
715	NM_001733	Complement component	716	NM_001734；NM_20 1442	Complement component 1, the s subcomponent; C1S		1, the r subcomponent; C1R
717	NM_000063	Complement component	716	NM_001734；NM_20 1442	Complement component 1, the s subcomponent; C1S	2; C2
717	NM_000063	Complement component	718	NM_000064	Complement component	2; C2	3; C3
719	NM_004054	C3a anaphylotoxin chemoattractant receptor (C3a-R) is the .[source (C3AR): Uniprot/SWISSPROT; Acc:Q16581]	718	NM_000064	Complement component		3; C3
719	NM_004054		720	NM_007293	Complement component C4 A; C4A
721	NM_000592	Complement component C4 B; C4B	720	NM_007293	Complement component C4 A; C4A
721	NM_000592	Complement component C4 B; C4B	722	NM_000715	Complement component C4 is conjugated protein, α; C4BPA
725	NM_001017364；NM _001017366；NM_001 017365；NM_000716；NM_001017367	Complement component C4 is conjugated protein, β; C4BPB	722	NM_000715	Complement component C4 is conjugated protein, α; C4BPA
725		Complement component C4 is conjugated protein, β; C4BPB	727	NM_001735	Complement component	5; C5

728	NM_001736	C5a anaphylotoxin chemoattractant receptor (C5a-R) is (CD88 antigen) (C5aR). [source: Uniprot/SWISSPROT; Acc:P21730]
728	NM_001736		729	NM_000065	Complement component	6; C6
730	NM_000587	C7; C7	729	NM_000065	Complement component	6; C6
730	NM_000587	C7; C7	731	NM_000562	Complement component	8, the α polypeptide; C8A
732	NM_000066	Complement component	731	NM_000562	Complement component	8, the α polypeptide; C8A	8, beta polypeptides; C8B
732	NM_000066	Complement component	733	NM_000606	Complement component C8 γ chain precursor .[source: Uniprot/SWISSPROT; Acc:P07360]		8, beta polypeptides; C8B
735	NM_001737	Complement component	733	NM_000606		9; C9
735	NM_001737	Complement component	796	NM_001741	The thyrocalcitonin precursor [comprises: thyrocalcitonin; Anticalcium element (thyrocalcitonin carboxyl-terminal peptide) is (PDN-21) (CCP)] .[source: Uniprot/SWISSPROT; Acc:P01258]	9; C9
801	NM_006888	Calmodulin 1 (phosphorylase kinase, δ); CALM1	796	NM_001741
801	NM_006888	Calmodulin 1 (phosphorylase kinase, δ); CALM1	805	NM_001743	Calmodulin 2 (phosphorylase kinase, δ); CALM2
808	NM_005184	Calmodulin 3 (phosphorylase kinase, δ); CALM3	805	NM_001743	Calmodulin 2 (phosphorylase kinase, δ); CALM2
808	NM_005184	Calmodulin 3 (phosphorylase kinase, δ); CALM3	810	NM_005185	Calmodulin-sample 3; CALML3
820	NM_004345	The cecropin antibacterial peptide; CAMP	810	NM_005185	Calmodulin-sample 3; CALML3
820	NM_004345	The cecropin antibacterial peptide; CAMP	836	NM_004346	Apoptosis enzyme-3 precursor (EC3.4.22.-) (CASP-3) (apoptosis element) (L-Cysteine HCL Anhydrous CPP32) (Yama albumen) (CPP-32) (SREBP shear active 1) (SCA-1) [comprise: apoptosis enzyme-3p17 subunit; Apoptosis enzyme-3p12 subunit] .[source: Uniprot/SWISSPROT; Acc:P42574]
865	NM_001755	Core-binding factor, (PEBP2-β) (PEA2-β) of β subunit (CBF-β) (polyomavirus enhancer binding protein 2 β subunits) (the SL3-3 enhanser factor 1 β subunit) (SL3/AKV core-binding factor β subunit) .[source: Uniprot/SWISSPROT; Acc:Q13951]	836	NM_004346
865	NM_001755		896	NM_001760	G1/S-specific cell cyclin-D3.[source: Uniprot/SWISSPROT; Acc:P30281]
909	NM_001763	CD1a antigen; CD1A	896	NM_001760
909	NM_001763	CD1a antigen; CD1A	910	NM_001764	CD1b antigen; CD1B
911	NM_001765	CD1C antigen, the c polypeptide; CD1C	910	NM_001764	CD1b antigen; CD1B
911	NM_001765	CD1C antigen, the c polypeptide; CD1C	912	NM_001766	CD1D antigen, the d polypeptide; CD1D
913	NM_030893	CD1E antigen, the e polypeptide; CD1E	912	NM_001766	CD1D antigen, the d polypeptide; CD1D
913	NM_030893	CD1E antigen, the e polypeptide; CD1E	914	NM_001767	CD2 antigen (p50), the sheep red blood cell acceptor; CD2
915	NM_000732	CD3D antigen, δ polypeptide (TiT3 complex body); CD3D	914	NM_001767	CD2 antigen (p50), the sheep red blood cell acceptor; CD2
915	NM_000732	CD3D antigen, δ polypeptide (TiT3 complex body); CD3D	916	NM_000733	CD3E antigen, ε polypeptide (TiT3 complex body); CD3E
917	NM_000073	CD3G antigen, γ polypeptide (TiT3 complex body); CD3G	916	NM_000733	CD3E antigen, ε polypeptide (TiT3 complex body); CD3E
917	NM_000073	CD3G antigen, γ polypeptide (TiT3 complex body); CD3G	919	NM_198053；NM_000734	CD3Z antigen, ζ polypeptide (TiT3 complex body); CD3Z
920	NM_000616	T4 antigen (p55); CD4	919	NM_198053；NM_000734	CD3Z antigen, ζ polypeptide (TiT3 complex body); CD3Z
920	NM_000616	T4 antigen (p55); CD4	922	NM_005894	CD5 antigen-sample precursor (SP-α) is (IgM-related peptides) .[source (CT-2): Uniprot/SWISSPROT; Acc:O43866]
923	NM_006725	T-cytodifferentiation antigens c D6 precursor (T12) is the .[source (TP120): Uniprot/SWISSPROT; Acc:P30203]	922	NM_005894

924	NM_006137	CD7 antigen (p41); CD7
924	NM_006137	CD7 antigen (p41); CD7	925	NM_001768；NM_171827	CD8 antigen, α polypeptide (p32); CD8A
926	NM_172101；NM_17 2213；NM_172099；N M_004931；NM_1721 02	CD8 antigen, beta polypeptides 1 (p37); CD8B1	925	NM_001768；NM_171827	CD8 antigen, α polypeptide (p32); CD8A
926	NM_172101；NM_17 2213；NM_172099；N M_004931；NM_1721 02	CD8 antigen, beta polypeptides 1 (p37); CD8B1	929	NM_000591	Monocyte differentiation antigen CD14 precursor (medullary cell-specificity leucine enriches glycoprotein) [comprises: monocyte differentiation antigen CD14, urine type; Monocyte differentiation antigen CD14, film mating type] .[source: Uniprot/SWISSPROT; Acc:P
930	NM_001770	CD19 antigen; CD19	929	NM_000591
930	NM_001770	CD19 antigen; CD19	931	NM_152866	B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1) is (Bp35) .[source (Leu-16): Uniprot/SWISSPROT; Acc:P11836]
933	NM_001771	CD22 antigen; CD22	931	NM_152866
933	NM_001771	CD22 antigen; CD22	934	NM_013230	Signal transducer CD24 precursor .[source: Uniprot/SWISSPROT; Acc:P25063]
939	NM_001242	Tumor necrosis factor receptor super family member 7 precursors (CD27L acceptor) (T-cell activation antigens c D27) are the .[source (T14): Uniprot/SWISSPROT; Acc:P26842]	934	NM_013230
939	NM_001242		940	NM_006139	CD28 antigen (Tp44); CD28
941	NM_005191	CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); CD80	940	NM_006139	CD28 antigen (Tp44); CD28
941	NM_005191	CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); CD80	942	NM_006889；NM_175862	CD86 antigen (CD28 antigen part 2, B7-2 antigen); CD86
944	NM_001244	Tumour necrosis factor part superfamily member 8 (CD30 part) is (CD153 antigen) .[source (CD30-L): Uniprot/SWISSPROT; Acc:P32971]	942	NM_006889；NM_175862	CD86 antigen (CD28 antigen part 2, B7-2 antigen); CD86
944	NM_001244		945	NM_001772	CD33 antigen (gp67); CD33
946	NM_198845；NM_00 1245；NM_198846	Sialic acid is in conjunction with Ig-sample lectin 6; SIGLEC6	945	NM_001772	CD33 antigen (gp67); CD33
946	NM_198845；NM_00 1245；NM_198846		953	NM_001776	Outer ribonucleoside triphosphote bisphosphate lytic enzyme 1 (EC 3.6.1.5) is (outer-ATP bisphosphate lytic enzyme) (ATPDase) (lymphocyte activation antigen) (outer-apyrase) (CD39 antigen) .[source (NTPDase1): Uniprot/SWISSPROT; Acc:P49961]
958	NM_001250	Tumor necrosis factor receptor super family member 5 precursors (CD40L acceptor) (B-cell-surface antigens CD40) are (Bp50) .[source (CDw40): Uniprot/SWISSPROT; Acc:P25942]	953	NM_001776
958	NM_001250		959	NM_000074	Tumour necrosis factor part superfamily member 5 (CD40 part) (CD40-L) (TNF-be correlated with activated protein) (TRAP) (T cell antigen Gp39) (CD154 antigen) [comprise: tumour necrosis factor part superfamily member 5, membranous type; Tumour necrosis factor liga
961	NM_001777；NM_00 1025080；NM_001025079；NM_198793	CD47 antigen (Rh-related antigen, integral protein-coherent signal conversion); CD47	959	NM_000074
961	NM_001777；NM_00 1025080；NM_001025079；NM_198793		962	NM_001778	CD48 antigen (B-epicyte protein); CD48

963	NM_000560	Leukocyte surface antigens c D53 (cell surface glycoprotein CD53) (tetratransmembrane albumen-25) is the .[source (Tspan-25): Uniprot/SWISSPROT; Acc:P19397]
963	NM_000560		965	NM_001779	Woods crust cell function-related antigen 3 precursors (Ag3) (antigens c D58) (surface glycoprotein LFA-3) .[source: Uniprot/SWISSPROT; Acc:P19256]
966	NM_203330	CD59 glycoprotein precursor (membrane attack complex inhibitory factor) is (MAC-arrestin) (MAC-IP) (MIRL) (20kDa homologous restriction factor) (HRF-20) (HRF20) (1F5 antigen of (protected protein) (MEM43 antigen) (reactive cracked film suppress son) (MACIF)	965	NM_001779
966	NM_203330		969	NM_001781	CD69 antigen (p60, earlier T-cell activation antigen); CD69
970	NM_001252	Tumour necrosis factor part superfamily member 7 (CD27 part) is (CD70 antigen) .[source (CD27-L): Uniprot/SWISSPROT; Acc:P32970]	969	NM_001781	CD69 antigen (p60, earlier T-cell activation antigen); CD69
970	NM_001252		971	NM_001782	B-cytodifferentiation antigens c D72 (Lyb-2) .[source: Uniprot/SWISSPROT; Acc:P21854]
972	NM_001025159；NM _004355；NM_001025158	CD74 antigen (the constant polypeptide of major histocompatibility complex, class II antigen-relevant); CD74	971	NM_001782
972	NM_001025159；NM _004355；NM_001025158		973	NM_001783；NM_02 1601	CD79A antigen (immunoglobulin (Ig)-relevant α); CD79A
974	NM_000626；NM_02 1602	CD79B antigen (immunoglobulin (Ig)-relevant β); CD79B	973	NM_001783；NM_02 1601	CD79A antigen (immunoglobulin (Ig)-relevant α); CD79A
974	NM_000626；NM_02 1602	CD79B antigen (immunoglobulin (Ig)-relevant β); CD79B	975	NM_004356	CD81 antigen (26kDa cell surface protein TAPA-1) (target of antiproliferation antibodies 1) (four transmembrane proteins-28) is the .[source (Tspan-28): Uniprot/SWISSPROT; Acc:P60033]
976	NM_078481	CD97 antigen precursor (human leucocyte antigen CD97) .[source: Uniprot/SWISSPROT; Acc:P48960]	975	NM_004356
976	NM_078481		987	NM_006726	LPS-replys the vesicle transportation, comprises beach strand (beach) and grappling (LRBA)
998	NM_001791；NM_04 4472	Cell division cycle 42 (gtp binding protein, 25kDa); CDC42	987	NM_006726
998	NM_001791；NM_04 4472	Cell division cycle 42 (gtp binding protein, 25kDa); CDC42	1026	NM_078467	Cyclin-dependant kinase suppresses (MDA-6) .[source: Uniprot/SWISSPROT of son 1 (p21) (CDK-interaction protein 1) (melanoma differentiation-associated protein 6); Acc:P38936]
1051	NM_005194	CCAAT/ enhancer binding protein β (C/EBP β) (nf NF-IL6) (transcription factor 5) .[source: Uniprot/SWISSPROT; Acc:P17676]	1026	NM_078467
1051	NM_005194		1053	NM_001805	CCAAT/ enhancer binding protein ε (C/EBP ε) .[source: Uniprot/SWISSPROT; Acc:Q15744]
1075	NM_001814	Dipeptides-peptase I precursor (EC 3.4.14.1) (DPP-I) (DPPI) (cathepsin C) (kethepsin J) (two peptidyl transferases) [comprises: dipeptides-peptase I eliminating structural domain chain; Dipeptides-peptase I heavy chain; Dipeptides-peptase I light chain] .[source: U	1053	NM_001805

1088	NM_001816	Carcinomebryonic antigen-relevant cell adhesion molecule 8 precursors (carcinomebryonic antigen CGM6) (NCA NCA-95) (antigens c D67) (CD66b antigen) .[source: Uniprot/SWISSPROT; Acc:P31997]
1088	NM_001816		1118	NM_003465	Chitotriose enzyme-1 precursor (EC 3.2.1.14) (chitinase-1) .[source: Uniprot/SWISSPROT; Acc:Q13231]
1130	NM_001005736	Lysosome transportation regulon (Beige homologue) .[source: Uniprot/SWISSPROT; Acc:Q99698]	1118	NM_003465
1130	NM_001005736		1147	NM_001278	The conservative general kinases of helix-loop-helix; CHUK
1178	NM_001828	Eosinophilic granulocyte lysophospholipase (EC 3.1.1.5) (Charcot-Leyden crystallin) (lysolecithin Acyl-hydrolase) is (prolactin-10) .[source (CLC): Uniprot/SWISSPROT; Acc:Q05315]	1147	NM_001278	The conservative general kinases of helix-loop-helix; CHUK
1178	NM_001828		1191	NM_203339	TRPM-2 precursor (complement-associated protein SP-40,40) (complementation cell dissolving supressor) (CLI) (NA1/NA2) (lipophorin J) (Apo-J) (the prostate gland information 2 of testosterone-inhibition) (TRPM-2) [comprises: TRPM-2 β chain (ApoJ α) (complementation cell dissolving
1230	NM_001295	C-C Chemokine Receptors Class1 (C-C CKR-1) (CC-CKR-1) (CCR-1) (CCR1) (macrophage inflammatory protein 1 alpha acceptor) (MIP-1 α-R) (RANTES-R) is (LD78 acceptor) (CD191 antigen) .[source (HM145): Uniprot/SWISSPROT; Acc:P32246]	1191	NM_203339
1230	NM_001295		1231	NM_000647	C-C Chemokine Receptors type 2 (C-C CKR-2) is (CCR-2) (CCR2) (monocyte chemoattractant albumen 1 acceptor) (MCP-1-R) (CD192 antigen) .[source: Uniprot/SWISSPROT (CC-CKR-2); Acc:P41597]
1232	NM_001837；NM_17 8329	C-C Chemokine Receptors type 3 (C-C CKR-3) is (CCR-3) (CCR3) (CKR3) (eosinophilic granulocyte chemotactic protein acceptor) (CD193 antigen) .[source: Uniprot/SWISSPROT (CC-CKR-3); Acc:P51677]	1231	NM_000647
1232	NM_001837；NM_17 8329		1233	NM_005508	C-C Chemokine Receptors type 4 (C-C CKR-4) is (CCR-4) (CCR4) (K5-5) .[source: Uniprot/SWISSPROT (CC-CKR-4); Acc:P51679]
1234	NM_000579	C-C Chemokine Receptors type 5 (C-C CKR-5) is (CCR-5) (CCR5) (HIV-1 merges accessory receptor) (CHEMR13) (CD195 antigen) .[source: Uniprot/SWISSPROT (CC-CKR-5); Acc:P51681]	1233	NM_005508
1234	NM_000579		1235	NM_031409；NM_00 4367	C-C Chemokine Receptors type 6 (C-C CKR-6) is (GPR-CY4) (CKR-L3) (DRY6) (G-protein linked receptor 29) (antigens c D196) .[source: Uniprot/SWISSPROT of (GPRCY4) (Chemokine Receptors-sample 3) of (CCR-6) (LARC acceptor) (CC-CKR-6); Acc:P51684]
1236	NM_001838	C-C Chemokine Receptors type 7 precursors (C-C CKR-7) (CC-CKR-7) (CCR-7) (MIP-3 beta receptor) (EBV-inductive G-protein linked receptor 1) (EBI1) (BLR2) (CD197 antigen) (CDw197). [source: Uniprot/SWISSPROT; Acc:P32248]	1235	NM_031409；NM_00 4367
1236	NM_001838		1237	NM_005201	C-C Chemokine Receptors type 8 (C-C CKR-8) is (CCR-8) (GPR-CY6) (CKR-L1) (TER1) (CMKBRL2) (CC-Chemokine Receptors of (GPRCY6) (Chemokine Receptors-sample 1) (CC-CKR-8)

		CHEMR1) (CDw198 antigen) .[source: Uniprot/SWISSPROT; Acc:P51685]
			1238	NM_001296	Chemokine-conjugated protein 2 (chemokine-conjugated protein D6) (C-C Chemokine Receptors D6) (Chemokine Receptors CCR-9) (Chemokine Receptors CCR-10) .[source: Uniprot/SWISSPROT; Acc:O00590]
1240	NM_004072	Chemokine Receptors-sample 1 (G-protein linked receptor DEZ) (G-protein linked receptor ChemR23) .[source: Uniprot/SWISSPROT; Acc:Q99788]	1238	NM_001296
1240	NM_004072		1241	NM_181657	Lipoid cpd B4 acceptor 1 (LTB4-R1) (P2Y purinoceptor 7) is (chemoattractant acceptor-sample 1) (G-protein linked receptor 16) .[source (P2Y7): Uniprot/SWISSPROT; Acc:Q15722]
1269	NM_001841	Cannabined receptor 2 (CB2) is (CX5) .[source (CB-2): Uniprot/SWISSPROT; Acc:P34972]	1241	NM_181657
1269	NM_001841		1316	NM_001008490	Core promoter element-conjugated protein (Kruppel-like factor 6) (albumen 1 in B-cell source) (former-oncogene BCD1) (transcription factor Zf9) (GC-enriches site binding factor GBF) .[source: Uniprot/SWISSPROT; Acc:Q99612]
1378	NM_000651；NM_000573	Complement component (3b/4b) acceptor 1 comprises the Knops blood group system; CR1	1316	NM_001008490
1378	NM_000651；NM_000573		1379	XM_114735	Complement component (3b/4b) acceptor 1-sample; CR1L
1380	NM_001006658；NM 001877	Complement component (3d/Epstein Barr virus) acceptor 2; CR2	1379	XM_114735	Complement component (3b/4b) acceptor 1-sample; CR1L
1380	NM_001006658；NM 001877		1392	NM_000756	Corticoliberin precursor (corticotropin releasing factor(CRF)) is (corticotropin releasing hormone) .[source (CRF): Uniprot/SWISSPROT; Acc:P06850]
1396	NM_001311	Halfcystine-Abundant protein 1 (albumen in halfcystine-the enrich intestines) is (halfcystine-enrich heart protein) (hCRHP) .[source: Uniprot/SWISSPROT (CRIP); Acc:P50238]	1392	NM_000756
1396	NM_001311		1401	NM_000567	Proteins C reactive, pentamer albumen-relevant; CRP
1432	NM_139013；NM_00 1315；NM_139012；NM_139014	Mitogen-activated protein kinase 14; MAPK14	1401	NM_000567	Proteins C reactive, pentamer albumen-relevant; CRP
1432	NM_139013；NM_00 1315；NM_139012；NM_139014	Mitogen-activated protein kinase 14; MAPK14	1436	NM_005211	Macrophage colony stimulating factor 1 acceptor precursor (CSF-1-R) (EC 2.7.1.112) (Fms former-oncogene) is (CD115 antigen) .[source (c-fms): Uniprot/SWISSPROT; Acc:P07333]
1437	NM_000758	Granulocyte-macrophage colony stimutaing factor precursor (GM-CSF) (G CFS) is (Sargramostim) (Molgramostin) .[source: Uniprot/SWISSPROT (CSF); Acc:P04141]	1436	NM_005211
1437	NM_000758		1439	NM_000395	Cytokine receptor common beta chain precursor (the common beta chain of GM-CSF/IL-3/IL-5 acceptor) (CD131 antigen) is the .[source (CDw131): Uniprot/SWISSPROT; Acc:P32927]

1440	NM_000759	Granulocyte colony-stimulating factor precursor (G-CSF) is (Filgrastim) (lenograstim) .[source (Pluripoietin): Uniprot/SWISSPROT; Acc:P09919]
1440	NM_000759		1441	NM_156039	Granulocyte colony stimulating factor receptor precursor (G-CSF-R) (CD114 antigen) .[source: Uniprot/SWISSPROT; Acc:Q99062]
1445	NM_004383	The c-src Tyrosylprotein kinase; CSK	1441	NM_156039
1445	NM_004383	The c-src Tyrosylprotein kinase; CSK	1493	NM_005214	Cytotoxic t-lymphocyte albumen 4 precursors (cytotoxic t-lymphocyte-antigen 4) are (CD152 antigen) .[source (CTLA-4): Uniprot/SWISSPROT; Acc:P16410]
1511	NM_001911	Cathepsin G's precursor (EC 3.4.21.20) is the .[source (CG): Uniprot/SWISSPROT; Acc:P08311]	1493	NM_005214
1511	NM_001911		1520	NM_004079	Cathepsin S precursor (EC 3.4.22.27) .[source: Uniprot/SWISSPROT; Acc:P25774]
1521	NM_001335	Kethepsin W precursor (EC 3.4.22.-) is the .[source (Lymphopain): Uniprot/SWISSPROT; Acc:P56202]	1520	NM_004079
1521	NM_001335		1524	NM_001337	CX3C Chemokine Receptors 1 (C-X3-C CKR-1) is (V28) (β Chemokine Receptors-sample 1) (CMK-BRL-1) (CMKBLR1) .[source: Uniprot/SWISSPROT of (Fractalkine acceptor) (G-protein linked receptor 13) (CX3CR1); Acc:P49238]
1536	NM_000397	Cytochrome B-245 heavy chain (P22 phagocytic cell B-cytopigment) (neutrophilic granulocyte cytochrome B, 91kDa polypeptide) is (GP91-PHOX) (GP91-1) (protoheme binding film glycoprotein GP91PHOX) (cytochrome B (558) β chain) (super-oxide-generation nadph oxidase hea (CGD91-PHOX)	1524	NM_001337
1536	NM_000397		1604	NM_000574	The decay accelerating factor that is used for complement (CD55, Cromer blood group system); DAF
1670	NM_021010	Alexin 5 precursors (alexin, α 5) .[source: Uniprot/SWISSPROT; Acc:Q01523]	1604	NM_000574
1670	NM_021010		1671	NM_001926	Alexin 6 precursors (alexin, α 6) .[source: Uniprot/SWISSPROT; Acc:Q01524]
1672	NM_005218	Alexin, β 1; DEFB1	1671	NM_001926
1672	NM_005218	Alexin, β 1; DEFB1	1673	NM_004942	Alexin, β 4; DEFB4
1675	NM_001928	The D composition (lipoprotein reducing) of complement; DF	1673	NM_004942	Alexin, β 4; DEFB4
1675	NM_001928	The D composition (lipoprotein reducing) of complement; DF	1755	NM_017579	The amyloid protein precursor (glycoprotein 340) that lacks in the malignant brain tumor 1 is (tensio-active agent lung-relevant D-is conjugated protein) .[source: Uniprot/SWISSPROT (Gp-340); Acc:Q9UGM3]
1791	NM_001017520	The circumscribed transferring enzyme of DNA Nucleotide (EC 2.7.7.31) (terminal addition enzyme) (terminal deoxynucleotidyl transferase) (terminal enzyme (DNA)) .[source: Uniprot/SWISSPROT; Acc:P04053]	1755	NM_017579
1791	NM_001017520		1794	NM_004946	Contribution body (Dedicator) the .[source of division of cytoplasm albumen 2: Uniprot/SWISSPROT; Acc:Q92608]

1803	NM_001935	Dipeptide peptidase 4 (EC 3.4.14.5) (dipeptide peptidase i V) (DPP IV) (T-cell activation antigens c D26) (TP103) (ADCP 2) (ADABP) [comprises: dipeptide peptidase 4 membranous types (dipeptide peptidase i V membranous type); Di
1803	NM_001935		1880	NM_004951	EBV-inductive G-protein linked receptor 2 (EBI2) .[source: Uniprot/SWISSPROT; Acc:P32249]
1896	NM_001005610	Outer M-band A (ectodermal dysplasia albumen) (EDA albumen) [comprises: outer M-band A, membranous type; Outer M-band A, secretor type] .[source: Uniprot/SWISSPROT; Acc:Q92838]	1880	NM_004951
1896	NM_001005610		1903	NM_005226	Sphingosine 1-phosphate acceptors Edg-3 (S1P acceptor Edg-3) (endothelium differentiation G-protein linked receptor 3) (sphingosine 1-phosphate acceptors 3) is .[source: Uniprot/SWISSPROT (S1P3); Acc:Q99500]
1947	NM_004429	Ephrin-B1 precursor (EPH-associated receptor Tyrosylprotein kinase part 2) is (ELK part) (ELK-L) .[source: Uniprot/SWISSPROT (LERK-2); Acc:P98172]	1903	NM_005226
1947	NM_004429		1958	NM_001964	Early growth response protein 1 (EGR-1) (Krox-24 albumen) (transcription factor Zif268) (nerve growth factor-inductive albumin A) (NGFI-A) (transcription factor ETR103) (zinc finger protein 22 5) is the .[source (AT225): Uniprot/SWISSPROT; Acc:P18146]
1997	NM_172373	ETS-associated transcription factor Elf-1 (E74-like factor 1) .[source: Uniprot/SWISSPROT; Acc:P32519]	1958	NM_001964
1997	NM_172373		2000		ETS-associated transcription factor Elf-4 (E74-like factor 4) (marrow Elf-1-like factor) .[source: Uniprot/SWISSPROT; Acc:Q99607]
2053	NM_001979	Epoxide hydrolase 2 (EC3.3.2.3) (solvable epoxide hydrolase) is (CEH) .[source: Uniprot/SWISSPROT of (epoxide hydratase) (endochylema epoxide hydrolase) (SEH); Acc:P34913]	2000
2053	NM_001979		2113	NM_005238	C-ets-1 albumen (p54) .[source: Uniprot/SWISSPROT; Acc:P14921]
2147	NM_000506	Thrombogen precursor (EC 3.4.21.5) (coagulation factors II) [comprises: activation peptide fragment 1; Activation peptide fragment 2; The zymoplasm light chain; The zymoplasm heavy chain] .[source: Uniprot/SWISSPROT; Acc:P00734]	2113	NM_005238
2147	NM_000506		2152	NM_001993	Coagulation factors III (thromboplastin, tissue factor); F3
2157	NM_000132	Doubting solid Factor IX precursor (short hemostatic composition) (antihemophilic factor) (AHF) [comprises: Factor IX a heavy chain, 200kDa hypotype; Factor IX a heavy chain, the 92kDa hypotype; Factor IX B chain; Factor IX a light chain] .[source: Uniprot/SWISSP	2152	NM_001993	Coagulation factors III (thromboplastin, tissue factor); F3
2157	NM_000132		2158	NM_000133	Coagulation factors IX (blood plasma thrombosis composition, Christmas disease, hemophilia B); F9
2159	NM_000504	Coagulation factors X; F10	2158	NM_000133
2159	NM_000504	Coagulation factors X; F10	2165	NM_001994	Coagulation factors XIII, the B polypeptide; F13B
2204	NM_133271；NM_13 3272；NM_133269；NM_133278；NM_0020	The Fc sheet receptor seq of IgA; FCAR	2165	NM_001994	Coagulation factors XIII, the B polypeptide; F13B

	00；NM_133273；NM_ 133277；NM_133279；NM_133280；NM_13 3274
	00；NM_133273；NM_ 133277；NM_133279；NM_133280；NM_13 3274		2205	NM_002001	The Fc fragment high-affinity receptor I of IgE; The α polypeptide; FCER1A
2206	NM_000139	Membrane spaning domain 4, subfamily A, member 2 (the Fc fragment high-affinity receptor I of IgE; Beta polypeptides); MS4A2	2205	NM_002001
2206	NM_000139		2207	NM_004106	The Fc fragment high-affinity receptor I of IgE; The γ polypeptide; FCER1G
2208	NM_002002	The Fc fragment low affinity receptor II (CD23A) of IgE; FCER2	2207	NM_004106
2208	NM_002002		2209	NM_000566	The Fc fragment high-affinity receptor Ia (CD64) of IgG; FCGR1A
2212	NM_021642	The Fc fragment high-affinity receptor IIa (CD32) of IgG; FCGR2A	2209	NM_000566
2212	NM_021642		2213	NM_004001；NM_00 1002275；NM_001002274；NM_001002273	The Fc fragment high-affinity receptor IIb (CD32) of IgG; FCGR2B
2214	NM_000569	The Fc fragment high-affinity receptor IIIa (CD16a) of IgG; FCGR3A	2213	NM_004001；NM_00 1002275；NM_001002274；NM_001002273
2214	NM_000569		2215	NM_000570	The Fc fragment high-affinity receptor IIIb (CD16b) of IgG; FCGR3B
2217	NM_004107	The Fc fragment of IgG, acceptor, transhipment thing, α; FCGRT	2215	NM_000570
2217	NM_004107		2219	NM_002003	Fiber gelatinized protein (collagen/fibrin prodomain comprises) 1; FCN1
2220	NM_015837；NM_00 4108	Fiber gelatinized protein (collagen/fibrin prodomain comprises lectin) 2 (hucolin); FCN2	2219	NM_002003
2220	NM_015837；NM_00 4108		2255	NM_004465	Desmocyte growth factor-21 0 precursor (FGF-10) (keratinocyte growth factor 2) .[source: Uniprot/SWISSPROT; Acc:O15520]
2268	NM_005248	Gardner-Rasheed cat sarcoma virus (v-fgr) oncogene homologue; FGR	2255	NM_004465
2268	NM_005248		2280	NM_054014	The conjugated protein 1A of FK506,12kDa (FKBP1A)
2289	NM_004117	Conjugated protein 5 (FKBP5) of FK506	2280	NM_054014	The conjugated protein 1A of FK506,12kDa (FKBP1A)
2289	NM_004117	Conjugated protein 5 (FKBP5) of FK506	2322	NM_004119	FL cytokine receptor precursor (EC 2.7.1.112) (tyrosine-protein kinase acceptor FLT3) (stem cell Tyrosylprotein kinase 1) is (CD135 antigen) .[source (STK-1): Uniprot/SWISSPROT; Acc:P36888]
2323	NM_001459	SL cytokine precursor (Fms-be correlated with Tyrosylprotein kinase 3 parts) (Flt3 part) is the .[source (Flt3L): Uniprot/SWISSPROT; Acc:P49771]	2322	NM_004119
2323	NM_001459		2335	NM_054034	Fibronectin precursor (FN) (cold-insoluble globin) is the .[source (CIG): Uniprot/SWISSPROT; Acc:P02751]
2353	NM_005252	V-fos FBJ mouse osteosarcoma virus oncogene homologue; FOS	2335	NM_054034
2353	NM_005252	V-fos FBJ mouse osteosarcoma virus oncogene homologue; FOS	2357	NM_002029	FMet-Leu-Phe acceptor (fMLP acceptor) (N-formyl peptide receptor) is (N-formyl peptides chemoattractant acceptor) .[source (FPR): Uniprot/SWISSPROT; Acc:P21462]
2358	NM_001005738	FMLP-associated receptor I (FMLP-R-I) (lipoxin A 4 acceptors) (LXA4 acceptor) (formyl peptide receptor-sample 1) is (HM63) .[source (RFP): Uniprot/SWISSPROT; Acc:P25090]	2357	NM_002029
2358	NM_001005738		2444	NM_002031	The fyn-associated kinase; FRK
2495	NM_002032	Ferritin heavy chain (EC 1.16.3.1) (ferritin H subunit) (propagation-induced gene 15 albumen) .[comes	2444	NM_002031	The fyn-associated kinase; FRK

		Source: Uniprot/SWISSPROT; Acc:P02794]
		Source: Uniprot/SWISSPROT; Acc:P02794]	2532	NM_002036	Duffy antigen/Chemokine Receptors (Fy glycoprotein) is (glycoprotein D) (Plasmodium vivax acceptor) (CD234 antigen) .[source (GpFy): Uniprot/SWISSPROT; Acc:Q16570]
2533	NM_001465	FYN-conjugated protein (FYN-T-is conjugated protein) is (SLAP-130) .[source: Uniprot/SWISSPROT of (p120/p130) (SLP-76 be correlated with phosphoric acid albumen) (FYB-120/130); Acc:O15117]	2532	NM_002036
2533	NM_001465		2534	NM_153048；NM_00 2037；NM_153047	With SRC, FGR, the FYN oncogene that YES is relevant; FYN
2537	NM_002038	Interferon, rabbit-inductive albumen 6-16 precursor (Ifi-6-16) .[source: Uniprot/SWISSPROT; Acc:P09912]	2534	NM_153048；NM_00 2037；NM_153047	With SRC, FGR, the FYN oncogene that YES is relevant; FYN
2537	NM_002038		2543	NM_001468	GAGE-1 albumen (G antigen 1) (MZ2-F antigen) .[source: Uniprot/SWISSPROT; Acc:Q13065]
2574	NM_012196	GAGE-1 albumen (G antigen 1) (MZ2-F antigen) .[source: Uniprot/SWISSPROT; Acc:Q13065]	2543	NM_001468
2574	NM_012196		2633	NM_002053	Interferon, rabbit-inductive guanylic acid-conjugated protein 1 (GTP-conjugated protein 1) (guanylic acid-conjugated protein 1) be the .[source (HuGBP-1): Uniprot/SWISSPROT; Acc:P32455]
2634	NM_004120	Interferon, rabbit-inductive guanylic acid-conjugated protein 2 (GTP-conjugated protein 2) (guanylic acid-conjugated protein 2) be the .[source (HuGBP-2): Uniprot/SWISSPROT; Acc:P32456]	2633	NM_002053
2634	NM_004120		2635	NM_018284	Guanine nucleotide binding protein 3[source: RefSeq_peptide; Acc:NP_060754]
2637	NM_001485	Homology frame Protein G BX-2 (gastrula forms and brain-specificity homology frame albumen 2) .[source: Uniprot/SWISSPROT; Acc:P52951]	2635	NM_018284
2637	NM_001485		2669	NM_181702	The conjugated protein GEM of GTP-(GTP-is in conjunction with mitogen-inductive T-cell protein) (RAS-sample albumen KIR) .[source: Uniprot/SWISSPROT; Acc:P55040]
2687	NM_004121	Gamma glutamyltransferase 5 precursors (EC 2.3.2.2) (gamma glutamyl transpeptidase 5) (gamma glutamyltransferase sample activity 1) (GGT-rel) [comprise: gamma glutamyltransferase 5 heavy chains; Gamma glutamyltransferase 5 light chains] .[source: Uniprot/SWISS	2669	NM_181702
2687	NM_004121		2821		Glucose-6-phosphate isomerase (EC 5.3.1.9) is (phosphoglucose isomerase) (PGI) (phosphohexoisomerase) (PHI) (neuroleukin) (NLK) (sperm antigen 36) (SA-36) .[source: Uniprot/SWISSPROT (GPI); Acc:P06744]
2829	NM_001024644	Chemokine XC acceptor 1 (XC Chemokine Receptors 1) (lymphocyte chemotactic factor (LCF) acceptor) (G-protein linked receptor 5) .[source: Uniprot/SWISSPROT; Acc:P46094]	2821
2829	NM_001024644		2833	NM_001504	C-X-C Chemokine Receptors type 3 (CXC-R3) is (Interferon, rabbit-inductive protein 10 acceptor) (IP-10 acceptor) (CKR-L2) (CD183 antigen) (G albumen-coupled receptor 9) .[source: Uniprot/SWISSPROT (CXCR-3); Acc:P49682]

2874	NM_004489	G albumen path suppresses son 2 (GPS2)
2874	NM_004489	G albumen path suppresses son 2 (GPS2)	2885	NM_002086；NM_20 3506	Growth factor receptors-conjugated protein 2; GRB2
2908	NM_001018076	Glucocorticoid receptor (GR) .[source: Uniprot/SWISSPROT; Acc:P04150]	2885	NM_002086；NM_20 3506	Growth factor receptors-conjugated protein 2; GRB2
2908	NM_001018076		2919	NM_001511	Growth regulator α precursor (CXCL1) (melanoma growth stimulating activity) (MGSA) (neutrophilic leukocyte-activated protein 3) (NAP-3) (GRO-α (1-73)) [comprise: GRO-α (4-73); GRO-α (5-73); GRO-α (6-73)] .[source: Uniprot/SWISSPROT; Acc:P09341
2920	NM_002089	Macrophage inflammatory protein 2-α precursor (MIP2-α) is (growth regulator β) (Gro-β) [comprise: GRO-β (5-73) (GRO-β-T) (SB-251353) (hematopoiesis cofactor) (HSF)] .[source (CXCL2): Uniprot/SWISSPROT; Acc:P19875]	2919	NM_001511
2920	NM_002089		2921	NM_002090	Macrophage inflammatory protein 2-β precursor (MIP2-β) is (growth regulator γ) (GRO-γ) (GRO-γ (1-73)) [comprising: GRO-γ (5-73)] .[source (CXCL3): Uniprot/SWISSPROT; Acc:P19876]
3001	NM_006144	Granzyme A precursor (EC3.4.21.78) (cytotoxic t-lymphocyte proteolytic enzyme 1) (the Hanukkah factor) (the H factor) is (granzyme-1) (CTL tryptase) (fragment-1) .[source (HF): Uniprot/SWISSPROT; Acc:P12544]	2921	NM_002090
3001	NM_006144		3055	NM_002110	The hematopoietic cell kinases; HCK
3069	NM_203346	High-density lipoprotein (HDL) conjugated protein (vigilin) (HDLBP)	3055	NM_002110	The hematopoietic cell kinases; HCK
3069	NM_203346		3070	NM_018063	Helicase, lymph-specificity [source: RefSeq_peptide; Acc:NP_060533]
3075	NM_000186；NM_001014975	Complement factor H; CFH	3070	NM_018063
3075	NM_000186；NM_001014975	Complement factor H; CFH	3077	NM_139006	The plain deposition of hereditary hemochromatosis amyloid protein precursor (HLA-H) .[source: Uniprot/SWISSPROT; Acc:Q30201]
3078	NM_002113	Complement factor H-relevant 1; CFHL1	3077	NM_139006
3078	NM_002113	Complement factor H-relevant 1; CFHL1	3080	NM_005666	Complement factor H-relevant 2; CFHL2
3082	NM_000601；NM_00 1010932；NM_001010 931；NM_001010933；NM_001010934	PHGF (pHGF A; Dispersion factor); HGF	3080	NM_005666	Complement factor H-relevant 2; CFHL2
3082		PHGF (pHGF A; Dispersion factor); HGF	3087	NM_002729	Homology frame albumen PRH (the homology frame is expressed in hematopoiesis) (homology frame albumen HEX) .[source: Uniprot/SWISSPROT; Acc:Q03014]
3105	NM_002116	Major histocompatibility complex, class I, A; HLA-A	3087	NM_002729
3105	NM_002116	Major histocompatibility complex, class I, A; HLA-A	3106	NM_005514	Major histocompatibility complex, class I, B; HLA-B
3107	NM_002117	Major histocompatibility complex, class I, C; HLA-C	3106	NM_005514	Major histocompatibility complex, class I, B; HLA-B
3107	NM_002117	Major histocompatibility complex, class I, C; HLA-C	3108	NM_006120	Major histocompatibility complex, class II, DM α; HLA-DMA
3109	NM_002118	Major histocompatibility complex, class II, DM β; HLA-DMB	3108	NM_006120	Major histocompatibility complex, class II, DM α; HLA-DMA
3109	NM_002118	Major histocompatibility complex, class II, DM β; HLA-DMB	3110	NM_005515	Homology frame albumen HB9.[source: Uniprot/SWISSPROT; Acc:P50219]
3111	NM_002119	Major histocompatibility complex, class II, DO α; HLA-DOA	3110	NM_005515

3112	NM_002120	Major histocompatibility complex, class II, DO β; HLA-DOB
3112	NM_002120	Major histocompatibility complex, class II, DO β; HLA-DOB	3113	NM_033554	Major histocompatibility complex, class II, DP α 1; HLA-DPA1
3115	NM_002121	Major histocompatibility complex, class II, DP β 1; HLA-DPB1	3113	NM_033554
3115	NM_002121		3117	NM_002122	Major histocompatibility complex, class II, DQ α 1; HLA-DQA1
3118	NM_020056	Major histocompatibility complex, class II, DQ α 2; HLA-DQA2	3117	NM_002122
3118	NM_020056		3119	NM_002123	Major histocompatibility complex, class II, DQ β 1; HLA-DQB1
3120	NM_182549	Major histocompatibility complex, class II, DQ β 2; HLA-DQB2	3119	NM_002123
3120	NM_182549		3122	NM_019111	Major histocompatibility complex, class II, DR α; HLA-DRA
3123	NM_002124	Major histocompatibility complex, class II, DR β 1; HLA-DRB1	3122	NM_019111	Major histocompatibility complex, class II, DR α; HLA-DRA
3123	NM_002124		3124	NM_001037638	Major histocompatibility complex, class II, DR β 2; HLA-DRB2
3125	NM_022555	Major histocompatibility complex, class II, DR β 3; HLA-DRB3	3124	NM_001037638
3125	NM_022555		3126	NM_021983	Major histocompatibility complex, class II, DR β 4; HLA-DRB4
3127	NM_002125	Major histocompatibility complex, class II, DR β 5; HLA-DRB5	3126	NM_021983
3127	NM_002125		3133	NM_005516	Major histocompatibility complex, class I, E; HLA-E
3134	NM_018950	Major histocompatibility complex, class I, F; HLA-F	3133	NM_005516	Major histocompatibility complex, class I, E; HLA-E
3134	NM_018950	Major histocompatibility complex, class I, F; HLA-F	3135	NM_002127	The HLA-G histocompatibility antigen, class I, G; HLA-G
3140	NM_001531	Major histocompatibility complex, class I-is relevant; MR1	3135	NM_002127	The HLA-G histocompatibility antigen, class I, G; HLA-G
3140	NM_001531	Major histocompatibility complex, class I-is relevant; MR1	3149	NM_005342	High mobility albumen 4 (HMG-4) (high mobility albumen 2a) is the .[source (HMG-2a): Uniprot/SWISSPROT; Acc:O15347]
3265	NM_176795；NM_00 5343	V-Ha-ras Harvey rat sarcoma virus oncogene homologue; HRAS	3149	NM_005342
3265	NM_176795；NM_00 5343	V-Ha-ras Harvey rat sarcoma virus oncogene homologue; HRAS	3269	NM_000861	Histamine H1-receptor .[source: Uniprot/SWISSPROT; Acc:P35367]
3274	NM_022304	Histamine H2-receptor (H2R) (motilin receptor I) .[source: Uniprot/SWISSPROT; Acc:P25021]	3269	NM_000861
3274	NM_022304		3320	NM_005348	Heat shock protein(HSP) HSP 90-α (HSP 86) .[source: Uniprot/SWISSPROT; Acc:P07900]
3324	NM_005348	Heat shock protein(HSP) HSP 90-α (HSP 86) .[source: Uniprot/SWISSPROT; Acc:P07900]	3320	NM_005348
3324	NM_005348		3394	NM_002163	Interferon regulatory factor 8 (IRF-8) (the Interferon, rabbit consensus sequence is conjugated protein) is the .[source (ICSBP): Uniprot/SWISSPROT; Acc:Q02556]
3426	NM_000204	The I factor (complement); IF	3394	NM_002163
3426	NM_000204	The I factor (complement); IF	3430	NM_005533	Interferon, rabbit-inductive 35kDa albumen (IFP 35) .[source: Uniprot/SWISSPROT; Acc:P80217]
3433	NM_001547	Have the triangle tetrapeptide and repeat (IFI-54K) (ISG-54K) .[source: Uniprot/SWISSPROT of Interferon, rabbit-inductive albumen (IFIT-2) (Interferon, rabbit-inductive 54kDa albumen) of 2; Acc:P09913]	3430	NM_005533
3433	NM_001547		3434	NM_001548	Have the triangle tetrapeptide and repeat (IFI-56K) .[source: Uniprot/SWISSPROT of Interferon, rabbit-inductive albumen (IFIT-1) (Interferon, rabbit-inductive 56kDa albumen) of 1; Acc:P09914]
3437	NM_001549	Have the triangle tetrapeptide and repeat (IFIT-4) (Interferon, rabbit-inductive 60kDa albumen) (IFI-60K) (ISG-60) (CIG49) (vitamin A acid-inductive gene G albumen) (RIG-G) .[source: Uniprot/SWISSPROT of Interferon, rabbit-inductive albumen (IFIT-3) of 3; Acc:O14879]	3434	NM_001548

3440	NM_000605	(interferon alpha-A) (LeIF A) .['s interferon precursor originates: Uniprot/SWISSPROT; Acc:P01563]
3440	NM_000605		3454	NM_000629	Interferon, rabbit (α, β and ω) acceptor 1, IFNAR1
3456	NM_002176	Interferon beta precursor (IFN-β) (fiblaferon) .[source: Uniprot/SWISSPROT; Acc:P01574]	3454	NM_000629	Interferon, rabbit (α, β and ω) acceptor 1, IFNAR1
3456	NM_002176		3458	NM_000619	Interferon-gamma precursor (IFN-γ) (type II interferon) .[source: Uniprot/SWISSPROT; Acc:P01579]
3459	NM_000416	Interferon gamma receptor 1 (IFNGR1)	3458	NM_000619
3459	NM_000416	Interferon gamma receptor 1 (IFNGR1)	3460	NM_005534	Interferon gamma receptor 2 (interferon-gamma conversion 1); IFNGR2
3476	NM_001551	Immunoglobulin (Ig) (CD79A) conjugated protein 1; IGBP1	3460	NM_005534
3476	NM_001551	Immunoglobulin (Ig) (CD79A) conjugated protein 1; IGBP1	3512	NM_144646	Immunoglobulin (Ig) J chain .[source: Uniprot/SWISSPROT; Acc:P01591]
3516		Atrichous recombinant binding protein suppresses (RBP-J) (RBP-JK) (CBF-1) .[source: Uniprot/SWISSPROT of son (J κ-recombination signal is conjugated protein) (RBP-J κ); Acc:Q06330]	3512	NM_144646
3516			3543	NM_020070；NM_15 2855	Immunoglobulin (Ig) λ-sample polypeptide 1; IGLL1
3547	NM_001555；NM_20 5833	Immunoglobulin superfamily, the member 1; IGSF1	3543	NM_020070；NM_15 2855	Immunoglobulin (Ig) λ-sample polypeptide 1; IGLL1
3547	NM_001555；NM_20 5833	Immunoglobulin superfamily, the member 1; IGSF1	3550	NM_006083	White (RER albumen) (the IK factor) (cytokine IK) .[of red eggs source: Uniprot/SWISSPROT; Acc:Q13123]
3551	NM_001556	Inhibition of kappa light polypeptide genetic enhancer in the B-cell, kinase beta; IKBKB	3550	NM_006083
3551	NM_001556		3552	NM_000575	Il-1 α precursor (IL-1 α) (erythropoietin-1) .[source: Uniprot/SWISSPROT; Acc:P01583]
3553	NM_000576	Il-1 β precursor (IL-1 β) (degraded product) .[source: Uniprot/SWISSPROT; Acc:P01584]	3552	NM_000575
3553	NM_000576		3554	NM_000877	Interleukin-1 receptor type i precursor (IL-1R-1) is (IL-1R-α) (p80) (antigens c D121a) .[source: Uniprot/SWISSPROT (IL-1RT1); Acc:P14778]
3556	NM_134470	Interleudin-1 receptor accessory Protein precursor (IL-1 acceptor accessory protein) is the .[source (IL-1RAcP): Uniprot/SWISSPROT; Acc:Q9NPH3]	3554	NM_000877
3556	NM_134470		3557	NM_000577	Interleukin-1 receptor antagonist amyloid protein precursor (IL-1ra) is (IL1 inhibitor) (IL-1RN) (ICIL-1RA) .[source: Uniprot/SWISSPROT (IRAP); Acc:P18510]
3558	NM_000586	Interleukin-2 precursor (IL-2) (T-cell growth factor) is (rIL-2) .[source (TCGF): Uniprot/SWISSPROT; Acc:P60568]	3557	NM_000577
3558	NM_000586		3559	NM_000417	Interleukin-2 receptor alpha chain precursor (IL-2 acceptor alpha subunit) is (IL2-RA) (p55) (TAC antigen) (CD25 antigen) .[source: Uniprot/SWISSPROT (IL-2-RA); Acc:P01589]
3560	NM_000878	Interleukin-2 acceptor β chain precursor (IL-2 acceptor) (P70-75) (CD122 antigen) .[of (p75) (high-affinity IL-2 acceptor β subunit) comes	3559	NM_000417

		Source: Uniprot/SWISSPROT; Acc:P14784]
		Source: Uniprot/SWISSPROT; Acc:P14784]	3561	NM_000206	((interleukin-2 receptor y chain) (the IL-2R γ chain) of γ-C) be (CD132 antigen) .[source (P64): Uniprot/SWISSPROT for the common γ chain of cytokine receptor precursor; Acc:P31785]
3562	NM_000588	Interleukin-3 precursor (IL-3) (pluripotency colony stimulating factor) (hemopoieticgrowth factor) (P-cell-stimulating factor) (Mast-cell growth factor) is the .[source (MCGF): Uniprot/SWISSPROT; Acc:P08700]	3561	NM_000206
3562	NM_000588		3565	NM_000589	Interleukin-4 precursor (IL-4) (B-cell stimulating factor 1) is (lymphocyte stimulating factor 1) .[source (BSF-1): Uniprot/SWISSPROT; Acc:P05112]
3566	NM_001008699	Interleukin-4 receptor alpha chain precursor (IL-4R-α) (CD124 antigen) [comprise: solvable interleukin-4 receptor alpha chain (sIL4R α/prot) (IL-4-is conjugated protein) is (IL4-BP)] .[source: Uniprot/SWISSPROT; Acc:P24394]	3565	NM_000589
3566	NM_001008699		3567	NM_000879	Interleukin-5 precursor (IL-5) (the T-cell exchange factor) is (eosinophilic granulocyte differentiation factor) (B cell differential factor I) .[source (TRF): Uniprot/SWISSPROT; Acc:P05113]
3569	NM_000600	Interleukin-6 precursor (IL-6) (B-cell stimulating factor 2) is (CDF) .[source: Uniprot/SWISSPROT of (interferon beta-2) (hybridoma growth factor) (CTL differentiation factor) (BSF-2); Acc:P05231]	3567	NM_000879
3569	NM_000600		3570	NM_000565	Interleukin-6 receptor alpha chain precursor (IL-6R-α) is (membrane glycoprotein 80) (gp80) (CD126 antigen) .[source: Uniprot/SWISSPROT (IL-6R1); Acc:P08887]
3572	NM_002184	Interleukin-6 acceptor β chain precursor (IL-6R-β) (interleukin 6 conversion of signals) (membrane glycoprotein 130) is (CDw130) .[source: Uniprot/SWISSPROT of (matter knurl plain m receptor) (CD130 antigen) (gp130); Acc:P40189]	3570	NM_000565
3572	NM_002184		3574	NM_000880	Interleukin-7 precursor (IL-7) .[source: Uniprot/SWISSPROT; Acc:P13232]
3575	NM_002185	Interleukin-7 receptor alpha chain precursor (IL-7R-α) (CD127 antigen) is the .[source (CDw127): Uniprot/SWISSPROT; Acc:P16871]	3574	NM_000880
3575	NM_002185		3576	NM_000584	Interleukin-8 precursor (IL-8) is (neutrophil chemotactic factor in monocyte-source) (MDNCF) (NAP-1) (GCP-1) (neutrophilic leukocyte of cells of monocytic origin of (albumen 3-10C) (granulocyte chemoattractant protein 1) of (T-cell chemotactic factor) (neutrophilic leukocyte-activated protein 1) (CXCL8)
3577	NM_000634	High-affinity interleukin-8 acceptor A (IL-8R A) (IL-8 acceptor type 1) is (CD181 antigen) (CDw128a antigen) .[source (CXCR-1): Uniprot/SWISSPROT; Acc:P25024]	3576	NM_000584
3577	NM_000634		3578	NM_000590	Interleukin-9 precursor (IL-9) (T-cell growth factor P40) (P40 cytokine) .[source: Uniprot/SWISSPROT; Acc:P15248]
3579	NM_001557	High-affinity interleukin-8 acceptor B (IL-8R B) is (GRO/MGSA acceptor) (IL-8 acceptor type 2) (CD182 antigen) (CXCR-2)	3578	NM_000590

		(CDw128b antigen) .[source: Uniprot/SWISSPROT; Acc:P25025]
		(CDw128b antigen) .[source: Uniprot/SWISSPROT; Acc:P25025]	3586	NM_000572	Interleukin-10 precursor (IL-10) (cytokine synthesis inhibitory factor(CSIF)) is the .[source (CSIF): Uniprot/SWISSPROT; Acc:P22301]
3587	NM_001558	Interleukin-11 0 acceptor, α (IL10RA)	3586	NM_000572
3587	NM_001558	Interleukin-11 0 acceptor, α (IL10RA)	3588	NM_000628	Interleukin-11 0 acceptor, β; IL10RB
3589	NM_000641	Interleukin-11 precursor (IL-11) (steatogenesis supressor) is (interleukin-11) .[source (AGIF): Uniprot/SWISSPROT; Acc:P20809]	3588	NM_000628	Interleukin-11 0 acceptor, β; IL10RB
3589	NM_000641		3590		Interleukin-11 receptor alpha chain precursor (IL-11R-α) is (IL-11RA). [source: Uniprot/SWISSPROT; Acc:Q14626]
3592	NM_000882	Il-1 2 α chain precursors (IL-12A) (cytotoxic lymphocytic maturation factor 35kDa subunit) (CLMF p35) (NK cell stimulating factor chain 1) are the .[source (NKSF1): Uniprot/SWISSPROT; Acc:P29459]	3590
3592	NM_000882		3593	NM_002187	Il-1 2 β chain precursors (IL-12B) are (NKSF2) .[source: Uniprot/SWISSPROT of (cytotoxic lymphocytic maturation factor 40kDa subunit) (CLMF p40) (NK cell stimulating factor chain 2) (IL-12p40); Acc:P29460]
3594	NM_153701；NM_00 5535	The interleukin 12 acceptor, β 1; IL12RB1	3593	NM_002187
3594	NM_153701；NM_00 5535	The interleukin 12 acceptor, β 1; IL12RB1	3596	NM_002188	Interleukin-13 precursor (IL-13) .[source: Uniprot/SWISSPROT; Acc:P35225]
3600	NM_000585	Interleukin-15 precursor (IL-15) .[source: Uniprot/SWISSPROT; Acc:P40933]	3596	NM_002188
3600	NM_000585		3603		IL-16 precursor (IL-16) (lymphocyte chemotactic factor (LCF)) is the .[source (LCF): Uniprot/SWISSPROT; Acc:Q14005]
3604	NM_001561	Tumor necrosis factor receptor super family member 9 precursors (4-1BB ligand receptor) (T-cell antigen 4-1BB homologue) (T-cell antigen ILA) (CD137 antigen) .[source: Uniprot/SWISSPROT; Acc:Q07011]	3603
3604	NM_001561		3605	NM_002190	Interleukin-17 precursor (IL-17) is (cytotoxic T lymphocyte-related antigen 8) (CTLA-8) .[source: Uniprot/SWISSPROT (IL-17A); Acc:Q16552]
3606	NM_001562	Il-1 8 precursors (IL-18) (interferon--inducible factor) (IFN-γ-inducible factor) (il-1 γ) (IL-1 γ) .[source: Uniprot/SWISSPROT; Acc:Q14116]	3605	NM_002190
3606	NM_001562		3608	NM_004515	Interleukin enhanser-binding factor 2 (nf of activation T-cell, 45 kDa) .[source: Uniprot/SWISSPROT; Acc:Q12905]
3614	NM_000883	Inosine-5 '-(IMPDH-I) (IMPD1) .[source: Uniprot/SWISSPROT of single phosphate dehydrogenase 1 (EC 1.1.1.205) (IMP dehydrogenase 1); Acc:P20839]	3608	NM_004515
3614	NM_000883		3615	NM_000884	Inosine-5 '-(IMPDH-II) (IMPD 2) .[source: Uniprot/SWISSPROT of single phosphate dehydrogenase 2 (EC 1.1.1.205) (IMP dehydrogenase 2); Acc:P12268]
3620	NM_002164	Indoleamine 2,3-dioxygenase (EC 1.13.11.42) is (indoles amine-pyrroles (IDO)	3615	NM_000884

		2, the 3-dioxygenase) .[source: Uniprot/SWISSPROT; Acc:P14902]
			3623	NM_002191	Statin α chain precursor .[source: Uniprot/SWISSPROT; Acc:P05111]
3624	NM_002192	Statin β A chain precursor (activin β-A chain) (red corpuscle differential protein) is the .[source (EDF): Uniprot/SWISSPROT; Acc:P08476]	3623	NM_002191
3624	NM_002192		3625	NM_002193	Statin β B chain precursor (activin β-B chain) .[source: Uniprot/SWISSPROT; Acc:P09529]
3627	NM_001565	I inductive cytokine B10 precursor (CXCL10) (10kDa interferon--inductive albumen) (γ-IP10) (IP-10) [comprising: CXCL10 (1-73)] .[source: Uniprot/SWISSPROT; Acc:P02778]	3625	NM_002193
3627	NM_001565		3630	NM_000207	Insulin precurosor [comprises: insulin B chain; The INSULIN A chain] .[source: Uniprot/SWISSPROT; Acc:P01308]
3635	NM_005541	SH2 comprises inositol monophosphate enzyme hypotype a[source: RefSeq_peptide; Acc:NP_001017915]	3630	NM_000207
3635	NM_005541		3656	NM_001570	Interleukin-1 receptor-associated kinase-sample 2 (IRAK-2) .[source: Uniprot/SWISSPROT; Acc:O43187]
3659	NM_002198	Interferon regulatory factor 1 (IRF-1) .[source: Uniprot/SWISSPROT; Acc:P10914]	3656	NM_001570
3659	NM_002198		3660	NM_002199	Interferon regulatory factor 2 (IRF-2) .[source: Uniprot/SWISSPROT; Acc:P14316]
3662	NM_002460	Interferon regulatory factor 4 (IRF-4) (lymphocyte-specificity interferon regulatory factor) (LSIRF) (NF-EM5) (multiple myeloma oncogene 1). [source: Uniprot/SWISSPROT; Acc:Q15306]	3660	NM_002199
3662	NM_002460		3665	NM_001572	Interferon regulatory factor 7 (IRF-7) .[source: Uniprot/SWISSPROT; Acc:Q92985]
3672	NM_181501	Pelota homologue .[source: Uniprot/SWISSPROT; Acc:Q9BRX2]	3665	NM_001572
3672	NM_181501	Pelota homologue .[source: Uniprot/SWISSPROT; Acc:Q9BRX2]	3681	NM_005353	Beta	2 integrin alpha-D precursor (leucocyte integrin α D) is (ADB2) .[source (CD11d): Uniprot/SWISSPROT; Acc:Q13349]
3683	NM_002209	Beta	3681	NM_005353	Beta		2 integrin alpha-L precursor (leukocyte adhesion glycoprotein LFA-1 α chain) is (leukocyte function associated molecule 1, α chain) (CD11a) .[source: Uniprot/SWISSPROT (LFA-1A); Acc:P20701]
3683	NM_002209	Beta	3684	NM_000632	Beta	2 integrin alpha-M precursor (cell surface glycoprotein MAC-1 alpha subunit) (CR-3 α chain) is (leukocyte adhesion acceptor MO1) (neutrophilic leukocyte adhesion receptor) .[source (CD11b): Uniprot/SWISSPROT; Acc; P11215]
3688	NM_002211	Integrin β-1 precursor (fibronectin receptor β subunit) (integrin VLA-4 β subunit) (CD29 antigen) .[source: Uniprot/SWISSPROT; Acc:P05556]	3684	NM_000632	Beta
3688	NM_002211		3689	NM_000211	Integrin β-2 precursor (cell surface adhesion glycoprotein s LFA-1/CR3/p150,95 beta subunits) is (complement receptor C3 beta subunit) .[source (CD18): Uniprot/SWISSPROT; Acc:P05107]

3697	NM_002215	Inter-heavy chain H1 precursor (ITI heavy chain H1) (-α-inhibitor heavy chain 1) (inter-complex body composition III) (the hyaluronic acid albumen-associated protein in serum source) is (SHAP). [source: Uniprot/SWISSPROT; Acc:P19
3697	NM_002215		3700	NM_002218	Inter-heavy chain H4 precursor (ITI heavy chain H4) (-α-inhibitor heavy chain 4) (inter-family heavy chain-relevant albumen) is (glycoprotein 120 of plasma kallikrein sensitivity) (PK-120) (GP120) [Co (IHRP)
3702	NM_005546	Tyrosine-protein kinase ITK/TSK (EC 2.7.1.112) (T-cell-specificity kinases) (tyrosine-protein kinase Lyk) (kinases EMT) .[source: Uniprot/SWISSPROT; Acc:Q08881]	3700	NM_002218
3702	NM_005546		3707	NM_002221	Inositol-triphosphoric acid 3-kinase b (EC 2.7.1.127) ( inositol 1,4,5-triphosphoric acid 3-kinase b) (IP3K B) (IP33-kinase b) be the .[source (IP3K-B): Uniprot/SWISSPROT; Acc:P27987]
3708	NM_002222	Inositol	3707	NM_002221		1,4,5-triphosphate receptor, 1 type; ITPR1
3708	NM_002222	Inositol	3709	NM_002223	Inositol	1,4,5-triphosphate receptor, 1 type; ITPR1	1,4,5-triphosphate receptor, 2 types; ITPR2
3710	NM_002224	Inositol	3709	NM_002223	Inositol	1,4,5-triphosphate receptor, 3 types; ITPR3	1,4,5-triphosphate receptor, 2 types; ITPR2
3710	NM_002224	Inositol	3714	NM_002226；NM_14 5159	jagged2；JAG2	1,4,5-triphosphate receptor, 3 types; ITPR3
3716	NM_002227	Janus kinases 1 (a protein tyrosine kinase) (JAK1)	3714	NM_002226；NM_14 5159	jagged2；JAG2
3716	NM_002227	Janus kinases 1 (a protein tyrosine kinase) (JAK1)	3718	BC028068	Janus kinases 3 (a protein tyrosine kinase, white corpuscle)
3725	NM_002228	V-jun sarcoma virus 17 oncogene homologues (fowl); JUN	3718	BC028068
3725	NM_002228	V-jun sarcoma virus 17 oncogene homologues (fowl); JUN	3802	NM_014218	Killer cell immunoglobulin (Ig)-sample acceptor 2DL1 precursor (MHC class I NK cell receptor) (natural killer cell associated retroviral thing 1) is (p58 natural killer cell receptor cloning CL-42/47.11) (p58NK acceptor) (p58.1MHC class-I-specificity NK acceptor) .[Sou (NKAT-1)
3803	NM_015868	Killer cell immunoglobulin (Ig)-sample acceptor 2DL2 precursor (MHC class I NK cell receptor) (natural killer cell associated retroviral thing 6) is (p58 natural killer cell receptor cloning CL-43) (p58NK acceptor) .[source (NKAT-6): Uniprot/SWISSPROT; Acc:P43627]	3802	NM_014218
3803	NM_015868		3804	NM_015868	Killer cell immunoglobulin (Ig)-sample acceptor 2DL2 precursor (MHC class I NK cell receptor) (natural killer cell associated retroviral thing 6) is (p58 natural killer cell receptor cloning CL-43) (p58NK acceptor) .[source (NKAT-6): Uniprot/SWISSPROT; Acc:P43627]
3805	NM_002255	Killer cell immunoglobulin (Ig)-sample acceptor, two structural domains, growing cells matter tail, 4; KIR2DL4	3804	NM_015868
3805	NM_002255		3806	NM_012313	Killer cell immunoglobulin (Ig)-sample acceptor 2DS1 precursor (MHC class INK cell receptor Eb6ActI) .[source: Uniprot/SWISSPROT; Acc:Q14954]
3807		Killer cell immunoglobulin (Ig)-sample acceptor 3DL3 precursor (killer cell inhibitory receptor 1) .[source: Uniprot/SWISSPROT; Acc:Q8N743]	3806	NM_012313
3807			3808	NM_012313	Killer cell immunoglobulin (Ig)-sample acceptor 2DS1 precursor (MHC class INK cell receptor Eb6ActI) .[source: Uniprot/SWISSPROT; Acc:Q14954]

3809	NM_178228；NM_01 2314	Killer cell immunoglobulin (Ig)-sample acceptor, two structural domains, short cell matter tail, 4; KIR2DS4
3809	NM_178228；NM_01 2314		3810		Killer cell immunoglobulin-like receptor 3DL3 precursor (killer cell inhibitory receptor 1) .[source: Uniprot/SWISSPROT; Acc:Q8N743]
3811	NM_013289	The killer cell immunoglobulin-like receptor, three structural domains, growing cells matter tail, 1; KIR3DL1	3810
3811	NM_013289		3812	NM_006737	Killer cell immunoglobulin (Ig)-sample acceptor, three structural domains, growing cells matter tail, 2; KIR3DL2
3818	NM_000892	Plasma kallikrein precursor (EC3.4.21.34) (blood plasma prekallikrein) (kininase discharges former) (the Fletcher factor) [comprises: the plasma kallikrein heavy chain; The plasma kallikrein light chain] .[source: Uniprot/SWISSPROT; Acc:P03952]	3812	NM_006737
3818	NM_000892		3820	NM_002258	Killer cell lectin-sample acceptor subfamily B, the member 1; KLRB1
3821	NM_002259；NM_21 3657；NM_007328；NM_213658	Killer cell lectin-sample acceptor subfamily C, the member 1; KLRC1	3820	NM_002258
3821	NM_002259；NM_21 3657；NM_007328；NM_213658		3822	NM_002260	Killer cell lectin-sample acceptor subfamily C, the member 2; KLRC2
3823	NM_007333；NM_00 2261	Killer cell lectin-sample acceptor subfamily C, the member 3; KLRC3	3822	NM_002260
3823	NM_007333；NM_00 2261		3824	NM_002262；NM_007334	Killer cell lectin-sample acceptor subfamily D, the member 1; KLRD1
3845	NM_033360；NM_004985	V-Ki-ras2Kirsten rat sarcoma virus oncogene homologue; KRAS	3824	NM_002262；NM_007334
3845	NM_033360；NM_004985	V-Ki-ras2Kirsten rat sarcoma virus oncogene homologue; KRAS	3848	NM_006121	Keratin sulfate, II type cytoskeletal protein 1 (cytokeratin-1) be (Keratin sulfate-1) (K1) (67kDa cytokeratin) (hair α albumen) .[source: Uniprot/SWISSPROT (CK-1); Acc:P04264]
3902	NM_002286	Lymphocyte activation gene 3 amyloid protein precursors (LAG-3) (FDC albumen) (CD223 antigen) .[source: Uniprot/SWISSPROT; Acc:P18627]	3848	NM_006121
3902	NM_002286		3903	NM_021708；NM_00 2287；NM_021706	White corpuscle-relevant Ig-sample acceptor 1; LAIR1
3904	NM_002288；NM_021270	White corpuscle-relevant Ig-sample acceptor 2; LAIR2	3903	NM_021708；NM_00 2287；NM_021706	White corpuscle-relevant Ig-sample acceptor 1; LAIR1
3904	NM_002288；NM_021270	White corpuscle-relevant Ig-sample acceptor 2; LAIR2	3929	NM_004139	Lipopolysaccharide binding protein; LBP
3932	NM_005356	Lymphocyte-specific proteins Tyrosylprotein kinase; LCK	3929	NM_004139	Lipopolysaccharide binding protein; LBP
3932	NM_005356	Lymphocyte-specific proteins Tyrosylprotein kinase; LCK	3933	NM_002297	Lipocalin-1 precursor (Von Ebner gland albumen) (VEG albumen) (tear prealbumin) be (tear lipocalin) (Tlc) .[source: Uniprot/SWISSPROT (TP); Acc:P31025]
3936	NM_002298	Lymphocyte cytosol albumen 1 (L-plastin) (LCP1)	3933	NM_002297
3936	NM_002298	Lymphocyte cytosol albumen 1 (L-plastin) (LCP1)	3937	NM_005565	Lymphocyte cytosol albumen 2 (the white corpuscle albumen that comprises the SH2 structural domain, 76kDa); LCP2
3959	NM_005567	Conjugated protein-3 conjugated protein precursors of galactose agglutinin (lectin galactoside-conjugated protein in conjunction with solvable 3) (Mac-2 is conjugated protein) are (MAC2BP) (tumour-related antigen 90K) .[source (Mac-2BP): Uniprot/SWISSPROT; Acc:Q08380]	3937	NM_005565

3976	NM_002309	Leukaemia inhibitory factor precursor (LIF) (differentiation-stimulating factor) (the D factor) (the LPL inhibitor in melanoma-source) is (Emfilermin) .[source (MLPLI): Uniprot/SWISSPROT; Acc:P15018]
3976	NM_002309		4046	NM_001013253	Lymphocyte-specific proteins 1 (albumen pp52) (52kDa phosphorprotein) (lymphocyte-specific antigens WP34) (47kDa actin binding protein) .[source: Uniprot/SWISSPROT; Acc:P33241]
4048	NM_000895	Leukotriene A-4 lytic enzyme (EC 3.3.2.6) (LTA-4 lytic enzyme) (leukotriene A (4) lytic enzyme) .[source: Uniprot/SWISSPROT; Acc:P09960]	4046	NM_001013253
4048	NM_000895		4049	NM_000595	Woods crust toxin-α precursor (LT-α) (TNF-β) (tumour necrosis factor part superfamily member 1) .[source: Uniprot/SWISSPROT; Acc:P01374]
4050	NM_002341	Woods crust toxin-β (LT-β) (tumour necrosis factor C) is (tumour necrosis factor part superfamily member 3) .[source (TNF-C): Uniprot/SWISSPROT; Acc:Q06643]	4049	NM_000595
4050	NM_002341		4055	NM_002342	Tumor necrosis factor receptor super family member 3 precursors (lymphotoxin-beta receptor) (tumor necrosis factor receptor 2 associated protein) (tumour necrosis factor C acceptor) .[source: Uniprot/SWISSPROT; Acc:P36941]
4057	NM_002343	Lactotransferrin precursor (EC3.4.21.-) (lactoferrin) [comprises: Kaliocin-1; Lactoferroxin A; Lactoferroxin B; LactoferroxinC] .[source: Uniprot/SWISSPROT; Acc:P02788]	4055	NM_002342
4057	NM_002343		4061	NM_002346	Lymphocyte antigen	6 complex bodys, locus E (LY6E)
4062	NM_002347	Woods crust cell antigen Ly-6H precursor .[source: Uniprot/SWISSPROT; Acc:O94772]	4061	NM_002346	Lymphocyte antigen	6 complex bodys, locus E (LY6E)
4062	NM_002347		4063	NM_001033667；NM002348	Lymphocyte antigen	9; LY9
4064	NM_005582	CD180 antigen precursor (lymphocyte antigen 64) (radiation proof 105 kDa albumen) .[source: Uniprot/SWISSPROT; Acc:Q99467]	4063	NM_001033667；NM002348	Lymphocyte antigen	9; LY9
4064	NM_005582		4065	NM_002349	Lymphocyte antigen 75 precursors (DEC-205) (CD205 antigen) are the .[source (gp200-MR6): Uniprot/SWISSPROT; Acc:O60449]
4067	NM_002350	The v-yes-1Yamaguchi sarcoma virus oncogene homologue of being correlated with; LYN	4065	NM_002349
4067	NM_002350		4068	NM_002351	SH2 domain protein 1A (signal lymphocyte activation molecule-associated protein) (SLAM-associated protein) (T cellular signal transduction molecule SAP) (the sick SH2-albumen of Duncan) .[source: Uniprot/SWISSPROT; Acc:O60880]
4069	NM_000239	N,O-Diacetylmuramidase (renal amyloidosis); LYZ	4068	NM_002351
4069	NM_000239	N,O-Diacetylmuramidase (renal amyloidosis); LYZ	4088	NM_005902	At (Mad3) (hMAD-3) (JV15-2) (hSMAD3) .[source: Uniprot/SWISSPROT of the parent (at the parent of DPP homologue 3) of decapentaplegic homologue 3 (SMAD 3); Acc:P84022]
4153	NM_000242	Seminose-binding lectin (PROTEIN C) 2, solvable (Opsonin shortage); MBL2	4088	NM_005902
4153	NM_000242		4155	NM_001025090	Myelin basic protein (MBP) (myelin A1 albumen) (myelin film encephalitogenic protein) .[source: Uniprot/SWISSPROT; Acc:P02686]

4179	NM_172359；NM_17 2356；NM_172351；N M_172353；NM_0023 89；NM_172350；NM_ 153826；NM_172361；NM_172354；NM_17 2360；NM_172355；N M_172358；NM_1723 57；NM_172352	Membrane cofactor protein (CD46, trophoderm-lymphocyte cross-reacting antigen); MCP
4179			4210	NM_000243	Pyrin (Marenostrin) .[source: Uniprot/SWISSPROT; Acc:O15553]
4215	NM_203351；NM_002401	Mitogen-activated protein kinase kinase kinase 3; MAP3K3	4210	NM_000243
4215	NM_203351；NM_002401	Mitogen-activated protein kinase kinase kinase 3; MAP3K3	4258	NM_002413	Microsome glutathione S-transferase 2 (EC 2.5.1.18) (microsome GST-2) (microsome GST-II) .[source: Uniprot/SWISSPROT; Acc:Q99735]
4259	NM_004528	Microsome glutathione S-transferase 3 (EC 2.5.1.18) (microsome GST-3) (microsome GST-III) .[source: Uniprot/SWISSPROT; Acc:O14880]	4258	NM_002413
4259	NM_004528		4261	NM_000246	MHC class II trans-activator (CIITA) .[source: Uniprot/SWISSPROT; Acc:P33076]
4276	NM_000247	MHC class I polypeptide-correlated series A; MICA	4261	NM_000246
4276	NM_000247	MHC class I polypeptide-correlated series A; MICA	4277	NM_005931	MHC class I polypeptide-correlated series B; MICB
4282	NM_002415	Macrophage migration inhibitory factor (MIF) (phenyl-pyruvic acid mutase) is (glycosylation-supressor) (GIF) .[source: Uniprot/SWISSPROT (EC5.3.2.1); Acc:P14174]	4277	NM_005931	MHC class I polypeptide-correlated series B; MICB
4282	NM_002415		4283	NM_002416	I inductive cytokine B9 precursor (CXCL9) (IFN--inductive monokine) is the .[source (MIG): Uniprot/SWISSPROT; Acc:Q07325]
4332	NM_002432	Medullary cell nuclear differentiation antigen .[source: Uniprot/SWISSPROT; Acc:P41218]	4283	NM_002416
4332	NM_002432		4345	NM_001004196；NM _005944；NM_001004197	CD200 antigen; CD200
4481	NM_002445；NM_138715；NM_138716	Scavenger cell scavenger receptor 1; MSR1	4345	NM_001004196；NM _005944；NM_001004197	CD200 antigen; CD200
4481	NM_002445；NM_138715；NM_138716	Scavenger cell scavenger receptor 1; MSR1	4485	NM_020998	Macrophage-stimulating 1 (pHGF-sample); MST1
4599	NM_002462	Interferon, rabbit-conjugated protein the Mx1 of inductive GTP-(the conjugated protein MxA of anti-GTP-of Interferon, rabbit-adjusting) (Interferon, rabbit-inductive albumen p78) is the .[source (IFI-78K): Uniprot/SWISSPROT; Acc:P20591]	4485	NM_020998	Macrophage-stimulating 1 (pHGF-sample); MST1
4599	NM_002462		4600	NM_002463	Interferon, rabbit-conjugated protein the Mx2 of inductive GTP-(the conjugated protein MxB of anti-GTP-of Interferon, rabbit-adjusting) (p78-associated protein) .[source: Uniprot/SWISSPROT; Acc:P20592]
4615	NM_002468	Marrow differentiation initial reaction albumen MyD88.[source: Uniprot/SWISSPROT; Acc:Q99836]	4600	NM_002463

4687	NM_000265	The neutrophil leucocyte cytosol factor 1 (NCF-1) (the neutrophilic leukocyte nadph oxidase factor 1) (the 47kDa neutrophilic leukocyte oxydase factor) (p47-phox) (NCF-47K) (47kDa euchromosome chronic granulomatous disease albumen) is the .[source (NOXO2): Uniprot/SWISSPROT; Acc:P14598]
4687	NM_000265		4688	NM_000433	The neutrophil leucocyte cytosol factor 2 (NCF-2) (the neutrophilic leukocyte nadph oxidase factor 2) (the 67kDa neutrophilic leukocyte oxydase factor) is (NOXA2) .[source (p67-phox): Uniprot/SWISSPROT; Acc:P19878]
4690	NM_006153	NCK joint albumen 1; NCK1	4688	NM_000433
4690	NM_006153	NCK joint albumen 1; NCK1	4772	NM_172387；NM_00 6162；NM_172388；N M_172390；NM_1723 89	The nf of activation T-cell, cytoplasmic, 1 of calcium neuroprotein-dependence; NFATC1
4773	NM_173091；NM_01 2340	The nf of tongue T-cell, cytoplasmic, 2 of calcium neuroprotein-dependence; NFATC2	4772	NM_172387；NM_00 6162；NM_172388；N M_172390；NM_1723 89
4773	NM_173091；NM_01 2340		4775	NM_173164；NM_00 4555；NM_173165；NM_173163	The nf of activation T-cell, cytoplasmic, 3 of calcium neuroprotein-dependence; NFATC3
4776	NM_004554	The nf of activation T-cell, cytoplasmic, 4 of calcium neuroprotein-dependence; NFATC4	4775	NM_173164；NM_00 4555；NM_173165；NM_173163
4776	NM_004554		4779	NM_003204	Nf red corpuscle 2 associated factor 1s (NF-E2 associated factor 1) (NFE2-associated factor 1) (nf, 2 of red corpuscle source, sample 1) (transcription factor 11) (transcription factor HBZ17) (transcription factor LCR-F1) (region-factor 1)
4783	NM_005384	[the source: RefSeq_peptide that nf, interleukin-13 are regulated; Acc:NP_005375]	4779	NM_003204
4783	NM_005384		4790	NM_003998	The nf (p105) of κ light polypeptide gene enhanser in the B-cell 1; NFKB1
4791	NM_002502	The nf (p49/p100) of κ light polypeptide gene enhanser in the B-cell 2; NFKB2	4790	NM_003998
4791	NM_002502		4792	NM_020529	The nf of κ light polypeptide gene enhanser in the B-cytostatics, α; NFKBIA
4793	NM_002503；NM_00 1001716	The nf of κ light polypeptide gene enhanser in the B-cytostatics, β; NFKBIB	4792	NM_020529
4793	NM_002503；NM_00 1001716		4795	NM_005007	The nf nf of κ light polypeptide gene enhanser in B-cytostatics-sample 1; NFKBIL1
4843	NM_000625	Nitric oxide synthase, derivable (EC 1.14.13.39) (NOS Type II) (derivable NO synthase) (derivable NOS) be (liver cell NOS) (HEP-NOS) .[source: Uniprot/SWISSPROT (iNOS); Acc:P35228]	4795	NM_005007
4843	NM_000625		4851	NM_017617	Notch homologue 1, transposition-relevant (fruit bat); NOTCH1
4853	NM_024408	Notch homologue 2 (fruit bat); NOTCH2	4851	NM_017617
4853	NM_024408	Notch homologue 2 (fruit bat); NOTCH2	4854	NM_000435	Notch homologue 3 (fruit bat); NOTCH3
4855	NM_004557	Notch homologue 4 (fruit bat); NOTCH4	4854	NM_000435	Notch homologue 3 (fruit bat); NOTCH3

4884	NM_002522	neuronal pentraxin I；NPTX1
4884	NM_002522	neuronal pentraxin I；NPTX1	4885	NM_002523	neuronal pentraxin II；NPTX2
4893	NM_002524	Neuroblastoma RAS virus (v-ras) oncogene homologue; NRAS	4885	NM_002523	neuronal pentraxin II；NPTX2
4893	NM_002524	Neuroblastoma RAS virus (v-ras) oncogene homologue; NRAS	4929	NM_173172	Orphan nuclear receptor NR4A2 (orphan nuclear receptor NURR1) (directly-and early response albumen NOT) (transcribing derivable nuclear receptor) .[source: Uniprot/SWISSPROT; Acc:P43354]
4938	NM_001032409；NM _016816；NM_002534	2 ', 5 '-oligoadenylate synthetase 1,40/46kDa; OAS1	4929	NM_173172
4938	NM_001032409；NM _016816；NM_002534	2 ', 5 '-oligoadenylate synthetase 1,40/46kDa; OAS1	4939	NM_016817；NM_00 1032731；NM_002535	'-5 '-oligoadenylate synthetase 2,69/71kDa; OAS2
4940	NM_006187	'-5 '-oligoadenylate synthetase 3,100kDa; OAS3	4939	NM_016817；NM_00 1032731；NM_002535	'-5 '-oligoadenylate synthetase 2,69/71kDa; OAS2
4940	NM_006187	'-5 '-oligoadenylate synthetase 3,100kDa; OAS3	4973	NM_002543	Oxidized ldl receptor 1 (Ox-LDL acceptor 1) (lectin-type oxidation ldl receptor 1) (lectin-sample oxidation ldl receptor 1) (lectin-sample oxLDL acceptor 1) (LOX-1) (hLOX-1) [comprise: oxidized ldl receptor 1, solvable
4985	NM_000911	Δ-type opioid receptor (DOR-1) .[source: Uniprot/SWISSPROT; Acc:P41143]	4973	NM_002543
4985	NM_000911		4986	NM_000912	K-type opioid receptor (KOR-1) .[source: Uniprot/SWISSPROT; Acc:P41145]
5004	NM_000607	A-1-acid glycoprotein 2 precursors (AGP2) (seromucoid-2) (OMD 2) .[source: Uniprot/SWISSPROT; Acc:P19652]	4986	NM_000912
5004	NM_000607		5005	NM_000608	A-1-acid glycoprotein 2 precursors (AGP2) (seromucoid-2) are the .[source (OMD2): Uniprot/SWISSPROT; Acc:P19652]
5008	NM_020530	Oncostatin M precursor (OSM) .[source: Uniprot/SWISSPROT; Acc:P13725]	5005	NM_000608
5008	NM_020530		5058	NM_002576	P21/Cdc42/Rac1-activated protein kinase 1 (STE20 homologue, yeast); PAK1
5062	NM_002577	P21 (CDKN1A)-activated protein kinase 2; PAK2	5058	NM_002576
5062	NM_002577	P21 (CDKN1A)-activated protein kinase 2; PAK2	5063	NM_002578	P21 (CDKN1A)-activated protein kinase 3; PAK3
5068	NM_002580	Albumen 3 α precursors (Reg III-α) (pancreatitis-associated protein 1) .[source in regeneration island-source: Uniprot/SWISSPROT; Acc:Q06141]	5063	NM_002578	P21 (CDKN1A)-activated protein kinase 3; PAK3
5068	NM_002580		5074	NM_002583	PRKC apoptosis WT1 regulates (Par-4) .[source: Uniprot/SWISSPROT of albumen (prostate gland apoptotic response-4 albumen); Acc:Q96IZ0]
5079	NM_016734	Box protein Pax-5 (B-cell-idiosyncratic transcription factor) is (BSAP) in pairs. [source: Uniprot/SWISSPROT; Acc:Q02548]	5074	NM_002583
5079	NM_016734		5133	NM_005018	Program necrocytosis albumen 1 precursor (albumen PD-1) is (CD279 antigen) .[source (hPD-1): Uniprot/SWISSPROT; Acc:Q15116]
5153	AB209200	Phosphodiesterase 1B, calmodulin-dependency misfolded proteins.	5133	NM_005018
5153	AB209200		5175	NM_000442	Thrombocyte/endothelial cell adhesion molecule (CD31 antigen); PECAM1
5196	NM_002619	Platelet factor	5175	NM_000442		4 precursor (PF-4) is (oncostatin A) (Iroplact) .[source: Uniprot/SWISSPROT (CXCL4); Acc:P02776]

5197	NM_002620	Platelet factor 4 variant precursor (PF4var1) (PF4alt) (CXCL4L1) [comprises: platelet factor 4 variant (4-74); Platelet factor 4 variant (5-74); Platelet factor 4 variant (6-74)] .[source: Uniprot/SWISSPROT; Acc:P10720]
5197	NM_002620		5199	NM_002621	Properdin precursor (factor P) .[source: Uniprot/SWISSPROT; Acc:P27918]
5265	NM_001002236	A-1-antitrypsin precursor (A-1 proteinase inhibitor) (A-1-protease inhibitor) .[source: Uniprot/SWISSPROT; Acc:P01009]	5199	NM_002621
5265	NM_001002236		5284	NM_002644	The polymerization immunoglobulin receptor; PIGR
5286	NM_002645	Phosphoinositide-3-kinases, class 2, α polypeptide; PIK3C2A	5284	NM_002644	The polymerization immunoglobulin receptor; PIGR
5286	NM_002645	Phosphoinositide-3-kinases, class 2, α polypeptide; PIK3C2A	5287	NM_002646	Phosphoinositide-3-kinases, class 2, beta polypeptides; PIK3C2B
5288	NM_004570	Phosphoinositide-3-kinases, class 2, γ polypeptide; PIK3C2G	5287	NM_002646
5288	NM_004570	Phosphoinositide-3-kinases, class 2, γ polypeptide; PIK3C2G	5289	NM_002647	Phosphoinositide-3-kinases, class 3; PIK3C3
5290	NM_006218	Phosphoinositide-3-kinases, catalytic, the α polypeptide; PIK3CA	5289	NM_002647	Phosphoinositide-3-kinases, class 3; PIK3C3
5290	NM_006218		5291	NM_006219	Phosphoinositide-3-kinases, catalytic, beta polypeptides; PIK3CB
5293	NM_005026	Phosphoinositide-3-kinases, catalytic, the δ polypeptide; PIK3CD	5291	NM_006219
5293	NM_005026		5294	NM_002649	Phosphoinositide-3-kinases, catalytic, the γ polypeptide; PIK3CG
5295	NM_181523；NM_18 1504；NM_181524	Phosphoinositide-3-kinases, regulator subunit 1 (p85 α); PIK3R1	5294	NM_002649
5295	NM_181523；NM_18 1504；NM_181524		5296	NM_005027	Phosphoinositide-3-kinases, regulator subunit 2 (p85 β); PIK3R2
5330	NM_004573	Phospholipase C, β 2 (PLCB2)	5296	NM_005027
5330	NM_004573	Phospholipase C, β 2 (PLCB2)	5335	NM_002660；NM_18 2811	Phospholipase C, γ 1; PLCG1
5336	NM_002661	Phospholipase C, γ 2 (phosphatidylinositols-specificity); PLCG2	5335	NM_002660；NM_18 2811	Phospholipase C, γ 1; PLCG1
5336	NM_002661		5345	NM_000934	A-2-antiplasmin precursor (A-2-plasmin inhibitor) is (A-2-AP) .[source (A-2-PI): Uniprot/SWISSPROT; Acc:P08697]
5360	NM_182676；NM_00 6227	The phosphatide translocator; PLTP	5345	NM_000934
5360	NM_182676；NM_00 6227	The phosphatide translocator; PLTP	5393	NM_001034194	Exosome complex body exonuclease RRP45 (EC 3.1.13.-) (exosome composition 9) (polymyositis/scleroderma autoantigen 1) (autoantigen PM/Scl1) (polymyositis/scleroderma autoantigen 75kDa) (PM/Scl-75) (be correlated with by P75 polymyositis-scleroderma overlap syndrome
5408	NM_005396	Steapsase-associated protein 2 precursors (EC 3.1.1.3) .[source: Uniprot/SWISSPROT; Acc:P54317]	5393	NM_001034194
5408	NM_005396		5450	NM_006235	POU structural domain class 2, associated factor 1 (B-cell-specificity coactivator OBF-1) (OCT binding factor 1) be (OCA-B) .[source (BOB-1): Uniprot/SWISSPROT; Acc:Q16633]
5452	NM_002698	The POU structural domain, class 2, and transcription factor 2 (octamer-in conjunction with transcription factor 2) (Oct-2) (OTF-2) (the conjugated protein NF-A2 of the restricted immunoglobulin (Ig) octamer of lymphocyte sample) .[source: Uniprot/SWISSPROT; Acc:P09086]	5450	NM_006235
5452	NM_002698		5468	NM_005037	Peroxisome Proliferators-activated receptor γ (PPAR-γ) .[source: Uniprot/SWISSPROT; Acc:P37231]

5473	NM_002704	Thrombocyte basis amyloid protein precursor (PBP) (I inductive cytokine B7) (CXCL7) (somatomedin in white corpuscle-source) (LDGF) (somatomedin in scavenger cell-source) (MDGF) [comprise: reticular tissue-activation peptide III (CTAP-III) (low-affinity antihemophilic factor V
5473	NM_002704		5479	NM_000942	Peptidyl prolyl isomerase B (cyclophilin B) (PPIB)
5530	NM_000944	Phosphoprotein phosphatase 3 (formerly 2B), catalytic subunit, alpha hypotype (calcineurin A α); PPP3CA	5479	NM_000942	Peptidyl prolyl isomerase B (cyclophilin B) (PPIB)
5530	NM_000944		5532	NM_021132	Phosphoprotein phosphatase 3 (formerly 2B), catalytic subunit, β hypotype (calcineurin A β); PPP3CB
5533	NM_005605	Phosphoprotein phosphatase 3 (formerly 2B), catalytic subunit, γ hypotype (calcineurin A γ); PPP3CC	5532	NM_021132
5533	NM_005605		5551	NM_005041	Perforin 1 precursor (P1) (the lymphocyte hole forms albumen) is (cytolysin) .[source: Uniprot/SWISSPROT (PFP); Acc:P14222]
5553	NM_002728	Proteoglycan 2, marrow (natural killer cell activator, the main basic protein of eosinophilic granulocyte); PRG2	5551	NM_005041
5553	NM_002728		5578	NM_002737	Protein kinase C, α; PRKCA
5579	NM_212535；NM_00 2738	Protein kinase C, β 1; PRKCB1	5578	NM_002737	Protein kinase C, α; PRKCA
5579	NM_212535；NM_00 2738	Protein kinase C, β 1; PRKCB1	5580	NM_006254；NM_21 2539	Protein kinase C, δ; PRKCD
5581	NM_005400	Protein kinase C, ε; PRKCE	5580	NM_006254；NM_21 2539	Protein kinase C, δ; PRKCD
5581	NM_005400	Protein kinase C, ε; PRKCE	5582	NM_002739	Protein kinase C, γ; PRKCG
5583	NM_006255	Protein kinase C, η; PRKCH	5582	NM_002739	Protein kinase C, γ; PRKCG
5583	NM_006255	Protein kinase C, η; PRKCH	5588	NM_006257	Protein kinase C, θ; PRKCQ
5594	NM_002745；NM_13 8957	Mitogen-activated protein kinase 1; MAPK1	5588	NM_006257	Protein kinase C, θ; PRKCQ
5594	NM_002745；NM_13 8957	Mitogen-activated protein kinase 1; MAPK1	5595	NM_002746	Mitogen-activated protein kinase 3; MAPK3
5599	NM_139046；NM_00 2750；NM_139049；NM_139047	Mitogen-activated protein kinase 8; MAPK8	5595	NM_002746	Mitogen-activated protein kinase 3; MAPK3
5599	NM_139046；NM_00 2750；NM_139049；NM_139047	Mitogen-activated protein kinase 8; MAPK8	5600	NM_138993；NM_00 2751	Mitogen-activated protein kinase 11; MAPK11
5601	NM_139069；NM_13 9070；NM_139068；NM_002752	Mitogen-activated protein kinase 9; MAPK9	5600	NM_138993；NM_00 2751	Mitogen-activated protein kinase 11; MAPK11
5601	NM_139069；NM_13 9070；NM_139068；NM_002752	Mitogen-activated protein kinase 9; MAPK9	5602	NM_138980；NM_00 2753；NM_138982；NM_138981	Mitogen-activated protein kinase 10; MAPK10
5603	NM_002754	Mitogen-activated protein kinase 13; MAPK13	5602	NM_138980；NM_00 2753；NM_138982；NM_138981	Mitogen-activated protein kinase 10; MAPK10
5603	NM_002754	Mitogen-activated protein kinase 13; MAPK13	5604	NM_002755	Mitogen-activated protein kinase kinases 1; MAP2K1
5605	NM_030662	Mitogen-activated protein kinase kinases 2; MAP2K2	5604	NM_002755	Mitogen-activated protein kinase kinases 1; MAP2K1
5605	NM_030662	Mitogen-activated protein kinase kinases 2; MAP2K2	5606	NM_145110	Dual specific mitogen-activated protein kinase kinases 3 (EC 2.7.1.-) (map kinase kinases 3) is (MAPK/ERK kinases 3) (MAPKK3). [source: Uniprot/SWISSPROT; Acc:P46734]

5610	NM_002759	Interferon, rabbit-inductive, double-stranded RNA-activated protein kinase (EC 2.7.1.-) (Interferon, rabbit-derivable RNA-deopendent protein kinase) (p68 kinases) (P1/eIF-2A protein kinase) .[source: Uniprot/SWISSPROT; Acc:P19525]
5610	NM_002759		5618	NM_000949	Hprl receptor precursor (PRL-R) .[source: Uniprot/SWISSPROT; Acc:P16471]
5624	NM_000312	PROTEIN C (inactivator of coagulation factors Va and VIIIa); PROC	5618	NM_000949
5624	NM_000312		5648	NM_001879	Complement-the activating component of Ra-response factor precursor (EC 3.4.21.-) (Ra-response factor serine protease p100) (RaRF) (the lectin serine protease 1 of mannan-binding) (in conjunction with relevant serine protease of albumen of seminose) (MASP-1) [comprises: complement-ac
5696	NM_148919	Proteasome subunit β type 8 precursors (EC 3.4.25.1) (proteasome composition C13) (C13 of Macropain subunit) (the catalytic endopeptidase complex body C13 of subunit of Multi) .[source: Uniprot/SWISSPROT; Acc:P28062]	5648	NM_001879
5696	NM_148919		5698	NM_002800	Proteasome subunit β type 9 precursors (EC 3.4.25.1) (proteasome chain 7) (Macropain chain 7) (the catalytic endopeptidase complex body of Multi chain 7) (RING12 albumen) (low molecular mass albumen 2) .[source: Uniprot/SWISSPROT; Acc:P28065]
5699	NM_002801	Proteasome subunit β type 10 precursors (EC 3.4.25.1) (proteasome MECl-1) (MECl-1 of Macropain subunit) (the how catalytic endopeptidase complex body MECl-1 of subunit) .[source: Uniprot/SWISSPROT; Acc:P40306]	5698	NM_002800
5699	NM_002801		5720	NM_176783	Proteasome activator complex body subunit 1 (proteasome activator 28-alpha subunit) (PA28 α) is (activator of how catalytic proteolytic enzyme subunit 1) (11S conditioning agent complex body alpha subunit) (REG-α) (I-5111 albumen that interferon-gamma up-regulates) (IGUP I-51 (PA28a)
5721	NM_002818	Proteasome activator complex body subunit 2 (proteasome activator 28-β subunit) (PA28 β) is (activator of how catalytic proteolytic enzyme subunit 2) (11S conditioning agent complex body β subunit) (REG-β) .[source (PA28b): Uniprot/SWISSPROT; Acc:Q9UL46]	5720	NM_176783
5721	NM_002818		5724	NM_000952	Thrombocyte-activation factor acceptor (PAF-R) .[source: Uniprot/SWISSPROT; Acc:P25105]
5733	NM_000957	Prostaglandin E2 acceptor, EP3 hypotype (prostanoid EP3 acceptor) (PGE acceptor, EP3 hypotype) be the .[source (PGE2-R): Uniprot/SWISSPROT; Acc:P43115]	5724	NM_000952
5733	NM_000957		5734	NM_000958	The prostaglandin E2 acceptor, EP4 hypotype (prostanoid EP4 acceptor) (PGE acceptor, EP4 hypotype) .[source: Uniprot/SWISSPROT; Acc:P35408]
5743	NM_000963	PGG/H synthase 2 precursors (EC 1.14.99.1) (cyclooxygenase-2) are (prostaglandin(PG)-endoperoxide synthase 2) (PGH2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II) .[source: Uniprot/SWISSPROT (COX-2); Acc:P35354]	5734	NM_000958
5743	NM_000963		5763	NM_002824	Parathymosin.[source: Uniprot/SWISSPROT; Acc:P20962]

5777	NM_002831；NM_08 0548；NM_080549	Protein-tyrosine-phosphatase, non--acceptor type 6; PTPN6
5777	NM_002831；NM_08 0548；NM_080549	Protein-tyrosine-phosphatase, non--acceptor type 6; PTPN6	5788	NM_080921；NM_08 0922；NM_002838；NM_080923	Protein-tyrosine-phosphatase, acceptor type, C; PTPRC
5806	NM_002852	Pentamer albumen-genes involved, by IL-1 β rapid induction; PTX3	5788	NM_080921；NM_08 0922；NM_002838；NM_080923	Protein-tyrosine-phosphatase, acceptor type, C; PTPRC
5806	NM_002852		5817	NM_006505	Poliovirus receptor; PVR
5818	NM_002855；NM_20 3285；NM_203286	(simplexvirus enters amboceptor C to poliovirus receptor-relevant 1; Nectin); PVRL1	5817	NM_006505	Poliovirus receptor; PVR
5818	NM_002855；NM_20 3285；NM_203286		5819	NM_002856	Poliovirus receptor-relevant 2 (simplexvirus enters amboceptor B); PVRL2
5871	NM_004579	Mitogen-activated protein four kinases 2 (EC 2.7.1.37) (MAPK/ERK three kinases 2) (MEK two kinases 2) are (germinal center's kinases) (GC kinases) (Rab8 interaction protein) (bone-marrow-derived lymphocyte serine/threonine-protein kinase) .[source (MEKKK2)	5819	NM_002856
5871	NM_004579		5879	NM_006908；NM_01 8890；NM_198829	The ras-C3 Toxins, botulin matrix 1 (rho family, the conjugated protein Rac1 of little GTP) of being correlated with; RAC1
5880	NM_002872	The ras-C3 Toxins, botulin matrix 2 (rho family, the conjugated protein Rac2 of little GTP) of being correlated with; RAC2	5879	NM_006908；NM_01 8890；NM_198829
5880	NM_002872		5881	NM_005052	The ras-C3 Toxins, botulin matrix 3 (rho family, little gtp binding protein Rac3) of being correlated with; RAC3
5894	NM_002880	V-raf-1 murine leukemia virus oncogene homologue 1; RAF1	5881	NM_005052
5894	NM_002880	V-raf-1 murine leukemia virus oncogene homologue 1; RAF1	5896	NM_000448	V (D) J reorganization-activated protein 1 (RAG-1) (ring finger protein 74) .[source: Uniprot/SWISSPROT; Acc:P15918]
5897	NM_000536	V (D) J reorganization-activated protein 2 (RAG-2) .[source: Uniprot/SWISSPROT; Acc:P55895]	5896	NM_000448
5897	NM_000536		5970	NM_021975	Transcription factor p65 (nf NF-κ-B p65 subunit) .[source: Uniprot/SWISSPROT; Acc:Q04206]
5971	NM_006509	Transcription factor RelB (I-Rel) .[source: Uniprot/SWISSPROT; Acc:Q01201]	5970	NM_021975
5971	NM_006509		5989	NM_002918	MHC class II regulatory factor RFX1 (RFX) (enhanser factor C) is the .[source (EF-C): Uniprot/SWISSPROT; Acc:P22670]
5996	NM_002922	The conditioning agent of G-protein signal 1 (RGS1) (early response albumen 1R20) (B-cell activating protein BL34) .[source: Uniprot/SWISSPROT; Acc:Q08116]	5989	NM_002918
5996	NM_002922		5997	NM_002923	The conditioning agent of G-protein signal 2,24kDa (RGS2)
6091	NM_002941；NM_13 3631	Roundabout, aixs cylinder guiding acceptor, homologue 1 (fruit bat); ROBO1	5997	NM_002923	The conditioning agent of G-protein signal 2,24kDa (RGS2)
6091	NM_002941；NM_13 3631		6092	NM_002942	Roundabout, aixs cylinder guiding acceptor, homologue 2 (fruit bat); ROBO2
6237	NM_006270	Relevant RAS virus (r-ras) oncogene homologue; RRAS	6092	NM_002942
6237	NM_006270	Relevant RAS virus (r-ras) oncogene homologue; RRAS	6279	NM_002964	Calgranulin A (migration inhibition factor-associated protein 8) is (cystic fibrosis antigen) (CFAG) (P8) (white corpuscle L1 complex body light chain) (S100 calcium-conjugated protein A8) (calprotectin L1L subunit) (urinary calculi protein band A) .[source: Uniprot/SWI (MRP-8)

6280	NM_002965	Calgranulin B (migration inhibition factor-associated protein 1 4) is the .[of (P14) (white corpuscle L1 complex body heavy chain) (S100 calcium-conjugated protein A9) (calprotectin L1H subunit) source (MRP-14): Uniprot/SWISSPROT; Acc:P06702]
6280	NM_002965		6283	NM_005621	(CGRP) .['s calgranulin C (CAGC) originated: Uniprot/SWISSPROT (neutrophilic leukocyte S100 albumen) (calcium in the amniotic fluid-conjugated protein 1) (CAAF1) (p6) [comprising: Calcitermin]; Acc:P80511]
6285	NM_006272	S-100 calcium-the .[of conjugated protein β subunit (S-100 albumen, β chain) source: Uniprot/SWISSPROT; Acc:P04271]	6283	NM_005621
6285	NM_006272		6288	NM_199161；NM_00 0331	Serum amyloid A 1; SAA1
6289	NM_030754	Serum amyloid A 2; SAA2	6288	NM_199161；NM_00 0331	Serum amyloid A 1; SAA1
6289	NM_030754	Serum amyloid A 2; SAA2	6291	NM_006512	Serum amyloid A 4, formation; SAA4
6300	NM_002969	Mitogen-activated protein kinase 12; MAPK12	6291	NM_006512	Serum amyloid A 4, formation; SAA4
6300	NM_002969	Mitogen-activated protein kinase 12; MAPK12	6318	NM_002974	Squamous cell carcinoma antigen 1 (SCCA-1) (albumen T4-A) .[source: Uniprot/SWISSPROT; Acc:P29508]
6346	NM_002981	I inductive cytokine A1 precursor (CCL1) (T lymphocyte-secretory protein I-309) .[source: Uniprot/SWISSPROT; Acc:P22362]	6318	NM_002974
6346	NM_002981		6347	NM_002982	I inductive cytokine A2 precursor (CCL2) (MCP 1) is (MCAF) (monocyte secretory protein JE) (HC11) .[source: Uniprot/SWISSPROT of (MCP 1) (monocyte chemotactic and activation factor) (MCP-1); Acc:P13500]
6348	NM_002983	I inductive cytokine A3 precursor (CCL3) (macrophage inflammatory protein 1 alpha) (MIP-1-α) (lymphocytes in tonsil LD78 α albumen) (the G0/G1 switch is regulated protein 19-1) (G0S19-1 albumen) (SIS-β) (PAT464.1) [comprises: MIP-1-α (4-69) (LD	6347	NM_002982
6348	NM_002983		6349	NM_021006	I inductive cytokine A3-sample 1 precursor (lymphocytes in tonsil LD78 β albumen) (LD78-β (1-70)) (the G0/G1 switch is regulated protein 19-2) (G0S19-2 albumen) (PAT464.2) [comprises: LD78-β (3-70); LD78-β (5-70)] .[source: Uniprot/SWISSPROT; Acc:P1661
6351	NM_002984	I inductive cytokine A4 precursor (CCL4) (macrophage inflammatory protein 1-β) (MIP-1-β) (MIP-1-β (1-69)) (T-cell activating protein 2) is (PAT744) (H400) (SIS-γ) (lymphocyte activation gene 1 albumen) (LAG-1) (HC21) (G-26T lymphocyte (lymphocy) (ACT-2)	6349	NM_021006
6351	NM_002984		6352	NM_002985	I inductive cytokine A5 precursor (CCL5) (T-cell-specificity RANTES albumen) (SIS-δ) (T cell-specific proteins P228) (TCP228) [comprises: RANTES (3-68); RANTES (4-68)] .[source: Uniprot/SWISSPROT; Acc:P13501]
6354	NM_006273	I inductive cytokine A7 precursor (CCL7) (monocyte chemotactic protein 3) is (monocyte chemotactic protein 3) (NC28) .[source: Uniprot/SWISSPROT (MCP-3); Acc:P80098]	6352	NM_002985

6355	NM_005623	I inductive cytokine A8 precursor (CCL8) (monocyte chemotactic protein-2) (MCP-2) (monocyte chemotactic protein-2) (HC14) [comprises: MCP-2 (6-76)] .[source: Uniprot/SWISSPROT; Acc:P80075]
6355	NM_005623		6356	NM_002986	Eotaxin precursor (I inductive cytokine A11) is (eosinophilic granulocyte chemotactic protein) .[source (CCL11): Uniprot/SWISSPROT; Acc:P51671]
6357	NM_005408	I inductive cytokine A13 precursor (CCL13) (MCP 4) (MCP-4) (MCP 4) (CK-β-10) (NCC-1) [comprises: I inductive cytokine A13, elongated; I inductive cytokine A13, medium hypotype; ... little	6356	NM_002986
6357	NM_005408		6359	NM_004167	I inductive cytokine A15 precursor (CCL15) (macrophage inflammatory protein 5) (MIP-5) (chemokine CC-2) (HCC-2) (NCC-3) (MIP-1 δ) (Leukotactin-1) (LKN-1) (Mrp-2b) [comprise: CCL15 (22-92); CCL15 (25-92); CCL15 (29-92)] .[source: Uniprot/SWISSPROT; Acc
6360	NM_004590	I inductive cytokine A16 precursor (CCL16) (the derivable chemokine of IL-10-) (chemokine LEC) (chemokine of liver-expression) is (HCC-4) (NCC-4) (lymphocyte and monocyte chemotactic) (LMC) (LCC-1) of (MTN-1) (chemokine CC-4) (Monotactin-1). [source: Uniprot/SWISSPR	6359	NM_004167
6360	NM_004590		6361	NM_002987	I inductive cytokine A17 precursor (CCL17) (chemokine that thymus gland and activation are regulated) (CC chemokine TARC) .[source: Uniprot/SWISSPROT; Acc:Q92583]
6362	NM_002988	I inductive cytokine A18 precursor (CCL18) (macrophage inflammatory protein 4) is (AMAC-1) (dendritic cell chemokine of (lung and activation-adjusting chemokine) (CC chemokine PARC) (optional macrophage activation-relevant CC chemokine 1) (MIP-4)	6361	NM_002987
6362	NM_002988		6363	NM_006274	I inductive cytokine A19 precursor (CCL19) (macrophage inflammatory protein 3 β) (MIP-3-β) (EBI1-part chemokine) is (B chemokine exodus-3) (CK β-11) .[source (ELC): Uniprot/SWISSPROT; Acc:Q99731]
6364	NM_004591	I inductive cytokine A20 precursor (CCL20) (macrophage inflammatory protein 3 α) (MIP-3-α) (liver and activation-adjusting chemokine) (CC chemokine LARC) (B chemokine exodus-1) [comprises: CCL20 (1-67); CCL20 (1-64); CCL20 (2-70)] .[source: Uni	6363	NM_006274
6364	NM_004591		6366	NM_002989	I inductive cytokine A21 precursor (CCL21) (B chemokine exodus-2) is (the second Lymphoid tissue chemokine) (SLC) .[source: Uniprot/SWISSPROT (6Ckine); Acc:O00585]
6367	NM_002990	I inductive cytokine A22 precursor (CCL22) (chemokine in scavenger cell-source) (MDC (1-69)) (the T cell chemotaxis albumen 1 of stimulation) (CC chemokine STCP-1) [comprises: MDC (3-69); MDC (5-69); MDC (7-69)] .[source: Uniprot/SWISSPROT; Acc:O00626]	6366	NM_002989

6368	NM_005064	I inductive cytokine A23 precursor (CCL23) (macrophage inflammatory protein 3) (MIP-3) (marrow founder subculture cell supressor 1) (MPIF-1) (CK-β-8) (CKB-8) [comprise: CCL23 (19-99); CCL23 (22-99); CCL23 (27-99); CCL23 (30-99)] .[source: Uniprot/SWISSPROT;
6368	NM_005064		6369	NM_002991	I inductive cytokine A24 precursor (CCL24) (marrow founder subculture cell supressor 2) is (Eotaxin-2) .[source: Uniprot/SWISSPROT of (CK-β-6) (eosinophilic granulocyte chemotactic protein-2) (MPIF-2); Acc:O00175]
6370	NM_005624	I inductive cytokine A25 precursor (CCL25) (chemokine TECK) (chemokine that thymus gland is expressed) .[source: Uniprot/SWISSPROT; Acc:O15444]	6369	NM_002991
6370	NM_005624		6372	NM_002993	I inductive cytokine B6 precursor (CXCL6) (granulocyte chemoattractant protein 2) (GCP-2) (chemokine alpha 3) (CKA-3) [comprises: I inductive cytokine B6, the variant 1 that N-handles; I inductive cytokine B6, the variant 2 that N-handles; I inductive cytoki
6373	NM_005409	I inductive cytokine B11 precursor (CXCL11) (Interferon, rabbit-derivable T-cell α chemotactic) is (interferon--inducible protein 9) (IP-9) (H174) (B-R1) .[source: Uniprot/SWISSPROT (I-TAC); Acc:O14625]	6372	NM_002993
6373	NM_005409		6374	NM_002994	I inductive cytokine B5 precursor (CXCL5) (neutrophilic leukocyte-activated protein 78 in epithelium-source) (neutrophilic leukocyte-activation peptide ENA-78) (ENA-78 (1-78)) [comprises: ENA-78 (8-78); ENA-78 (9-78)] .[source: Uniprot/SWISSPROT; Acc:P42830]
6375	NM_002995	Woods crust cell chemotactic factor precursor (XCL1) (cytokine SCM-1) is (Lymphotaxin) (SCM-1-α) (I inductive cytokine Cl) (XC chemokine ligand 1) .[source (ATAC): Uniprot/SWISSPROT; Acc:P47992]	6374	NM_002994
6375	NM_002995		6376	NM_002996	Fractalkine precursor (CX3CL1) is (chemokine of CX3C film-grappling) (I inductive cytokine D1) .[source (Neurotactin): Uniprot/SWISSPROT; Acc:P78423]
6383	NM_002998	Syndecan2 (heparan sulfate proteoglycan 1, cell surface-relevant, fibroglycan); SDC2	6376	NM_002996
6383	NM_002998		6385	NM_002999	syndecan4(amphiglycan，ryudocan)；SDC4
6387	NM_000609	The factor 1 precursor (SDF-1) in mesenchymal cell-source (CXCL12) (Pre-B cell growth-stimulating factor) (PBSF) (hIRH) [comprises: SDF-1-β (3-72); SDF-1-α (3-67)] .[source: Uniprot/SWISSPROT; Acc:P48061]	6385	NM_002999	syndecan4(amphiglycan，ryudocan)；SDC4
6387	NM_000609		6398	NM_003004	Secretion and transmembrane protein 1 precursor (albumen K12) .[source: Uniprot/SWISSPROT; Acc:Q8WVN6]
6401	NM_000450	E-selects (ELAM-1) (white corpuscle-endothelial cell adhesion molecule 2) (LECAM2) (CD62E antigen) .[source: Uniprot/SWISSPROT of amyloid protein precursor (endothelial leukocyte adhesion molecule 1); Acc:P16581]	6398	NM_003004

6403	NM_003005	P-selects (GMP-140) (LECAM3) .[source: Uniprot/SWISSPROT of (PADGEM) (CD62P antigen) (white corpuscle-endothelial cell adhesion molecule 3) of amyloid protein precursor (membrane granulosa protein 140); Acc:P16109]
6403	NM_003005		6435	NM_005411	Tensio-active agent, lung-associated protein A1; SFTPA1
6436	NM_006926	Tensio-active agent, lung-associated protein A2; SFTPA2	6435	NM_005411	Tensio-active agent, lung-associated protein A1; SFTPA1
6436	NM_006926	Tensio-active agent, lung-associated protein A2; SFTPA2	6441	NM_003019	Tensio-active agent, lung-associated protein D; SFTPD
6461	NM_003028	SHB (Src homologue y2 structural domain comprises) joint protein B [source: RefSeq_peptide; Acc:NP_003019]	6441	NM_003019	Tensio-active agent, lung-associated protein D; SFTPD
6461	NM_003028		6480	NM_173217	CMP-N-n acetylneuraminic acid n-β-galactosamide-α-2,6-sialytransferase (EC2.4.99.1) (beta-galactose-glycoside α-2, the 6-sialytransferase) (A2,6-ST) (sialytransferase 1) (ST6GalI) (B-cell antigen CD75) .[source: Uniprot/SWISSPROT; Acc:P15907]
6504	NM_003037	Signal lymphocyte activation molecule family member 1; SLAMF1	6480	NM_173217
6504	NM_003037		6556	AF229163	Natural resistance-associated macrophages albumen 1 (SLC11A1)
6614	NM_023068	Sialoadhesin precursor (sialic acid-in conjunction with Ig-sample lectin-1) is (CD169 antigen) .[source (Siglec-1): Uniprot/SWISSPROT; Acc:Q9BZZ2]	6556	AF229163
6614	NM_023068		6648	NM_001024465	Superoxide-dismutase [Mn], plastosome precursor (EC 1.15.1.1) .[source: Uniprot/SWISSPROT; Acc:P04179]
6654	NM_005633	The filial generation of non-seven homologues 1 (fruit bat); SOS1	6648	NM_001024465
6654	NM_005633		6655	NM_006939	The filial generation of non-seven homologues 2 (fruit bat); SOS2
6668	NM_003110	Transcription factor Sp2.[source: Uniprot/SWISSPROT; Acc:Q02086]	6655	NM_006939
6668	NM_003110		6670	NM_001017371	Transcription factor Sp3 (SPR-2) .[source: Uniprot/SWISSPROT; Acc:Q02447]
6688	NM_003120	Transcription factor PU.1 (31kDa transitional protein) .[source: Uniprot/SWISSPROT; Acc:P17947]	6670	NM_001017371
6688	NM_003120		6693	NM_001030288	Leukosialin precursor (white corpuscle sialoglycoprotein) is (GALGP) .[source: Uniprot/SWISSPROT of (CD43 antigen) (Galacto glycoprotein) (Sialophorin); Acc:P16150]
6696	NM_000582	Excretory phosphorprotein 1 (osteopontin, bone silaoprotein I, earlier T-lymphocyte activation 1); SPP1	6693	NM_001030288
6696	NM_000582		6714	NM_005417；NM_19 8291	V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homologue (bird); SRC
6774	NM_139276	Transcribe 3 conversion of signals agent and activator (acute-the elementary reaction factor). [source: Uniprot/SWISSPROT; Acc:P40763]	6714	NM_005417；NM_19 8291
6774	NM_139276		6776	NM_003152	Transcribe conversion of signals agent and activator .[source: the Uniprot/SWISSPROT of 5A; Acc:P42229]
6777	NM_012448	Transcribe conversion of signals agent and activator .[source: the Uniprot/SWISSPROT of 5B; Acc:P51692]	6776	NM_003152
6777	NM_012448		6846	NM_003175	Cytokine SCM-1 β precursor (XCL2) (XC chemokine ligand 2) .[source: Uniprot/SWISSPROT; Acc:Q9UBD3]
6850	NM_003177	Spleen tyrosine kinase; SYK	6846	NM_003175

6863	NM_003182	Protachykinin	1 precursor (PPT) [comprises: matrix P; Neurokinin A (NKA) (matrix K) (neuromedin L); Neuropeptide K (NPK); Neuropeptide γ; The terminal flank peptide of C-] .[source: Uniprot/SWISSPROT; Acc:P20366]
6863	NM_003182	Protachykinin		6869	NM_015727	Material-P acceptor (SPR) (nk 1 receptor) is (tachykinin receptor 1) .[source (NK-1R): Uniprot/SWISSPROT; Acc:P25103]
6890	NM_000593	Antigen peptide transport agents 1 (APT1) (peptide transport agents TAP1) (the ATP-binding cassette Asia-B member of family 2) (peptide transport agents PSF1) (the peptide supply factor 1) is (the peptide transport agents that relates in the antigen processing 1) .[source: Uniprot/SWISSPROT (PSF-1); Ac		6869	NM_015727
6890	NM_000593		6891	NM_018833	Antigen peptide transport agents 2 (APT2) (peptide transport agents TAP2) (peptide transport agents PSF2) (the peptide supply factor 2) is (the peptide transport agents that relates in the antigen processing 2) .[source: Uniprot/SWISSPROT (PSF-2); Acc:Q03519]
6892	NM_003190；NM_172209；NM_172208	TAP conjugated protein (first mercapto albumen); TAPBP	6891	NM_018833
6892	NM_003190；NM_172209；NM_172208	TAP conjugated protein (first mercapto albumen); TAPBP	6932	NM_201633	Transcription factor 7 (T-cell-idiosyncratic transcription factor 1) is (T-cytokine 1) .[source (TCF-1): Uniprot/SWISSPROT; Acc:P36402]
6935	NM_030751	Transcription factor 8 (NIL-2-A zinc finger protein) (the negativity conditioning agent of IL2). [source: Uniprot/SWISSPROT; Acc:P37275]	6932	NM_201633
6935	NM_030751		6938	NM_003205	Transcription factor 12 (transcription factor HTF-4) (E-box-conjugated protein) (the conjugated protein HTF4 of DNA-) .[source: Uniprot/SWISSPROT; Acc:Q99081]
6955	BC100294	TXi Baoshouti α locus	6938	NM_003205
6955	BC100294	TXi Baoshouti α locus	6957	K02885	T-cell receptors β locus
7006	NM_003215	The tec protein tyrosine kinase; TEC	6957	K02885	T-cell receptors β locus
7006	NM_003215	The tec protein tyrosine kinase; TEC	7031	NM_003225	The trefoil factor 1 (oestrogenic hormon-derivable sequence is expressed in mammary cancer); TFF1
7040	NM_000660	Transforming growth factor-beta-1 precursor (TGF-β-1) .[source: Uniprot/SWISSPROT; Acc:P01137]	7031	NM_003225
7040	NM_000660		7096	NM_003263	Toll-sample acceptor 1 precursor (Toll/ interleukin-1 receptor-sample albumen) is (CD281 antigen) .[source (TIL): Uniprot/SWISSPROT; Acc:Q15399]
7097	NM_003264	Toll-sample acceptor 2 precursors (Toll/ interleukin 1 receptor-sample albumen 4) (CD282 antigen) .[source: Uniprot/SWISSPROT; Acc:O60603]	7096	NM_003263
7097	NM_003264		7098	NM_003265	Toll-sample acceptor 3 precursors (CD283 antigen) .[source: Uniprot/SWISSPROT; Acc:O15455]
7099	NM_138554	Toll-sample acceptor 4 precursors (hToll) (CD284 antigen) .[source: Uniprot/SWISSPROT; Acc:O00206]	7098	NM_003265
7099	NM_138554		7100	NM_003268	Toll-sample acceptor 5 precursors (Toll/ interleukin-1 receptor-sample albumen 3). [source: Uniprot/SWISSPROT; Acc:O60602]
7124	NM_000594	Tumour necrosis factor precursor (TNF-α) (tumour necrosis factor part superfamily member 2) (TNF-a) (Cachectin) [comprises: tumour necrosis factor, membranous type; Tumour necrosis factor, solvable type] .[	7100	NM_003268

		Source: Uniprot/SWISSPROT; Acc:P01375]
		Source: Uniprot/SWISSPROT; Acc:P01375]	7130	NM_007115	Tumour necrosis factor-inducible protein TSG-6 precursor (gene 6 albumen that TNF-stimulates) (hyaluronic acid-conjugated protein) .[source: Uniprot/SWISSPROT; Acc:P98066]
7132	NM_001065	Tumor necrosis factor receptor super family member 1A precursor (p60) (TNF-R1) (TNF-RI) (TNFR-I) (p55) (CD120a antigen) [comprise: tumor necrosis factor receptor super family member 1A, membranous type; Tumour necrosis factor-conjugated protein 1 (TBPI)] the .[source	7130	NM_007115
7132	NM_001065		7133	NM_001066	Tumor necrosis factor receptor super family, member 1B; TNFRSF1B
7177	NM_003294	Tryptase β-1 precursor (EC3.4.21.59) (tryptase-1) (tryptase I) .[source: Uniprot/SWISSPROT; Acc:Q15661]	7133	NM_001066
7177	NM_003294		7187	AF110908	TNF-receptor associated factor-3 (TRAF-3)
7189	NM_145803	TNF acceptor-correlation factor 6 (agent of interleukin-11 conversion of signals) (ring finger protein 8 5) .[source: Uniprot/SWISSPROT; Acc:Q9Y4K3]	7187	AF110908	TNF-receptor associated factor-3 (TRAF-3)
7189	NM_145803		7273	NM_133379	Titin hypotype novex-3[source: RefSeq_peptide; Acc:NP_596870]
7292	NM_003326	Tumour necrosis factor part superfamily member 4 (OX40 part) is (glycoprotein GP34) (TAX transcribes-activate glycoprotein 1) (CD252 antigen) .[source (OX40L): Uniprot/SWISSPROT; Acc:P23510]	7273	NM_133379
7292	NM_003326		7293	NM_003327	Tumor necrosis factor receptor super family member 4 precursors (OX40L acceptor) (ACT35 antigen) (TAX transcribes-activate glycoprotein 1 acceptor) (CD134 antigen) .[source: Uniprot/SWISSPROT; Acc:P43489]
7294	NM_003328	The TXK Tyrosylprotein kinase; TXK	7293	NM_003327
7294	NM_003328	The TXK Tyrosylprotein kinase; TXK	7305	NM_198125；NM_00 3332	The TYRO protein tyrosine kinase is conjugated protein; TYROBP
7369	NM_003361	Uromodulin precursor (Tamm-Horsfall uropoiesis glycoprotein) is (THP). [source: Uniprot/SWISSPROT; Acc:P07911]	7305	NM_198125；NM_00 3332
7369	NM_003361		7409	NM_005428	The vav1 oncogene; VAV1
7410	NM_003371	The vav2 oncogene; VAV2	7409	NM_005428	The vav1 oncogene; VAV1
7410	NM_003371	The vav2 oncogene; VAV2	7422	NM_001025366	Vascular endothelial growth factor A precursor (VEGF-A) (the vascular permeability factor) is the .[source (VPF): Uniprot/SWISSPROT; Acc:P15692]
7433	NM_004624	Blood vessel intestines polypeptide receptor 1 precursor (VIP-R-1) (pituitary adenylate cyclase-activated polypeptides II receptor) (PACAP II receptor) is the .[source (PACAP-R-2): Uniprot/SWISSPROT; Acc:P32241]	7422	NM_001025366
7433	NM_004624		7441	NM_007128	Pre-B lymphocyte gene 1; VPREB1
7448	NM_000638	Vitronectin precursor (serum spreading factor) (S-albumen) (V75) [comprises: vitronectin V65 subunit; Vitronectin V10 subunit; SM-B] .[source: Uniprot/SWISSPROT; Acc:P04004]	7441	NM_007128	Pre-B lymphocyte gene 1; VPREB1
7448	NM_000638		7454	NM_000377	Wiskott-Ald enriches syndrome (eczema-thrombocytopenia); WAS

7462	NM_022040	Be used to activate T-cell family member 2 linking agent (non--T-cell activation linking agent) (linking agent that is used for the B-cell activation) (film-relevant adaptor molecule) (Williams-Beuren syndrome critical zone 15 albumen) .[source: Uniprot/SWISSPROT; Acc:Q9GZY6]
7462	NM_022040		7494	NM_005080	X box binding protein 1 (XBP-1) (Tax-reactive element-conjugated protein 5) .[source: Uniprot/SWISSPROT; Acc:P17861]
7525	NM_005433	V-yes-1Yamaguchi sarcoma virus oncogene homologue 1; YES1	7494	NM_005080
7525	NM_005433	V-yes-1Yamaguchi sarcoma virus oncogene homologue 1; YES1	7528	NM_003403	Transcription repression protein Y Y1 (Yin and yang1) is (Δ transcription factor) (NF-E1) .[source: Uniprot/SWISSPROT (YY-1); Acc:P25490]
7535	NM_001079；NM_20 7519	Zeta-chain (TCR) related protein kinase 70kDa; ZAP70	7528	NM_003403
7535	NM_001079；NM_20 7519	Zeta-chain (TCR) related protein kinase 70kDa; ZAP70	7538	NM_003407	Tristetra proline(Pro) (TTP) (zinc finger protein 36 homologue) is (TIS11A albumen) (TIS11) (somatomedin-derivable nucleoprotein NUP475) (G0/G1 switch regulate protein 24) .[source: Uniprot/SWISSPROT (Zfp-36); Acc:P26651]
7551	NM_032924	Zinc finger protein 38 (zinc finger protein KOX25) (zinc finger protein HF.12) (zinc finger protein 3) (HZF3.1 albumen) .[source: Uniprot/SWISSPROT; Acc:P17036]	7538	NM_003407
7551	NM_032924		7707	NM_021964	Zinc finger protein 14 8 (zinc finger dna conjugated protein 89) (transcription factor ZBP-89) .[source: Uniprot/SWISSPROT; Acc:Q9UQR1]
7716	NM_007146	Zinc finger protein 16 1 (putative transcription factor DB1) .[source: Uniprot/SWISSPROT; Acc:Q14119]	7707	NM_021964
7716	NM_007146		7732	NM_007148	Zinc finger protein 17 9 (brain finger protein) (ring finger protein 112) .[source: Uniprot/SWISSPROT; Acc:Q9ULX5]
7791	NM_001010972	Zyxin(ZYX)	7732	NM_007148
7791	NM_001010972	Zyxin(ZYX)	7837		PXDN albumen (fragment) .[source: Uniprot/SPTREMBL; Acc:Q4KMG2]
7850	NM_173343	Interleukin-1 receptor II type precursor (IL-1R-2) (IL-1R-β) (antigens c D121b) (antigens c Dw121b) .[source: Uniprot/SWISSPROT; Acc:P27930]	7837
7850	NM_173343		7852	NM_001008540	C-X-C Chemokine Receptors type 4 (CXC-R4) is (factor 1 acceptor in mesenchymal cell-source) (SDF-1 acceptor) (Fusin) (the seven-transmembrane domain receptor in white corpuscle-source) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD184 antigen) .[source: Uniprot/SWISSPROT (CXCR-4); Ac
7940	NM_007161	White corpuscle-specific transcriptional thing 1 albumen (B144 albumen) .[source: Uniprot/SWISSPROT; Acc:O00453]	7852	NM_001008540
7940	NM_007161		7941	NM_005084	Thrombocyte-activation factor PAF-AH precursor (EC 3.1.1.47) (PAF PAF-AH) (PAF2-Acyl-hydrolase) (LDL-be correlated with Phospholipase A2) (LDL-PLA (2)) (2-ethanoyl-1-alkylglycerophosphocholine esterase) (1-alkyl-2-acetylglycerophosphocholine esterase)

8061	NM_005438	Fos-related antigen 1 (FRA-1) .[source: Uniprot/SWISSPROT; Acc:P15407]
8061	NM_005438		8111	NM_003485	Sphingosylphosphocholine acceptor (ovarian cancer G-protein linked receptor 1) is (G-protein linked receptor 68) (GPR12A) .[source: Uniprot/SWISSPROT (OGR-1); Acc:Q15743]
8174	NM_130761	Mucous membrane addressin cell adhesion molecule 1 precursor (MAdCAM-1) is the .[source (hMAdCAM-1): Uniprot/SWISSPROT; Acc:Q13477]	8111	NM_003485
8174	NM_130761		8227	NM_005088	B-lymphocyte antigen precursor (B-lymphocyte surface antigen) is (albumin X E7) .[source (721P): Uniprot/SWISSPROT; Acc:Q02040]
8302	NM_013431	Killer cell lectin-sample acceptor subfamily C, the member 4; KLRC4	8227	NM_005088
8302	NM_013431		8440	NM_001004720；NM _003581；NM_001004722	NCK joint albumen 2; NCK2
8455	NM_139321	Attract (DPPT-L) .[source: Uniprot/SWISSPROT of plain precursor (Mahogany homologue); Acc:O75882]	8440	NM_001004720；NM _003581；NM_001004722	NCK joint albumen 2; NCK2
8455	NM_139321		8460	NM_003596	Albumen-tyrosine sulfotransferase 1 (EC 2.8.2.20) (tyrosyl albumen sulfotransferase-1) is the .[source (TPST-1): Uniprot/SWISSPROT; Acc:O60507]
8477	NM_003608	Psychosine acceptor (G-protein linked receptor 65) (T cell-dead associated protein 8) .[source: Uniprot/SWISSPROT; Acc:Q8IYL9]	8460	NM_003596
8477	NM_003608		8482	NM_003612	Semaphorin-7A precursor (Semaphorin L) (Sema L) (Semaphorin K1) (Sema K1) (John-Milton-Hargen human blood group Ag) (JMH blood group antigen) (CD108 antigen) is the .[source (CDw108): Uniprot/SWISSPROT; Acc:O75326]
8517	NM_003639	The basic conditioning agent of NF-κ-B (NEMO) (the basic conditioning agent of NF-κ-B) (inhibitor of nf κ-B kinases γ subunit) (IkB kinases γ subunit) (I-κ-B kinases γ) (IKK-γ) is (IkB kinases-associated protein 1) (IKKAP1) (FIP-3) .[So (IKKG)	8482	NM_003612
8517	NM_003639		8518	NM_003640	I kappa b kinase complex body-associated protein (IKK complex body-associated protein) is the .[source (p150): Uniprot/SWISSPROT; Acc:O95163]
8519	NM_003641	Interferon, rabbit-inductive transmembrane protein 1 (Interferon, rabbit-inductive protein 17) (Interferon, rabbit-inducible protein 9-27) (Leu-13 antigen) (CD225 antigen) .[source: Uniprot/SWISSPROT; Acc:P13164]	8518	NM_003640
8519	NM_003641		8527	NM_152879	The triglyceride kinases, δ (EC 2.7.1.107) (triglyceride kinases) (DGK-δ) (DAG kinase delta) (130kDa triglyceride kinases) .[source: Uniprot/SWISSPROT; Acc:Q16760]
8530	NM_003650	Cystatin F precursor (Leukocystatin) (cystatin-7) (cystatin-sample transfer-associated protein) is the .[source (CMAP): Uniprot/SWISSPROT; Acc:O76096]	8527	NM_152879
8530	NM_003650		8534	NM_003654	Carbohydrate sulfotransferase 1 (EC 2.8.2.21) (keratan sulfate Gal-6 sulfotransferase) is (KSGal6ST) (KS6ST) (semi-lactosi/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 1) (GST-1) .[source (KSST):

		Uniprot/SWISSPROT；Acc:O43916]
		Uniprot/SWISSPROT；Acc:O43916]	8546	NM_003664	Joint-associated protein complex body 3 β 1 subunit (B3A-joint albumen) (joint protein complexes AP-3 β-1 subunit) (AP-3 complex body β-1 subunit) (the big chain of clathrin assembly protein complex body 3 β-1) [source: Uniprot/SWISSPROT; Acc:O00203]
8547	NM_173452；NM_00 3665	Ficolin (collagen/scleroproein prodomain comprises) 3 (Hakata antigens); FCN3	8546	NM_003664
8547	NM_173452；NM_00 3665		8575	NM_003690	Protein kinase, Interferon, rabbit-derivable double-stranded RNA dependency activator; PRKRA
8600	NM_003701	Tumour necrosis factor part superfamily member 11 (receptor activator of nf κ B part) is (TNF-be correlated with activation-inductive cytokine) (TRANCE) (osteoprotegerin part) (OPGL) (osteoclast differentiation factor) (ODF) (CD254 antigen) (RANKL)	8575	NM_003690
8600	NM_003701		8605	NM_003706	Cytosol Phospholipase A2 γ (EC 3.1.1.4) (cPLA2-γ) (Phospholipase A2 group IVC) .[source: Uniprot/SWISSPROT; Acc:Q9UP65]
8625	NM_003721	The conjugated protein RFXANK of DNA-(the regulatory factor X B of subunit) is (ankyrin repeats the A of family albumen 1) .[source (RFX-B): Uniprot/SWISSPROT; Acc:O14593]	8605	NM_003706
8625	NM_003721		8631	NM_003726	Src family relevant phosphorprotein 1[source: RefSeq_peptide; Acc:NP_003717]
8638	NM_003733；NM_19 8213	2 '-5 '-oligoadenylate synthetase-sample; OASL	8631	NM_003726
8638	NM_003733；NM_19 8213	2 '-5 '-oligoadenylate synthetase-sample; OASL	8639	NM_003734	Film copper amine oxidase (EC 1.4.3.6) (Urea,amino--responsive amine oxidase) is (blood vessel attachment proteins 1) (VAP-1) (HPAO) .[source: Uniprot/SWISSPROT (SSAO); Acc:Q16853]
8678	NM_003766	Beclin-1 (curling-myosin-sample BCL2-interaction protein curls) (Protein G T197) .[source: Uniprot/SWISSPROT; Acc:Q14457]	8639	NM_003734
8678	NM_003766		8681	NM_005090	Phospholipase A2, group IVB[source: RefSeq_peptide; Acc:NP_005081]
8698	NM_003775	Sphingosine 1-phosphate acceptors Edg-6 (S1P acceptor Edg-6) (endothelium differentiation G-protein linked receptor 6) (sphingosine 1-phosphate acceptors 4) is .[source: Uniprot/SWISSPROT (S1P4); Acc:O95977]	8681	NM_005090
8698	NM_003775		8712	NM_003785	G antigen family B1 albumen (Prostato-genes involved albumen 1) is (GAGE-9) (AL5) .[source: Uniprot/SWISSPROT (PAGE-1); Acc:O75459]
8718	NM_148972	(Apo-3) (lymphocyte is relevant for tumor necrosis factor receptor super family member 25 precursors (WSL-1 albumen) (apoptosis-mediation acceptor DR3) (apoptosis-mediation acceptor TRAMP) (death domain receptor 3) (WSL albumen) (apoptosis-induce acceptor AIR)	8712	NM_003785

8740	NM_003807	Tumour necrosis factor part superfamily member 14 (simplexvirus enters amboceptor-part) (HVEM-L) (CD258 antigen) [comprises: tumour necrosis factor part superfamily member 14, membranous type; Tumour necrosis factor part superfamily member 14, solvable type]
8740	NM_003807		8741	NM_172088	Tumour necrosis factor part superfamily member 13 precursors (propagation-inducing ligand) are (TNF-relevant white corpuscle express with APOL-part 2) (TALL-2) (TNF-associated death part-1) (TRDL-1) (CD256 antigen) .[source: Uniprot/SWISSPROT (APRIL); Acc:O75888
8742	NM_003809	Tumour necrosis factor part superfamily member 13 precursors (propagation-inducing ligand) are (TNF-relevant white corpuscle express with APOL-part 2) (TALL-2) (TNF-related apoptosis ligand-1) (TRDL-1) (CD256 antigen) .[source: Uniprot/SWISSPROT (APRIL); Acc:O75888	8741	NM_172088
8742	NM_003809		8743	NM_003810	Tumour necrosis factor part superfamily member 10 (TNF-related apoptosis-inducing ligand) (trail protein) (Apo-2 part) is (CD253 antigen) .[source (Apo-2L): Uniprot/SWISSPROT; Acc:P50591]
8744	NM_003811	Tumour necrosis factor part superfamily member 9 (4-1BB part) (4-1BBL) .[source: Uniprot/SWISSPROT; Acc:P41273]	8743	NM_003810
8744	NM_003811		8764	NM_003820	Tumor necrosis factor receptor super family member 14 precursors (simplexvirus enters amboceptor A) (Tumor Necrosis Factor Receptors-sample 2) are the .[source (TR2): Uniprot/SWISSPROT; Acc:Q92956]
8767	NM_003821	(RIP-2) (CARD-comprises il-1 β-saccharase-associated kinase) (CARD-comprises IL-1 β ICE-kina to acceptor-interaction serine/threonine-protein kinase 2 (EC 2.7.1.37) (RIP-sample interaction CLARP kinases) (acceptor-interaction protein 2)	8764	NM_003820
8767	NM_003821		8772	NM_003824	FADD albumen (FAS-associated death domain-comprise albumen) (the toxic medium of receptor-inducible) .[source: Uniprot/SWISSPROT; Acc:Q13158]
8778	NM_003830	Sialic acid is in conjunction with Ig-sample lectin 5; SIGLEC5	8772	NM_003824
8778	NM_003830		8792	NM_003839	Tumor necrosis factor receptor super family member 11A precursor (receptor activator of NF-KB) (osteoclast differentiation factor receptors) is (CD265 antigen) .[source (ODFR): Uniprot/SWISSPROT; Acc:Q9Y6Q6]
8807	NM_003853	Il-1 8 acceptor accessory protein precursors (IL-18 acceptor accessory protein) are (il-1 8 acceptor accessory protein-samples) (IL-18R β) (IL-1R accessory protein sample) (IL-1RAcPL) (accessory protein-sample) (AcPL) (IL-1R7) (CDw218b a (IL-18RAcP)	8792	NM_003839
8807	NM_003853		8808	NM_003854	Interleukin-1 receptor-sample 2 precursors (IL-1Rrp2) (interleukin-1 receptor-associated protein 2) are the .[source (IL1R-rp2): Uniprot/SWISSPROT; Acc:Q9HB29]
8809	NM_003855	Il-1 8 acceptors 1 precursors (IL1 acceptor-associated protein) are (CDw218a antigen) .[source (IL-1Rrp): Uniprot/SWISSPROT; Acc:Q13478]	8808	NM_003854
8809	NM_003855		8832	NM_003874	CD84 antigen (human leucocyte antigen); CD84
8835	NM_003877	The inhibitor of cytokine signaling 2 (SOCS2)	8832	NM_003874	CD84 antigen (human leucocyte antigen); CD84

8841	NM_003883	Histone deacetylase enzyme 3 (HDAC3)
8841	NM_003883	Histone deacetylase enzyme 3 (HDAC3)	8862	NM_017413	Apelin precursor (APJ endogenous ligands) [comprises: Apelin-36; Apelin-31; Apelin-28; Apelin-13] .[source: Uniprot/SWISSPROT; Acc:Q9ULZ1]
8878	NM_003900	Sequestosome-1 (phosphorylated tyrosine-dependent/non-dependent part, be used for the LckSH2 structural domain, 62kDa) (ubiquitin-conjugated protein p62) (EBI3-associated protein, 60kDa) (p60) (EBIAP) .[source: Uniprot/SWISSPROT; Acc:Q13501]	8862	NM_017413
8878	NM_003900		8915		B cell lymphoma/leukemia 10 (B-cell CLL/ lymphoma 10) (Bcl-10) (CED-3/ICH-1 prodomain homologue ous E10-sample conditioning agent) (CIPER) (CARD-comprises molecule and strengthens NF κ B) (the cell homologue of vCARMEN) (cCARMEN) (Mammals CARD-comprises linkers
8976	NM_003941	Wiskott-Ald syndrome-sample; WASL	8915
8976	NM_003941	Wiskott-Ald syndrome-sample; WASL	8991	NM_003944	Selenium conjugated protein 1; SELENBP1
8993	NM_005091	Peptidoglycan recognition protein 1; PGLYRP1	8991	NM_003944	Selenium conjugated protein 1; SELENBP1
8993	NM_005091	Peptidoglycan recognition protein 1; PGLYRP1	8995	NM_005092	Tumour necrosis factor part superfamily member 18 (glucocorticosteroid-inductive TNF-associated ligands) is (activation-derivable TNF-associated ligands) (AITRL) .[source: Uniprot/SWISSPROT (hGITRL); Acc:Q9UNG2]
9103	NM_001005411；NM _201563；NM_001005410；NM_001005412	The Fc fragment of IgG, low affinity IIc, acceptor is used for (CD32); FCGR2C	8995	NM_005092
9103	NM_001005411；NM _201563；NM_001005410；NM_001005412		9111	NM_004688	N-myc-interaction agent (Nmi) (N-myc and STAT interaction agent) .[source: Uniprot/SWISSPROT; Acc:Q13287]
9173	NM_016232	Interleukin-1 receptor-sample 1 precursor (ST2 albumen) .[source: Uniprot/SWISSPROT; Acc:Q01638]	9111	NM_004688
9173	NM_016232		9214	NM_005449	The Fas apoptosis suppresses molecule 3[source: RefSeq_peptide; Acc:NP_005440]
9235	NM_001012631	Interleukin-13 2 (IL32)	9214	NM_005449
9235	NM_001012631	Interleukin-13 2 (IL32)	9240	NM_006029	Secondary tumour antigen MA1; PNMA1
9244	NM_004750	Cytokine receptor-like factor 1 precursor (cytokine-like factor 1) is (ZcytoR5) .[source (CLF-1): Uniprot/SWISSPROT; Acc:O75462]	9240	NM_006029	Secondary tumour antigen MA1; PNMA1
9244	NM_004750		9255		Many synthetic enzyme complex body ancillary component p43[comprises: endothelial mononuclear cell-activated polypeptides II (EMAP-II) (I inductive cytokine subfamily E member 1)] .[source: Uniprot/SWISSPROT; Acc:Q12904]
9308	NM_004233	CD83 antigen precursor (cell surface protein HB15) (B-cell activating protein) .[source: Uniprot/SWISSPROT; Acc:Q01151]	9255
9308	NM_004233		9332	NM_004244	CD163 antigenic subtype a[source: RefSeq_peptide; Acc:NP_004235]
9373	NM_001031689	Phospholipase A-2-activated protein (PLAP) is the .[source (PLA2P): Uniprot/SWISSPROT; Acc:Q9Y263]	9332	NM_004244
9373	NM_001031689		9398	NM_004258	Immunoglobulin superfamily, member 2[source: RefSeq_peptide; Acc:NP_004249]

9402	NM_004810	GRB2-associated adapter albumen 2; GRAP2
9402	NM_004810	GRB2-associated adapter albumen 2; GRAP2	9435	NM_004267	Carbohydrate sulfotransferase 2 (EC 2.8.2.-) (N-acetylglucosamine 6-O-sulfotransferase 1) (GlcNAc6ST-1) (Gn6ST) (semi-lactosi/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 2) is the .[source (GST-2): Uniprot/SWISSPROT; Acc:Q9Y4C5]
9436	NM_004828	Natural cytotoxicity triggers acceptor 2 precursors (natural killer cell p44-associated protein) (NKp44) (NK-p44) (NK cell-activated receptor) (lymphocyte antigen 95 homologues) (CD336 antigen) .[source: Uniprot/SWISSPROT; Acc:O95944]	9435	NM_004267
9436	NM_004828		9437	NM_004829	Natural cytotoxicity triggers acceptor 1; NCR1
9447	NM_004833	Interferon, rabbit-inducible protein AIM2 (lacking in the melanoma 2) .[source: Uniprot/SWISSPROT; Acc:O14862]	9437	NM_004829	Natural cytotoxicity triggers acceptor 1; NCR1
9447	NM_004833		9450	NM_004271	Woods crust cell antigen 86 precursors (MD-1 albumen) .[source: Uniprot/SWISSPROT; Acc:O95711]
9466	NM_004843	Interleukin-22 7 acceptors, α; IL27RA	9450	NM_004271
9466	NM_004843	Interleukin-22 7 acceptors, α; IL27RA	9536	NM_004878	Prostaglandin E synthase (EC 5.3.99.3) (microsome glutathione S-transferring enzyme 1-sample 1) is (p53-inductive apoptotic proteins 12) .[source (MGST1-L1): Uniprot/SWISSPROT; Acc:O14684]
9547	NM_004887	I inductive cytokine B14 precursor (CXCL14) (chemokine BRAK) .[source: Uniprot/SWISSPROT; Acc:O95715]	9536	NM_004878
9547	NM_004887		9560	NM_001001435	Chemokine (C-C motif) part 4-sample 2 precursors [source: RefSeq_peptide; Acc:NP_996890]
9567	NM_004286	Conjugated protein 1 (the G-albumen 1) of GTP-is (GP1) .[source (GP-1): Uniprot/SWISSPROT; Acc:O00178]	9560	NM_001001435
9567	NM_004286		9636	NM_005101	Interferon, rabbit-inductive 17kDa amyloid protein precursor [comprising: ubiquitin cross-reacting protein (Interferon, rabbit-inductive 15kDa albumen)] .[source: Uniprot/SWISSPROT; Acc:P05161]
9641	NM_014002	The inhibitor (EC 2.7.1.-) of nf κ-B kinases ε subunit (I κ-B kinases ε) is (IKK-ε) (IKK-E) (derivable I κ-B kinases) (IKK-i) .[source: Uniprot/SWISSPROT (IkBKE); Acc:Q14164]	9636	NM_005101
9641	NM_014002		9655	NM_014011	The derivable SH2-of cytokine comprises (SOCS-5) (cytokine-derivable SH2 albumen 6) (CIS-6) .[source: Uniprot/SWISSPROT of albumen 5 (inhibitor of cytokine signaling 5); Acc:O75159]
9682	NM_014663	The Jumonji structural domain comprises 2A (JMJD2A)	9655	NM_014011
9682	NM_014663	The Jumonji structural domain comprises 2A (JMJD2A)	9734	NM_178423	Histone deacetylase enzyme 9 (HD9) is (HD7) .[source (HD7B): Uniprot/SWISSPROT; Acc:Q9UKV0]
9759	NM_006037	Histone deacetylase enzyme 4 (HD4) .[source: Uniprot/SWISSPROT; Acc:P56524]	9734	NM_178423
9759	NM_006037		9966	NM_005118	Tumour necrosis factor (part) superfamily, member 15[source: RefSeq_peptide; Acc:NP_005109]
9976	NM_005127	C type lectin structural domain family 2, member B; CLEC2B	9966	NM_005118
9976	NM_005127	C type lectin structural domain family 2, member B; CLEC2B	10000	NM_181690；NM_00 5465	V-akt mouse thymoma viral oncogene homologue 3 (protein kinase B, γ); AKT3

10005	NM_005469	Peroxidase acetyl-CoA thioesterase lytic enzyme 1 (EC 3.1.2.2) (peroxidase length-chain acetyl-coA thioesterase 1) (Acyl-CoA thioesterase 8) (HIV-Nef be correlated with acetyl coA thioesterase) (thioesterase II) is (hACTEIII) (hACTE-III) (PTE-2) .[source: Uniprot/SW (hTE)
10005	NM_005469		10014	NM_001015053	Histone deacetylase enzyme 5 (HD5) (antigen NY-CO-9) .[source: Uniprot/SWISSPROT; Acc:Q9UQL6]
10068		The conjugated protein precursor of il-1 8-(IL-18BP) (Tadekinig-α). [source: Uniprot/SWISSPROT; Acc:O95998]	10014	NM_001015053
10068			10087	NM_005713	Goodpasture antigen-binding proteins (EC 2.7.1.37) is (StARD11) (START structural domain-comprise protein 11) .[source: Uniprot/SWISSPROT of (collagen-type IV α 3 is conjugated protein) (StAR-be correlated with lipid transfer protein 11) (GPBP); Acc:Q9Y5P4]
10134	NM_005745	B-cell receptor-related protein 31 (BCR-associated protein Bap31) is (DXS1357E) .[source: Uniprot/SWISSPROT of (CDM albumen) (6C6-AG tumour-related antigen) (p28Bap31); Acc:P51572]	10087	NM_005713
10134	NM_005745		10148	NM_005755	Interleukin-2 7 β chain precursors (IL-27B) (Epstein-Barr virus-inductive gene 3 albumen) (EBV-inductive gene 3 albumen) .[source: Uniprot/SWISSPROT; Acc:Q14213]
10164	NM_005769	Carbohydrate sulfotransferase 4 (EC 2.8.2.-) (N-acetylglucosamine 6-O-sulfotransferase 2) is (high endotheliocyte N-acetylglucosamine 6-O-sulfotransferase) (HEC-GlcNAc6ST) (L-select protein ligands sulfotransferase) (LSST) (semi-lactosi/N-acetyl-glucosamine base (acetylgluc) (GlcNAc6ST-2)	10148	NM_005755
10164	NM_005769		10175	NM_001009551	Cornichon homologue (TGAM77) .[source: Uniprot/SWISSPROT; Acc:O95406]
10178	NM_014253	Odz, oddOz/ten-m homologue 1[source: RefSeq_peptide; Acc:NP_055068]	10175	NM_001009551
10178	NM_014253		10219	NM_005810	Killer cell lectin-sample acceptor subfamily G, the member 1; KLRG1
10225	NM_005816；NM_19 8196	CD96 antigen; CD96	10219	NM_005810
10225	NM_005816；NM_19 8196	CD96 antigen; CD96	10261	NM_005849	Immunoglobulin superfamily, member 6[source: RefSeq_peptide; Acc:NP_005840]
10288	NM_005874	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily B (with TM and [TIM structural domain), the member 2; LILRB2	10261	NM_005849
10288	NM_005874		10298	NM_001014832；NM _001014835；NM_001014833；NM_001014831；NM_005884；NM_001014834	P21 (CDKN1A)-activated protein kinase 4; PAK4
10312	NM_006053	The cavity proton transposition ATP enzyme 116kDa a of subunit hypotype 3 (V-ATP enzyme 116-kDa hypotype a3) (osteoclast proton pump 116kDa subunit) (OC-116kDa) (OC116) (T-cell immunomodulator 1) (T cell immune response cDNA7 albumen) is the .[source (TIRC7): Uniprot/SWI	10298		P21 (CDKN1A)-activated protein kinase 4; PAK4
10312	NM_006053		10318	NM_006058	TNFAIP3 interaction protein 1 (TNIP1)

10321	NM_006061	Halfcystine-enrich secretory protein 3 precursors (CRISP-3) (SGP28 albumen) .[to originate: Uniprot/SWISSPROT; Acc:P54108]
10321	NM_006061		10332	NM_214679	CD209 antigen-sample albumen 1 (dendritic cell-specificity ICAM-3-grasps non-integrin 2) is (DC-SIGN-associated protein) (DC-SIGNR) (glycosides/lymphoglandula-specificity ICAM-3-grasps non-integrin) (L-SIGN) .[source: Uniprot/SWISSPROT (DC-SIGN2); Acc:Q9H2X3]
10333	NM_006068	Toll sample acceptor 6 precursor .[source: Uniprot/SWISSPROT; Acc:Q9Y2C9]	10332	NM_214679
10333	NM_006068		10344	NM_006072	I inductive cytokine A26 precursor (CCL26) is (TSC-1) (CC chemokine IMAC) .[source: Uniprot/SWISSPROT of (macrophage inflammatory protein 4-α) (MIP-4-α) (matter chemokine-1 between thymus gland) (Eotaxin-3); Acc:Q9Y258]
10379	NM_006084	Transcriptional regulatory agent ISGF3 γ subunit (interferon regulatory factor 9) is (IFN-α-reaction transcription factor subunit) (Interferon, rabbit-stimulated gene factor 3 γ) (ISGF3 p48 subunit) (ISGF-3 γ) .[source (IRF-9): Uniprot/SWISSPROT; Acc:Q0097	10344	NM_006072
10379	NM_006084		10394	NM_006093	Proteoglycan 3; PRG3
10410	NM_021034	Interferon, rabbit-inductive transmembrane protein 3 (Interferon, rabbit-inducible protein 1-8U) .[source: Uniprot/SWISSPROT; Acc:Q01628]	10394	NM_006093	Proteoglycan 3; PRG3
10410	NM_021034		10417	NM_012445	Spondin-2 precursor (Mindin) (difference is expressed in cancer and non-cancer pneumonocyte 1) is .[source: Uniprot/SWISSPROT (DIL-1); Acc:Q9BUD6]
10421	NM_006110	CD2 cell antigen matter tail-conjugated protein 2 (CD2 tenuigenin structural domain is conjugated protein) (CD2 caudal knot hop protein) .[source: Uniprot/SWISSPROT; Acc:O95400]	10417	NM_012445
10421	NM_006110		10435	NM_006779	CDC42 effector albumen (combination of Rho GTP enzyme) 2 (CDC42EP2)
10437	NM_006332	The derivable lysosome mercaptan of gamma-interferon reductase enzyme precursor (gamma-interferon-inducible protein IP-30) .[source: Uniprot/SWISSPROT; Acc:P13284]	10435	NM_006779
10437	NM_006332		10451	NM_006113	The vav3 oncogene; VAV3
10462	NM_182906	The C-type lectin structural domain 10 member A of family (C-type lectin, superfamily member 14) (macrophage lectin element 2) (CD301 antigen) .[source: Uniprot/SWISSPROT; Acc:Q8IUN9]	10451	NM_006113	The vav3 oncogene; VAV3
10462	NM_182906		10507	NM_006378	Semaphorin-4D precursor (leukocyte activation antigens c D100) is (A8) (GR3) .[source: Uniprot/SWISSPROT (BB18); Acc:Q92854]
10512	NM_006379	Semaphorin-3C precursor (Semaphorin E) (Sema E) .[source: Uniprot/SWISSPROT; Acc:Q99985]	10507	NM_006378
10512	NM_006379		10537	NM_006398	γ-An Jidingsuan Type B acceptor, subunit's 1 precursor (GABA-B acceptor 1) be (Gb1) .[source (GABA-B-R1): Uniprot/SWISSPROT; Acc:Q9UBS5]
10538	NM_006399	ATF-sample alkalescence leucine zipper transcription factor B-ATF (SF-HT-activating gene 2) is the .[source (SFA-2):	10537	NM_006398

		Uniprot/SWISSPROT；Acc:Q16520]
		Uniprot/SWISSPROT；Acc:Q16520]	10544	NM_006404	Endothelium PROTEIN C acceptor precursor (endothelial cell protein C acceptor) (activated protein C acceptor) (APC acceptor) (CD201 antigen) .[source: Uniprot/SWISSPROT; Acc:Q9UNN8]
10563	NM_006419	I inductive cytokine B13 precursor (CXCL13) (bone-marrow-derived lymphocyte chemotactic) (CXC chemokine BLC) (the plain g chemokine 1 of B cell-attraction) is (ANGIE) .[source (BCA-1): Uniprot/SWISSPROT; Acc:O43927]	10544	NM_006404
10563	NM_006419		10578	NM_006433；NM_012483	Particle cytolysin; GNLY
10581	NM_006435	Interferon, rabbit-inductive transmembrane protein 2 (Interferon, rabbit-inducible protein 1-8D) .[source: Uniprot/SWISSPROT; Acc:Q01629]	10578	NM_006433；NM_012483	Particle cytolysin; GNLY
10581	NM_006435		10584	NM_006438	Col lectin Asia-family member 10 (C type lectin); COLEC10
10602	NM_006449	CDC42 effector albumen (combination of Rho GTP enzyme) 3 (CDC42EP3)	10584	NM_006438	Col lectin Asia-family member 10 (C type lectin); COLEC10
10602	NM_006449		10666	NM_006566	CD226 antigen precursor (DNAX accessory molecule 1) is (DNAM-1). [source: Uniprot/SWISSPROT; Acc:Q15762]
10673	NM_006573	Tumour necrosis factor part superfamily member 13B (TNF-relevant white corpuscle express with APOL-ligand 1) (TALL-1) (bone-marrow-derived lymphocyte stimulant) (BLyS) (B cell-activation factor) (BAFF) (the TNF-sample molecule in dendritic cell-source) (CD257 antigen) [comprise: Tum	10666	NM_006566
10673	NM_006573		10687	NM_007257	Secondary tumour antigen MA2; PNMA2
10746	NM_006609	Mitogen-activated protein three kinases 2; MAP3K2	10687	NM_007257	Secondary tumour antigen MA2; PNMA2
10746	NM_006609	Mitogen-activated protein three kinases 2; MAP3K2	10747	NM_006610	Lectin serine protease 2 precursors (EC 3.4.21.104) of mannan-binding (in conjunction with the relevant serine protease 2 of the albumen of seminose) (MASP-2) (MBL-be correlated with serine protease 2) [comprise: the lectin serine protease 2A chain of mannan-binding; The lectin Serine of mannan-binding
10748	NM_006611	Killer cell lectin-sample acceptor subfamily A, member 1[source: RefSeq_peptide; Acc:NP_006602]	10747	NM_006610
10748	NM_006611		10750	NM_006613	GRB2-associated adapter albumen; GRAP
10758	NM_147200	Joint PROTEIN C IKS (being connected to IKK and SAPK/JNK) (TRAF3-interaction protein 2) (nf NF-κ-B activator 1) is the .[source (ACT1): Uniprot/SWISSPROT; Acc:O43734]	10750	NM_006613	GRB2-associated adapter albumen; GRAP
10758	NM_147200		10803	NM_031200	C-C Chemokine Receptors type 9 (C-C CKR-9) is (CCR-9) (GPR-9-6) (G-protein linked receptor 28) (CDw199 antigen) .[source: Uniprot/SWISSPROT (CC-CKR-9); Acc:P51686]
10849	NM_012099	CD3E antigen, ε polypeptide associated protein [source: RefSeq_peptide; Acc:NP_036231]	10803	NM_031200
10849	NM_012099		10850	NM_006664	I inductive cytokine A27 precursor (CCL27) (CC chemokine ILC) (IL-11R-α-locus chemokine) (Skinkine) (ESkine) (the plain chemokine of Cuteaneous T-cytotaxis) is .[source: Uniprot/SWISSPROT (CTACK); Acc:Q9Y4X3]

10855	NM_006665	Heparan enzyme precursor (EC 3.2.-.-) (heparitinase-1) (Hpal) (inscribe glycuronidase (Endo-glucoronidase)) [comprises: heparitinase 8kDa subunit; Heparitinase 50kDa subunit] .[source: Uniprot/SWISSPROT; Acc:Q9Y251]
10855	NM_006665		10859	NM_006669	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily B (with TM and ITIM structural domain), the member 1; LILRB1
10871	NM_006678	CD300C antigen; CD300C	10859	NM_006669
10871	NM_006678	CD300C antigen; CD300C	10877	NM_006684	Complement factor H-relevant 4; CFHL4
10878	NM_021023	Complement factor H-relevant 3; CFHL3	10877	NM_006684	Complement factor H-relevant 4; CFHL4
10878	NM_021023	Complement factor H-relevant 3; CFHL3	10882	NM_006688	Complement component	1, q subcomponent-sample 1; C1QL1
10912	NM_006705	Growth stops and DNA-infringement-inducible protein GADD45 γ (cytokine-reactive protein CR6) .[source: Uniprot/SWISSPROT; Acc:O95257]	10882	NM_006688	Complement component	1, q subcomponent-sample 1; C1QL1
10912	NM_006705		10964	NM_006820	Histocompatibility 28[source: RefSeq_peptide; Acc:NP_006811]
10982	NM_014268	Microtubule-associated protein RP/EB family member 2 (the conjugated protein EB2 of APC-) (End-conjugated protein 2) is the .[source (EB2): Uniprot/SWISSPROT; Acc:Q15555]	10964	NM_006820
10982	NM_014268		10990	NM_006840	Leukocytic immunity sphaeroprotein-sample acceptor, and subfamily B (with TM and [the TIM structural domain), the member 5; LILRB5
11006	NM_006847	Leukocytic immunity sphaeroprotein-sample acceptor subfamily B member 4 precursors (leukocytic immunity sphaeroprotein-sample acceptor 5) are (immunoglobulin (Ig)-sample transcript 3) (ILT-3) (monocyte suppress acceptor HM18) (CD85k antigen) .[source: Uniprot/SWISSPROT (LIR-5); Acc:Q8NHJ6]	10990	NM_006840
11006	NM_006847		11009	NM_006850	Interleukin-24 precursor (tumorigenicity 16 proteic inhibition) (melanoma differentiation-genes involved 7 albumen) is the .[source (MDA-7): Uniprot/SWISSPROT; Acc:Q13007]
11024	NM_006863	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily A (having the TM structural domain), the member 1; LILRA1	11009	NM_006850
11024	NM_006863		11025	NM_006864	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily B (having TM and ITIM structural domain), the member 3; LILRB3
11026	NM_006865	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily A (not having the TM structural domain), the member 3; LILRA3	11025	NM_006864
11026	NM_006865		11027	NM_006866	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily A (having the TM structural domain), the member 2; LILRA2
11059		NEDD4-sample E3 uiquitin-protease ligase enzyme WWP1 (EC 6.3.2.-) (comprising WW domain protein 1) (coromegine-1 interaction protein 5) is the .[source (AIP5): Uniprot/SWISSPROT; Acc:Q9H0M0]	11027	NM_006866
11059			11126	NM_007053	CD160 antigen precursor (natural killer cell acceptor BY55) .[source: Uniprot/SWISSPROT; Acc:O95971]
11146	NM_053274	Glomulin (FKBP-associated protein) (FK506-conjugated protein-associated protein) is the .[source (FAP): Uniprot/SWISSPROT; Acc:Q92990]	11126	NM_007053

11251	NM_004778	Suppose G-protein linked receptor 44 (chemoattractant receptor of on the Th2 cell, expressing-homologue molecule) (CD294 antigen) .[source: Uniprot/SWISSPROT; Acc:Q9Y5Y4]
11251	NM_004778		11311	NM_007259	Cavity albumen classification-associated protein 45 (h-VPS45) is the .[source (hlVps45): Uniprot/SWISSPROT; Acc:Q9NRW7]
11314	NM_007261	CD300A antigen; CD300A	11311	NM_007259
11314	NM_007261	CD300A antigen; CD300A	11343	NM_007283	Monoglyceride lipase (EC 3.1.1.23) is (lysophospholipase homologue) (lysophospholipase-sample) .[source (HU-K5): Uniprot/SWISSPROT; Acc:Q99685]
22800	NM_012250	Relevant RAS virus (r-ras) oncogene homologue 2; RRAS2	11343	NM_007283
22800	NM_012250	Relevant RAS virus (r-ras) oncogene homologue 2; RRAS2	22914	NM_007360	Killer cell lectin-sample acceptor subfamily K, the member 1; KLRK1
22918	NM_012072	Complement component C1 q acceptor precursor (complement component 1, q subcomponent, acceptor 1) is (C1qR (p)) (C1q/MBL/SPA acceptor) (CD93 antigen) (CDw93) .[source: Uniprot/SWISSPROT (C1qRp); Acc:Q9NPY3]	22914	NM_007360
22918	NM_012072		23030	NM_015015	The Jumonji structural domain comprises 2B (JMJD2B)
23075		SWAP-70 albumen [source: RefSeq_peptide; Acc:NP_055870]	23030	NM_015015	The Jumonji structural domain comprises 2B (JMJD2B)
23075		SWAP-70 albumen [source: RefSeq_peptide; Acc:NP_055870]	23139	NM_015112	Microtubule-relevant serine/threonine-protein kinase 2 (EC 2.7.1.37). [source: Uniprot/SWISSPROT; Acc:Q6P0Q8]
23166	NM_015136	Stabilin-1 precursor (FEEL-1 albumen) (MS-1 antigen) .[source: Uniprot/SWISSPROT; Acc:Q9NY15]	23139	NM_015112
23166	NM_015136		23303		Kinesin-sample albumen KIF13B (kinesin-sample Protein G AKIN). [source: Uniprot/SWISSPROT; Acc:Q9NQT8]
23308	NM_015259	[COS ligand precursor (B7 homologue 2) is (B7-sample Protein G 150) (B7-associated protein 1) (B7RP-1) (CD275 antigen) .[source: Uniprot/SWISSPROT (B7-H2); Acc:O75144]	23303
23308	NM_015259		23418	NM_012076；NM_201253	Crumbs homologue 1 (fruit bat); CRB1
23430	NM_012217	Tryptase δ precursor (EC3.4.21.59) (Δ tryptase) (mastocyte mMCP-7-sample) (tryptase-3) (HmMCP-3-sample tryptase III) .[source: Uniprot/SWISSPROT; Acc:Q9BZJ3]	23418	NM_012076；NM_201253	Crumbs homologue 1 (fruit bat); CRB1
23430	NM_012217		23433	NM_012249	Ras homologue gene family, member Q; RHOQ
23467	NM_014293；NM_05 8178	Neurone pentamer protein receptor; NPTXR	23433	NM_012249	Ras homologue gene family, member Q; RHOQ
23467	NM_014293；NM_05 8178	Neurone pentamer protein receptor; NPTXR	23495	NM_012452	Tumor necrosis factor receptor super family member 13B (striding film activator and CAML interaction agent) (CD267 antigen) .[source: Uniprot/SWISSPROT; Acc:O14836]
23529	NM_013246	B cell-stimulating factor 3 precursors (BSF-3) (novel neurotrophic element-1) are (the heart nutrient substance-like cell factor) .[source (NNT-1): Uniprot/SWISSPROT; Acc:Q9UBD9]	23495	NM_012452
23529	NM_013246		23545	NM_012463	The cavity proton translocation ATP enzyme 116kDa a of subunit hypotype 2 (V-ATP enzyme 116-kDa hypotype a2) is the .[source (TJ6): Uniprot/SWISSPROT; Acc:Q9Y487]
23547	NM_012276	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily A (has the TM structure	23545	NM_012463

		The territory), the member 4; LILRA4
		The territory), the member 4; LILRA4	23586	NM_014314	Possible ATP-RNA-dependent helicase DDX58 (EC 3.6.1.-) (DEAD-box protein 58) (vitamin A acid-derivable gene 1 albumen) is (RIG-I) .[source (RIG-1): Uniprot/SWISSPROT; Acc:O95786]
23601	NM_013252	C type lectin structural domain family 5, member A; CLEC5A	23586	NM_014314
23601	NM_013252	C type lectin structural domain family 5, member A; CLEC5A	23643	NM_015364	Lymphocyte antigen 96 precursors (MD-2 albumen) are the .[source (ESOP-1): Uniprot/SWISSPROT; Acc:Q9Y6Y9]
23677	NM_014521	SH3-structural domain conjugated protein 4; SH3BP4	23643	NM_015364
23677	NM_014521	SH3-structural domain conjugated protein 4; SH3BP4	23780	NM_145637	Lipophorin-L2 (lipophorin L-II) is the .[source (ApoL-II): Uniprot/SWISSPROT; Acc:Q9BQE5]
24138	NM_012420	Having the triangle tetrapeptide repeats Interferon, rabbit-inductive albumen (IFIT-5) of 5 (vitamin A acid-and Interferon, rabbit-derivable 58kDa albumen) .[and originates: Uniprot/SWISSPROT; Acc:Q13325]	23780	NM_145637
24138	NM_012420		25801	NM_012198	Grancalcin.[source: Uniprot/SWISSPROT; Acc:P28676]
25824	NM_012094	Peroxiredoxin5, plastosome precursor (EC 1.11.1.15) be (peroxidase antioxidase) (PLP) (AOEB166) (TPx type VI) (hepatic tissue 2D-page or leaf point 71B) (Alu corepresso of (thioredoxin reductase) (thioredoxin peroxidase PMP20) (antioxidase B166) (Prx-V)	25801	NM_012198	Grancalcin.[source: Uniprot/SWISSPROT; Acc:P28676]
25824	NM_012094		25923	NM_015459	atlastin-3
25939	NM_015474	SAM structural domain and HD structural domain 1; SAMHD1	25923	NM_015459	atlastin-3
25939	NM_015474	SAM structural domain and HD structural domain 1; SAMHD1	25945	NM_015480	Poliovirus receptor-relevant 3; PVRL3
25992	XM_059482	Sushi, nidogen and EGF-spline structure territory 1; SNED1	25945	NM_015480	Poliovirus receptor-relevant 3; PVRL3
25992	XM_059482	Sushi, nidogen and EGF-spline structure territory 1; SNED1	26133	NM_015638	Trpc4-associated protein (short transition acceptor potential passage 4 associated protein) (Trp4-associated protein) (TAP1 albumen) (the general support/signal protein of TNF-acceptor) (TRUSS albumen) .[source: Uniprot/SWISSPROT; Acc:Q8TEL6]
26228	NM_012108	Signal transduction joint albumen 1 (STAP-1) (stem cell joint albumen 1) (BCR downstream signal albumen 1) (docking protein BRDG1) .[source: Uniprot/SWISSPROT; Acc:Q9ULZ2]	26133	NM_015638
26228	NM_012108		26253	NM_014358	The C type lectin structural domain 4 member E of family (C type lectin superfamily member 9) (scavenger cell-derivable C type lectin) .[source: Uniprot/SWISSPROT; Acc:Q9ULY5]
26279	NM_012400	Group IID secretion Phospholipase A2 precursor (EC 3.1.1.4) (phosphatidylcholine 2-Acyl-hydrolase GIID) (GIID sPLA2) is (sPLA (2)-IID) (secretor type PLA, a matter-relevant homologue) .[source: Uniprot/SWISSPROT (PLA2IID); Acc:Q9UNK4]	26253	NM_014358
26279	NM_012400		26525	NM_173170	Il-1 family member 5 (IL-1F5) (il-1 δ) (IL-1 δ) (FIL1 δ) (il-1-sample albumen 1) is (il-1 HY1) (IL-1HY1) (interleukin-1 receptor antagonist homologue 1) (IL-1ra homologue 1) (IL-1-associated protein 3) (IL-1RP3 (IL-1L1)
26749	NM_012196	GAGE-1 albumen (G antigen 1) (MZ2-F antigen) .[source: Uniprot/SWISSPROT; Acc:Q13065]	26525	NM_173170

26762	NM_012206	Hepatitis A virus cell receptor 1; HAVCR1
26762	NM_012206	Hepatitis A virus cell receptor 1; HAVCR1	27033	NM_014383	Testis zinc finger protein [source: RefSeq_peptide; Acc:NP_055198]
27036	NM_016543；NM_014385	Sialic acid is in conjunction with Ig-sample lectin 7; SIGLEC7	27033	NM_014383
27036	NM_016543；NM_014385		27040		The linking agent (36kDa phosphoric acid-tyrosine joint albumen) that is used to activate T-cell family member 1 is (p36-38) .[source (pp36): Uniprot/SWISSPROT; Acc:O43561]
27159		Acidic mammalian chitinase precursor (EC 3.2.1.14) (AMC enzyme) is the .[source (TSA1902): Uniprot/SWISSPROT; Acc:Q9BZP6]	27040
27159			27166	NM_013237	Px19-sample albumen (the 25kDa albumen of relevant evolution and lymph interest) is .[source: Uniprot/SWISSPROT (PRELI); Acc:Q9Y255]
27177	NM_014438	Il-1 family member 8 (IL-1F8) (il-1 eta) is (IL-1H2) .[source: Uniprot/SWISSPROT of (FIL1 eta) (il-1 homologue 2) (IL-1eta); Acc:Q9NZH7]	27166	NM_013237
27177	NM_014438		27178	NM_014439	Il-1 family member 7 precursors (IL-1F7) (il-1 zeta) are (IL-1H4) (il-1-associated protein) (IL-1RP1) (IL-1X albumen) .[source: Uniprot/SWISSPROT of (FIL1zeta) (il-1 homologue 4) (IL-1zeta); Acc:Q9NZH6]
27179	NM_014440	Il-1 family member 6 (IL-1F6) (il-1 ε) (IL-1 ε) (FIL1 ε) .[source: Uniprot/SWISSPROT; Acc:Q9UHA7]	27178	NM_014439
27179	NM_014440		27180	NM_014441	Sialic acid is in conjunction with Ig-sample lectin 9; SIGLEC9
27181	NM_014442	Sialic acid is in conjunction with Ig-sample lectin 8; SIGLEC8	27180	NM_014441
27181	NM_014442		27189	NM_013278	Interleukin-17 C precursor (IL-17C) (cytokine CX2) .[source: Uniprot/SWISSPROT; Acc:Q9P0M4]
27190	NM_014443	Interleukin-17 B precursor (IL-17B) (cytokine-sample albumen Zcyto7) (neurone interleukin-17-correlation factor) (interleukin-2 0) be the .[source (IL-20): Uniprot/SWISSPROT; Acc:Q9UHF5]	27189	NM_013278
27190	NM_014443		27240	NM_014450	(gp30/40) .[source: Uniprot/SWISSPROT of film joint 1 precursor (suppressing-induce to stride film joint 1) (SHP2-interacts and strides film joint albumen) is striden in signal threshold-adjusting; Acc:Q9Y3P8]
28303	XM_496157	The heavy variable 3/OR16-13 of immunoglobulin (Ig); IGHV3OR16-13	27240	NM_014450
28303	XM_496157		28514	NM_005618	δ-sample 1 (fruit bat); DLL1
28566	BC036926	The variable 21-1 of TXi Baoshouti β	28514	NM_005618	δ-sample 1 (fruit bat); DLL1
28566	BC036926	The variable 21-1 of TXi Baoshouti β	28619	BC070387	The variable 3-1 of TXi Baoshouti β
28663	BC025727	TXi Baoshouti α variable 20	28619	BC070387	The variable 3-1 of TXi Baoshouti β
28663	BC025727	TXi Baoshouti α variable 20	28988	NM_014063	Drebrin-sample albumen (albumen 7 that comprises the SH3 structural domain) (Drebrin F) (uterine neck SH3P7) (HPK1-interaction protein, 55kDa) (HIP-55) (uterine neck Saliva Orthana-associated protein) .[source: Uniprot/SWISSPROT; Acc:Q9UJU6]
29108	NM_013258	Comprise the apoptosis of CARD-relevant spot-sample albumen (hASC) (albumen that comprises PYD and the CARD structural domain) target of inductive silence 1 (methylate-) (the apoptosis enzyme is raised domain protein 5) .[source: Uniprot/SWISSPROT; Acc:Q9ULZ3]	28988	NM_014063

29121	NM_013269；NM_00 1004419；NM_001004420	C type lectin structural domain family 2, member D; CLEC2D
29121	NM_013269；NM_00 1004419；NM_001004420	C type lectin structural domain family 2, member D; CLEC2D	29126	NM_014143	Program necrocytosis 1 ligand 1 precursor (programmed cell death ligand 1) is (B7-H1) .[source: Uniprot/SWISSPROT of (PDCD1 ligand 1) (CD274 antigen) (B7-homologue 1) (PD-L1); Acc:Q9NZQ7]
29760	NM_013314	B-cell linking agent; BLNK	29126	NM_014143
29760	NM_013314	B-cell linking agent; BLNK	29802	NM_013378	Pre-B lymphocyte gene 3; VPREB3
29851	NM_012092	Derivable T-cell is total to-stimulator precursor (molecule of activation-derivable lymphocyte immunity mediation) (CD278 antigen) .[source: Uniprot/SWISSPROT; Acc:Q9Y6W8]	29802	NM_013378	Pre-B lymphocyte gene 3; VPREB3
29851	NM_012092		29949	NM_153758	Il-1 9 precursors (IL-19) (melanoma differentiation associated protein-sample albumen) are .[source: Uniprot/SWISSPROT (NG.1); Acc:Q9UHD0]
29990	NM_013440；NM_17 8238；NM_175047	Paired immunoglobulin (Ig)-template 2 acceptor β; PILRB	29949	NM_153758
29990	NM_013440；NM_17 8238；NM_175047	Paired immunoglobulin (Ig)-template 2 acceptor β; PILRB	29992	NM_178273；NM_17 8272；NM_013439	Paired immunoglobulin (Ig)-template 2 acceptor α; PILRA
30009	NM_013351	T-box transcription factor TBX21 (T-box protein 21) (transcription factor TBLYM) (T-cell-specificity T-box Transcription Factor T-bet) .[source: Uniprot/SWISSPROT; Acc:Q9UL17]	29992	NM_178273；NM_17 8272；NM_013439	Paired immunoglobulin (Ig)-template 2 acceptor α; PILRA
30009	NM_013351		30814	NM_014589	Group IIE secretion Phospholipase A2 precursor (EC 3.1.1.4) (phosphatidylcholine 2-Acyl-hydrolase GIIE) (GIIE sPLA2) (sPLA (2)-IIE) .[source: Uniprot/SWISSPROT; Acc:Q9NZK7]
30835	NM_021155	CD209 antigen (dendritic cell-specificity ICAM-3-grasps non-integrin 1) is (DC-SIGN) .[source (DC-SIGN1): Uniprot/SWISSPROT; Acc:Q9NNX6]	30814	NM_014589
30835	NM_021155		50604	NM_018724	Interleukin-2 0 precursor (IL-20) (four α spiral cell factor Z cyto10) .[source: Uniprot/SWISSPROT; Acc:Q9NYY1]
50615	NM_181078	Interleukin-21 receptor precursor (IL-21R) (novel interleukin-2-receptor) .[source: Uniprot/SWISSPROT; Acc:Q9HBE5]	50604	NM_018724
50615	NM_181078		50616	NM_020525	Interleukin-22 precursor (IL-22) the derivable factor of T-cell-source (IL-10-be correlated with) is the .[source (IL-TIF): Uniprot/SWISSPROT; Acc:Q9GZX6]
50848	NM_016946	Connect (JAM) (platelet adhesion reaction molecule 1) (PAM-1) (thrombocyte F11 acceptor) (CD321 antigen) .[source: Uniprot/SWISSPROT of adhesion molecule A precursor (JAM-A) (connecting adhesion molecule 1); Acc:Q9Y624]	50616	NM_020525
50848	NM_016946		50852	NM_016388	T-cell receptors-relevant (TRIM) (pp29/30) .[source: the Uniprot/SWISSPROT of film joint 1 (T-cell receptors-interacting molecule) that strides; Acc:Q6PIZ9]
50856	NM_016184	The C-type lectin structural domain 4 member A of family (C type lectin superfamily member 6) (dendritic cell vaccination acceptor) (lectin-sample immunity receptor) (C type lectin DDB27) are the .[source (HDCGC13P): Uniprot/SWISSPROT; Acc:Q9UMR7]	50852	NM_016388

50943	NM_014009	Forkhead box protein P3 (Scurfin) .[source: Uniprot/SWISSPROT; Acc:Q9BZS1]
50943	NM_014009		51062	NM_015915	Atlastin (GTP-conjugated protein 3) (guanylic acid-conjugated protein 3) (brain-specificity GTP-is conjugated protein) .[source: Uniprot/SWISSPROT; Acc:Q8WXF7]
51110	NM_016027	Lactamase, β 2; LACTB2	51062	NM_015915
51110	NM_016027	Lactamase, β 2; LACTB2	51192	NM_016951	Chemokine-like factor (C32) .[source: Uniprot/SWISSPROT; Acc:Q9UBR5]
51206	NM_016363	Glycoprotein VI (thrombocyte); GP6	51192	NM_016951
51206	NM_016363	Glycoprotein VI (thrombocyte); GP6	51266	NM_016509	C type lectin structural domain family 1, member B; CLEC1B
51284	NM_016562	Toll sample acceptor 7 precursor .[source: Uniprot/SWISSPROT; Acc:Q9NYK1]	51266	NM_016509	C type lectin structural domain family 1, member B; CLEC1B
51284	NM_016562		51297	NM_130852；NM_016583	Palate, lung is relevant with the nasal epithelium cancer; PLUNC
51311	NM_138636	Toll sample acceptor 8 precursor .[source: Uniprot/SWISSPROT; Acc:Q9NR97]	51297	NM_130852；NM_016583
51311	NM_138636		51348	NM_016523	Killer cell lectin-sample acceptor subfamily F, the member 1; KLRF1
51435	NM_016240；NM_182826	Blue or green doffer's acceptor class A, the member 3; SCARA3	51348	NM_016523
51435	NM_016240；NM_182826		51473	NM_016356	Albumen 2 (RU2S albumen) the .[source that contains microtubule-associated protein (Doublecortin) structural domain: Uniprot/SWISSPROT; Acc:Q9UHG0]
51554	NM_178445	C-C Chemokine Receptors Class1 1 (C-C CKR-11) is (CCRL1) (CCX CKR) .[source: Uniprot/SWISSPROT of (CCR-11) (Chemokine Receptors-sample 1) (CC-CKR-11); Acc:Q9NPB9]	51473	NM_016356
51554	NM_178445		51561	NM_016584	Interleukin-22 3, alpha subunit p19 precursor [source: RefSeq_peptide; Acc:NP_057668]
51564	NM_015401	Histone deacetylase enzyme 7a (HD7a) .[source: Uniprot/SWISSPROT; Acc:Q8WUI4]	51561	NM_016584
51564	NM_015401		51665	NM_016114	Ankyrin repeats and SOCS box protein 1 (ASB-1) .[source: Uniprot/SWISSPROT; Acc:Q9Y576]
51744	NM_016382	CD244 natural killer cell acceptor 2B4; CD244	51665	NM_016114
51744	NM_016382	CD244 natural killer cell acceptor 2B4; CD244	51752	NM_016442	The leucine aminopeptidase precursor (EC3.4.11.-) in adipocyte-source is (PILS-AP) (1 type Tumor Necrosis Factor Receptors come off aminopeptidase conditioning agent) .[source: U of (ARTS-1) (aminopeptidase PILS) (tetracycline-insensitive leucyl-specificity aminopeptidase) (A-LAP)
53335		B-cell lymphoma/leukemia 11A (B-cell CLL/ lymphoma 11A) (COUP-TF interaction protein 1) (close preferendum viral integrase site 9 albumen) is the .[source (EVI-9): Uniprot/SWISSPROT; Acc:Q9H165]	51752	NM_016442
53335			53342	NM_138284	Interleukin-17 D precursor (IL-17D) (interleukin-2 7) is the .[source (IL-27): Uniprot/SWISSPROT; Acc:Q8TAD2]
53347	NM_018961	UBASH3A albumen .[source: Uniprot/SWISSPROT; Acc:P57075]	53342	NM_138284
53347	NM_018961	UBASH3A albumen .[source: Uniprot/SWISSPROT; Acc:P57075]	54106	NM_017442	Toll sample receptor 9 precursor (CD289 antigen) .[source: Uniprot/SWISSPROT; Acc:Q9NR96]

54209	NM_018965	The triggering acceptor of expressing on cord cell 2 precursors (the triggering acceptor of expressing on monocyte 2) is .[source: Uniprot/SWISSPROT (TREM-2); Acc:Q9NZC2]
54209	NM_018965		54210	NM_018643	The triggering acceptor (TREM-1) of on cord cell 1 precursor, expressing (the triggering acceptor of on monocyte 1, expressing) .[source: Uniprot/SWISSPROT; Acc:Q9NP99]
54472	NM_019009	Toll interaction protein .[source: Uniprot/SWISSPROT; Acc:Q9H0E2]	54210	NM_018643
54472	NM_019009		54878		(DP8) (Prolyl pepx DPP8) (dipeptide peptidase i V-associated protein 1) be (DPRP-1) for dipeptide peptidase 8 (EC 3.4.14.5) (dipeptide peptidase VIII). [source: Uniprot/SWISSPROT; Acc:Q6V1X1]
54900	NM_017773	Woods crust cell transmembrane joint 1 (film-associated adapter albumen LAX) (being used to activate the linking agent of X cell) .[source: Uniprot/SWISSPROT; Acc:Q8IWV1]	54878
54900	NM_017773		54941	NM_017831	Ring finger protein 125 (EC 6.3.2.-) (T-cell ring activated protein 1) is the .[source (TRAC-1): Uniprot/SWISSPROT; Acc:Q96EQ8]
55075	NM_018003	Have rolling-coiled structure territory and ankyrin repeat the uveal tract self antigen [source: RefSeq_peptide of hypotype 1; Acc:NP_060473]	54941	NM_017831
55075	NM_018003		55080	NM_018009	TAP is conjugated protein-sample; TAPBPL
55611	NM_017670	Ubiquitin thiolesterase albumen OTUB1 (EC 3.4.-.-) (Otubain1) (comprises OTU structural domain ubiquitin aldehyde-conjugated protein 1), and (ubiquitin-specificity processing protease OTUB1) (Deubiquitinating enzyme OTUB1) .[originates: Uniprot/SWISSPROT; Acc:Q96FW1]	55080	NM_018009	TAP is conjugated protein-sample; TAPBPL
55611	NM_017670		55787	NM_018360	Chromosome x open reading frame 15; CXorf15
55801	NM_018402	Interleukin-2 6 precursors (AK155 albumen) .[source: Uniprot/SWISSPROT; Acc:Q9NPH9]	55787	NM_018360	Chromosome x open reading frame 15; CXorf15
55801	NM_018402		55824	NM_018440	Phosphorprotein (stride film joint albumen PAG) (Csk-conjugated protein) (stride phospholamban Cbp) the .[source relevant: Uniprot/SWISSPROT with the microstructure territory 1 of sphingoglycolipid-enrichment; Acc:Q9NWQ8]
55894	NM_018661	Alexin, β 103A; DEFB103A	55824	NM_018440
55894	NM_018661	Alexin, β 103A; DEFB103A	56253	NM_019604	The T cell associated molecule of class-IMHC-restriction; CRTAM
56269	NM_019612	Immunity-correlative GTP enzyme family, cinema1[source: RefSeq_peptide; Acc:NP_062558]	56253	NM_019604
56269	NM_019612		56300	NM_019618	Il-1 family member 9 (IL-1F9) (il-1 homologue 1) is (IL-1RP2) .[source: Uniprot/SWISSPROT of (il-1 ε) (IL-1 ε) (IL-1-associated protein 2) (IL-1H1); Acc:Q9NZH8]
56413	NM_019839	Leukotriene B42 receptor 2 (LTB4-R2) (seven transmembrane receptor BLTR2) (leukotriene B42 receptor BLT2) (LTB4 acceptor JULF2) .[source: Uniprot/SWISSPROT; Acc:Q9NPC1]	56300	NM_019618
56413	NM_019839		56477	NM_148672	I inductive cytokine A28 precursor (CCL28) (mucous membrane-relevant epithelium chemokine) is (CCK1 albumen) .[source: Uniprot/SWISSPROT (MEC); Acc:Q9NRJ3]
56832	NM_020124	Interferon, rabbit κ precursor (IFN-κ) .[source:	56477	NM_148672

		Uniprot/SWISSPROT；Acc:Q9P0W0]
		Uniprot/SWISSPROT；Acc:Q9P0W0]	56833	NM_020125	SLAM family member 8; SLAMF8
56924	NM_020168	P21 (CDKN1A)-activated protein kinase 6; PAK6	56833	NM_020125	SLAM family member 8; SLAMF8
56924	NM_020168	P21 (CDKN1A)-activated protein kinase 6; PAK6	57105	NM_020377	Cysteinyl leukotriene receptor 2 (CysLTR2) is (HPN321) (hGPCR21) .[source: Uniprot/SWISSPROT (HG57); Acc:Q9NS75]
57115	NM_020393	Peptidoglycan recognition protein 4; PGLYRP4	57105	NM_020377
57115	NM_020393	Peptidoglycan recognition protein 4; PGLYRP4	57144	NM_020341；NM_177990	P21 (CDKN1A)-activated protein kinase 7; PAK7
57151	NM_020426	N,O-Diacetylmuramidase-sample 6; LYZL6	57144	NM_020341；NM_177990	P21 (CDKN1A)-activated protein kinase 7; PAK7
57151	NM_020426	N,O-Diacetylmuramidase-sample 6; LYZL6	57292	NM_020535	Killer cell immunoglobulin (Ig)-sample acceptor, two structural domains, growing cells matter tail, 5A; KIR2DL5A
57379	NM_020661	Tongue inductive cytidine deaminase (EC 3.5.4.5) (cytidine amidohydrolase). [source: Uniprot/SWISSPROT; Acc:Q9GZX7]	57292	NM_020535
57379	NM_020661		57381	NM_020663	Ras homologue gene family, member J; RHOJ
57506	NM_020746	The antiviral signal protein of plastosome (interferon-beta promotor stimulatory protein(SP) 1) is (virus-inductive Signal connector) (CARD joint inducing interferon-β) (Cardif) (supposition NF-κ-B-activated protein 031N) .[source: Uniprot/SWISSPROT (IPS-1);	57381	NM_020663	Ras homologue gene family, member J; RHOJ
57506	NM_020746		57580	NM_020820	Phosphatidylinositols		3,4,5-triphosphoric acid-dependency Rac exchange 1 albumen (P-Rex1 albumen) .[source: Uniprot/SWISSPROT; Acc:Q8TCU6]
57817	NM_021175	Hepcidin precursor (antibacterial peptide of liver-expression) (LEAP-1) (supposition liver tumor regressor) (PLTR) [comprises: Hepcidin25 (Hepc25); Hepcidin20 (Hepc20)] .[source: Uniprot/SWISSPROT; Acc:P81172]	57580	NM_020820	Phosphatidylinositols
57817	NM_021175		57823	NM_021181	SLAM family member 7; SLAMF7
58191	NM_022059	I inductive cytokine B16 precursor (striding film chemokine CXCL16) is (scavenger receptor is used for phosphatidylserine and Ox LDL) .[source (SR-PSOX): Uniprot/SWISSPROT; Acc:Q9H2A7]	57823	NM_021181	SLAM family member 7; SLAMF7
58191	NM_022059		59067	NM_021803	Interleukin-21 precursor (IL-21) is the .[source (Za11): Uniprot/SWISSPROT; Acc:Q9HBE4]
59082	NM_021571	Apoptosis enzyme-1 suppresses iceberg .[source: Uniprot/SWISSPROT; Acc:P57730]	59067	NM_021803
59082	NM_021571		59307	NM_021805	Single Ig IL-1-associated receptor (single Ig IL-1R-associated molecule) (comprising single immunoglobulin domains IL1R associated protein) (Toll/ interleukin-1 receptor 8) is the .[source (TIR8): Uniprot/SWISSPROT; Acc:Q6IA17]
59340	NM_021624	Histamine H	59307	NM_021805		4 acceptors (HH4R) are (G-protein linked receptor 105) (GPCR105) (SP9144) (AXOR35) .[source: Uniprot/SWISSPROT (GPRv53); Acc:Q9H3N8]
59340	NM_021624	Histamine H	60489		DNAdC-〉dU editing enzymes APOBEC-3G (EC 3.5.4.-) (APOBEC-be correlated with cytidine deaminase) (ARCD) (APOBEC-associated protein) (ARP-9) (CEM15) (CEM-15) .[come

		Source: Uniprot/SWISSPROT; Acc:Q9HC16]
		Source: Uniprot/SWISSPROT; Acc:Q9HC16]	64112	NM_022151	The conditioning agent of apoptosis 1; MOAP1
64135	NM_022168	Helicase C-structure territory albumen 1 inductive Interferon, rabbit (EC 3.6.1.-) (helicase has the 2CARD structural domain) is (melanoma differentiation-associated protein 5) (MDA-5) (rna helicase enzyme-DEAD box protein 116) (Murabutide-down-regulation protein) .[source: Uniprot/SW (Helicard)	64112	NM_022151	The conditioning agent of apoptosis 1; MOAP1
64135	NM_022168		64167	NM_022350	The arginine aminopeptidase in white corpuscle-source [source: RefSeq_peptide; Acc:NP_071745]
64221	NM_022370	Roundabout, aixs cylinder guiding acceptor, homologue 3 (fruit bat); ROBO3	64167	NM_022350
64221	NM_022370		64225	NM_022374	ADP-ribosylation factor-sample 6 interaction protein 2[source: RefSeq_peptide; Acc:NP_071769]
64332	NM_001005474	The nf of the K light polypeptide genetic enhancer of B-cytostatics, zeta hypotype a[source: RefSeq_peptide; Acc:NP_113607]	64225	NM_022374
64332	NM_001005474		64342	NM_022460	The conjugated protein 3[of HS1-source: RefSeq_peptide; Acc:NP_071905]
64386	NM_022468	Matrix metalloproteinase-25 precursor (EC 3.4.24.-) is (film-type matrix metalloproteinase 6) (MT-MMP6) (film-type-6 matrix metalloproteinase) (MT6-MMP) (leucolysin) .[source: Uniprot/SWISSPROT (MMP-25); Acc:Q9NPA2]	64342	NM_022460
64386	NM_022468		64421	NM_001033858	Artemis albumen (EC 3.1.-.-) (the crosslinked reparation of DNA 1C albumen) (SNM1-sample albumen) (A-SCID albumen) is the .[source (hSNM1C): Uniprot/SWISSPROT; Acc:Q96SD1]
64499	NM_003294	Tryptase β-1 precursor (EC 3.4.21.59) (tryptase-1) (tryptase I) .[source: Uniprot/SWISSPROT; Acc:Q15661]	64421	NM_001033858
64499	NM_003294		64581	NM_197947；NM_02 2570；NM_197948；N M_197952；NM_1979 50；NM_197949；NM_ 197954；NM_197953；NM_197951	C-type lectin structural domain family 7, member A; CLEC7A
64806	NM_172314	Interleukin-17 E precursor (IL-17E) (interleukin-2 5) is the .[source (IL-25): Uniprot/SWISSPROT; Acc:Q9H293]	64581		C-type lectin structural domain family 7, member A; CLEC7A
64806	NM_172314		65125	NM_018979	WNK Methionin lacks protein kinase 1; WNK1
65266	NM_032387	WNK Methionin lacks protein kinase 4; WNK4	65125	NM_018979	WNK Methionin lacks protein kinase 1; WNK1
65266	NM_032387	WNK Methionin lacks protein kinase 4; WNK4	65267	NM_001002838；NM 020922	WNK Methionin lacks protein kinase 3; WNK3
78989	NM_024027；NM_19 9235	Collect plain Asia-family member 11; COLEC11	65267	NM_001002838；NM 020922	WNK Methionin lacks protein kinase 3; WNK3
78989	NM_024027；NM_19 9235	Collect plain Asia-family member 11; COLEC11	79168	NM_024318	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily A (having the TM structural domain), the member 6; LILRA6
79368	NM_030764；NM_13 8738	Fc acceptor-sample 2; FCRL2	79168	NM_024318
79368	NM_030764；NM_13 8738	Fc acceptor-sample 2; FCRL2	79400	NM_024505	Nadph oxidase, EF hand-type calcium-binding domains 5[source: RefSeq_peptide; Acc:NP_078781]

79465	NM_024518	UL16 conjugated protein 3; ULBP3
79465	NM_024518	UL16 conjugated protein 3; ULBP3	79589	NM_194463	Ring finger protein 128 hypotype 1[source: RefSeq_peptide; Acc:NP_919445]
79679	NM_024626	The T cell activation inhibitor 1[source that contains V-group structural domain: RefSeq_peptide; Acc:NP_078902]	79589	NM_194463
79679	NM_024626		79930	BC004867	Docking protein 3
80122	NM_025052；NM_001018046	Yeast Sps1/Ste20-associated kinase 4 (S.cerevisiae); YSK4	79930	BC004867	Docking protein 3
80122	NM_025052；NM_001018046	Yeast Sps1/Ste20-associated kinase 4 (S.cerevisiae); YSK4	80274	NM_173050	The relevant 1[of signal peptide-CUB structural domain-EGF-source: RefSeq_peptide; Acc:NP_766638]
80328	NM_025217	UL16 conjugated protein 2; ULBP2	80274	NM_173050
80328	NM_025217	UL16 conjugated protein 2; ULBP2	80329	NM_025218	UL16 conjugated protein 1; ULBP1
80332	NM_025220	ADAM33 precursor (EC 3.4.24.-) (disintegrin and metalloprotease structural domain 33) .[source: Uniprot/SWISSPROT; Acc:Q9BZ11]	80329	NM_025218	UL16 conjugated protein 1; ULBP1
80332	NM_025220		80341	NM_025227	Sterilization/permeability-enhanced albumen sample 1; BPIL1
80380	NM_025239	Program necrocytosis	80341	NM_025227	Sterilization/permeability-enhanced albumen sample 1; BPIL1	1 part 2 precursors (programmed cell death part 2) are (B7-DC) (CD273 antigen) .[source: Uniprot/SWISSPROT of (PD-1-part 2) (PDCD1 part 2) (butyrophilin B7-DC) (PD-L2); Acc:Q9BQ51]
80380	NM_025239	Program necrocytosis	80381	NM_025240	CD276 antigenic subtype a[source: RefSeq_peptide; Acc:NP_001019907]
80833	NM_145640	Lipophorin-L3 (lipophorin L-III) is (TNF-inducible protein CG12-1) (CG12_1) .[source: Uniprot/SWISSPROT (ApoL-III); Acc:O95236]	80381	NM_025240
80833	NM_145640		80741	NM_001002849	Lymphocyte antigen	6 complex bodys, locus G5C (LY6G5C)
81035	NM_030781；NM_13 0386	Collect plain Asia-family member 12; COLEC12	80741	NM_001002849	Lymphocyte antigen	6 complex bodys, locus G5C (LY6G5C)
81035	NM_030781；NM_13 0386	Collect plain Asia-family member 12; COLEC12	81494	NM_030787	Complement factor H-relevant 5; CFHL5
81542	NM_030755	Albumen	81494	NM_030787	Complement factor H-relevant 5; CFHL5	1 precursor (striding film Trx-associated protein) (Trx-relevant transmembrane protein) .[source: the Uniprot/SWISSPROT that comprises the Trx structural domain; Acc; Q9H3N1]
81542	NM_030755	Albumen	81607	NM_030916	Poliovirus receptor-relevant 4; PVRL4
81793	NM_030956	Toll sample acceptor 10 precursor .[source: Uniprot/SWISSPROT; Acc:Q9BXR5]	81607	NM_030916	Poliovirus receptor-relevant 4; PVRL4
81793	NM_030956		83416	NM_031281	Fc acceptor-sample 5; FCRL5
83417	NM_031282	Fc acceptor-sample 4; FCRL4	83416	NM_031281	Fc acceptor-sample 5; FCRL5
83417	NM_031282	Fc acceptor-sample 4; FCRL4	83903	NM_031965	Protoblast 2 (haspin) that are correlated with; GSG2
83953	NM_032029	The Fc acceptor, IgA, IgM, high-affinity; FCAMR	83903	NM_031965	Protoblast 2 (haspin) that are correlated with; GSG2
83953	NM_032029	The Fc acceptor, IgA, IgM, high-affinity; FCAMR	84174		Src-sample-joint 2 (Src-sample joint albumen 2) is (conditioning agent of antigen receptor signal) (MARS) .[source: Uniprot/SWISSPROT (SLAP-2); Acc:Q9H6Q3]
84569	NM_032517	N,O-Diacetylmuramidase-sample 1; LYZL1	84174

84639	NM_032556	Il-1 family member 10 (IL-1F10) (interleukin-1 receptor antagonist-sample FIL1 θ) (il-1 θ) (IL-1 θ) (FIL1 θ) (il-1 HY2) be the .[source (IL-1HY2): Uniprot/SWISSPROT; Acc:Q8WWZ1]
84639	NM_032556		84659	NM_032572	Rnase	7 precursors (EC 3.1.27.-) (RNA enzyme 7) (antibacterial protein 2 in skin-source) are the .[source (SAP-2): Uniprot/SWISSPROT; Acc:Q9H1E1]
84663	NM_032576	Karyomit(e) Y open reading frame 15B; CYorf15B	84659	NM_032572	Rnase
84663	NM_032576	Karyomit(e) Y open reading frame 15B; CYorf15B	84824	NM_032738	Fc acceptor-sample and Saliva Orthana-sample 1; FCRLM1
84868	NM_032782	Hepatitis A virus cell receptor 2; HAVCR2	84824	NM_032738	Fc acceptor-sample and Saliva Orthana-sample 1; FCRLM1
84868	NM_032782	Hepatitis A virus cell receptor 2; HAVCR2	84941	NM_032855	Comprise hematopoiesis SH2 structural domain [source: RefSeq_peptide; Acc:NP_116244]
84968	NM_032882	Secondary tumprigenicity antigen sample 6A; PNMA6A	84941	NM_032855
84968	NM_032882	Secondary tumprigenicity antigen sample 6A; PNMA6A	89790	NM_033130	Sialic acid is in conjunction with Ig-sample lectin 10; SIGLEC10
89858	NM_033329；NM_05 3003	Sialic acid is in conjunction with Ig-sample lectin 12; SIGLEC12	89790	NM_033130
89858	NM_033329；NM_05 3003		89886	NM_033438	SLAM family member 9; SLAMF9
90925	NM_175870	Imagination albumen LOC90925; LOC90925	89886	NM_033438	SLAM family member 9; SLAMF9
90925	NM_175870	Imagination albumen LOC90925; LOC90925	91353	NM_001013618	Be similar to Ω albumen; CTA-246H3.1
91662	NM_144687	Comprise NACHT-, the protein 12 of LRR-and PYD (the APAF1 sample albumen 7 that comprises PYRIN) (Monarch-1) (is regulated) .[and is originated by nitrogen protoxide: Uniprot/SWISSPROT; Acc:P59046]	91353	NM_001013618	Be similar to Ω albumen; CTA-246H3.1
91662	NM_144687		91937	NM_138379	T-cell immunoglobulin and Saliva Orthana structural domain comprise 4; TIMD4
92747	NM_033197	Karyomit(e) 20 open reading frame 114; C20orf114	91937	NM_138379
92747	NM_033197	Karyomit(e) 20 open reading frame 114; C20orf114	112744	NM_052872	Interleukin-17 F precursor (IL-17F) (interleukin-24) is (cytokine ML-1) .[source (IL-24): Uniprot/SWISSPROT; Acc:Q96PD4]
114132	NM_052884	Sialic acid is in conjunction with Ig-sample lectin 11; SIGLEC11	112744	NM_052872
114132	NM_052884		114548	NM_004895	Cold self inflammatory syndrome 1 albumen (Cryopyrin) (comprising NACHT-, the albumen 3 of LRR-and PYD-) (the APAF1-sample albumen 1 that comprises PYRIN-) (Angiotensin/vasopressin receptor AII/AVP-sample) .[source: Uniprot/SWISSPROT; Acc:Q96P20]
114609	NM_052887	Joint albumen (the joint albumen that comprises the TIR structural domain) (MyD88 joint sample albumen) (joint albumen Wyatt) the .[source that comprises Toll-interleukin 1 receptor structural domain: Uniprot/SWISSPROT; Acc:P58753]	114548	NM_004895
114609	NM_052887		114771	NM_052891	Peptidoglycan recognition protein 3; PGLYRP3
114824	NM_052926	Secondary tumprigenicity antigen sample 5; PNMA5	114771	NM_052891	Peptidoglycan recognition protein 3; PGLYRP3
114824	NM_052926	Secondary tumprigenicity antigen sample 5; PNMA5	114836	NM_052931	SLAM family member 6; SLAMF6
114897	NM_198593；NM_19 8594；NM_030968	C1q and tumour necrosis factor associated protein 1; C1QTNF1	114836	NM_052931	SLAM family member 6; SLAMF6
114897	NM_198593；NM_19 8594；NM_030968		114898	NM_031908	C1q and tumour necrosis factor associated protein 2; C1QTNF2
114899	NM_181435；NM_03 0945	C1q and tumour necrosis factor associated protein 3; C1QTNF3	114898	NM_031908
114899	NM_181435；NM_03 0945		114900	NM_031909	C1q and tumour necrosis factor associated protein 4; C1QTNF4
114902	NM_015645	C1q and tumour necrosis factor associated protein 5; C1QTNF5	114900	NM_031909

114904	NM_182486；NM_031910	C1q and tumour necrosis factor associated protein 6; C1QTNF6
114904	NM_182486；NM_031910		114905	NM_031911	C1q and tumour necrosis factor associated protein 7; C1QTNF7
115350	NM_052938	Fc acceptor-sample 1; FCRL1	114905	NM_031911
115350	NM_052938	Fc acceptor-sample 1; FCRL1	115352	NM_052939；NM_001024667	Fc acceptor-sample 3; FCRL3
115361	NM_052941	Guanine nucleotide binding protein 4.[source: Uniprot/SWISSPROT; Acc:Q96PP9]	115352	NM_052939；NM_001024667	Fc acceptor-sample 3; FCRL3
115361	NM_052941		115362	NM_052942	Interferon, rabbit-inductive guanylic acid-conjugated protein 5 (GTP-conjugated protein 5) (guanylic acid-conjugated protein 5) (GBP-TA antigen) .[source: Uniprot/SWISSPROT; Acc:Q96PP8]
115650	NM_052945	Tumor necrosis factor receptor super family member 13C (B cell-activation factor acceptor) (BAFF acceptor) is (BLyS acceptor 3) (CD268 antigen) .[source (BAFF-R): Uniprot/SWISSPROT; Acc:Q96RJ3]	115362	NM_052942
115650	NM_052945		115653	NM_153443	Killer cell immunoglobulin (Ig)-sample acceptor, three structural domains, growing cells matter tail, 3; KIR3DL3
116379	NM_052962；NM_181309；NM_181310	Interleukin-22 2 acceptors, α 2; IL22RA2	115653	NM_153443
116379	NM_052962；NM_181309；NM_181310	Interleukin-22 2 acceptors, α 2; IL22RA2	116449	NM_052964	Mastocyte immunity receptor signal transduction agent [source: RefSeq_peptide; Acc:NP_443196]
117285	NM_054112	B-alexin 118 precursors (alexin, β 118) (B-alexin 18) are (epididymis secretory protein 13.6) (ESP13.6) .[source: Uniprot/SWISSPROT (DEFB-18); Acc:Q96PH6]	116449	NM_052964
117285	NM_054112		119180	NM_183058	N,O-Diacetylmuramidase sample 2; LYZL2
124599	NM_174892	The CD300 antigen of similar family member B; CD300LB	119180	NM_183058	N,O-Diacetylmuramidase sample 2; LYZL2
124599	NM_174892	The CD300 antigen of similar family member B; CD300LB	124912	NM_173847	Perforatorium relevant 3; SPACA3
126014	NM_133168；NM_20 6818；NM_133169；N M_206817；NM_1307 71	Osteoclast-associated receptor; OSCAR	124912	NM_173847	Perforatorium relevant 3; SPACA3
126014	NM_133168；NM_20 6818；NM_133169；N M_206817；NM_1307 71	Osteoclast-associated receptor; OSCAR	127150	XM_497717	Be similar to mucous membrane pentamer albumen; LOC127150
127943	NM_001002901	Fc acceptor-sample and Saliva Orthana-sample 2; FCRLM2	127150	XM_497717	Be similar to mucous membrane pentamer albumen; LOC127150
127943	NM_001002901	Fc acceptor-sample and Saliva Orthana-sample 2; FCRLM2	128859	NM_174897	Sterilization/permeability-enhancing albumen-sample 3; BPIL3
130120	NM_198448	The albumen 3 γ precursors (Reg III-γ) (pancreatitis-associated protein 1 B) in regeneration island-source are the .[source (PAPIB): Uniprot/SWISSPROT; Acc:Q6UW15]	128859	NM_174897
130120	NM_198448		131375	NM_144634	N,O-Diacetylmuramidase-sample 4; LYZL4
133396	NM_139017	Gp130-sample monocyte acceptor [source: RefSeq_ peptide; Acc:NP_620586]	131375	NM_144634	N,O-Diacetylmuramidase-sample 4; LYZL4
133396	NM_139017		135250	NM_139165	Vitamin A acid early transcription body 1E; RAET1E
140850	NM_139074	B-alexin 127 precursors (alexin, β 127) (B-alexin 27) are the .[source (DEFB-27): Uniprot/SWISSPROT; Acc:Q9H1M4]	135250	NM_139165	Vitamin A acid early transcription body 1E; RAET1E
140850	NM_139074		146722	NM_139018	CD300 antigen sample family member F; CD300LF
146894	NM_145273	CD300 antigen sample family member G; CD300LG	146722	NM_139018	CD300 antigen sample family member F; CD300LF

149954	NM_182519	Karyomit(e) 20 open reading frame 186; C20orf186
149954	NM_182519	Karyomit(e) 20 open reading frame 186; C20orf186	150372	NM_145912	NFAT activated molecule 1 precursor (albumen that comprises calcineurin/NFAT-activation ITAM) (NFAT-activated protein) .[source: Uniprot/SWISSPROT with ITAM motif 1; Acc:Q8NET5]
151888	NM_181780	B and T lymphocyte attenuator precursor (B and T lymphocyte-associated protein) (CD272 antigen) .[source: Uniprot/SWISSPROT; Acc:Q7Z6A9]	150372	NM_145912
151888	NM_181780		152028	NM_144717	Contain III type fibronectin structural domain 6; FNDC6
154064	NM_130900	Vitamin A acid early transcription thing 1L; RAET1L	152028	NM_144717	Contain III type fibronectin structural domain 6; FNDC6
154064	NM_130900	Vitamin A acid early transcription thing 1L; RAET1L	163351	NM_198460	Guanine nucleotide binding protein family, member 6[source: RefSeq_peptide; Acc:NP_940862]
163702	NM_173065；NM_17 3064；NM_170743	Interleukin-22 8 acceptors, α (Interferon, rabbit, λ acceptor); IL28RA	163351	NM_198460
163702	NM_173065；NM_17 3064；NM_170743		165257	NM_182528	Complement component	1, q subcomponent-sample 2; C1QL2
167838	NM_153235	taxilin β；TXLNB	165257	NM_182528	Complement component	1, q subcomponent-sample 2; C1QL2
167838	NM_153235	taxilin β；TXLNB	170482	NM_130441	The C-type lectin structural domain 4 member C of family (C-type lectin superfamily member 7) (blood dendritic cell antigen 2 albumen) are (dendron shape lectin) (CD303 antigen) .[source (BDCA-2): Uniprot/SWISSPROT; Acc:Q8WTT0]
200081	NM_175852	taxilinα；TXLNA	170482	NM_130441
200081	NM_175852	taxilinα；TXLNA	201633	NM_173799	Imagination albumen FLJ39873; FLJ39873
246126	NM_001005852	Karyomit(e) Y open reading frame 15A; CYorf15A	201633	NM_173799	Imagination albumen FLJ39873; FLJ39873
246126	NM_001005852	Karyomit(e) Y open reading frame 15A; CYorf15A	246778	NM_145659	Interleukin-22 7[source: RefSeq_peptide; Acc:NP_663634]
254240	NM_174932	Sterilization/permeability-enhancing albumen-sample 2; BPIL2	246778	NM_145659	Interleukin-22 7[source: RefSeq_peptide; Acc:NP_663634]
254240	NM_174932		260434	NM_152901	Contain Pyrin structural domain 1[source: RefSeq_peptide; Acc:NP_690865]
284021	XM_211305	Karyomit(e) 17 open reading frame 60; C17orf60	260434	NM_152901
284021	XM_211305	Karyomit(e) 17 open reading frame 60; C17orf60	284367	XM_290822	Sialic acid is in conjunction with Ig-sample lectin, and pseudogene 3; SIGLECP3
284415	NM_198481	LAIR hlog；UNQ3033	284367	XM_290822
284415	NM_198481	LAIR hlog；UNQ3033	284988	XM_209429	Be similar to ARHQ albumen; LOC284988
285830	NM_001003807	Imagination albumen FLJ35429; RP3-377H14.5	284988	XM_209429	Be similar to ARHQ albumen; LOC284988
285830	NM_001003807	Imagination albumen FLJ35429; RP3-377H14.5	286204	NM_173689	Crumbs homologue 2 (fruit bat); CRB2
286310	NM_002297	Lipocalin-1 precursor (Von Ebner gland albumen) (VEG albumen) (tear prealbumin) be (tear lipocalin) (Tlc) .[source: Uniprot/SWISSPROT (TP); Acc:P31025]	286204	NM_173689	Crumbs homologue 2 (fruit bat); CRB2
286310	NM_002297		338339	NM_080387	The C type lectin structural domain 4 member D of family (C type lectin superfamily member 8) (C type lectin-sample acceptor 6) are the .[source (CLEC-6): Uniprot/SWISSPROT; Acc:Q8WXI8]
338761	NM_001008223	Complement component	338339	NM_080387		1, q subcomponent-sample 4; C1QL4
338761	NM_001008223	Complement component	338902	XM_497405	Be similar to immunoglobulin (Ig)-conjugated protein 1 (CD79a-conjugated protein 1) (B cellular signal transduction molecule α 4) (A4 albumen); LOC338902	1, q subcomponent-sample 4; C1QL4
339377	XM_290866	Be similar to 4930572L20Rik albumen; LOC339377	338902	XM_497405
339377	XM_290866	Be similar to 4930572L20Rik albumen; LOC339377	339390	NM_198492	C type lectin superfamily 4, member G; CLEC4G
339562	XM_291643	Be similar to Ig κ chain; LOC339562	339390	NM_198492	C type lectin superfamily 4, member G; CLEC4G

342510	NM_181449	CD300 antigen sample family member E; CD300LE
342510	NM_181449	CD300 antigen sample family member E; CD300LE	343413	NM_001004310	Fc acceptor-sample 6; FCRL6
346689	NM_198508	FLJ44186 albumen; FLJ44186	343413	NM_001004310	Fc acceptor-sample 6; FCRL6
346689	NM_198508	FLJ44186 albumen; FLJ44186	353091	NM_001001788	Vitamin A acid early transcription thing 1G; RAET1G
353219	NM_181337	Kidney related antigen 1	353091	NM_001001788	Vitamin A acid early transcription thing 1G; RAET1G
353219	NM_181337	Kidney related antigen 1	353376	NM_021649	Contain the albumen 7 precursor .[source of striding film emp24 structural domain: Uniprot/SWISSPROT; Acc:Q9Y3B3]
353514	NM_021250；NM_18 1879；NM_181985；NM_181986	Leukocytic immunity sphaeroprotein-sample acceptor, subfamily A (having the TM structural domain), the member 5; LILRA5	353376	NM_021649
353514	NM_021250；NM_18 1879；NM_181985；NM_181986		359710	NM_182658	Karyomit(e) 20 open reading frame 185; C20orf185
378829	AF304442	Bone-marrow-derived lymphocyte activation-associated protein BC-1514	359710	NM_182658	Karyomit(e) 20 open reading frame 185; C20orf185
378829	AF304442		387836	NM_207375	C type lectin structural domain family 2, member A; CLEC2A
388077	XM_370834	The heavy variable 1/OR15-1 of immunoglobulin (Ig); IGHV1OR15-1	387836	NM_207375	C type lectin structural domain family 2, member A; CLEC2A
388077	XM_370834		388078	XM_370835	Contain V-group and immunoglobulin domains 6; VSIG6
388372	NM_001001435	Chemokine (C-C motif) part 4-sample 2 precursors [source: RefSeq_peptide; Acc:NP_996890]	388078	XM_370835	Contain V-group and immunoglobulin domains 6; VSIG6
388372	NM_001001435		388503	NM_001013640	Be similar to complement C3 precursor; LOC388503
388646	NM_207398	Interferon, rabbit-inductive guanylic acid-conjugated protein 2 (GTP-conjugated protein 2) (guanylic acid-conjugated protein 2) be the .[source (HuGBP-2): Uniprot/SWISSPROT; Acc:P32456]	388503	NM_001013640	Be similar to complement C3 precursor; LOC388503
388646	NM_207398		388677	NM_203458	The terminal sample of Notch homologue 2 (fruit bat) N-; NOTCH2NL
389405	XM_371829	Be similar to neurone locus Notch amyloid protein precursor; RP1-303F19.1	388677	NM_203458
389405	XM_371829		389852	NM_205856	PNPK6288；RP11-38O23.2
389941	NM_001010908	Complement component	389852	NM_205856	PNPK6288；RP11-38O23.2	1, q subcomponent-sample 3; C1QL3
389941	NM_001010908	Complement component	389950	XM_372307	Be similar to immunoglobulin (Ig) λ-1 variable region; LOC389950	1, q subcomponent-sample 3; C1QL3
390530	XM_372543	Be similar to immunoglobulin (Ig) heavy-chain-2 is light-chain-2VH section; LOC390530	389950	XM_372307
390530	XM_372543		390531	XM_496025	Contain V-group and immunoglobulin domains 7; VSIG7
390667	NM_001013658	Be similar to neurone pentamer protein I I precursor (NP-II) (NP2); LOC390667	390531	XM_496025	Contain V-group and immunoglobulin domains 7; VSIG7
390667	NM_001013658		390712	XM_372630	Be similar to the immunoglobulin M chain; 0LOC390712
390714	XM_372632	Be similar to Ig heavy chain V-III district VH26 precursor; LOC390714	390712	XM_372630	Be similar to the immunoglobulin M chain; 0LOC390712
390714	XM_372632		391105	XM_497715	Be similar to dJ801G22.2 (novel protein is similar to immunoglobulin (Ig) γ FC acceptor 1 (FGCR1)); LOC391105
391142	XM_496426	Imaginary gene by the AJ249778 support; NM_001531; LOC391142	391105	XM_497715
391142	XM_496426		391405	XM_372941	Be similar to Ig κ chain V district (Z4)-mankind; LOC391405
391427	XM_372952	Be similar to Ig κ chain precursor V district (orphon V108)-mankind's (fragment); LOC391427	391405	XM_372941	Be similar to Ig κ chain V district (Z4)-mankind; LOC391405
391427	XM_372952		392217	XM_373249	Be similar to Ig lambda light chain leader and V-district; LOC392217
392965	XM_374637	Be similar to α-2-glycoprotein 1, zinc; A-2-glycoprotein, zinc; LOC392965	392217	XM_373249
392965	XM_374637		400581	XM_375418	GRB2-associated adapter albumen-sample; LOC400581
400668	NM_214710	Proteolytic enzyme, Serine-sample 1; PRSSL1	400581	XM_375418	GRB2-associated adapter albumen-sample; LOC400581

400709	XM_375634	Sialic acid is in conjunction with Ig-sample lectin, pseudogene 16; SIGLECP16
400709	XM_375634		400759	NM_002053	Interferon, rabbit-inductive guanylic acid-conjugated protein 1 (GTP-conjugated protein 1) (guanylic acid-conjugated protein 1) be the .[source (HuGBP-1): Uniprot/SWISSPROT; Acc:P32455]
400760	NM_002053	Interferon, rabbit-inductive guanylic acid-conjugated protein 1 (GTP-conjugated protein 1) (guanylic acid-conjugated protein 1) be the .[source (HuGBP-1): Uniprot/SWISSPROT; Acc:P32455]	400759	NM_002053
400760	NM_002053		400792	XM_375816	Be similar to Slamf7 albumen; LOC400792
400943	NM_207480	AILT5830	400792	XM_375816	Be similar to Slamf7 albumen; LOC400792
400943	NM_207480	AILT5830	401262	NM_206922	Halfcystine-Abundant protein 3[source: RefSeq_peptide; Acc:NP_996805]
401393	XM_376658	Be similar to zinc-α-2-glycoprotein precursor (Zn-α-2-glycoprotein) (Zn-α-2-GP); LOC401393	401262	NM_206922
401393	XM_376658		401845	XM_377426	Be similar to the IGHV gene product; LOC401845
401887	XM_497555	Be similar to calmodulin-rabbit (interim sequence); LOC401887	401845	XM_377426	Be similar to the IGHV gene product; LOC401845
401887	XM_497555		402571	XM_379897	Be similar to zinc-α-2-glycoprotein precursor (Zn-α-2-glycoprotein) (Zn-α-2-GP); LOC402571
404552	NM_206998	The secretion sphaeroprotein 1D member of family 4 precursors (IFN-γ-derivable secretion sphaeroprotein) are the .[source (IIS): Uniprot/SWISSPROT; Acc:Q6XE38]	402571	XM_379897
404552	NM_206998		407977	NM_172089	Tumour necrosis factor part superfamily member 13 precursors (propagation-inducing ligand) are (part 2 that the relevant white corpuscle with APOL-of TNF-is expressed) (TALL-2) (TNF-associated death part-1) (TRDL-1) (CD256 antigen) .[source: Uniprot/SWISSPROT (APRIL); Acc:O75888
432395	NM_001002029	Complement component C4 B telomerizes; XXbac-BPG116M5.7	407977	NM_172089
432395	NM_001002029	Complement component C4 B telomerizes; XXbac-BPG116M5.7	439957	XM_495805	Be similar to Ig κ chain V district (Z4)-mankind; LOC439957
440361	XM_496145	Be similar to the immunoglobulin M chain; LOC440361	439957	XM_495805	Be similar to Ig κ chain V district (Z4)-mankind; LOC439957
440361	XM_496145	Be similar to the immunoglobulin M chain; LOC440361	440370	XM_496158	Be similar to the immunoglobulin M chain; LOC440370
440508	XM_496285	Be similar to liver and lymphoglandula sinusoid endotheliocyte C-type lectin; DTTR431; LOC440508	440370	XM_496158	Be similar to the immunoglobulin M chain; LOC440370
440508	XM_496285		440607	NM_001017986；NM_001004340	Fc-γ acceptor I B2; LOC440607
440786	XM_496488	Be similar to Ig κ chain; LOC440786	440607	NM_001017986；NM_001004340	Fc-γ acceptor I B2; LOC440607
440786	XM_496488	Be similar to Ig κ chain; LOC440786	440871	XM_496558	Be similar to Ig κ variable region; LOC440871
440891	XM_496578	Be similar to Ig kappa light chain variable district; LOC440891	440871	XM_496558	Be similar to Ig κ variable region; LOC440871
440891	XM_496578		441140	NM_001004349	FLJ45422 albumen; FLJ45422
441800	XM_497557	Be similar to RIKEN cDNA B230315M08; Polymeric immunoglobulin receptor 4; Paired immunoglobulin (Ig)-sample the acceptor 1 in mastocyte-source; LOC441800	441140	NM_001004349	FLJ45422 albumen; FLJ45422
441800	XM_497557		441864	XM_497642	Be similar to RIKEN cDNA 9930022N03 gene; LOC441864
441868	XM_497647	Be similar to cSH-PTP2; LOC441868	441864	XM_497642	Be similar to RIKEN cDNA 9930022N03 gene; LOC441864
441868	XM_497647	Be similar to cSH-PTP2; LOC441868	441971	XM_497790	Be similar to phosphoinositide 3-hydroxyl kinases p110-alpha subunit; LOC441971
442031	XM_497854	Be similar to immunoglobulin kappa chain; LOC442031	441971	XM_497790

442032	XM_497855	Be similar to Ig κ chain V district (A2)-mankind; LOC442032
442032	XM_497855	Be similar to Ig κ chain V district (A2)-mankind; LOC442032	442033	XM_497856	Be similar to Ig κ chain V district (A2)-mankind; LOC442033
442034	XM_497857	Be similar to immunoglobulin kappa chain; LOC442034	442033	XM_497856	Be similar to Ig κ chain V district (A2)-mankind; LOC442033
442034	XM_497857	Be similar to immunoglobulin kappa chain; LOC442034	442043	XM_497871	Be similar to ARHQ albumen; LOC442043
442084	XM_497926	Be similar to roundabout homologue 2; LOC442084	442043	XM_497871	Be similar to ARHQ albumen; LOC442043
442084	XM_497926	Be similar to roundabout homologue 2; LOC442084	442203	XM_498087	Be similar to MHC HLA-SX-α; LOC442203
442219	XM_498102	Be similar to transitional protein p21b (K-Ras2B) (Ki-Ras) (c-K-ras); LOC442219	442203	XM_498087	Be similar to MHC HLA-SX-α; LOC442203
442219	XM_498102		442606	XM_499352	Be similar to α-2-glycoprotein 1, zinc; α-2-glycoprotein, zinc; LOC442606
553128	NM_001018081	Killer cell immunoglobulin (Ig)-similar acceptor, two structural domains, growing cells matter tail, 5B; KIR2DL5B	442606	XM_499352
553128	NM_001018081			AB209870	HLA class I histocompatibility antigen, E α chain precursor
	L29376	Homo sapiens (clone 3.8-1) MHC class I		AB209870	HLA class I histocompatibility antigen, E α chain precursor

Claims

1. be used for detecting the existence of Mammals cancer or the method for developing risk, be included in the described mammiferous biological sample and detect:

A) comprise the sequence shown in the SEQ ID No:23,52,53,148 and 225 (group 11), perhaps have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

D) by according to a) to c) the polypeptide of nucleic acid encoding,

The existence of these target molecules in the described sample, shortage or (relatively) amount are that cancer exists or the indication of developing risk in this Mammals.

2. method according to claim 1, it is characterized in that, according to a) described nucleic acid be selected from comprise the sequence that provides among one of group 1-10 in the table 4 or have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases.

3. method according to claim 1 and 2, it is characterized in that, comprise according to a) described nucleic acid: comprise the sequence that provides in the group 10 in the table 4 or have at least 15, the nucleic acid of its specific fragment of preferred at least 16,17,18,19,20,25 or 30 continuous bases.

4. exsomatize or the vitro detection Mammals in cancer exist or the method for developing risk, comprise and measuring in the described mammiferous biological sample, exist (or the shortage) that relates to the secretion of stimulation, cytokine of TLR or the change among lymphocytic activatory gene of T-or the RNA in preferred blood (source) sample, described gene or RNA advantageously are selected from the factor, chemokine, cytokine and the interleukin that acceptor, aptamers, enzyme, genetic expression relate in regulating, and the existence of described change is that cancer exists or the indication of developing risk in this Mammals.

5. method according to claim 4, comprise and measuring in the described mammiferous biological sample, the change of shown in the table 5 at least one, preferred at least 2,3,4,5,6,7,8,9 or 10 genes or corresponding RNA in preferred blood (source) sample, the existing of the change of the montage of especially described gene or RNA (or shortage), the existence of described change is that cancer exists or the indication of developing risk in this Mammals.

6. method according to claim 4, comprise and measuring in the described mammiferous biological sample, the change of shown in the table 6 at least one, preferred at least 2,3,4,5,6,7,8,9 or 10 genes or corresponding RNA in preferred blood (source) sample, the existing of the change of the montage of especially described gene or RNA (or shortage), the existence of described change is that cancer exists or the indication of developing risk in this Mammals.

7. according to any one described method in the aforementioned claim, comprise the existence or the shortage that detect nucleic acid by selective cross or selective amplification.

8. according to the existence of cancer or the method for developing risk in the described detection of any one claim of aforementioned claim the Mammals, be included under the condition that allows the hybridization between the complementary sequence, the nucleic acid that is derived from described mammiferous blood sample contacted for being selected from the special probe of one group of following target molecule with one group:

A) nucleic acid of one of group 1 to 11 that limits in the claim 1 and 2, or have at least 15, its specific fragments of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

9. method according to claim 8 is included under the condition that allows the hybridization between the complementary sequence, and the nucleic acid that is derived from described mammiferous blood sample is contacted for the special probe of following target molecule with one group:

A) group 11 nucleic acid or have at least 15, its specific fragments of preferred at least 16,17,18,19,20,25 or 30 continuous bases, and/or

10. method according to claim 5 is included under the condition that allows the hybridization between the complementary sequence, and the nucleic acid that is derived from described mammiferous blood sample is contacted for the special probe of table 5 and two genes shown in 6 or corresponding RNA with one group at least.

11. to any one described method of 10, it is characterized in that described probe stationary is on carrier according to Claim 8.

12. according to the existence of cancer or the method for developing risk in any one described detection Mammals of claim 1 to 8, be included under the condition that allows amplified reaction, the nucleic acid that is derived from described mammiferous blood sample contacted for being selected from the special primer of one group of following target molecule with one group:

To obtain the amplification collection of illustrative plates, described amplification collection of illustrative plates is the existence of cancer in this Mammals or the feature of developing risk.

13. according to claim 6 or 7 described methods, be included under the condition that allows amplified reaction, the nucleic acid that is derived from described mammiferous blood sample contacted for the special primer of table 5 and two genes shown in 6 or corresponding RNA with one group at least.

14., comprise by specific antibody or its fragment or derivative and detect existence or shortage by described gene or RNA encoded polypeptides according to any one described method of claim 1 to 7.

15. any one the described method according to aforementioned claim is characterized in that, described sample is the sample in blood source, preferred whole blood sample.

16. according to any one described method of aforementioned claim, with existing of the breast carcinoma of early stage of detecting stage I or II.

17. according to any one described method of claim 1 to 15, to detect existing of the breast carcinoma of early stage that can't detect by the mammary gland maskaperture mask.

18. for the application as the special nucleic acid probe of the target nucleic acid that limits in any one of claim 1 to 8, described probe comprises 15 to 400 bases, is used for the vitro detection of human individual's cancer.

19. can increase as the application of all or part of nucleic acid primer of the target nucleic acid that limits in any one of claim 1 to 7, described primer is the strand with length of 5 to 50 bases, is used for the vitro detection of human individual's cancer.

20. comprise the product of the carrier that is fixed with at least two different nucleic acid probes on it, described nucleic acid probe comprises: be complementary to and/or be specific at least two different sequences that comprise the target nucleic acid of at least two sequences that are selected from SEQ ID NO:1-437, or be complementary to and/or be specific at least one gene shown in table 5 or 6 or the sequence of RNA.

21. product according to claim 20 comprises the carrier that is fixed with a different set of at least nucleic acid probe on it, described nucleic acid probe comprises the sequence of the nucleic acid that is complementary to and/or is specific in the claim 1 one of group 1 to 11 of limiting.

22., be used for exsomatizing or the existence or the developing risk of vitro detection Mammals cancer according to the application of the product of claim 20.

23., be used for exsomatizing or the existence or the developing risk of vitro detection Mammals mammary cancer according to the application of the product of claim 21.